WorldWideScience

Sample records for planar 90y bremsstrahlung

  1. Evaluation of quantitative planar 90Y bremsstrahlung whole-body imaging

    International Nuclear Information System (INIS)

    Minarik, D; Ljungberg, M; Gleisner, K Sjoegreen; Segars, P

    2009-01-01

    With high-dose administration of 90 Y labeled antibodies, it is possible to image 90 Y without an admixture of 111 In. We have earlier shown that it is possible to perform quantitative 90 Y bremsstrahlung SPECT for dosimetry purposes with reasonable accuracy. However, whole-body (WB) activity quantification with the conjugate view method is not as time consuming as SPECT and has been the method of choice for dosimetry. We have investigated the possibility of using a conjugate view method where scatter-, backscatter- and septal-penetration compensations are performed by inverse filtering and attenuation correction is performed with a WB x-ray image, for total-body and organ activity quantification of 90 Y. The method was evaluated using both Monte Carlo simulated scintillation camera images using realistic source distributions, and by an experimental phantom study. The method was evaluated in terms of image quality and accuracy of the activity quantification. The experimental phantom study was performed using the RSD torso phantom with 90 Y activity uniformly distributed in the liver insert. A GE Discovery VH/Hawkeye system was used to acquire the image. The simulation study was performed for a realistic activity distribution in the NCAT anthropomorphic phantom where 90 Y bremsstrahlung images were generated using the SIMIND MC program. Two different phantom configurations and two activity distributions were simulated. To mimic the RSD phantom experiment one simulation study was also made with 90 Y activity located only in the liver. The SIMIND program was configured to resemble a GE Discovery VH/Hawkeye system. An x-ray projector program was used to generate whole-body x-ray images from the NCAT phantom for attenuation correction in the conjugate view method. Organ activities were calculated from ROIs that exactly covered the organs. Corrections for background activity, overlapping activity and source extension in the depth direction were applied on the ROI data

  2. 90Y microsphere therapy: does 90Y PET/CT imaging obviate the need for 90Y Bremsstrahlung SPECT/CT imaging?

    Science.gov (United States)

    Zade, Anand A; Rangarajan, Venkatesh; Purandare, Nilendu C; Shah, Sneha A; Agrawal, Archi R; Kulkarni, Suyash S; Shetty, Nitin

    2013-11-01

    Transarterial radioembolization using Y microspheres is a novel therapeutic option for inoperable hepatic malignancies. As these spheres are radiolucent, real-time assessment of their distribution during the infusion process under fluoroscopic guidance is not possible. Bremsstrahlung radiations arising from 90Y have conventionally been used for imaging its biodistribution. Recent studies have proved that sources of 90Y also emit positrons, which can further be used for PET/computed tomography (CT) imaging. This study aimed to assess the feasibility of 90Y PET/CT imaging in evaluating microsphere distributions and to compare its findings with those of Bremsstrahlung imaging. Thirty-five sessions of 90Y microsphere transarterial radioembolization were performed on 30 patients with hepatic malignancies. 90Y PET/CT imaging was performed within 3 h of therapy. Bremsstrahlung imaging was also performed for each patient. The imaging findings were compared for concordance in the distribution of microspheres. Exact one-to-one correspondence between 90Y PET/CT imaging and 90Y Bremsstrahlung imaging was observed in 97.14% of cases (i.e. in 34/35 cases). Discordance was observed only in one case in which 90Y PET/CT imaging resolved the microsphere uptake in the inferior vena cava tumor thrombus, which was, however, not visualized on Bremsstrahlung imaging. There is good concordance in the imaging findings of 90Y PET/CT and 90Y Bremsstrahlung imaging. 90Y PET/CT imaging scores over the conventionally used Bremsstrahlung imaging in terms of better resolution, ease of technique, and comparable image acquisition time. This makes it a preferred imaging modality for assessment of the distribution of 90Y microspheres.

  3. Collimator and energy window optimization for 90Y bremsstrahlung SPECT imaging: A SIMIND Monte Carlo study

    International Nuclear Information System (INIS)

    Roshan, Hoda Rezaei; Mahmoudian, Babak; Gharepapagh, Esmaeil; Azarm, Ahmadreza; Pirayesh Islamian, Jalil

    2016-01-01

    Treatment efficacy of radioembolization using Yttrium-90 ( 90 Y) microspheres is assessed by the 90 Y bremsstrahlung single photon emission computed tomography (SPECT) imaging following radioembolization. The radioisotopic image has the potential of providing reliable activity map of 90 Y microspheres distribution. One of the main reasons of the poor image quality in 90 Y bremsstrahlung SPECT imaging is the continuous and broad energy spectrum of the related bremsstrahlung photons. Furthermore, collimator geometry plays an impressive role in the spatial resolution, sensitivity and image contrast. Due to the relatively poor quality of the 90 Y bremsstrahlung SPECT images, we intend to optimize the medium-energy (ME) parallel-hole collimator and energy window. The Siemens e.cam gamma camera equipped with a ME collimator and a voxelized phantom was simulated by the SImulating Medical Imaging Nuclear Detectors (SIMIND) program. We used the SIMIND Monte Carlo program to generate the 90 Y bremsstrahlung SPECT projection of the digital Jaszczak phantom. The phantom consist of the six hot spheres ranging from 9.5 to 31.8 mm in diameter, which are used to evaluate the image contrast. In order to assess the effect of the energy window on the image contrast, three energy windows ranging from 60 to 160 KeV, 160 to 400 KeV, and 60 to 400 KeV were set on a 90 Y bremsstrahlung spectrum. As well, the effect of the hole diameter of a ME collimator on the image contrast and bremsstrahlung spectrum were investigated. For the fixed collimator and septa thickness values (3.28 cm and 1.14 mm, respectively), a hole diameter range (2.35–3.3 mm) was chosen based on the appropriate balance between the spatial resolution and sensitivity. The optimal energy window for 90 Y bremsstrahlung SPECT imaging was extended energy window from 60 to 400 KeV. Besides, The optimal value of the hole diameter of ME collimator was obtained 3.3 mm. Geometry of the ME parallel-hole collimator and energy

  4. Practical reconstruction protocol for quantitative 90Y bremsstrahlung SPECT/CT

    International Nuclear Information System (INIS)

    Siman, W.; Mikell, J. K.; Kappadath, S. C.

    2016-01-01

    Purpose: To develop a practical background compensation (BC) technique to improve quantitative 90 Y-bremsstrahlung single-photon emission computed tomography (SPECT)/computed tomography (CT) using a commercially available imaging system. Methods: All images were acquired using medium-energy collimation in six energy windows (EWs), ranging from 70 to 410 keV. The EWs were determined based on the signal-to-background ratio in planar images of an acrylic phantom of different thicknesses (2–16 cm) positioned below a 90 Y source and set at different distances (15–35 cm) from a gamma camera. The authors adapted the widely used EW-based scatter-correction technique by modeling the BC as scaled images. The BC EW was determined empirically in SPECT/CT studies using an IEC phantom based on the sphere activity recovery and residual activity in the cold lung insert. The scaling factor was calculated from 20 clinical planar 90 Y images. Reconstruction parameters were optimized in the same SPECT images for improved image quantification and contrast. A count-to-activity calibration factor was calculated from 30 clinical 90 Y images. Results: The authors found that the most appropriate imaging EW range was 90–125 keV. BC was modeled as 0.53× images in the EW of 310–410 keV. The background-compensated clinical images had higher image contrast than uncompensated images. The maximum deviation of their SPECT calibration in clinical studies was lowest (<10%) for SPECT with attenuation correction (AC) and SPECT with AC + BC. Using the proposed SPECT-with-AC + BC reconstruction protocol, the authors found that the recovery coefficient of a 37-mm sphere (in a 10-mm volume of interest) increased from 39% to 90% and that the residual activity in the lung insert decreased from 44% to 14% over that of SPECT images with AC alone. Conclusions: The proposed EW-based BC model was developed for 90 Y bremsstrahlung imaging. SPECT with AC + BC gave improved lesion detectability and activity

  5. Practical reconstruction protocol for quantitative {sup 90}Y bremsstrahlung SPECT/CT

    Energy Technology Data Exchange (ETDEWEB)

    Siman, W.; Mikell, J. K.; Kappadath, S. C., E-mail: skappadath@mdanderson.org [Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 and The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas 77030 (United States)

    2016-09-15

    Purpose: To develop a practical background compensation (BC) technique to improve quantitative {sup 90}Y-bremsstrahlung single-photon emission computed tomography (SPECT)/computed tomography (CT) using a commercially available imaging system. Methods: All images were acquired using medium-energy collimation in six energy windows (EWs), ranging from 70 to 410 keV. The EWs were determined based on the signal-to-background ratio in planar images of an acrylic phantom of different thicknesses (2–16 cm) positioned below a {sup 90}Y source and set at different distances (15–35 cm) from a gamma camera. The authors adapted the widely used EW-based scatter-correction technique by modeling the BC as scaled images. The BC EW was determined empirically in SPECT/CT studies using an IEC phantom based on the sphere activity recovery and residual activity in the cold lung insert. The scaling factor was calculated from 20 clinical planar {sup 90}Y images. Reconstruction parameters were optimized in the same SPECT images for improved image quantification and contrast. A count-to-activity calibration factor was calculated from 30 clinical {sup 90}Y images. Results: The authors found that the most appropriate imaging EW range was 90–125 keV. BC was modeled as 0.53× images in the EW of 310–410 keV. The background-compensated clinical images had higher image contrast than uncompensated images. The maximum deviation of their SPECT calibration in clinical studies was lowest (<10%) for SPECT with attenuation correction (AC) and SPECT with AC + BC. Using the proposed SPECT-with-AC + BC reconstruction protocol, the authors found that the recovery coefficient of a 37-mm sphere (in a 10-mm volume of interest) increased from 39% to 90% and that the residual activity in the lung insert decreased from 44% to 14% over that of SPECT images with AC alone. Conclusions: The proposed EW-based BC model was developed for {sup 90}Y bremsstrahlung imaging. SPECT with AC + BC gave improved lesion

  6. Internal Bremsstrahlung accompanying beta decay of 90 Y

    International Nuclear Information System (INIS)

    Elsayed, A.M.A.; Abdelhady, E.E.

    1992-01-01

    The internal Bremsstrahlung (IB) spectrum associated with the unique first-forbidden β decay of 9 0Y is measured employing the conventional β-stopper technique with a 5 x 5 cm NaI (T 1) scintillation spectrometer in the energy range (50-2000 keV). All the necessary corrections are made. In order to analyze the experimental data, a response matrix having the dimensions of 64 energy bins and 474 channels is constructed.with the help of the detector assembly response matrix, the true IB energy spectrum is obtained by iteratively unfolding the experimental pulse-height spectrum. The experimental results are compared with the corresponding theoretical distributions due to Knipp and Uhlenbeck and Bloch (KUB), lewis and ford (L F), and ford and martin (FM). The results show reasonable agreement with the detour theory of ford and martin.3 fig

  7. Comparative analysis of hepatopulmonary shunt obtained from pretherapy 99mTc MAA scintigraphy and post-therapy 90Y Bremsstrahlung imaging in 90Y microsphere therapy.

    Science.gov (United States)

    Jha, Ashish Kumar A; Zade, Anand A; Rangarajan, Venkatesh; Purandare, Nilendu; Shah, Sneha A; Agrawal, Archi; Kulkarni, Suyash S; Shetty, Nitin

    2012-05-01

    (99m)Tc macroaggregate albumin (MAA) scintigraphy is routinely used to estimate the hepatopulmonary shunt (HPS) of (90)Y microspheres because of their comparable average particle sizes (20-30 µm). However, the MAA particle size can vary from 10 to 90 µm. Therefore, HPS computed from (99m)Tc MAA scintigraphy may not accurately represent the HPS of (90)Y microspheres. In view of this, the present study was undertaken to investigate the accuracy of (99m)Tc MAA scintigraphy in estimating the HPS of (90)Y microspheres. Nineteen sessions of transarterial radioembolization using (90)Y therasphere were carried out in 17 patients for hepatic malignancies (both primary and secondary). For each session of therapy, a pretherapeutic (99m)Tc MAA scintigraphy and post-therapeutic (90)Y Bremsstrahlung scintigraphy were performed. The HPSs obtained from these images were compared. The mean HPS fractions calculated from the pretherapeutic (99m)Tc MAA study and the post-therapeutic (90)Y Bremsstrahlung images were 4.77 ± 2.81 and 4.52 ± 2.5%, respectively. The coefficient of correlation (r) was 0.96. (99m)Tc MAA scintigraphy accurately predicts the HPS of (90)Y microspheres.

  8. Improved quantitative 90 Y bremsstrahlung SPECT/CT reconstruction with Monte Carlo scatter modeling.

    Science.gov (United States)

    Dewaraja, Yuni K; Chun, Se Young; Srinivasa, Ravi N; Kaza, Ravi K; Cuneo, Kyle C; Majdalany, Bill S; Novelli, Paula M; Ljungberg, Michael; Fessler, Jeffrey A

    2017-12-01

    In 90 Y microsphere radioembolization (RE), accurate post-therapy imaging-based dosimetry is important for establishing absorbed dose versus outcome relationships for developing future treatment planning strategies. Additionally, accurately assessing microsphere distributions is important because of concerns for unexpected activity deposition outside the liver. Quantitative 90 Y imaging by either SPECT or PET is challenging. In 90 Y SPECT model based methods are necessary for scatter correction because energy window-based methods are not feasible with the continuous bremsstrahlung energy spectrum. The objective of this work was to implement and evaluate a scatter estimation method for accurate 90 Y bremsstrahlung SPECT/CT imaging. Since a fully Monte Carlo (MC) approach to 90 Y SPECT reconstruction is computationally very demanding, in the present study the scatter estimate generated by a MC simulator was combined with an analytical projector in the 3D OS-EM reconstruction model. A single window (105 to 195-keV) was used for both the acquisition and the projector modeling. A liver/lung torso phantom with intrahepatic lesions and low-uptake extrahepatic objects was imaged to evaluate SPECT/CT reconstruction without and with scatter correction. Clinical application was demonstrated by applying the reconstruction approach to five patients treated with RE to determine lesion and normal liver activity concentrations using a (liver) relative calibration. There was convergence of the scatter estimate after just two updates, greatly reducing computational requirements. In the phantom study, compared with reconstruction without scatter correction, with MC scatter modeling there was substantial improvement in activity recovery in intrahepatic lesions (from > 55% to > 86%), normal liver (from 113% to 104%), and lungs (from 227% to 104%) with only a small degradation in noise (13% vs. 17%). Similarly, with scatter modeling contrast improved substantially both visually and in

  9. Planar gamma camera imaging and quantitation of Yttrium-90 bremsstrahlung

    International Nuclear Information System (INIS)

    Shen, S.; DeNardo, G.L.; Yuan, A.

    1994-01-01

    Yttrium-90 is a promising radionuclide for radioimmunotherapy of cancer because of its energetic beta emissions. Therapeutic management requires quantitative imaging to assess the pharmacokinetics and radiation dosimetry of the 90 Y-labeled antibody. Conventional gamma photon imaging methods cannot be easily applied to imaging of 90 Y-bremsstrahlung because of its continuous energy spectrum. The sensitivity, resolution and source-to-background signal ratio (S/B) of the detector system for 90 Y-bremsstrahlung were investigated for various collimators and energy windows in order to determine optimum conditions for quantitative imaging. After these conditions were determined, the accuracy of quantitation of 90 Y activity in an Alderson abdominal phantom was examined. When the energy-window width was increased, the benefit of increased sensitivity outweighed degradation in resolution and S/B ratio until the manufacturer's energy specifications for the collimator were exceeded. Using the same energy window, the authors improved resolution and S/B for the medium-energy (ME) collimator when compared to the low-energy, all-purpose (LEAP) collimator, and there was little additional improvement using the high-energy (HE) collimator. Camera sensitivity under tissue equivalent conditions was 4.2 times greater for the LEAP and 1.7 times greater for the ME collimators when compared to the HE collimator. Thus, the best, most practical selections were found to be the ME collimator and an energy window of 55-285 keV. When they used these optimal conditions for image acquisition, the estimation of 90 Y activity in organs and tumors was within 15% of the true activities. The results for this study suggest that reasonable accuracy can be achieved in clinical radioimmunotherapy using 90 Y-bremsstrahlung quantitation. 28 refs., 5 figs., 7 tabs

  10. Does 99mTc MAA study accurately predict the Hepatopulmonary shunt fraction of 90Y theraspheres?

    International Nuclear Information System (INIS)

    Jha, Ashish; Zade, A.; Monteiro, P.; Shah, S.; Purandare, N.C.; Rangarajan, V.; Kulkarni, S.; Kulkarni, A.; Shetty, Nitin

    2010-01-01

    Full text: Transarterial-radioembolisation (TARE) is FDA approved therapeutic option for primary and metastatic liver malignancy when patient is inoperable; which in addition to the embolic effect (as seen with Transarterial- chemoembolisation-TACE) also gives the benefit of selectively irradiation to the target lesions with minimal toxicity to adjacent normal hepatocytes. However there is a risk of shunting of radioactive spheres to pulmonary circulation and subsequent pulmonary toxicity if the hepatopulmonary shunt fraction is high. The estimated lung dose becomes the limiting factor for the dose that can be delivered trans-arterially for radioembolisation of hepatic neoplasms.This is achieved by a pretreatment 99m Tc MAA study. Aim: The accuracy of 99m Tc-MAA Scintigraphy to predict the hepatopulmonary shunt fraction of 90 Y Theraspheres was evaluated by comparing it with that obtained by post therapeutic Bremsstrahlung imaging. Materials and Methods: Patients: 13 patients who underwent 90 Y Theraspheres radioembolisation of hepatic malignancies (both primary and secondary) underwent pre therapeutic 99m Tc- MAA Scintigraphy and post therapeutic 90 Y Bremsstrahlung Scintigraphy. 10-12 mCi of freshly prepared 99m Tc MAA was administered by selective hepatic artery cauterization. Planar and tomographic images were acquired within 1hr of radiopharmaceutical administration. IMAGE ACQUISITION 99m Tc MAA static images were acquired in 256 x 256 matrix (1000 KCnts) and SPECT were a 128 x 128 matrix with 64 frames (20 s/frame). The scan parameters for CT were 140 kV, 2.5 mAs, and 1-cm slices. SPECT images were corrected for attenuation and scatter. Post therapeutic 90 Y Bremsstrahlung imaging was done with HEGP collimator with photo peak centered at 140 KeV - 64.29% and +56% window width. SPECT/CT images were obtained using a dual-detector gamma-camera with a mounted 1-row CT scanner (Infinia Hawkeye; GE medical systems) to evaluate hepatic and extra hepatic tracer

  11. Internal Dosimetry in therapy with 90Y

    International Nuclear Information System (INIS)

    Torres, Leonel; Vergara, Alex; García, Leonardo

    2016-01-01

    Introduction: 90 Y has shown satisfactory results in the therapy of multiple oncological diseases. This radionuclide has been widely used in therapy of diseases such as NHL (Zevalin), TNE ( 90 Y-DOTATOC), liver cancer, etc. Its safe and effective use presupposes the availability of accurate dosimetry methods and reproducible.El objective of this work is to standardize and optimize images use procedures that allow for dosimetric estimates braking during therapy of malignant diseases 90 Y. Materials and Methods: To quantify the activity in absolute units from scans correction methods that consider the peculiarities of the bremsstrahlung of 90 Y were proposed. acquisition parameters such as the selection of the collimator and the definition of energy windows as well as methods of scatter correction, attenuation, interactions of radiation with the collimator (septal penetration and degradation of information with distance) were considered and sensitivity or calibration factor was estimated. They were evaluated and calibrated parameters for dosimetry at the level of organ and estimates of distributions 3D dose, using experimental measurements with SPECT Mediso Nucline ™ Spirit DH-V system and simulations were performed using the Monte Carlo method, using the SIMIND v5 software .0. Results: The optimum position-energy window width and collimator to be used is determined from the relationship between total photons and primary photons (T / P), calculated with SIMIND. The results were favorable to employ HEGP collimator and energy window between 90-170kev. the sensitivity of the system for the selected collimator (HEGP for 90 Y) was estimated. He was evaluated and determined the MTF order to correct dispersive plane images, the source-detector and interactions of radiation with the collimator distance, using filtering methods (Wiener filter), including empirical estimates of the SNR component. Similarly the procedure for the use of transmission maps obtained from

  12. Peptide Receptor Radionuclide Therapy with ''9''0Y DOTA TATE - First Results

    International Nuclear Information System (INIS)

    Artiko, V.; Sobic-Saranovic, D.; Petrovic, N.; Damjanovic, S.; Obradovic, V.

    2009-01-01

    Aim: The aim of this work is presentation of the preliminary results of the therapy of NETs with 90 Y DOTA TATE. Patients and methods: We investigated 15 patients with various neuroendocrine tumors. In all of them, together with other laboratory analyses and imaging methods, scintigraphy with somatostatin analogues was performed (in 3 with 111 In Octreoscan and in the other 4 with 99m Tc Tektrotyd) and high tumor uptake observed. The therapy was performed with 2-4,5 GBq 90 Y DOTA TATE per patient per one cycle, in the slow infusion in the physiological liquid (150 ml/15 min).Between the cycles, there was a time delay of 6-8 weeks. 30 minutes before the therapy, patients began receiving the infusion of amino acids (arginine and lysine) which lasted 4h. Before that, all therapies with somatostatin analogues were withdrawn. 24h-96h after the therapy, ''bremsstrahlung'' whole body imaging, SPECT and particular planar images were performed with gamma camera. Results: Analysis of the ''bremsstrahlung'' images showed uptake of the radiopharmaceutical in the liver, but the most of the activity was observed in the regions of the ''hot spots'' registered with previous 99m Tc Tektrotyd and 111 In Octreoscan images. According to our results, after the therapy, in two patients occurred progressive disease (PD), in seven stable disease (SD), and in six partial remission (PR). Up to now, there were no major clinical side effects hepatic function. Transient pancytopenia occurred in two patients, and impairment of kidney function in one. Conclusion: In spite of insufficient data, beneficial effects on clinical symptoms, hormone production and tumor proliferation were found, without major clinical side effects. Thus, according to preliminary results, treatment with 90 Y DOTA TATE is feasible method and might be useful for the management of patients with inoperable or disseminated neuroendocrine tumors. (author)

  13. Extractive {sup 90}Y generator

    Energy Technology Data Exchange (ETDEWEB)

    Kodina, G.E. [State Scientific Center, Moscow (Russian Federation). Institute of Giophysics; Korpusov, G.V.; Filyanin, A.T. [Russian Academy of Sciences, Moscow (Russian Federation). Institute of Physical Chemistry

    1997-10-01

    The generator for {sup 90}Y production is made up of two units - an extractive unit and a unit for deep purification. Contrary to the well-known methods of {sup 90}Y separation two mineral acids are used in the developed technology. The solutions of nitric acid are used for preliminary separation of {sup 90}Y and the solutions of hydrochloric acid are used for the deep purification of {sup 90}Y from {sup 90}Sr and stripping. The optimum conditions for carrying out this technology were found. The following results are reported: the carry-over of the stationary phase is excluded in this generator; the separation time is 30-60 minutes; the yield of the final product is not less than 95%; impurity of {sup 90}Sr is not more than 10{sup -9-}-{sup -10}%; the content of the chemical (nonactive) impurities is not more than the allowed one for radiopharmaceuticals 4 refs., 4 tabs., 5 figs.

  14. Progress of 90Y generator preparation

    International Nuclear Information System (INIS)

    Yin Bangshun; Li Mingqi; Deng Qimin; Cheng Zuoyong

    2009-01-01

    90 Y is an important radionuclide in radioimmunotherapy. The medical 90 Y is mainly obtained from 90 Y generator through methods of precipitation,coprecipitation, electrodeposition, solvent extraction, chromatography and so on. The progress of 90 Y generator, the advantages and disadvantages of different types of 90 Y generator, and the tendency of 90 Y generator preparation were described respectively. Comprehensive analysis showed that inorganic ion-exchange chromatography will be the main tendency of future 90 Y generator preparation. (authors)

  15. Clinical feasibility of {sup 90}Y digital PET/CT for imaging microsphere biodistribution following radioembolization

    Energy Technology Data Exchange (ETDEWEB)

    Wright, Chadwick L.; Binzel, Katherine; Zhang, Jun; Knopp, Michael V. [The Ohio State University Wexner Medical Center, Wright Center of Innovation in Biomedical Imaging, Department of Radiology, Columbus, OH (United States); Wuthrick, Evan J. [The Ohio State University Wexner Medical Center, Department of Radiation Oncology, Columbus, OH (United States)

    2017-07-15

    The purpose of this study was to evaluate the clinical feasibility of next generation solid-state digital photon counting PET/CT (dPET/CT) technology and imaging findings in patients following {sup 90}Y microsphere radioembolization in comparison with standard of care (SOC) bremsstrahlung SPECT/CT (bSPECT/CT). Five patients underwent SOC {sup 90}Y bremsstrahlung imaging immediately following routine radioembolization with 3.5 ± 1.7 GBq of {sup 90}Y-labeled glass microspheres. All patients also underwent dPET/CT imaging at 29 ± 11 h following radioembolization. Matched pairs comparison was used to compare image quality, image contrast and {sup 90}Y biodistribution between dPET/CT and bSPECT/CT images. Volumetric assessments of {sup 90}Y activity using different isocontour thresholds on dPET/CT and bSPECT/CT images were also compared. Digital PET/CT consistently provided better visual image quality and {sup 90}Y-to-background image contrast while depicting {sup 90}Y biodistribution than bSPECT/CT. Isocontour volumetric assessment using a 1% threshold precisely outlined {sup 90}Y activity and the treatment volume on dPET/CT images, whereas a more restrictive 20% threshold on bSPECT/CT images was needed to obtain comparable treatment volumes. The use of a less restrictive 10% threshold isocontour on bSPECT/CT images grossly overestimated the treatment volume when compared with the 1% threshold on dPET/CT images. Digital PET/CT is clinically feasible for the assessment of {sup 90}Y microsphere biodistribution following radioembolization, and provides better visual image quality and image contrast than routine bSPECT/CT with comparable acquisition times. With further optimization and clinical validation, dPET technology may allow faster and more accurate imaging-based assessment of {sup 90}Y microsphere biodistribution. (orig.)

  16. Monte Carlo simulation of PET and SPECT imaging of {sup 90}Y

    Energy Technology Data Exchange (ETDEWEB)

    Takahashi, Akihiko, E-mail: takahsr@hs.med.kyushu-u.ac.jp; Sasaki, Masayuki [Department of Health Sciences, Faculty of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582 (Japan); Himuro, Kazuhiko; Yamashita, Yasuo; Komiya, Isao [Division of Radiology, Department of Medical Technology, Kyushu University Hospital, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582 (Japan); Baba, Shingo [Department of Clinical Radiology, Kyushu University Hospital, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582 (Japan)

    2015-04-15

    Purpose: Yittrium-90 ({sup 90}Y) is traditionally thought of as a pure beta emitter, and is used in targeted radionuclide therapy, with imaging performed using bremsstrahlung single-photon emission computed tomography (SPECT). However, because {sup 90}Y also emits positrons through internal pair production with a very small branching ratio, positron emission tomography (PET) imaging is also available. Because of the insufficient image quality of {sup 90}Y bremsstrahlung SPECT, PET imaging has been suggested as an alternative. In this paper, the authors present the Monte Carlo-based simulation–reconstruction framework for {sup 90}Y to comprehensively analyze the PET and SPECT imaging techniques and to quantitatively consider the disadvantages associated with them. Methods: Our PET and SPECT simulation modules were developed using Monte Carlo simulation of Electrons and Photons (MCEP), developed by Dr. S. Uehara. PET code (MCEP-PET) generates a sinogram, and reconstructs the tomography image using a time-of-flight ordered subset expectation maximization (TOF-OSEM) algorithm with attenuation compensation. To evaluate MCEP-PET, simulated results of {sup 18}F PET imaging were compared with the experimental results. The results confirmed that MCEP-PET can simulate the experimental results very well. The SPECT code (MCEP-SPECT) models the collimator and NaI detector system, and generates the projection images and projection data. To save the computational time, the authors adopt the prerecorded {sup 90}Y bremsstrahlung photon data calculated by MCEP. The projection data are also reconstructed using the OSEM algorithm. The authors simulated PET and SPECT images of a water phantom containing six hot spheres filled with different concentrations of {sup 90}Y without background activity. The amount of activity was 163 MBq, with an acquisition time of 40 min. Results: The simulated {sup 90}Y-PET image accurately simulated the experimental results. PET image is visually

  17. Beta Bremsstrahlung dose in concrete shielding

    Energy Technology Data Exchange (ETDEWEB)

    Manjunatha, H.C., E-mail: manjunatha@rediffmail.com [Department of Physics, Government college for women, Kolar 563101, Karnataka (India); Chandrika, B.M. [Shravana, 592, Ist Cross, Behind St.Anne s School, PC Extension, Kolar 563101, Karnataka (India); Rudraswamy, B. [Department of Physics, Bangalore University, Bangalore 560056, Karnataka (India); Sankarshan, B.M. [Shravana, 592, Ist Cross, Behind St.Anne s School, PC Extension, Kolar 563101, Karnataka (India)

    2012-05-11

    In a nuclear reactor, beta nuclides are released during nuclear reactions. These betas interact with shielding concrete and produces external Bremsstrahlung (EB) radiation. To estimate Bremsstrahlung dose and shield efficiency in concrete, it is essential to know Bremsstrahlung distribution or spectra. The present work formulated a new method to evaluate the EB spectrum and hence Bremsstrahlung dose of beta nuclides ({sup 32}P, {sup 89}Sr, {sup 90}Sr-{sup 90}Y, {sup 90}Y, {sup 91}Y, {sup 208}Tl, {sup 210}Bi, {sup 234}Pa and {sup 40}K) in concrete. The Bremsstrahlung yield of these beta nuclides in concrete is also estimated. The Bremsstrahlung yield in concrete due to {sup 90}Sr-{sup 90}Y is higher than those of other given nuclides. This estimated spectrum is accurate because it is based on more accurate modified atomic number (Z{sub mod}) and Seltzer's data, where an electron-electron interaction is also included. Presented data in concrete provide a quick and convenient reference for radiation protection. The present methodology can be used to calculate the Bremsstrahlung dose in nuclear shielding materials. It can be quickly employed to give a first pass dose estimate prior to a more detailed experimental study. - Highlights: Black-Right-Pointing-Pointer Betas released in a nuclear reactor interact with shielding concrete and produces Bremsstrahlung. Black-Right-Pointing-Pointer The present work formulated a new method to evaluate the Bremsstrahlung spectrum and dose in concrete. Black-Right-Pointing-Pointer Presented data in concrete provide a quick and convenient reference for radiation protection.

  18. Preparation of 90Sr-90Y generator

    International Nuclear Information System (INIS)

    Jin Xiaohai; Yu Haibin; Zhang Jinming; Zhang Peixin; Lin Qiongfang

    1990-01-01

    In recent years, 90 Y has been considered as one of the best radionuclides for tumor radioimmunotherapy when chelated to tumor-associated antibodies. This evaluation is based on the superior properties of this radionuclide (suitable half-life, pure β-ray emitter of intermediate energy, stable daughters, and suitable chemical properties) and because it is available as a radionuclide generator product by decay of its 28a parent 90 Sr. The experimental conditions of 90 Sr- 90 Y generator are described. The elution efficiency of 90 Sr- 90 Y generator reaches 98%. One of the most important problems is the 90 Sr contamination breakthrough from the generator. The level of 90 Sr contamination must be controlled to the clinical standard. The cation exchange resin 732 (100-150 mesh) was successfully used for the separation of 90 Y from 90 Sr. The method used by the authors provides a 90 Y-HAc solution which is very simple and safe for administration to the patients. 90 Y was separated from 90 Sr almost completely, the level of the 90 Sr contamination per 740 MBq 90 Y product was only 0.74 kBq. However the toxicity of 90 Sr is extremely high, the human life-time permissible dose is 74 kBq, then 740 MBq of 90 Y is allowed to be administrated to a patient for 50-100 times

  19. A gate evaluation of the sources of error in quantitative90 Y PET.

    Science.gov (United States)

    Strydhorst, Jared; Carlier, Thomas; Dieudonné, Arnaud; Conti, Maurizio; Buvat, Irène

    2016-10-01

    Accurate reconstruction of the dose delivered by 90 Y microspheres using a postembolization PET scan would permit the establishment of more accurate dose-response relationships for treatment of hepatocellular carcinoma with 90 Y. However, the quality of the PET data obtained is compromised by several factors, including poor count statistics and a very high random fraction. This work uses Monte Carlo simulations to investigate what impact factors other than low count statistics have on the quantification of 90 Y PET. PET acquisitions of two phantoms-a NEMA PET phantom and the NEMA IEC PET body phantom-containing either 90 Y or 18 F were simulated using gate. Simulated projections were created with subsets of the simulation data allowing the contributions of random, scatter, and LSO background to be independently evaluated. The simulated projections were reconstructed using the commercial software for the simulated scanner, and the quantitative accuracy of the reconstruction and the contrast recovery of the reconstructed images were evaluated. The quantitative accuracy of the 90 Y reconstructions were not strongly influenced by the high random fraction present in the projection data, and the activity concentration was recovered to within 5% of the known value. The contrast recovery measured for simulated 90 Y data was slightly poorer than that for simulated 18 F data with similar count statistics. However, the degradation was not strongly linked to any particular factor. Using a more restricted energy range to reduce the random fraction in the projections had no significant effect. Simulations of 90 Y PET confirm that quantitative 90 Y is achievable with the same approach as that used for 18 F, and that there is likely very little margin for improvement by attempting to model aspects unique to 90 Y, such as the much higher random fraction or the presence of bremsstrahlung in the singles data. © 2016 American Association of Physicists in Medicine.

  20. A GATE evaluation of the sources of error in quantitative {sup 90}Y PET

    Energy Technology Data Exchange (ETDEWEB)

    Strydhorst, Jared, E-mail: jared.strydhorst@gmail.com; Buvat, Irène [IMIV, U1023 Inserm/CEA/Université Paris-Sud and ERL 9218 CNRS, Université Paris-Saclay, CEA/SHFJ, Orsay 91401 (France); Carlier, Thomas [Department of Nuclear Medicine, Centre Hospitalier Universitaire de Nantes and CRCNA, Inserm U892, Nantes 44000 (France); Dieudonné, Arnaud [Department of Nuclear Medicine, Hôpital Beaujon, HUPNVS, APHP and Inserm U1149, Clichy 92110 (France); Conti, Maurizio [Siemens Healthcare Molecular Imaging, Knoxville, Tennessee, 37932 (United States)

    2016-10-15

    Purpose: Accurate reconstruction of the dose delivered by {sup 90}Y microspheres using a postembolization PET scan would permit the establishment of more accurate dose–response relationships for treatment of hepatocellular carcinoma with {sup 90}Y. However, the quality of the PET data obtained is compromised by several factors, including poor count statistics and a very high random fraction. This work uses Monte Carlo simulations to investigate what impact factors other than low count statistics have on the quantification of {sup 90}Y PET. Methods: PET acquisitions of two phantoms—a NEMA PET phantom and the NEMA IEC PET body phantom-containing either {sup 90}Y or {sup 18}F were simulated using GATE. Simulated projections were created with subsets of the simulation data allowing the contributions of random, scatter, and LSO background to be independently evaluated. The simulated projections were reconstructed using the commercial software for the simulated scanner, and the quantitative accuracy of the reconstruction and the contrast recovery of the reconstructed images were evaluated. Results: The quantitative accuracy of the {sup 90}Y reconstructions were not strongly influenced by the high random fraction present in the projection data, and the activity concentration was recovered to within 5% of the known value. The contrast recovery measured for simulated {sup 90}Y data was slightly poorer than that for simulated {sup 18}F data with similar count statistics. However, the degradation was not strongly linked to any particular factor. Using a more restricted energy range to reduce the random fraction in the projections had no significant effect. Conclusions: Simulations of {sup 90}Y PET confirm that quantitative {sup 90}Y is achievable with the same approach as that used for {sup 18}F, and that there is likely very little margin for improvement by attempting to model aspects unique to {sup 90}Y, such as the much higher random fraction or the presence of

  1. Complexation studies with 90Y from a novel 90Sr-90Y generator

    International Nuclear Information System (INIS)

    Venkatesh, M.; Pandey, U.; Banerjee, S.; Samuel, G.; Pillai, M.R.A.; Dhami, P.S.; Kannan, R.; Achuthan, P.V.; Chitnis, R.R.; Gopalakrishnan, V.; Ramanujam, A.

    2001-01-01

    Some features of a novel 90 Sr- 90 Y generator which employs supported liquid membrane (SLM) to separate carrier-free 90 Y from 90 Sr present in the high level waste of the spent fuel of reactor are described. After ascertaining the purity of 90 Y particularly with respect to 90 Sr breakthrough, its complexation was studied with a few oxo/aza donor ligands, such as DTPA, EDTMP, DOTA, TETA and a cyclic phosphonate, CTMP. These studies were primarily carried out to adjudge the quality of the 90 Y obtained from a novel 90 Sr- 90 Y generator and ascertain its usability for labelling biomolecules such as antibodies and peptides. The DOTA complexes are most stable at 37 C in human serum; they appear to be ideal bifunctional chelating agent for use in radioimmunotherapy with 90 Y. (orig.)

  2. Country report: Syria. Development of 90Y/90Sr Generator and 90Y Radiopharmaceuticals

    International Nuclear Information System (INIS)

    Yassine, Taufik; Mukhallalati, Ch. Heyam

    2010-01-01

    The aim of this project is to develop a technique for preparation of 90 Sr- 90 Y generator, we have developed a separation technique for isolation of 90 Y from 90 Sr based on using Sr – Spec resin packed in three columns for separation and purification of 90 Sr- 90 Y .The resulting Y90 is used for therapeutic applications. The first part of this project describe a prototype design for the 90 Sr- 90 Y generator in order to get a very accurate method to obtain the minimum possible 90 Sr Breakthrough. 25 mci of 90 Sr was used in the generator 90 Sr- 90 Y and we obtained the elution yield of 90 Y higher than 88%, Also the eluate was used for preparation of several 90 Y radiopharmaceuticals such as 90 YEDTMP and 90 Y-DOTA-HR 3 . And the work is continues to investigate more radiopharmaceuticals applications in the second part of this project such as 90 Y– FHMA. In this part of the co-coordination research programmer, A protocol based on results of this studies was developed to prepare and operate a higher activity generator (50-100mci), the resulting elution yield was approximately 94% of 90 Y . The elute was used in preparation of new 90 Y radiopharmaceuticals. The monoclonal antibodies is still evolving by conjugate Rituximab to The macrocyclic bifunctional chelating agent,(p-SCN-Bn-DOTA)S-2-(4-Isothiocyanatobenzyle)-1,4,7,10- tetraazacyclododecane-tetraaceticacid to obtain the inmunoconjugate DOTA-Rituximub in simple way and then investigating the radio labeling conditions with 90 Y. (author)

  3. Development of 90Sr-90Y generators

    International Nuclear Information System (INIS)

    Barrio, Graciela

    2007-01-01

    Yttrium-90 is a radioisotope of great interest in the field of Nuclear Medicine. It is considered one of the most important and most used radionuclides for radioimmunotherapeutical applications, especially promising for the treatment of certain types of cancer. Another important application of 90 Y is radio synovectomy. This radionuclide has a half-life of 64 hours, emits long range beta particles (maximum energy of 2.3 MeV) and decays, without intermediate nuclides, to a stable daughter. 90 Y may be obtained carrier-free, generated by the decay of its parent 90 Sr (half-life=28 years). 90 Sr is a product from uranium fission, and due to its long half-life, can be indefinitely used, which is certainly advantageous. It is present in great amounts, and needs to be processed and purified in order to be used as raw material for the generators. Generators of 90 Sr- 90 Y may thus be used during various months, due to 90 Sr long half-life. Several methods for the separation of 90 Y from 90 Sr by solvent extraction and ion exchange have been reported in literature. Thanks to its simplicity, ion exchange techniques have been more commonly used for this generator system. The main objective of this work was to develop a methodology for the preparation of 90 Sr- 90 Y generators, using cationic exchange resins. In such method, 90 Sr is strongly adsorbed in the resin and 90 Y is eluted by a 0.003 M EDTA solution. According to the quality control carried out, results showed that elution yields are greater than 65%, thus confirming the efficiency of the separation method used.

  4. Synovectomy of the knee with 90Y

    International Nuclear Information System (INIS)

    Spooren, P.F.M.J.; Rasker, J.J.; Arens, R.P.J.H.; Ziekenhuis Ziekenzorg, Enschede

    1985-01-01

    In 33 patients with chronic arthritis of the knee, 48 knees were treated with an intra-articular injection of 5 mCi yttrium silicate 90 Y. There were 27 patients with rheumatoid arthritis (RA) and 6 with osteoarthrosis (OA); the mean follow-up period was 33 months. At clinical investigation after 1 year, no signs of pain or swelling were found in 15 knees. In most cases, pain and swelling improved subjectively, with a mean duration of 11 months; in 20 knees, the improvement lasted more than 22 months. When radiographs showed severse destruction, 90 Y treatment was unsuccessful, but an important new finding was that most patients with mild or moderate radiological abormalities appeared to have a long-lasting improvement. The result did not correlate with erythrocyte sedimentation rate (ESR), haemoglobin or Rose titre at the time of injection or at follow up, suggesting that the result of the treatment is more dependent on local factors than on the disease activity. The results of 90 Y treatment in 6 OA knees with persistent swelling were promising regarding swelling, even in patients with moderate radiological abnormalities. The main side-effect was a sometimes painful swelling of the knee, which was always successfully treated with an intra-articular corticosteroid injection. In 90 Y-treated knees, the incidence of unstable joints was not significantly higher than in non-treated knees. In conclusion, 90 Y synovectomy may be a succesful treatment for patients older than 50 years with chronic arthritis of the knee due to RA and probably also OA, even when moderate radiological abnormalities are present. (orig.)

  5. Radioembolization and the dynamic role of 90Y PET/CT

    Directory of Open Access Journals (Sweden)

    Alexander S Pasciak

    2014-02-01

    Full Text Available Before the advent of tomographic imaging, it was postulated that decay of 90Y to the 0+ excited state of 90Zr may result in emission of a positron-electron pair. While the branching ratio for pair production is small (~32x10-6, PET has been successfully used to image 90Y in numerous recent patient and phantom studies. 90Y PET imaging has been performed on a variety of PET/CT systems, with and without time-of-flight (TOF and/or resolution recovery capabilities as well as on both BGO and L(YSO based scanners. On all systems, resolution and contrast superior to bremsstrahlung SPECT has been reported. The intrinsic radioactivity present in L(YSO-based PET scanners is a potential limitation associated with accurate quantification of 90Y. However, intrinsic radioactivity has been shown to have a negligible effect at the high activity concentrations common in 90Y radioembolization. Accurate quantification is possible on a variety of PET scanner models, with or without TOF, although TOF improves accuracy at lower activity concentrations. Quantitative 90Y PET images can be transformed into 3D maps of absorbed dose based on the premise that the 90Y activity distribution does not change after infusion. This transformation has been accomplished primarily with the use of 3D dose point-kernel convolution. From a clinical standpoint, 90Y PET provides a superior post-infusion evaluation of treatment technical success owing to its improved resolution. Absorbed dose maps generated from quantitative PET data can be used to predict treatment efficacy and manage patient follow-up. For patients who receive multiple treatments, this information can also be used to provide patient-specific treatment planning for successive therapies, potentially improving response. The broad utilization of 90Y PET has the potential to provide a wealth of dose-response information, which may lead to development of improved radioembolization treatment-planning models in the future.

  6. Polarization Bremsstrahlung

    CERN Document Server

    Korol, Andrey V

    2014-01-01

    This book introduces and reviews both theory and applications of polarizational bremsstrahlung, i.e. the electromagnetic radiation emitted during collisions of charged particles with structured, thus polarizable targets, such as atoms, molecules and clusters.   The subject, following the first experimental evidence a few decades ago, has gained importance through a number of modern applications.  Thus, the study of several radiative mechanisms is expected to lead to the design of novel light sources, operating in various parts of the electromagnetic spectrum. Conversely, the analysis of the spectral and angular distribution of the photon emission constitutes a new tool for extracting information on the interaction of the colliding particles, and on their internal structure and dynamical properties.   Last but not least, accurate quantitative descriptions of the photon emission processes determine the radiative energy losses of particles in various media, thereby providing essential  information required f...

  7. The origin and reduction of spurious extrahepatic counts observed in 90Y non-TOF PET imaging post radioembolization

    Science.gov (United States)

    Walrand, Stephan; Hesse, Michel; Jamar, François; Lhommel, Renaud

    2018-04-01

    Our literature survey revealed a physical effect unknown to the nuclear medicine community, i.e. internal bremsstrahlung emission, and also the existence of long energy resolution tails in crystal scintillation. None of these effects has ever been modelled in PET Monte Carlo (MC) simulations. This study investigates whether these two effects could be at the origin of two unexplained observations in 90Y imaging by PET: the increasing tails in the radial profile of true coincidences, and the presence of spurious extrahepatic counts post radioembolization in non-TOF PET and their absence in TOF PET. These spurious extrahepatic counts hamper the microsphere delivery check in liver radioembolization. An acquisition of a 32P vial was performed on a GSO PET system. This is the ideal setup to study the impact of bremsstrahlung x-rays on the true coincidence rate when no positron emission and no crystal radioactivity are present. A MC simulation of the acquisition was performed using Gate-Geant4. MC simulations of non-TOF PET and TOF-PET imaging of a synthetic 90Y human liver radioembolization phantom were also performed. Internal bremsstrahlung and long energy resolution tails inclusion in MC simulations quantitatively predict the increasing tails in the radial profile. In addition, internal bremsstrahlung explains the discrepancy previously observed in bremsstrahlung SPECT between the measure of the 90Y bremsstrahlung spectrum and its simulation with Gate-Geant4. However the spurious extrahepatic counts in non-TOF PET mainly result from the failure of conventional random correction methods in such low count rate studies and poor robustness versus emission-transmission inconsistency. A novel proposed random correction method succeeds in cleaning the spurious extrahepatic counts in non-TOF PET. Two physical effects not considered up to now in nuclear medicine were identified to be at the origin of the unusual 90Y true coincidences radial profile. TOF reconstruction removing

  8. Beta radiation exposure of staff during and after therapies with 90Y-labelled substances

    International Nuclear Information System (INIS)

    Rimpler, A.; Barth, I.; Baum, R. B.; Senftleben, S.; Geworski, L.

    2008-01-01

    Radio-immuno-therapies (RITs) and peptide receptor radio-therapies (PRRTs) with 90 Y-labelled compounds offer promising prospects for tumor treatment in nuclear medicine. However, when preparing and performing these therapies, which require manipulations of high activities of 90 Y (>1 GBq), technicians and physicians may receive high exposures, mainly to the skin of the hands. Even non-occupationally exposed persons, such as caregivers and family members, receive external exposures in the initial period after therapy, arising from the 90 Y in the patient. The local skin doses of the individual staff members, measured during RITs and PRRTs with thermoluminescence detectors fixed with tapes to the fingers, vary considerably. The exposure of staff can exceed the annual permissible dose limit of 500 mSv if radiation protection standards are low. Thus, adequate safety measures are needed. Measurements of the dose rate around patients, made using survey meters with sufficient response to beta particles, indicate that the exposure of caregivers and family members is considerably higher than previously assumed, and was dominated by primary beta radiation instead of Bremsstrahlung. Nevertheless, under normal circumstances, the annual dose limits for the public (effective dose: 1 mSv, skin dose: 50 mSv) will be complied with. (authors)

  9. Proton-proton bremsstrahlung

    International Nuclear Information System (INIS)

    Fearing, H.W.

    1990-01-01

    We summarize some of the information about the nucleon-nucleon force which has been obtained by comparing recent calculations of proton-proton bremsstrahlung with cross section and analyzing power data from the new TRIUMF bremsstrahlung experiment. Some comments are made as to how these results can be extended to neutron-proton bremsstrahlung. (Author) 17 refs., 6 figs

  10. 90Y of high purity for medical applications

    International Nuclear Information System (INIS)

    Castillo, A.X.; Alvarez, E.O.; Olive, K.I.

    2001-01-01

    Several 90 Sr/ 90 Y-generator systems have been developed and used to produce 90 Y. The most important parameter of the 90 Y to be assayed is 90 Sr content. In addition, when labelling monoclonal antibodies for therapy trace metal quantities accompanying 90 Y (Fe 3+ , Zn 2+ , Cu 2+ , ZrO 2+ , etc.) are to be kept as low as possible in order to obtain high labelling efficiencies. Generally generators' lifetime is limited due to the 90 Sr breakthrough which increases in eluates as a result of the radiolytic degradation of the resin used as support. In the study a described procedure for 90 Y purification from metal contamination is modified in order to lower the amount of 90 Sr present in eluates from generators. As a result a very low 90 Sr content is always assured ( 90 Sr/ 90 Y -6 ). (author)

  11. PET optimization for improved assessment and accurate quantification of {sup 90}Y-microsphere biodistribution after radioembolization

    Energy Technology Data Exchange (ETDEWEB)

    Martí-Climent, Josep M., E-mail: jmmartic@unav.es; Prieto, Elena; Elosúa, César; Rodríguez-Fraile, Macarena; Domínguez-Prado, Inés; Vigil, Carmen; García-Velloso, María J.; Arbizu, Javier; Peñuelas, Iván; Richter, José A. [Nuclear Medicine Department, Clínica Universidad de Navarra, 36, Pío XII Avenue, 31008 Pamplona (Spain)

    2014-09-15

    Purpose: {sup 90}Y-microspheres are widely used for the radioembolization of metastatic liver cancer or hepatocellular carcinoma and there is a growing interest for imaging {sup 90}Y-microspheres with PET. The aim of this study is to evaluate the performance of a current generation PET/CT scanner for {sup 90}Y imaging and to optimize the PET protocol to improve the assessment and the quantification of {sup 90}Y-microsphere biodistribution after radioembolization. Methods: Data were acquired on a Biograph mCT-TrueV scanner with time of flight (TOF) and point spread function (PSF) modeling. Spatial resolution was measured with a{sup 90}Y point source. Sensitivity was evaluated using the NEMA 70 cm line source filled with {sup 90}Y. To evaluate the count rate performance, {sup 90}Y vials with activity ranging from 3.64 to 0.035 GBq were measured in the center of the field of view (CFOV). The energy spectrum was evaluated. Image quality with different reconstructions was studied using the Jaszczak phantom containing six hollow spheres (diameters: 31.3, 28.1, 21.8, 16.1, 13.3, and 10.5 mm), filled with a 207 kBq/ml {sup 90}Y concentration and a 5:1 sphere-to-background ratio. Acquisition time was adjusted to simulate the quality of a realistic clinical PET acquisition of a patient treated with SIR-Spheres{sup ®}. The developed methodology was applied to ten patients after SIR-Spheres{sup ®} treatment acquiring a 10 min per bed PET. Results: The energy spectrum showed the{sup 90}Y bremsstrahlung radiation. The {sup 90}Y transverse resolution, with filtered backprojection reconstruction, was 4.5 mm in the CFOV and degraded to 5.0 mm at 10 cm off-axis. {sup 90}Y absolute sensitivity was 0.40 kcps/MBq in the center of the field of view. Tendency of true and random rates as a function of the {sup 90}Y activity could be accurately described using linear and quadratic models, respectively. Phantom studies demonstrated that, due to low count statistics in {sup 90}Y PET

  12. Development of activity standard for 90Y microspheres

    CSIR Research Space (South Africa)

    Mo, L

    2005-08-01

    Full Text Available 90Y is a therapeutic radiopharmaceuticals used in the treatment of liver cancer following implantation via a catheter in the hepatic artery, 90Y microspheres are embolised in the microvasculature of liver cancer where they irradiate the tumour by a...

  13. Development of an electrochemical 90Sr-90Y generator for separation of 90Y suitable for targeted therapy

    International Nuclear Information System (INIS)

    Chakravarty, Rubel; Pandey, Usha; Manolkar, Remani B.; Dash, Ashutosh; Venkatesh, Meera; Pillai, M.R. Ambikalmajan

    2008-01-01

    90 Y of high specific activity and very high radionuclidic purity (>99.998%) is essential for targeted therapy. Since the current methods used for the preparation of 90 Y from 90 Sr are not adaptable for use in a central/hospital radiopharmacy, a simple 90 Sr- 90 Y generator system based on electrochemical separation technique was developed. Methods: Two-cycle electrolysis procedure was developed for separation of 90 Y from 90 Sr in nitrate solution. The first electrolysis was performed for 90 min in 90 Sr(NO 3 ) 2 feed solution at pH 2-3 at a potential of -2.5V with 100-200 mA current using platinum electrodes. The second electrolysis was performed for 45 min in 3 mM HNO 3 at a potential of -2.5V with 100 mA current. In this step, the cathode from the first electrolysis containing 90 Y was used as anode along with a fresh circular platinum electrode as cathode. The 90 Y deposited on the circular cathode after the second electrolysis was dissolved in acetate buffer to obtain 90 Y acetate, suitable for radiolabeling. Results: >96% recovery of 90 Y could be achieved in each cycle, with an overall decay corrected yield of >90%. The recovered 90 Y had high radionuclidic purity with barely 30.2±15.2 kBq (817±411 nCi) of 90 Sr per 37 GBq (1 Ci) of 90 Y (0.817±0.411 ppm). Consistent and repeated separation could be demonstrated using up to 1.85 GBq (50 mCi) of 90 Sr. The generator was named 'Kamadhenu,' the eternally milk-yielding Indian mythological cow. Conclusions: A technique suitable for adaptation at central radiopharmacies for obtaining therapeutic quantities of pure 90 Y has been developed

  14. Country report: Syria. Development of {sup 90}Y/{sup 90}Sr Generator and {sup 90}Y Radiopharmaceuticals

    Energy Technology Data Exchange (ETDEWEB)

    Yassine, Taufik; Mukhallalati, Ch. Heyam, E-mail: atomic@aec.org.sy [Atomic Energy Commission of Syria, Damascus (Syrian Arab Republic)

    2010-07-01

    The aim of this project is to develop a technique for preparation of {sup 90}Sr-{sup 90}Y generator, we have developed a separation technique for isolation of {sup 90}Y from {sup 90}Sr based on using Sr – Spec resin packed in three columns for separation and purification of {sup 90}Sr-{sup 90}Y .The resulting Y90 is used for therapeutic applications. The first part of this project describe a prototype design for the {sup 90}Sr- {sup 90}Y generator in order to get a very accurate method to obtain the minimum possible {sup 90}Sr Breakthrough. 25 mci of {sup 90}Sr was used in the generator {sup 90}Sr-{sup 90}Y and we obtained the elution yield of {sup 90}Y higher than 88%, Also the eluate was used for preparation of several {sup 90}Y radiopharmaceuticals such as {sup 90}YEDTMP and {sup 90}Y-DOTA-HR{sub 3}. And the work is continues to investigate more radiopharmaceuticals applications in the second part of this project such as {sup 90}Y– FHMA. In this part of the co-coordination research programmer, A protocol based on results of this studies was developed to prepare and operate a higher activity generator (50-100mci), the resulting elution yield was approximately 94% of {sup 90}Y . The elute was used in preparation of new {sup 90}Y radiopharmaceuticals. The monoclonal antibodies is still evolving by conjugate Rituximab to The macrocyclic bifunctional chelating agent,(p-SCN-Bn-DOTA)S-2-(4-Isothiocyanatobenzyle)-1,4,7,10- tetraazacyclododecane-tetraaceticacid to obtain the inmunoconjugate DOTA-Rituximub in simple way and then investigating the radio labeling conditions with {sup 90}Y. (author)

  15. Labeling of monoclonal antibody conjugates with 90Y

    International Nuclear Information System (INIS)

    Motta-Hennessy, Cecilia; Sharkey, R.M.; Goldenberg, D.M.

    1991-01-01

    An anti-carcinoembryonic antigen (CEA) antibody, NP-4, was labeled with 90 Y using p-isothiocyanatobenzyl DTPA (SCN-Bz-DTPA) and its derivatives 1-(p-isothiocyanatobenzyl)-3-methyl-DTPA (1B3M), 2-(p-isothiocyanatobenzyl)-4-methyl-DTPA (1M3B), 1-(2)-methyl-4-isothiocyanatobenzyl-DTPA (MX-DTPA) as the chelating agents. The 90 Y conjugates were purified from unbound 90 Y by two different methods, HPLC or acrylamide size exclusion gel chromatography, in order to evaluate the best purification method. Labeling efficiency, reaction kinetics and immunoreactivity were compared to the same antibodies labeled with [ 111 In]citrate. Labeling efficiency, as determined by either HPLC or ITLC (instant thin layer chromatography), was consistently higher by ITLC than HPLC for 90 Y-labeled MAb, but equal for 111 In-labeled MAbs. Discrepancies between the 2 methods were linked to impurities in the 90 Y that remained at the origin of ITLC plates. After purification by acrylamide gel filtration, recovery was 50-60% of loaded 90 Y activity, but was more than 87% for the 111 In compounds. Using HPLC, the recovery measured 85% for 90 Y-labeled MAb and more than 93% for 111 In-labeled conjugates. Immunoreactivity of the [ 90 Y]MAb was comparable to the 111 In-labeled conjugates. These studies indicate that HPLC purification of the [ 90 Y] MAbs improves recovery of activity, and suggests that impurities found in the 90 Y and metal-binding properties of acrylamide may have contributed to the poor recoveries from acrylamide gels. (author)

  16. Labeling of monoclonal antibody conjugates with sup 90 Y

    Energy Technology Data Exchange (ETDEWEB)

    Motta-Hennessy, Cecilia; Sharkey, R.M.; Goldenberg, D.M. (Center for Molecular Medicine and Immunology, Newark, NJ (USA))

    1991-01-01

    An anti-carcinoembryonic antigen (CEA) antibody, NP-4, was labeled with {sup 90}Y using p-isothiocyanatobenzyl DTPA (SCN-Bz-DTPA) and its derivatives 1-(p-isothiocyanatobenzyl)-3-methyl-DTPA (1B3M), 2-(p-isothiocyanatobenzyl)-4-methyl-DTPA (1M3B), 1-(2)-methyl-4-isothiocyanatobenzyl-DTPA (MX-DTPA) as the chelating agents. The {sup 90}Y conjugates were purified from unbound {sup 90}Y by two different methods, HPLC or acrylamide size exclusion gel chromatography, in order to evaluate the best purification method. Labeling efficiency, reaction kinetics and immunoreactivity were compared to the same antibodies labeled with ({sup 111}In)citrate. Labeling efficiency, as determined by either HPLC or ITLC (instant thin layer chromatography), was consistently higher by ITLC than HPLC for {sup 90}Y-labeled MAb, but equal for {sup 111}In-labeled MAbs. Discrepancies between the 2 methods were linked to impurities in the {sup 90}Y that remained at the origin of ITLC plates. After purification by acrylamide gel filtration, recovery was 50-60% of loaded {sup 90}Y activity, but was more than 87% for the {sup 111}In compounds. Using HPLC, the recovery measured 85% for {sup 90}Y-labeled MAb and more than 93% for {sup 111}In-labeled conjugates. Immunoreactivity of the ({sup 90}Y)MAb was comparable to the {sup 111}In-labeled conjugates. These studies indicate that HPLC purification of the ({sup 90}Y) MAbs improves recovery of activity, and suggests that impurities found in the {sup 90}Y and metal-binding properties of acrylamide may have contributed to the poor recoveries from acrylamide gels. (author).

  17. Pion-proton bremsstrahlung

    International Nuclear Information System (INIS)

    Liou, M.K.; Nutt, W.T.

    1978-01-01

    A method for applying the soft-photon theorem to bremsstrahlung is described and a detailed derivation of the formulae for π + -p bremsstrahlung is presented. The consistent treatment of the expansion of the bremsstrahlung cross-section around k=0 results in excellent fits to the experimental data. The data are consistent with small off-shell effects and no radiation from the Δ(1236) resonance

  18. Treatment of pains from bone metastases with 90Y

    International Nuclear Information System (INIS)

    Kutzner, J.; Daehnert, W.; Schreyer, T.; Grimm, W.; Brod, K.H.; Becker, M.

    1981-01-01

    For palliation of pain caused by bone metastases beta radiation isotope therapy was successful. As shown in experimental work on animals bone uptake of 90 Y with its shorter half-life is high when it is administered as a citrate complex. 90 Y can be eluted with high purity from a 90 Sr cow. The retention in man was found by whole-body counting to be higher than 80%. In preliminary trials on 16 patients the analgetic effect was the same as that of 89 Sr. The properties of 90 Y therapy are discussed. (orig.) [de

  19. Beta Emission and Bremsstrahlung

    Energy Technology Data Exchange (ETDEWEB)

    Karpius, Peter Joseph [Los Alamos National Lab. (LANL), Los Alamos, NM (United States)

    2017-11-13

    Bremsstrahlung is continuous radiation produced by beta particles decelerating in matter; different beta emitters have different endpoint energies; high-energy betas interacting with high-Z materials will more likely produce bremsstrahlung; depending on the data, sometimes all you can say is that a beta emitter is present.

  20. Bremsstrahlung and neutral currents

    International Nuclear Information System (INIS)

    Ellis, R.G.; McKellar, B.H.J.

    1979-01-01

    The utility of the bremsstrahlung process in detecting parity violations from V-A weak neutral current interference is analysed in two ways. Firstly, bremsstrahlung from polarized lepton-nucleus scattering has an asymmetry with respect to the polarization of the incident leptons, and secondly, bremsstrahlung from unpolarized lepton nucleus scattering has a small circular polarization. The magnitude of each effect is calculated. The ratio of the parity violating contribution and the parity conserving contribution to the cross section is shown to be a misleading measure of the utility of these experiments. A parameter, the figure of merit, is introduced and used to discuss the feasibility of possible experiments

  1. Preparation & in vitro evaluation of 90Y-DOTA-rituximab

    Science.gov (United States)

    Kameswaran, Mythili; Pandey, Usha; Dash, Ashutosh; Samuel, Grace; Venkatesh, Meera

    2016-01-01

    Background & objectives: Radioimmunotherapy is extensively being used for the treatment of non-Hodgkin's lymphoma (NHL). Use of rituximab, a chimeric anti-CD20 antibody directed against the CD20 antigen in combination with suitable beta emitters is expected to result in good treatment response by its cross-fire and bystander effects. The present work involves the conjugation of p-isothiocyanatobenzyl DOTA (p-SCN-Bn-DOTA) to rituximab, its radiolabelling with 90Y and in vitro and in vivo evaluation to determine its potential as a radioimmunotherapeutic agent. Methods: Rituximab was conjugated with p-SCN-Bn-DOTA at 1:1 antibody: DOTA molar ratio. The number of DOTA molecules linked to one molecule of rituximab was determined by radioassay and spectroscopic assay. Radiolabelling of rituximab with 90Y was carried out and its in vitro stability was evaluated. In vitro cell binding studies were carried out in Raji cells expressing CD20 antigen. Biodistribution studies were carried out in normal Swiss mice. Results: Using both radioassay and spectroscopic method, it was determined that about five molecules of DOTA were linked to rituximab. Radiolabelling of the rituximab conjugate with 90Y and subsequent purification on PD-10 column gave a product with radiochemical purity (RCP) > 98 per cent which was retained at > 90 per cent up to 72 h when stored at 37°C. In vitro cell binding experiments of 90Y-DOTA-rituximab with Raji cells exhibited specific binding of 20.7 ± 0.1 per cent with 90Y-DOTA-rituximab which reduced to 15.5 ± 0.2 per cent when incubated with cold rituximab. The equilibrium constant Kd for 90Y-DOTA-Rituximab was determined to be 3.38 nM. Radiolabelled antibody showed clearance via hepatobiliary and renal routes and activity in tibia was found to be quite low indicating in vivo stability of 90Y-DOTA-rituximab. Interpretation & conclusions: p-SCN-Bn-DOTA was conjugated with rituximab and radiolabelling with 90Y was carried out. In vitro studies carried

  2. Radiolabeling oligo nuclieotide with 90Y and its radiolysis

    International Nuclear Information System (INIS)

    Liu Changbin; Tian Jiahe; Zhang Jinming; Yin Dayi; Guo Zhe

    2005-01-01

    Objective: To evaluate labeling Morpholinos (MORF), a DNA analogue, with 90 Y using p-isothiocyanatobenzyl-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) as chelater and assess its stability and hybridization in vitro. Methods: A 25 mer MORF with a primary amine on the 3' equivalent end attached via a 10 member linker was conjugated with an isothiocyanate backbone derivative of DOTA. The conjugated product was labeled in various buffers over a different range of concentrations (0.5-2 mol/L) and pH(3-8.5). The labeled MORF was investigated for stability and hybridization in vitro. Results: By size exclusion high performance liquid chromatogram (HPLC) and instant thin layer chromatography (ITLC) analysis, the DOTA conjugated MORF was successfully radiolabeled, the labeling efficiency was (50 ± 12)%, the specific radioactivity was 5.05 x 10 6 MBq/mmol, radiochemistry purity >95%. The labeled MORF showed one sharp peak by HPLC that shifted completely to earlier retention times following addition of a polymer conjugated with the complementary MORF. In saline at room temperature and in serum at 37 degree C, the radioactivity profile of 90 Y showed a pronounced lower molecular weight peak which did not shifted and was shown due to 90 Y-DOTA resulting from radiolysis. Conclusion: MORF can be successfully labeled with 90 Y via DOTA as chelater, but care it must be taken to avoid the effect of radiolysis. (authors)

  3. Electron - atom bremsstrahlung

    International Nuclear Information System (INIS)

    Kim, L.

    1986-01-01

    Features of bremsstrahlung radiation from neutral atoms and atoms in hot dense plasmas are studied. Predictions for the distributions of electron-atom bremsstrahlung radiation for both the point-Coulomb potential and screened potentials are obtained using a classical numerical method. Results agree with exact quantum-mechanical partial-wave results for low incident electron energies in both the point-Coulomb and screened potentials. In the screened potential, the asymmetry parameter of a spectrum is reduced from the Coulomb values. The difference increases with decreasing energy and begins to oscillate at very low energies. The scaling properties of bremsstrahlung spectra and energy losses were also studied. It was found that the ratio of the radiative energy loss for positrons to that for electrons obeys a simple scaling law, being expressible fairly accurately as a function only of the quantity T 1 /Z 2 . This scaling is exact in the case of the point-Coulomb potential, both for classical bremsstrahlung and for the nonrelativistic dipole Sommerfeld formula. Bremsstrahlung from atoms in hot dense plasmas were also studied describing the atomic potentials by the temperature-and-density dependent Thomas-Fermi mode. Gaunt factors were obtained with the relativistic partial-wave method for atoms in plasmas of various densities and temperatures

  4. Verification dosimetry of intravascular 90Sr/90Y source trains

    International Nuclear Information System (INIS)

    Sharma, S.D.; Shanta, A.; Tripathi, U.B.; Bhatt, B.C.

    2001-01-01

    90 Sr/ 90 Y source trains (Novoste Beta-Cath System) are currently under clinical trials in India and abroad for intracoronary brachytherapy for prevention of restenosis. Each source train of the Beta-Cath system is supplied with a source certificate giving dose rate at the reference distance of 2 mm from the centerline of the source train. It is essential that the user should check dose rates of brachytherapy sources before its application on the patients. Dose rates and depth dose measurements for 90 Sr/ 90 Y source trains of active length 40 mm using radiochromic films in a tissue equivalent phantom have been carried out. The objectives of these measurements were (1) to verify the dose rates stated in the source certificate, and (2) to obtain relative depth dose data for treatment planning. This paper presents the results of these measurements

  5. Resin 90Y microsphere activity measurements for liver brachytherapy

    International Nuclear Information System (INIS)

    Dezarn, William A.; Kennedy, Andrew S.

    2007-01-01

    The measurement of the radioactivity administered to the patient is one of the major components of 90 Y microsphere liver brachytherapy. The activity of 90 Y microspheres in a glass delivery vial was measured in a dose calibrator. The calibration value to use for 90 Y in the dose calibrator was verified using an activity calibration standard provided by the microsphere manufacturer. This method allowed for the determination of a consistent, reproducible local activity standard. Additional measurements were made to determine some of the factors that could affect activity measurement. The axial response of the dose calibrator was determined by the ratio of activity measurements at the bottom and center of the dose calibrator. The axial response was 0.964 for a glass shipping vial, 1.001 for a glass V-vial, and 0.988 for a polycarbonate V-vial. Comparisons between activity measurements in the dose calibrator and those using a radiation survey meter were found to agree within 10%. It was determined that the dose calibrator method was superior to the survey meter method because the former allowed better defined measurement geometry and traceability of the activity standard back to the manufacturer. Part of the preparation of resin 90 Y microspheres for patient delivery is to draw out a predetermined activity from a shipping vial and place it into a V-vial for delivery to the patient. If the drawn activity was placed in a glass V-vial, the activity measured in the dose calibrator with a glass V-vial was 4% higher than the drawn activity from the shipping vial standard. If the drawn activity was placed in a polycarbonate V-vial, the activity measured in the dose calibrator with a polycarbonate V-vial activity was 20% higher than the drawn activity from the shipping vial standard. Careful characterization of the local activity measurement standard is recommended instead of simply accepting the calibration value of the dose calibrator manufacturer

  6. The Cherenkov Bremsstrahlung

    International Nuclear Information System (INIS)

    Strel'tsov, V.N.

    1995-01-01

    The vanishing of the 'retardation factor' leads to a significant growth of the intensity of the electromagnetic field 'velocity part' of the moving charge. The Cherenkov radiation is its physical consequence. The same reason also conditions the growth of another term: the 'acceleration part' of the field which gives rise to the 'Cherenkov Bremsstrahlung'. 4 refs

  7. Polarization of Bremsstrahlung

    International Nuclear Information System (INIS)

    Miller, J.

    1957-01-01

    The numerical results for the polarization of Bremsstrahlung are presented. The multiple scattering of electrons in the target is taken into account. The angular-and photon energy dependences are seen on the curves for an incident 25 MeV electron energy. (Author) [fr

  8. A collimator optimization method for quantitative imaging: application to Y-90 bremsstrahlung SPECT.

    Science.gov (United States)

    Rong, Xing; Frey, Eric C

    2013-08-01

    Post-therapy quantitative 90Y bremsstrahlung single photon emission computed tomography (SPECT) has shown great potential to provide reliable activity estimates, which are essential for dose verification. Typically 90Y imaging is performed with high- or medium-energy collimators. However, the energy spectrum of 90Y bremsstrahlung photons is substantially different than typical for these collimators. In addition, dosimetry requires quantitative images, and collimators are not typically optimized for such tasks. Optimizing a collimator for 90Y imaging is both novel and potentially important. Conventional optimization methods are not appropriate for 90Y bremsstrahlung photons, which have a continuous and broad energy distribution. In this work, the authors developed a parallel-hole collimator optimization method for quantitative tasks that is particularly applicable to radionuclides with complex emission energy spectra. The authors applied the proposed method to develop an optimal collimator for quantitative 90Y bremsstrahlung SPECT in the context of microsphere radioembolization. To account for the effects of the collimator on both the bias and the variance of the activity estimates, the authors used the root mean squared error (RMSE) of the volume of interest activity estimates as the figure of merit (FOM). In the FOM, the bias due to the null space of the image formation process was taken in account. The RMSE was weighted by the inverse mass to reflect the application to dosimetry; for a different application, more relevant weighting could easily be adopted. The authors proposed a parameterization for the collimator that facilitates the incorporation of the important factors (geometric sensitivity, geometric resolution, and septal penetration fraction) determining collimator performance, while keeping the number of free parameters describing the collimator small (i.e., two parameters). To make the optimization results for quantitative 90Y bremsstrahlung SPECT more

  9. {sup 90}Y Production and Its Biodistribution in Mice; Pembuatan {sup 90}Y dan Biodistribusinya ke Mencit

    Energy Technology Data Exchange (ETDEWEB)

    Tri-Murni,; Cahyana,; Triyanto,; Djoharly,; Abidin,; Dede-K,; Karyadi, [Center for Development of Radioisotope and Radiopharmacentical(Indonesia)

    2001-11-15

    Yttrium - 90 is radioisotope emitting pure {beta} with maximum energy of 2.27 MeV while its average {beta} energy is 0.93 MeV. {sup 90}Y radioisotope was produced utilizing G.A Siwabessy reactor employing thermal neutron capture process. In nuclear medicine this radioisotope is utilized for bone mettastase palliative and curative therapies. Parameters in this research were the weight of natural Y{sub 2}O{sub 3} target, irradiation time in the reactor, radiochemical purity and specific activity. The end product of the process is YCl{sub 3}, in saline solution. Then sterility of the {sup 90}Y radioisotope so produced is tested and its biodistribution analysis results in mice organs show that the percentage of this radioisotope in the liver is much higher than the ones in heart, kidneys, lung and intestine. Therefore it is concluded that {sup 90}Y radioisotope in the form of YCl{sub 3} can be utilized as a radiopharmaceutical in nuclear medicine. (author)

  10. Neutron-proton bremsstrahlung experiments

    Energy Technology Data Exchange (ETDEWEB)

    Koster, J.E. (Los Alamos National Lab., NM (United States)); Nelson, R.O. (Los Alamos National Lab., NM (United States)); Schillaci, M.E. (Los Alamos National Lab., NM (United States)); Wender, S.A. (Los Alamos National Lab., NM (United States)); Mayo, D. (Univ. of California at Davis, CA (United States)); Brady, F.P. (Univ. of California at Davis, CA (United States)); Romero, J. (Univ. of California at Davis, CA (United States)); Krofcheck, D. (Lawrence Livermore National Lab., CA (United States)); Blann, M. (Lawrence Livermore National Lab., CA (United States)); Anthony, P. (Lawrence Livermore National Lab., CA (United States)); Brown, V.R. (Lawrence Livermore National Lab., CA (United States)); Hansen, L. (Lawrence Livermore National Lab., CA (United States)); Pohl, B. (Lawrence Livermore National Lab., CA (United States)); Sangster, T.C. (Lawrence Livermore National Lab., CA (United States)); Nifenecker, H. (Inst. des Sciences Nucleaires, Grenoble (France)); Pinston,

    1993-06-01

    It is well known that charged particles emit bremsstrahlung radiation when they are accelerated. Classical electron bremsstrahlung occurs when a proton is emitted by an electron accelerated in the field of a nucleus. The bremsstrahlung process also occurs in the scattering of nucleons, for which it is the lowest energy inelastic process that can occur. Like electron bremsstrahlung, nucleon-nucleon bremsstrahlung also requires the exchange of a virtual particle to conserve energy and momentum. In electron bremsstrahlung a virtual photon is exchanged but with two nucleons a meson can be exchanged. Unlike electron bremsstrahlung, in nucleon-nucleon bremsstrahlung the photon can originate from the exchanged meson. This exchange contribution has been shown in calculations to be a significant fraction of bremsstrahlung events. Thus bremsstrahlung serves as a probe of exchange currents in the nucleon-nucleon interaction. Because of a lack of a free neutron target or an intense neutron beam, few measurements of neutron-proton bremsstrahlung exist, each having poor statistical accuracy and poor energy resolution. The white neutron source at the Weapons Neutron Research (WNR) target area at the Los Alamos Meson Physics Facility (LAMPF) produces neutrons with energies from below 50 to above 400 MeV. Using time-of-flight techniques and a liquid hydrogen target, we are measuring the outgoing photons of energies up to 250 MeV at gamma ray angles of around 90 relative to the incident beam. Protons scattered at very forward angles are also detected in coincidence with the gamma rays. (orig.)

  11. Radiolabeling, characterization and preliminary studies of 90Y-octreotate

    International Nuclear Information System (INIS)

    Klementyeva, O.E.; Bruskin, A.B.; Larenkov, A.A.; Kodina, G.E.; Korsunsky, V.N.

    2015-01-01

    Full text of publication follows. Introduction: Overexpression of the somatostatin receptors in neuroendocrine tumors has become the molecular basis for the use of somatostatin analogues in diagnosis and therapy for these neoplasms. The high energy (maximum 2.2 MeV) and penetration range (R 95 5.7 mm) of β-particles from 90 Y are advantageous, with a direct killing of somatostatin receptor positive cells and a crossfire effect which hits nearby receptor-negative tumour cells [Ref. 1]. Aim: the investigation of the reaction conditions for the preparation of 90 Y-Octreotate and its in vitro characterization. Materials and methods: DOTA-Octreotate (Farm-Syntez Ltd.) and 88 YCl 3 (V/O Isotop) were used without purification. 88 Y-Octreotate was prepared in acetate buffer solution and its radiochemical purity was controlled by ITLC. In-vitro experiments were carried out with melanoma B16. Studies of internalization were performed as described in [Ref. 2]. Results: the maximal accumulation in the cells was observed after 90 min from the beginning of incubation and was about 3.9%. In our experiments, we found high level of internalization of the surface-bound 88 Y-Octreotate into B16 cells. Maximal internalization level was 80% after 60 min of incubation. Conclusion: the optimal conditions for effective labeling (> 95%) of DOTA-Octreotate were found. The results obtained using the gamma-emitting 88 Y, provide a basis for in vivo research 90 Y octreotate as radiotherapeutic agent. References: [Ref. 1] Bodei, L.; Pepe, G.; Paganelli, G.; Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues. Eur. Rev. Med. Pharmacol. Sci., 2010; v. 14: 347-351. [Ref. 2] Garcia Garayoa E., Allemann-Tannahill L., et al. In vitro and in vivo evaluation of new radiolabeled neurotensin (8-13) analogs with high affinity for NT1 receptors. Nucl. Med. Biol. 2001; 28: 75-84. (authors)

  12. Multiphoton polarization Bremsstrahlung effect

    International Nuclear Information System (INIS)

    Golovinskij, P.A.

    2001-01-01

    A general approach to induced polarization effects was formulated on the basis of theory of many particles in a strong periodic field. Correlation with the perturbation theory is shown and the types of effective polarization potentials both for isolated atoms and ions, and for ions in plasma, are provided. State of art in the theory of forced polarization Bremsstrahlung effect is analyzed and some outlooks for further experimental and theoretical studies are outlined [ru

  13. 90Y production of high purity by electrochemical separation

    International Nuclear Information System (INIS)

    Alberti Ramírez, Alejandro; Serra Águila, Rolando; Morín Zorrilla, José Antonio; Pino Peraza, Madián; Soler Iglesias, Joel; Cruz Morales, Amed

    2016-01-01

    In this paper 90 Y is obtained without added carrier, by electrolytic separation from a solution in secular equilibrium Sr-Y and further purification in three cycles electrolytic automated, at constant current. The process productivity was 60-80 mCi (2220-2960 MBq). The long half-life of 90 Sr to be used by virtually indefinitely ensuring the stability of the raw material for generator operation, which helps sustainability and production stability. In 18 productions to date could be found to both content of 90 Sr equal to 0.110 ± 0.004 (k = 2) kBq / g by various methods, for their ability combination with DTPA, bifunctional chelate appropriate range of concentrations and even in the presence of trace metals, resulting in excellent characteristics for use as precursor in the preparation of therapeutic radiopharmaceuticals including radioimmunotherapy. The latter being a pure beta emitter with physical half-life, comparable to the time of capture and residence of many antibodies in tumors. The influence of Fe (III) was studied by the method of addition and concluded that only affects the performance of DTPA 90 Y marking if their presence is above a concentration of 0.018 mol / L. We show that the presence of other metals such as Pb (II), Zn (II) and Cu (II) also affects performance complexation

  14. Polarization bremsstrahlung in α decay

    International Nuclear Information System (INIS)

    Amusia, M. Ya.; Zon, B. A.; Kretinin, I. Yu.

    2007-01-01

    A mechanism of formation of electromagnetic radiation that accompanies α decay and is associated with the emission of photons by electrons of atomic shells due to the scattering of α particles by these atoms (polarization bremsstrahlung) is proposed. It is shown that, when the photon energy is no higher than the energy of K electrons of an atom, polarization bremsstrahlung makes a significant contribution to the bremsstrahlung in α decay

  15. The elementary process of Bremsstrahlung

    CERN Document Server

    Haug, Eberhard

    2004-01-01

    This book deals with the theory and experiment of the elementary process of bremsstrahlung, where photons are detected in coincidence with decelerated outgoing electrons. Such experiments allow for a more stringent check of the theoretical work. The main emphasis is laid on electron-atom bremsstrahlung and electron-electron bremsstrahlung, but further bremsstrahlung processes are also dealt with. In the theoretical parts, triply differential cross sections are derived in various approximations, including electron spin and photon-polarization. In the experimental sections, electron-photon coinc

  16. Radiochemical schemes of obtaining 89Sr and 90Y radionuclides

    International Nuclear Information System (INIS)

    Usarov, Z. O.

    2010-03-01

    Key words: strontium-89, yttrium-90, extraction and extraction-chromatographic purification of radionuclides, radiopharmaceuticals. Subjects of research: strontium-89 and yttrium-90 radionuclides and their chloride forms. Purpose of work is developing of radiochemical technologies on obtaining of 89 Sr and 90 Y on the WWR-SM reactor with high radionuclide purity. Methods of research: extraction and extraction-chromatographic methods of radionuclides separation, beta- and gamma-spectrometric methods of activity measuring. The results obtained and their novelty: Were determined the conformity to laws of Y and Sr distribution in two-phase systems TBP-HNO 3 , TBP-NH 4 NO 3 , TBP-HCI, HDEHP-NO 3 , HDEHP-NH 4 NO 3 and HDEHP-HCI. Were determined the conformity to laws of Y and Sr distribution in systems with craun ethers DB-18K-6 and DTBDB-18K-6 from water solutions of HNO 3 . Radiochemical technologies on obtaining of 89 Sr and 90 Y radionuclides including radiochemical process of yttrium target with using the systems TBP-HNO 3 and HDEHP/Teflone were developed. Practical value: the radiochemical technology of obtaining 89 Sr with high radionuclide purity was developed. The method of preparation a chloride compound of 89 SrCl 2 which is used as a drug form for preparation of 89 Sr- 'Metastron' was developed. The relatively simple method of on the way obtaining 90 Y in the reactor with high radionuclidic purity that is useful for follow using in medical practice was offered. Degree of embed and economic effectivity: the developed technologies have approbation in manufacturing conditions in Radiopreparat Enterprise of INP AS RU and were offered for receiving of domestic preparations against of import foreign analogues. The statement about using the invention by obtained patent is attached to dissertation. Field of application: the received results will be introduced in manufacture at Radiopreparat Enterprise of INP AS RU for receiving of domestic preparations

  17. {sup 90}Y -PET imaging: Exploring limitations and accuracy under conditions of low counts and high random fraction

    Energy Technology Data Exchange (ETDEWEB)

    Carlier, Thomas, E-mail: thomas.carlier@chu-nantes.fr [Department of Nuclear Medicine, University Hospital of Nantes, Place Alexis Ricordeau, Nantes 44093, France and CRCNA–UMR 892 INSERM 6299 CNRS, 8 quai Moncousu BP 70721, Nantes 44007 (France); Willowson, Kathy P. [Institute of Medical Physics, University of Sydney, Camperdown, New South Wales 2006 (Australia); Fourkal, Eugene [Department of Radiation Oncology, Allegheny General Hospital, Pittsburgh, Pennsylvania 15212 (United States); Bailey, Dale L. [Faculty of Health Sciences, University of Sydney, Lidcombe 2141, Australia and Department of Nuclear Medicine, Royal North Shore Hospital, St Leonards, New South Wales 2065 (Australia); Doss, Mohan [Department of Diagnostic Imaging, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 (United States); Conti, Maurizio [Siemens Healthcare Molecular Imaging, 810 Innovation Drive, Knoxville, Tennessee 37932 (United States)

    2015-07-15

    Purpose: {sup 90}Y -positron emission tomography (PET) imaging is becoming a recognized modality for postinfusion quantitative assessment following radioembolization therapy. However, the extremely low counts and high random fraction associated with {sup 90}Y -PET may significantly impair both qualitative and quantitative results. The aim of this work was to study image quality and noise level in relation to the quantification and bias performance of two types of Siemens PET scanners when imaging {sup 90}Y and to compare experimental results with clinical data from two types of commercially available {sup 90}Y microspheres. Methods: Data were acquired on both Siemens Biograph TruePoint [non-time-of-flight (TOF)] and Biograph microcomputed tomography (mCT) (TOF) PET/CT scanners. The study was conducted in three phases. The first aimed to assess quantification and bias for different reconstruction methods according to random fraction and number of true counts in the scan. The NEMA 1994 PET phantom was filled with water with one cylindrical insert left empty (air) and the other filled with a solution of {sup 90}Y . The phantom was scanned for 60 min in the PET/CT scanner every one or two days. The second phase used the NEMA 2001 PET phantom to derive noise and image quality metrics. The spheres and the background were filled with a {sup 90}Y solution in an 8:1 contrast ratio and four 30 min acquisitions were performed over a one week period. Finally, 32 patient data (8 treated with Therasphere{sup ®} and 24 with SIR-Spheres{sup ®}) were retrospectively reconstructed and activity in the whole field of view and the liver was compared to theoretical injected activity. Results: The contribution of both bremsstrahlung and LSO trues was found to be negligible, allowing data to be decay corrected to obtain correct quantification. In general, the recovered activity for all reconstruction methods was stable over the range studied, with a small bias appearing at extremely

  18. (90)Y -PET imaging: Exploring limitations and accuracy under conditions of low counts and high random fraction.

    Science.gov (United States)

    Carlier, Thomas; Willowson, Kathy P; Fourkal, Eugene; Bailey, Dale L; Doss, Mohan; Conti, Maurizio

    2015-07-01

    (90)Y -positron emission tomography (PET) imaging is becoming a recognized modality for postinfusion quantitative assessment following radioembolization therapy. However, the extremely low counts and high random fraction associated with (90)Y -PET may significantly impair both qualitative and quantitative results. The aim of this work was to study image quality and noise level in relation to the quantification and bias performance of two types of Siemens PET scanners when imaging (90)Y and to compare experimental results with clinical data from two types of commercially available (90)Y microspheres. Data were acquired on both Siemens Biograph TruePoint [non-time-of-flight (TOF)] and Biograph microcomputed tomography (mCT) (TOF) PET/CT scanners. The study was conducted in three phases. The first aimed to assess quantification and bias for different reconstruction methods according to random fraction and number of true counts in the scan. The NEMA 1994 PET phantom was filled with water with one cylindrical insert left empty (air) and the other filled with a solution of (90)Y . The phantom was scanned for 60 min in the PET/CT scanner every one or two days. The second phase used the NEMA 2001 PET phantom to derive noise and image quality metrics. The spheres and the background were filled with a (90)Y solution in an 8:1 contrast ratio and four 30 min acquisitions were performed over a one week period. Finally, 32 patient data (8 treated with Therasphere(®) and 24 with SIR-Spheres(®)) were retrospectively reconstructed and activity in the whole field of view and the liver was compared to theoretical injected activity. The contribution of both bremsstrahlung and LSO trues was found to be negligible, allowing data to be decay corrected to obtain correct quantification. In general, the recovered activity for all reconstruction methods was stable over the range studied, with a small bias appearing at extremely high random fraction and low counts for iterative algorithms

  19. 90Y -PET imaging: Exploring limitations and accuracy under conditions of low counts and high random fraction

    International Nuclear Information System (INIS)

    Carlier, Thomas; Willowson, Kathy P.; Fourkal, Eugene; Bailey, Dale L.; Doss, Mohan; Conti, Maurizio

    2015-01-01

    Purpose: 90 Y -positron emission tomography (PET) imaging is becoming a recognized modality for postinfusion quantitative assessment following radioembolization therapy. However, the extremely low counts and high random fraction associated with 90 Y -PET may significantly impair both qualitative and quantitative results. The aim of this work was to study image quality and noise level in relation to the quantification and bias performance of two types of Siemens PET scanners when imaging 90 Y and to compare experimental results with clinical data from two types of commercially available 90 Y microspheres. Methods: Data were acquired on both Siemens Biograph TruePoint [non-time-of-flight (TOF)] and Biograph microcomputed tomography (mCT) (TOF) PET/CT scanners. The study was conducted in three phases. The first aimed to assess quantification and bias for different reconstruction methods according to random fraction and number of true counts in the scan. The NEMA 1994 PET phantom was filled with water with one cylindrical insert left empty (air) and the other filled with a solution of 90 Y . The phantom was scanned for 60 min in the PET/CT scanner every one or two days. The second phase used the NEMA 2001 PET phantom to derive noise and image quality metrics. The spheres and the background were filled with a 90 Y solution in an 8:1 contrast ratio and four 30 min acquisitions were performed over a one week period. Finally, 32 patient data (8 treated with Therasphere ® and 24 with SIR-Spheres ® ) were retrospectively reconstructed and activity in the whole field of view and the liver was compared to theoretical injected activity. Results: The contribution of both bremsstrahlung and LSO trues was found to be negligible, allowing data to be decay corrected to obtain correct quantification. In general, the recovered activity for all reconstruction methods was stable over the range studied, with a small bias appearing at extremely high random fraction and low counts for

  20. Country report: Vietnam. Setting Up of a 90Sr/90Y Generator System Based on Supported Liquid Membrane (SLM) Technique and Radiolabeling of Eluted 90Y with Biomolecules

    International Nuclear Information System (INIS)

    Nguyen Thi Thu; Duong Van Dong; Bui Van Cuong; Chu Van Khoa

    2010-01-01

    In the course of participating in the IAEA-CRP during the last two years, Vietnam has achieved the goal of setting up a 90 Sr/ 90 Y generator system based on Supported Liquid Membrane (SLM) technique and also radiolabeling of the eluted 90 Y with antibody, peptides and albumin. A two stage SLM based 90 Sr- 90 Y generator was set up in-house to generate carrier-free 90 Y at different activity levels viz. 5, 20, 50 mCi. The generator system was operated in sequential mode in which 2-ethylhexyl 2-ethylhexyl phosphonic acid (PC88A) based SLM was used in the first stage for the transport 90 Y in 4.0 M nitric acid from source phase where 90 Sr- 90 Y equilibrium mixture is placed in nitric acid medium at pH to 1-2. In the second stage, octyl (phenyl)-N,N-diisobutylcarbamoylmethyl phosphine oxide (CMPO) based SLM was used for the transport of 90 Y selectively to 1.0 M acetic acid which is the best medium for radiolebeling. The eluted 90 Y from the generator was tested for the presence of any traces of 90 Sr using the Extraction Paper Chromatography (EPC) and was found suitable for radiolabeling. The generator system could be upgraded to 100 mCi level successfully due to an expert mission from India through IAEA. The 90 Y product obtained from the generator system was used for radiolabeling of antibody and peptides viz. Rituximab, DOTATATE and albumin particles under different experimental conditions. A new chromatography system could be developed for analyzing 90 Y labeled albumin using the TAE buffer as mobile phase in PC and ITLC

  1. Radiochemistry, pre-clinical studies and first clinical investigation of 90Y-labeled hydroxyapatite (HA) particles prepared utilizing 90Y produced by (n,γ) route

    International Nuclear Information System (INIS)

    Vimalnath, K.V.; Chakraborty, Sudipta; Rajeswari, A.; Sarma, H.D.; Nuwad, Jitendra; Pandey, Usha; Kamaleshwaran, K.; Shinto, Ajit; Dash, Ashutosh

    2015-01-01

    Introduction: The scope of using no carrier added (NCA) 90 Y [T 1/2 = 64.1 h, E β(max) = 2.28 MeV] obtained from 90 Sr/ 90 Y generator in radiation synovectomy (RSV) is widely accepted. In the present study, the prospect of using 90 Y produced by (n,γ) route in a medium flux research reactor for use in RSV was explored. Methods: Yttrium-90 was produced by thermal neutron irradiation of Y 2 O 3 target at a neutron flux of ~ 1 × 10 14 n/cm 2 .s for 14 d. The influence of various experimental parameters were systematically investigated and optimized to arrive at the most favorable conditions for the formulation of 90 Y labeled hydroxyapatite (HA) using HA particles of 1–10 μm size range. An optimized kit formulation strategy was developed for convenient one-step compounding of 90 Y-HA, which is easily adaptable at hospital radiopharmacy. The pre-clinical biological evaluation of 90 Y-HA particles was studied by carrying out biodistribution and bioluminiscence imaging studies in Wistar rats. The first clinical investigation using the radiolabeled preparation was performed on a patient suffering from chronic arthritis in knee joint by administering 185 MBq 90 Y-HA formulated at the hospital radiopharmacy deploying the proposed strategy. Results: Yttrium-90 was produced with a specific activity of 851 ± 111 MBq/mg and radionuclidic purity of 99.95 ± 0.02%. 90 Y-labeled HA particles (185 ± 10 MBq doses) were formulated in high radiochemical purity (> 99%) and excellent in vitro stability. The preparation showed promising results in pre-clinical studies carried out in Wistar rats. The preliminary results of the first clinical investigation of 90 Y-HA preparation in a patient with rheumatoid arthritis in knee joints demonstrated the effectiveness of the formulation prepared using 90 Y produced via (n,γ) route in the management of the disease. Conclusion: The studies revealed that effective utilization of 90 Y produced via (n,γ) route in a medium flux research

  2. Development of 90Sr/90Y Generator Systems Based on SLM Techniques for Radiolabelling of Therapeutic Biomolecules with 90Y. Chapter 14

    International Nuclear Information System (INIS)

    Thu, N.T.; Van Dong, D.; Van Cuong, B.; Van Khoa, C.; Cam Hoa, V.T.

    2015-01-01

    Yttrium-90 is one of the most useful radionuclides for radioimmunotherapeutic applications, especially for labelling peptides and antibodies. Studies were carried out to develop a 90 Sr/ 90 Y generator system based on the SLM technique. Two stages of 90 Sr/ 90 Y generator systems were developed at different activity levels of 5, 20, 50 and 100 mCi and operated with semiautomation in sequential mode. In the first stage of the system, PC88A based SLM was used, which transported 90 Y from a nitric acid medium containing 0.01–4M HNO 3 . In the second stage, the 90 Y from the first stage was transferred to the first compartment of the second stage using carbamoylmethyl phosphine oxide (CMPO) based SLM where 1M acetic acid was used as the receiving phase for 90 Y. Quality control was carried out for the products of 90 Y using EPC with paper chromatography and Tec control chromatography. Peptides and antibodies were labelled using the 90 Y product obtained from the generator developed in house. (author)

  3. New modalities (setting, fractionation) of radioimmunotherapy by 90Y-ibritumomab tiuxetan (90Y zevalin) in first line treatment of follicular type non Hodgkin malignant lymphomas: efficiency, toxicity and personalized dosimetry approach

    International Nuclear Information System (INIS)

    Morschhauser, F.

    2008-12-01

    Rationale: radioimmunotherapy (R.I.T.) with 90 Y-ibritumomab tiuxetan ([ 90 Y] Zevalin ) is a new treatment option for patients with relapsed/refractory non Hodgkin follicular lymphoma (F.L.). Efficacy increases when Zevalin is used earlier in the disease course. Currently, Zevalin dosage is based on weight and not dosimetry. This most likely results in a wide range of absorbed dose to critical organs and tumor, which in turn translates in unpredictable efficacy and toxicity. Optimizing R.I.T. with [ 90 Y] Zevalin will require its use as part of first-line therapy and implementation of patient-specific dosimetry methods in clinical trials. Objectives and methods: we have consecutively studied 2 new modalities of using Zevalin in first line therapy of F.L.. First, we conducted an international, randomized, phase 3 trial to evaluate the efficacy and safety of consolidation with Zevalin(15 MBq/Kg) in patients with advanced-stage F.L. achieving at least a partial response after induction immuno chemotherapy. A second approach consisted of evaluating a fractionated schedule with 2 doses of Zevalin (11.1 MBq/kg each), 9 to 13 weeks apart, as front line therapy in F.L. patients with high tumor burden. As part of this second approach, we designed a refined imaging-based (planar and 3-dimensional) dosimetry protocol to improve prediction of dose efficacy and toxicity after each dose of zevalin. Data acquisition was performed in 3 centers (Lille, Nantes and Manchester) while data treatment and specific dose calculations for major organ, tumor masses and bone marrow were centralized. Conclusion: Consolidation of first remission with 90 Y-ibritumomab tiuxetan in advanced-stage follicular lymphoma is highly effective with no unexpected toxicities, prolonging P.F.S. by 2 years and resulting in high P.R.-to-C.R. conversion rates regardless of type of first-line induction treatment. Preliminary data show the feasibility of front line fractionated R.I.T. with Zevalin in patient

  4. Development of techniques for rapid analysis of 90Sr breakthrough and 90Y activity from a 90Sr-90Y generator

    International Nuclear Information System (INIS)

    Chism, S.E.; Goodwin, D.A.; Meares, C.F.

    1986-01-01

    Recently there has been interest in labelling monoclonal antibodies with therapeutic amounts of a pure beta emitting isotope. 90 Y offers many desirable features and may be conveniently and economically obtained from a 90 Sr- 90 Y generator. A potential hazard with this system is breakthrough of the parent 90 Sr which has a half life of 28 years and is an extremely toxic bone seeking isotope. Therefore it is essential that the daughter be completely separated from its parent. We have devised two simple techniques which allow us to monitor rapidly the amount of 90 Sr breakthrough and quantitate the 90 Y activity over a 5 log range. (author)

  5. Hanford isotope project strategic business analysis yttrium-90 (Y-90)

    Energy Technology Data Exchange (ETDEWEB)

    NONE

    1995-10-01

    The purpose of this analysis is to address the short-term direction for the Hanford yttrium-90 (Y-90) project. Hanford is the sole DOE producer of Y-90, and is the largest repository for its source in this country. The production of Y-90 is part of the DOE Isotope Production and Distribution (IP and D) mission. The Y-90 is ``milked`` from strontium-90 (Sr-90), a byproduct of the previous Hanford missions. The use of Sr-90 to produce Y-90 could help reduce the amount of waste material processed and the related costs incurred by the clean-up mission, while providing medical and economic benefits. The cost of producing Y-90 is being subsidized by DOE-IP and D due to its use for research, and resultant low production level. It is possible that the sales of Y-90 could produce full cost recovery within two to three years, at two curies per week. Preliminary projections place the demand at between 20,000 and 50,000 curies per year within the next ten years, assuming FDA approval of one or more of the current therapies now in clinical trials. This level of production would incentivize private firms to commercialize the operation, and allow the government to recover some of its sunk costs. There are a number of potential barriers to the success of the Y-90 project, outside the control of the Hanford Site. The key issues include: efficacy, Food and Drug Administration (FDA) approval and medical community acceptance. There are at least three other sources for Y-90 available to the US users, but they appear to have limited resources to produce the isotope. Several companies have communicated interest in entering into agreements with Hanford for the processing and distribution of Y-90, including some of the major pharmaceutical firms in this country.

  6. Hanford isotope project strategic business analysis yttrium-90 (Y-90)

    International Nuclear Information System (INIS)

    1995-10-01

    The purpose of this analysis is to address the short-term direction for the Hanford yttrium-90 (Y-90) project. Hanford is the sole DOE producer of Y-90, and is the largest repository for its source in this country. The production of Y-90 is part of the DOE Isotope Production and Distribution (IP and D) mission. The Y-90 is ''milked'' from strontium-90 (Sr-90), a byproduct of the previous Hanford missions. The use of Sr-90 to produce Y-90 could help reduce the amount of waste material processed and the related costs incurred by the clean-up mission, while providing medical and economic benefits. The cost of producing Y-90 is being subsidized by DOE-IP and D due to its use for research, and resultant low production level. It is possible that the sales of Y-90 could produce full cost recovery within two to three years, at two curies per week. Preliminary projections place the demand at between 20,000 and 50,000 curies per year within the next ten years, assuming FDA approval of one or more of the current therapies now in clinical trials. This level of production would incentivize private firms to commercialize the operation, and allow the government to recover some of its sunk costs. There are a number of potential barriers to the success of the Y-90 project, outside the control of the Hanford Site. The key issues include: efficacy, Food and Drug Administration (FDA) approval and medical community acceptance. There are at least three other sources for Y-90 available to the US users, but they appear to have limited resources to produce the isotope. Several companies have communicated interest in entering into agreements with Hanford for the processing and distribution of Y-90, including some of the major pharmaceutical firms in this country

  7. Country report: India. Development of Radiopharmaceuticals Based on 188Re and 90Y for Radionuclide Therapy

    International Nuclear Information System (INIS)

    Venkatesh, M.; Pandey, U.; Dhami, P.S.; Chakravarty, R.; Kameswaran, M.; Subramanian, S.; Dash, A.; Samuel, G.

    2010-01-01

    During the past decade, our group has focused attention on the development of therapeutic radiopharmaceuticals incorporating radioisotopes such as 90 Y, 188 Re etc. As the primary source of the radioisotopes 90 Y and 188 Re are the 90 Sr/ 90 Y generators and 188 W/ 188 Re generators respectively, the local availability of these generator systems is very important for the successful development of radiopharmaceuticals incorporating these radioisotopes. In this context, 90 Sr/ 90 Y generators based on Supported Liquid Membrane (SLM) [1-3] and electrochemical techniques [4] could be designed and deployed in our laboratories for the elution of 90 Y to be used for preparation of 90 Y labeled products. This work formed a part of the IAEA co-ordinated CRP on “Development of Generator Technologies for Therapeutic Radionuclides: 90 Y and 188 Re”. In this report, work on the development of 90 Y radiopharmaceuticals for treatment of liver cancer and non-Hodgkin’s lymphoma (NHL) is reported. In addition, comparison of the Extraction Paper Chromatography technique (EPC) developed for determination of 90 Sr contamination in 90 Y samples with the US Pharmacopeia recommended method as well as the validation of the EPC technique is presented

  8. Comparison of positron emission tomography/CT and bremsstrahlung imaging following Y-90 radiation synovectomy

    International Nuclear Information System (INIS)

    Barber, Thomas W.; Yap, Kenneth S.K.; Cherk, Martin H.; Kalff, Victor; Powell, Anne

    2013-01-01

    The aim of this study is to compare the results of positron emission tomography (PET)/CT with bremsstrahlung imaging following Y-90 radiation synovectomy. All patients referred to our institution for Y-90 radiation synovectomy between July 2011 and February 2012 underwent both PET/CT and bremsstrahlung planar (±single photon emission computed tomography (SPECT) or SPECT/CT) imaging at 4 or 24 h following administration of Y-90 silicate colloid. PET image acquisition was performed for between 15 and 20min. In patients who underwent SPECT, side-by-side comparison with PET was performed and image quality/resolution scored using a five-point scale. The distribution pattern of Y-90 on PET and bremsstrahlung imaging was compared with the intra- or extra-articular location of Y-90 activity on fused PET/CT. Thirteen joints (11 knees and two ankles) were imaged with both PET/CT and planar bremsstrahlung imaging with 12 joints also imaged with bremsstrahlung SPECT. Of the 12 joints imaged with SPECT, PET image quality/resolution was superior in 11 and inferior in one. PET demonstrated a concordant distribution pattern compared with bremsstrahlung imaging in all scans, with the pattern classified as diffuse in 12 and predominantly focal in one. In all 12 diffuse scans, PET/CT confirmed the Y-90 activity to be located intra-articularly. In the one predominantly focal scan, the fused PET/CT images localised the Y-90 activity to mostly lie in the extra-articular space of the knee. PET/CT can provide superior image quality compared with bremsstrahlung imaging and may enable reliable detection of extra-articular Y-90 activity when there are focal patterns on planar bremsstrahlung imaging.

  9. 90Sr-90Y radionuclide generator based on ionex chromatography. Part 1 - project

    International Nuclear Information System (INIS)

    Miler, V.; Budsky, F.; Malek, Z.

    2003-09-01

    This part contains a proposal for the generator column design, materials to be used (chemicals, ionexes) and technological procedures. The proposal was inspired by the 90 Sr- 90 Y generator operated by Zfk Rossendorf. The aim was to develop and launch a generator for the preparation of carrier-free 90 Y in the form of [ 90 Y] chloride solution in dilute hydrochloric acid. The separation of Y from Sr is based on ionex chromatography by sorbing the two radionuclides on a catex. While Sr remains sorbed, 90 Y is eluted with lithium citrate. During this process, 90 Y is bonded in a citrate complex which, having a negative charge, is subsequently trapped by an anex. A guard column is inserted before the anex column to trap any traces of 90 Sr. 90 Y is eluted from the anex in the yttrium chloride form by using dilute hydrochloric acid. The product from the generator can be used for the preparation of [ 90 Y] - Fe colloid injection or [ 90 Y] - yttrium citrate injection for intra-articular application or for the development of monoclonal antibodies and peptides

  10. Polarizational radiation or 'atomic' bremsstrahlung

    International Nuclear Information System (INIS)

    Ya Amusia, M.

    1992-01-01

    It is demonstrated that a new kind of continuum spectrum radiation exists, where the mechanism of formation is quite different from that of ordinary bremsstrahlung. The latter originates due to slowing down of the charged projectile in the target field, while the former, called polarization radiation or 'atomic' bremsstrahlung, is a result of radiation either of the target or the projectile particles dipolarly polarized during the collision process. Not only general formulae, but also results of concrete calculations are presented. These demonstrate, that for electron-atom collisions the atomic contribution to the total bremsstrahlung spectrum becomes dominant for photon energies near and above the atomic ionization potential. As to atom-atom or ion-atom collisions, the bremsstrahlung spectrum is completely determined by the atomic contribution. The specific features of the case when the incoming particles are relativistic are discussed at length. A number of examples of colliding pairs are considered, for which the atomic bremsstrahlung process is quite essential: A bare nucleus and an atom, pair of atoms, at least one of which is excited, electron, or atom interacting with a molecule. The same mechanism is essential also in formation of radiation in nuclear and elementary particle collisions. (orig.)

  11. Validation of an extraction paper chromatography (EPC) technique for estimation of trace levels of 90Sr in 90Y solutions obtained from 90Sr/90Y generator systems

    International Nuclear Information System (INIS)

    Usha Pandey; Yogendra Kumar; Ashutosh Dash

    2014-01-01

    While the extraction paper chromatography (EPC) technique constitutes a novel paradigm for the determination of few Becquerels of 90 Sr in MBq quantities of 90 Y obtained from 90 Sr/ 90 Y generator, validation of the technique is essential to ensure its usefulness as a real time analytical tool. With a view to explore the relevance and applicability of EPC technique as a real time quality control (QC) technique for the routine estimation of 90 Sr content in generator produced 90 Y, a systematic validation study was carried out diligently not only to establish its worthiness but also to broaden its horizon. The ability of the EPC technique to separate trace amounts of Sr 2+ in the presence of large amounts of Y 3+ was verified. The specificity of the technique for Y 3+ was demonstrated with 90 Y obtained by neutron irradiation. The method was validated under real experimental conditions and compared with a QC method described in US Pharmacopeia for detection of 90 Sr levels in 90 Y radiopharmaceuticals. (author)

  12. The effect of correction factors on internal bremsstrahlung spectrum

    International Nuclear Information System (INIS)

    Elias, M.M.

    1985-01-01

    Correction factors affecting the experimental spectrum of internal bremsstrahlung (IB) accompanying B-decay have been studied. A wide survey of previous experimental studies, show a discrepancy between experimental results and the available theories of IB production especially for heavy nuclides and forbidden B-transitions, with some agreement in bounded regions in IB spectrum. This is due to the uncertainity in evaluating correction factors and neglecting others. The experimental distributions of IB from 147 Pm, 204 Tl and 90 Y are measured by using two different crystals of NaI(Tl) scintillators (2''x2'' and 3'''x3'') with suitable geometrical arrangements designed to minimize the effect of several factors. The present study covers overlapped ranges of energy from 0.05 to 2.2 MeV to observe the effect of these factors along this wide region of energy. The experimental probabilities are compared with theories. It agrees fairly well with Lewis and Ford theory in case of 14 '7Pm, 204 Tl, and with detour transitions theory in the intermediate region of energies of IB spectrum from 90 Y. Deviation of our results from theories is less than all previous experimental work. 20 tabs.; 43 figs.; 84 refs.; 5 apps

  13. Development of {sup 90}Sr-{sup 90}Y generators; Desenvolvimento de geradores de {sup 90}Sr-{sup 90}Y

    Energy Technology Data Exchange (ETDEWEB)

    Barrio, Graciela, E-mail: gracielabarrio@gmail.co [Pontificia Univ. Catolica de Sao Paulo (PUC-SP), SP (Brazil). Dept. de Fisica; Osso Junior, Joao Alberto, E-mail: jaossoj@ipen.b [Instituto de Pesquisas Energeticas e Nucleares (IPEN/CNEN-SP), Sao Paulo, SP (Brazil)

    2007-07-01

    Yttrium-90 is a radioisotope of great interest in the field of Nuclear Medicine. It is considered one of the most important and most used radionuclides for radioimmunotherapeutical applications, especially promising for the treatment of certain types of cancer. Another important application of {sup 90}Y is radio synovectomy. This radionuclide has a half-life of 64 hours, emits long range beta particles (maximum energy of 2.3 MeV) and decays, without intermediate nuclides, to a stable daughter. {sup 90}Y may be obtained carrier-free, generated by the decay of its parent {sup 90}Sr (half-life=28 years). {sup 90}Sr is a product from uranium fission, and due to its long half-life, can be indefinitely used, which is certainly advantageous. It is present in great amounts, and needs to be processed and purified in order to be used as raw material for the generators. Generators of {sup 90}Sr-{sup 90}Y may thus be used during various months, due to {sup 90}Sr long half-life. Several methods for the separation of {sup 90}Y from {sup 90}Sr by solvent extraction and ion exchange have been reported in literature. Thanks to its simplicity, ion exchange techniques have been more commonly used for this generator system. The main objective of this work was to develop a methodology for the preparation of {sup 90}Sr-{sup 90}Y generators, using cationic exchange resins. In such method, {sup 90}Sr is strongly adsorbed in the resin and {sup 90}Y is eluted by a 0.003 M EDTA solution. According to the quality control carried out, results showed that elution yields are greater than 65%, thus confirming the efficiency of the separation method used.

  14. 90Sr content in 90Y-labeled SIR-spheres and Zevalin.

    Science.gov (United States)

    Metyko, John; Erwin, William; Poston, John; Jimenez, Sandra

    2014-11-01

    Three different 90Y internally administered radionuclide therapies are currently used in both standard-of-care and clinical trial procedures atMD Anderson Cancer Center. TheraSphere and SIR-Spheres therapies utilize 90Y-labeled microspheres, while Zevalin is an 90Y-labeled radioimmunotherapeutic agent. Several publications have indicated radionuclidic impurities resulting from 90Y production methods. The 90Y in SIR-Spheres and Zevalin are produced from a 90Sr/90Y generator, which leaves measurable quantities of 90Sr in the final product. TheraSphere 90Y is produced in a nuclear reactor which results in a large number of impurities, most notably 88Y and 91Y. Product information sheets reference these impurities with specific limits given. These limits represent a tiny fraction of the total product activity, and in the case of TheraSphere and SIR-Spheres gamma-emitting impurities, this has been verified in the literature. An analysis of 90Sr impurities in SIR-Spheres and Zevalin is presented in this paper. Impurity quantities were found to be within the vendors’ documented limits.

  15. Study of radionuclide 90Sr-90Y on cell proliferation and apoptosis in benign prostatic hyperplasia

    International Nuclear Information System (INIS)

    Zhang Tong; Wei Wei; Zou Benjie; Liu Fang; Xu Zhishun

    2003-01-01

    Objective: To investigate the effect of 90 Sr- 90 Yon cell proliferation and apoptosis in benign prostatic hyperplasia. Methods: The apoptosis and expression of Ki-67 in benign prostatic hyperplasia (BPH) before and after irradiation 90 Sr- 90 Y were detected by transferase-mediated dUTP-biotin nick end labeling (TUNEL) method and immunohistochemical technique, respectively. Results: The proliferation index (PI) of BPH after 90 Sr- 90 Y irradiation was much lower than that before irradiation, but there was no significant change in apoptosis index (AI). Conclusion: Irradiation with 90 Sr- 90 Y could restrain cell proliferation of BPH, but could not induce apoptosis

  16. Therapy with {sup 90}Y microspheres: radiation protection in new medical therapies; Terapia con microesferas de {sup 90}Y: proteccion radiologica en nuevas terapias medicas

    Energy Technology Data Exchange (ETDEWEB)

    Rojo, Ana; Puerta, Nancy, E-mail: arojo@arn.gob.ar [Autoridad Regulatoria Nuclear (ARN), Buenos Aires (Argentina)

    2013-07-01

    Primary liver cancer is one of the most frequent in the world and with a low cure rate. Radioembolization using 90y spheres is a promising treatment of this pathology and involves the percutaneous vascular application of radioisotope-labeled the order of Micron size particles. The advantages of this technique include the permit administered high doses of radiation to small volumes with low relative toxicity, offer the possibility of treating all the liver including microscopic tumors, and finally, the feasibility of combined with other therapies. Radiation protection in new medical therapies requires justification and optimization, as requirements for their implementation. The application of the principle of optimization in the context of the protection of the patient must be the minimum that it can be reasonably reached compatible with the required doses of treatment dose to healthy tissue. With {sup 90}Y microspheres therapy this optimization applies to the activity of 90y which is administered to the patient, and estimation methods are postulated. in this work are analyzed comparatively these methods, described the early physicists, equations and the limitations of each. Finally, it is concluded that the optimal method to be implemented for the evaluation of the activity of {sup 90}Y manage must be based in a voxel dosimetric model specific for each patient, however, the partitional method may be a good alternative if you don't have the tools to apply the method.

  17. Enrichment and determination of small amounts of 90Sr/90Y in water samples

    International Nuclear Information System (INIS)

    Mundschenk, H.

    1979-01-01

    Small amounts of 90 Sr/ 90 Y can be concentrated from large volumes of surface water (100 l) by precipitation of the phosphates, using bentonite as adsorber matrix. In the case of samples containing no or nearly no suspended matter (tap water, ground water, sea water), the daughter 90 Y can be extracted directly by using filter beds impregnated with HDEHP. The applicability of both techniques is demonstrated under realistic conditions. (orig.) 891 HP/orig. 892 MKO [de

  18. Rapid determination of 90Sr impurities in freshly 'generator eluted'90Y for radiopharmaceutical preparation

    International Nuclear Information System (INIS)

    Bonardi, Mauro L.; Martano, Luigi; Groppi, Flavia; Chinol, Marco

    2009-01-01

    90 Y is one of the most useful radionuclides for radioimmunotherapeutic applications and has a half-life (t 1/2 =64.14 h) suitable for most therapeutic applications, beta particles of high energy and decays to a stable daughter. It is significant that 90 Y is available conveniently and inexpensively from a radionuclide 'generator' by decay of its parent, 90 Sr. Nevertheless, current and planned clinical applications with [ 90 Y] labelled compounds employ activity levels that cannot be readily obtained from an in-house generator, but from commercial sources. We have evaluated Eichrom's Sr-resin, either as an 'in-house' generator or as a fast QC method for analysis of 90 Y solutions. In particular, for the development as a generator, we investigated the percentage of the radio-Sr in the first 8 M HNO 3 eluate: in this fraction the concentration of 90 Sr must be smaller than 10 -5 % (recommendations of the International Commission on Radiological Protection). For evaluation as a rapid QC method, we analyzed the concentration of 90 Y in all the fractions containing 'only' radio-Sr: 90 Y should not be present in these eluates. After the collection of β - and γ spectra and analysis of them, we concluded that commercial Sr-resin minicolumn cannot give us the results expected; we developed an in-house system loaded with 4 mL of Sr-resin which gave better results as a generator and a rapid QC method.

  19. Evaluation of Effective Parameters on Labeling of Hydroxyapatite Compound with 90Y and Introducing the Best Method to Produce 90Y-HAp Radiopharmaceutical for Radio synovectomy

    International Nuclear Information System (INIS)

    Davarpanah, M. R.; Khoshhosn, H. A.; Attar Nosrati, S.; Harati, S. M.; Aghamiri, S. M.; Ghannadi Maragheh, M.

    2012-01-01

    Radio synovectomy is a local intra-articular injection of radionuclides in colloidal form for treatment of articular inflammatory in rheumatoid arthritis, hemophilia or orthopedic troubles. β-emitting radionuclides can be used for various joints based on radiation energy. 90 Y is a pure β-emitter with a half-life of 64.1 hours that is used for treatment of the knee joint. β-radiation of this radionuclide possesses maximum energy of 2.281 MeV (99.98%), mean pathway of 3.6 mm in the soft tissue and maximum 11 mm. In this project, hydroxyapatite (HAp) is applied as a colloid maker agent that interacts with 90 Y 3+ ions via ion-dipole bonds and produces 90 Y-HAp. The colloidal pharmaceutical is produced by adding an acidic solution of 90 YCl 3 to an HAp suspension in saline. Effective parameters within which the colloid is applied, such as the volume of diluent, HAp particle size and sonication effect were evaluated and tested. First, these determinative parameters were optimized in the simulated conditions and then examined in the active phase. Finally, the best procedure was determined for the production of the radiopharmaceutical. Radionuclide purity of the radiopharmaceutical according to the primary 90 YCl 3 solution was over 99.9%. Labeling yield and radiochemical purity were obtained over 99% using TLC method in saline solvent up to three days after production of radiopharmaceutical. Radiochemical purity of 90 Y-HAp colloid was also evaluated in human serum albumin solution for three days at room temperature. The amount of released activity was between 0.3 to 2%.

  20. Radioembolization of hepatocarcinoma with 90Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology

    International Nuclear Information System (INIS)

    Chiesa, C.; Maccauro, M.; Aliberti, G.; Padovano, B.; Seregni, E.; Crippa, F.; Mira, M.; Negri, A.; Spreafico, C.; Morosi, C.; Civelli, E.; Lanocita, R.; Marchiano, A.; Romito, R.; Sposito, C.; Bhoori, S.; Facciorusso, A.; Mazzaferro, V.; Camerini, T.; Carrara, M.; Pellizzari, S.; Migliorisi, M.; De Nile, M.C.

    2015-01-01

    The aim of this study was to optimize the dosimetric approach and to review the absorbed doses delivered, taking into account radiobiology, in order to identify the optimal methodology for an individualized treatment planning strategy based on 99m Tc-macroaggregated albumin (MAA) single photon emission computed tomography (SPECT) images. We performed retrospective dosimetry of the standard TheraSphere registered treatment on 52 intermediate (n = 17) and advanced (i.e. portal vein thrombosis, n = 35) hepatocarcinoma patients with tumour burden < 50 % and without obstruction of the main portal vein trunk. Response was monitored with the densitometric radiological criterion (European Association for the Study of the Liver) and treatment-related liver decompensation was defined ad hoc with a time cut-off of 6 months. Adverse events clearly attributable to disease progression or other causes were not attributed to treatment. Voxel dosimetry was performed with the local deposition method on 99m Tc-MAA SPECT images. The reconstruction protocol was optimized. Concordance of 99m Tc-MAA and 90 Y bremsstrahlung microsphere biodistributions was studied in 35 sequential patients. Two segmentation methods were used, based on SPECT alone (home-made code) or on coregistered SPECT/CT images (IMALYTICS trademark by Philips). STRATOS trademark absorbed dose calculation was validated for 90 Y with a single time point. Radiobiology was used introducing other dosimetric variables besides the mean absorbed dose D: equivalent uniform dose (EUD), biologically effective dose averaged over voxel values (BED ave ) and equivalent uniform biologically effective dose (EUBED). Two sets of radiobiological parameters, the first derived from microsphere irradiation and the second from external beam radiotherapy (EBRT), were used. A total of 16 possible methodologies were compared. Tumour control probability (TCP) and normal tissue complication probability (NTCP) were derived. The area under the

  1. Calibration of the 90Sr+90Y ophthalmic and dermatological applicators with an extrapolation ionization minichamber

    International Nuclear Information System (INIS)

    Antonio, Patrícia L.; Oliveira, Mércia L.; Caldas, Linda V.E.

    2014-01-01

    90 Sr+ 90 Y clinical applicators are used for brachytherapy in Brazilian clinics even though they are not manufactured anymore. Such sources must be calibrated periodically, and one of the calibration methods in use is ionometry with extrapolation ionization chambers. 90 Sr+ 90 Y clinical applicators were calibrated using an extrapolation minichamber developed at the Calibration Laboratory at IPEN. The obtained results agree satisfactorily with the data provided in calibration certificates of the sources. - Highlights: • 90 Sr+ 90 Y clinical applicators were calibrated using a mini-extrapolation chamber. • An extrapolation curve was obtained for each applicator during its calibration. • The results were compared with those provided by the calibration certificates. • All results of the dermatological applicators presented lower differences than 5%

  2. A special mini-extrapolation chamber for calibration of 90Sr+90Y sources

    International Nuclear Information System (INIS)

    Oliveira, Mercia L; Caldas, Linda V E

    2005-01-01

    90 Sr+ 90 Y applicators are commonly utilized in brachytherapy, including ophthalmic procedures. The recommended instruments for the calibration of these applicators are extrapolation chambers, which are ionization chambers that allow the variation of their sensitive volume. Using the extrapolation method, the absorbed dose rate at the applicator surface can be determined. The aim of the present work was to develop a mini-extrapolation chamber for the calibration of 90 Sr+ 90 Y beta ray applicators. The developed mini-chamber has a 3.0 cm outer diameter and is 11.3 cm in length. An aluminized polyester foil is used as the entrance window while the collecting electrode is made of graphited polymethylmethacrylate. This mini-chamber was tested in 90 Sr+ 90 Y radiation beams from a beta particle check source and with a plane ophthalmic applicator, showing adequate results

  3. Toxicity of 90Y in a relatively insoluble form inhaled by Beagle dogs. XIV

    International Nuclear Information System (INIS)

    Hahn, F.F.; Hobbs, C.H.; Kusewitt, D.F.; McClellan, R.O.; Mauderly, J.L.; Pickrell, J.A.

    1982-01-01

    The metabolism, dosimetry and biological effects of inhaled 90 Y in fused aluminosilicate particles in Beagle dogs are being studied. Eighty-nine dogs with initial lung burdens ranging from 80 to 5200 μCi 90 Y/kg body weight and 12 control dogs are being maintained for life span observations. The lung burdens achieved, short physical half-life and relative insolubility of the 90 Y in this vector resulted in a relatively high, rapidly decreasing radiation dose rate to the lung. To date, 69 exposed dogs have died; 38 from radiation pneumonitis, seven with pulmonary neoplasms and 24 from other causes. Four control dogs have died. Twenty-nine surviving exposed and eight control dogs are being studied for their life spans

  4. Calculation of Bremsstrahlung yield for thin target

    International Nuclear Information System (INIS)

    Demir, N.; Akkurt, I.; Tekin, H. O.; Cakirli, R. B.; Akkus, B.; Kupa, I.

    2010-01-01

    The Bremsstrahlung photon is created by de-accelerating electron beam in an electric field which is usually a thin material so-called radiator. The obtained Bremsstrahlung yield depends on some parameter such as incoming electron beam energy, the thickness and also Z number of the radiator. The main aim of this work is to obtain optimum radiator to be used at Bremsstrahlung photon beam facility at TAC. For this purposes the Bremsstrahlung photon yield has been obtained using FLUKA code for different types materials.

  5. Bremsstrahlung in atom-atom collisions

    International Nuclear Information System (INIS)

    Amus'ya, M.Y.; Kuchiev, M.Y.; Solov'ev, A.V.

    1985-01-01

    It is shown that in the collision of a fast atom with a target atom when the frequencies are on the order of the potentials or higher, there arises bremsstrahlung comparable in intensity with the bremsstrahlung emitted by an electron with the same velocity in the field of the target atom. The mechanism by which bremsstrahlung is produced in atom-atom collisions is elucidated. Results of specific calculations of the bremsstrahlung spectra are given for α particles and helium atoms colliding with xenon

  6. Development of methodology for the preparation of 90Sr-90Y generators

    International Nuclear Information System (INIS)

    Barrio, Graciela; Osso, Joao A.

    2008-01-01

    Among the more attractive radionuclides for therapeutic applications is yttrium-90. Its relatively short half-life (64.0h), maximum beta energy (2.28 MeV) make it well suited for a variety of applications, ranging from the radiolabeling of antibodies for tumor therapy to the production of radiolabeled particles for the treatment of liver malignancies. Yttrium-90 results from the decay of strontium-90 (28y) and decays to a stable daughter ( 90 Zr) and has no γ-ray, what makes this nuclide very attractive for therapeutic applications. 90 Y is produced through a generator system, from the decay of 90 Sr. Before it can safely employed in clinical applications, the 90 Y must be made essentially free of 90 Sr, an isotope known to cause bone marrow suppression. The objective of this work is to develop 90 Sr- 90 Y generator using a cation exchange method resin. This method was the most effects for the separation of 90 Y and 90 Sr. 90 Sr is strongly adsorbed in the resin and 90 Y is eluted in 0.003M EDTA. The generator efficiency and radionuclide control results were also evaluated using 85 Sr (γ-ray emitter). The generator was developed, using AG 50WX8 exchange resin converted to the Na+ form and then conditioned with 0.003M EDTA solution (pH=4.8). The quality control showed that 90 Y had no 8 '5Sr impurities, inside the detection limits of the detector. The results presented here are very promising, showing that the methodology is able to separate the two nuclides, with low quantities of 90 Sr impurity and satisfactory elution yields. (author)

  7. Adsorption of 90Sr and 90Y by bottom-set beds in the Atlantic ocean

    International Nuclear Information System (INIS)

    Gromov, V.V.; Shakhova, N.F.; Emel'yanov, E.M.

    1978-01-01

    The behaviour of 90 Sr and 90 Y has been studied in an adsorption system of sea water-bottom-set beds of the Atlantic ocean (red clay; pelitic silt). It has been shown that strontium is present in the sea water in one form, viz, Sr 2+ . Adsorption of 90 Sr with bottom-set beds follows the ion-exchange mechanism. Yttrium is present in the sea water at least three forms (two absorbable and one non-absorbable). Yttrium-90 adsorption is an irreversible process and only about 10% 90 Y is desorbed by the sea water from red clay and silt

  8. The somatostatin receptor-targeted radiotherapeutic [90Y-DOTA-dPhe1,Tyr3]octreotide (90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours

    International Nuclear Information System (INIS)

    Stolz, B.; Weckbecker, G.; Smith-Jones, P.M.; Albert, R.; Raulf, F.; Bruns, C.

    1998-01-01

    Somatostatin receptor-expressing tumours are potential targets for therapy with radiolabelled somatostatin analogues. We have synthesized a number of such analogues in the past and identified [DOTA-dPhe 1 , Tyr 3 ]octreotide (SMT 487) as the most promising candidate molecule because of its advantageous properties in cellular and in vivo tumour models. In the current paper we describe the radiotherapeutic effect of yttrium-90 labelled SMT 487 in Lewis rats bearing the somatostatin receptor-positive rat pancreatic tumour CA 20948. SMT 487 binds with nanomolar affinity to both the human and the rat somatostatin receptor subtype 2 (sst 2 ) (human sst 2 IC 50 =0.9 nM, rat sst 2 IC 50 =0.5 nM). In vivo, 90 Y-SMT 487 distributed rapidly to the sst 2 expressing CA 20948 rat pancreatic tumour, with a tumour-to-blood ratio of 49.15 at 24 h post injection. A single intravenous administration of 10 mCi/kg 90 Y-SMT 487 resulted in a complete remission of the tumours in five out of seven CA 20948 tumour-bearing Lewis rats. No regrowth of the tumours occurred 8 months post injection. Control animals that were treated with 30 μg/kg of unlabelled SMT 487 had to be sacrificed 10 days post injection due to excessive growth or necrotic areas on the tumour surface. Upon re-inoculation of tumour cells into those rats that had shown complete remission, the tumours disappeared after 3-4 weeks of moderate growth without any further treatment. The present study shows for the first time the curative potential of 90 Y-SMT 487-based radiotherapy for somatostatin receptor-expressing tumours. Clinical phase I studies with yttrium-labelled SMT 487 have started in September 1997. (orig.)

  9. Therapy with 90Y microspheres: radiation protection in new medical therapies

    International Nuclear Information System (INIS)

    Rojo, Ana; Puerta, Nancy

    2013-01-01

    Primary liver cancer is one of the most frequent in the world and with a low cure rate. Radioembolization using 90y spheres is a promising treatment of this pathology and involves the percutaneous vascular application of radioisotope-labeled the order of Micron size particles. The advantages of this technique include the permit administered high doses of radiation to small volumes with low relative toxicity, offer the possibility of treating all the liver including microscopic tumors, and finally, the feasibility of combined with other therapies. Radiation protection in new medical therapies requires justification and optimization, as requirements for their implementation. The application of the principle of optimization in the context of the protection of the patient must be the minimum that it can be reasonably reached compatible with the required doses of treatment dose to healthy tissue. With 90 Y microspheres therapy this optimization applies to the activity of 90y which is administered to the patient, and estimation methods are postulated. in this work are analyzed comparatively these methods, described the early physicists, equations and the limitations of each. Finally, it is concluded that the optimal method to be implemented for the evaluation of the activity of 90 Y manage must be based in a voxel dosimetric model specific for each patient, however, the partitional method may be a good alternative if you don't have the tools to apply the method

  10. Polarizational bremsstrahlung in non-relativistic collisions

    International Nuclear Information System (INIS)

    Korol, A.V.; Solov'yov, A.V.

    2006-01-01

    We review the developments made during the last decade in the theory of polarization bremsstrahlung in the non-relativistic domain. A literature survey covering the latest history of the phenomenon is given. The main features which distinguish the polarization bremsstrahlung from other mechanisms of radiation are discussed and illustrated by the results of numerical calculations

  11. Radiation protection in radionuclide therapies with (90)Y-conjugates: risks and safety.

    Science.gov (United States)

    Cremonesi, Marta; Ferrari, Mahila; Paganelli, Giovanni; Rossi, Annalisa; Chinol, Marco; Bartolomei, Mirco; Prisco, Gennaro; Tosi, Giampiero

    2006-11-01

    The widespread interest in (90)Y internal radionuclide treatments has drawn attention to the issue of radiation protection for staff. Our aim in this study was to identify personnel at risk and to validate the protection devices used. (90)Y-MoAb (Zevalin, 15 cases, 1.1 GBq/patient) and (90)Y-peptide ((90)Y-DOTATOC) systemic (i.v., 50 cases, 3.0 GBq/patient) and locoregional (l.r., 50 cases, 0.4 GBq/patient) treatments were considered. Radiolabelling was carried out in a dedicated hot cell. Tele-tongs, shielded (PMMA: polymethylmethacrylate) syringes/vials and an automatic dose fractionating system were used. Operators wore anti-X-ray and anti-contamination gloves, with TLD dosimeters placed over the fingertips. For i.v. administration, activity was administered by a dedicated system; for l.r. administration, during activity infusion in the brain cavity, tongs were used and TLDs were placed over the fingertips. The air kerma-rate was measured around the patients. The use of devices provided a 75% dose reduction, with mean fingertip doses of 2.9 mGy (i.v. MoAbs), 0.6 mGy (i.v. peptides)/radiolabelling procedure and 0.5 mGy/l.r. administration. The mean effective dose to personnel was 5 microSv/patient. The air kerma-rate around the patients administered i.v. (90)Y-peptides were 3.5 (1 h) and 1.0 (48 h) microGy/h at 1 m. Patient hospitalisation of 6 h (l.r.)/48 h (i.v.) guaranteed that the recommended limits of 3 mSv/year to family members and 0.3 mSv/year to the general population (Council Directive 97/43/Euratom) were respected. When specific procedures are adopted, a substantial improvement in (90)Y manipulation is attainable, reducing doses and increasing safety. For the widespread clinical use of (90)Y-conjugates, a completely automatic labelling procedure is desirable.

  12. Comparison of Classical and Quantum Bremsstrahlung

    International Nuclear Information System (INIS)

    Pratt, R.H.; Uskov, D.B.; Korol, A.V.; Obolensky, O.I.

    2003-01-01

    Classical features persist in bremsstrahlung at surprisingly high energies, while quantum features are present at low energies. For Coulomb bremsstrahlung this is related to the similar properties of Coulomb scattering. For bremsstrahlung in a screened potential, the low energy spectrum and angular distribution exhibit structures. In quantum mechanics these structures are associated with zeroes of particular angular-momentum transfer matrix elements at particular energies, a continuation of the Cooper minima in atomic photoeffect. They lead to transparency windows in free-free absorption. The trajectories of these zeroes in the plane of initial and final transition energies (bound and continuum) has been explored. Corresponding features have now been seen in classical bremsstrahlung, resulting from reduced contributions from particular impact parameters at particular energies. This has suggested the possibility of a more unified treatment of classical and quantum bremsstrahlung, based on the singularities of the scattering amplitude in angular momentum

  13. Country report: India. Development of Radiopharmaceuticals Based on {sup 188}Re and {sup 90}Y for Radionuclide Therapy

    Energy Technology Data Exchange (ETDEWEB)

    Venkatesh, M.; Pandey, U.; Dhami, P. S.; Chakravarty, R.; Kameswaran, M.; Subramanian, S.; Dash, A.; Samuel, G. [Bhabha Atomic Research Centre, Trombay, Mumbai 400 085 (India)

    2010-07-01

    During the past decade, our group has focused attention on the development of therapeutic radiopharmaceuticals incorporating radioisotopes such as {sup 90}Y, {sup 188}Re etc. As the primary source of the radioisotopes {sup 90}Y and {sup 188}Re are the {sup 90}Sr/{sup 90}Y generators and {sup 188}W/{sup 188}Re generators respectively, the local availability of these generator systems is very important for the successful development of radiopharmaceuticals incorporating these radioisotopes. In this context, {sup 90}Sr/{sup 90}Y generators based on Supported Liquid Membrane (SLM) [1-3] and electrochemical techniques [4] could be designed and deployed in our laboratories for the elution of {sup 90}Y to be used for preparation of {sup 90}Y labeled products. This work formed a part of the IAEA co-ordinated CRP on “Development of Generator Technologies for Therapeutic Radionuclides: {sup 90}Y and {sup 188}Re”. In this report, work on the development of {sup 90}Y radiopharmaceuticals for treatment of liver cancer and non-Hodgkin’s lymphoma (NHL) is reported. In addition, comparison of the Extraction Paper Chromatography technique (EPC) developed for determination of {sup 90}Sr contamination in {sup 90}Y samples with the US Pharmacopeia recommended method as well as the validation of the EPC technique is presented.

  14. Post-Newtonian gravitational bremsstrahlung

    International Nuclear Information System (INIS)

    Turner, M.; Will, C.M.

    1978-01-01

    We present formulae and numerical results for the gravitational radiation emitted during a low-deflection encounter between two massive bodies (''gravitational bremsstrahlung''). Our results are valid through post-Newtonian order within general relativity. We discuss in detail the gravitational waveform (transverse-traceless part of the metric perturbation tensor), the toal luminosity and total emitted energy, the angular distribution of emitted energy (antenna pattern), and the frequency spectrum. We also present a method of ''boosting'' the accuracy of these quantities to post-3/2-Newtonian order. A numerical comparison of our results with those of Peters and of Kovacs and Thorne shows that the post-Newtonian method is reliable to better than 0.1% at v=0.1c, to a few percent at v=0.35c, and to 10--20% at v=0.5c. We also compare our results with those of Smarr

  15. Same-day {sup 90}Y radioembolization: implementing a new treatment paradigm

    Energy Technology Data Exchange (ETDEWEB)

    Gabr, Ahmed; Kallini, Joseph Ralph; Gates, Vanessa L.; Hickey, Ryan; Desai, Kush; Thornburg, Bartley; Marshall, Karen; Salzig, Krystina; Williams, Melissa; Del Castillo, Carlene; Hohlastos, Elias; Lewandowski, Robert J. [Northwestern Memorial Hospital, Robert H. Lurie Comprehensive Cancer Center, Department of Radiology, Section of Interventional Radiology, Chicago, IL (United States); Kulik, Laura; Ganger, Daniel [Northwestern University, Department of Medicine, Division of Hepatology, Chicago, IL (United States); Baker, Talia [Northwestern University, Department of Surgery, Division of Transplantation, Comprehensive Transplant Center, Chicago, IL (United States); Salem, Riad [Northwestern Memorial Hospital, Robert H. Lurie Comprehensive Cancer Center, Department of Radiology, Section of Interventional Radiology, Chicago, IL (United States); Northwestern University, Department of Surgery, Division of Transplantation, Comprehensive Transplant Center, Chicago, IL (United States); Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Department of Medicine, Division of Hematology and Oncology, Chicago, IL (United States)

    2016-12-15

    To assess the feasibility of conducting pretreatment mesenteric angiography, coil embolization, {sup 99m}Tc macroaggregated albumin ({sup 99m}Tc-MAA) scintigraphy, and {sup 90}Y radioembolization treatment in a single, same-day, combined outpatient encounter. This was a retrospective study of 78 patients treated during the period 2008 - 2015 who were managed in a single outpatient encounter under the guidance of the Interventional Radiology Department and The Nuclear Medicine Department. Pretreatment planning was performed by reviewing baseline imaging and estimated perfused liver volume bearing the tumor. The region of interest was estimated using 3-D software; this value was used for dosimetry planning. Maximum lung shunting fractions of 10 % for hepatocellular carcinoma and 5 % for liver metastases were assumed. Subsequently, hepatic angiography and {sup 99m}Tc-MAA scintigraphy were performed followed by {sup 90}Y treatment in one outpatient encounter. Total in-room procedure time was recorded. All patients underwent same-day angiography, {sup 99m}Tc-MAA scintigraphy and {sup 90}Y radioembolization. Of the 78 patients, 16 received multiple segmental treatments to both lobes, 44 received treatment to the right lobe, and 18 received treatment to the left lobe. The median dose was 106 Gy. The median number of {sup 90}Y vials needed was two (range one to six). The median in-room time was 160 min (75 - 250 min). The residential status of the patients was as follows, 18 % (14/78) were local residents, 55 % (43/78) traveled from outside the city limits, 18 % (14/78) were from out-of-state, and 9 % (7/78) were resident abroad. Of the 78 patients, 61 (77 %) had hepatocellular carcinoma, and 17 (22 %) had liver metastases. The median lung dose was 3.5 Gy. This study demonstrated the feasibility of same-day {sup 90}Y evaluation and treatment while maintaining the principles of safe and effective {sup 90}Y infusion including tumoricidal dosimetry (lobar, segmentectomy

  16. Using Cherenkov Counting For Fast Determination of 90Sr/90Y Activity in Milk

    International Nuclear Information System (INIS)

    Tsroya, S.; Dolgin, B.; German, U.; Pelled, O.; Alfassi, Z. B.

    2014-01-01

    90Sr is one of the main long-lived fission products, and it is transferred into human body primarily by food, with milk being a substantial contributor. Due to its biochemical similarity to calcium, most strontium is efficiently incorporated into bone tissues. 90Sr is characterized by a long physical half life (28.8 y) and decays by beta particles with an Emax of 0.546 MeV to 90Y. This daughter isotope has a half life of 64 h and decays into 90Zr by beta particles with an Emax of 2.284 MeV. The milk components produce a high turbidity and light attenuation, causing a significant decrease of the counting efficiency in liquid scintillation counting (LSC) systems, mostly used for beta emitters detection. Most methods proposed in the past are time-consuming, as they are based on several stages of chemical and physical treatments, including precipitation, ashing, ion exchange and extraction (Wikins et al., 1984, Porter et al, 1961, Kimura et al., 1979). When measuring 90Sr/90Y activity by Cherenkov counting, most of the Cherenkov radiation is produced by 90Y (about 98.6%), due to the much higher energy of its beta particles relative to these from 90Sr. The counting efficiency varies strongly with color quenching, at a greater extent than in standard liquid scintillation counting (L'Annunziata, 2012), and therefore the quench correction is critical. The ‘‘external source area ratio’’ (ESAR) quench correction method was applied to measure 90Sr/90Y activities in aqueous samples with a wide range of quenching levels (Tsroya et al., 2009). This method was proved to be superior to all other quench correction methods (Tsroya et al., 2012) and is applicable also for determination of 90Sr/90Y in human urine (Tsroya et al., 2013). In the present work the applicability of the ESAR method to measurement of 90Sr/90Y activities in milk and some of its products was investigated

  17. Country report: Vietnam. Setting Up of a {sup 90}Sr/{sup 90}Y Generator System Based on Supported Liquid Membrane (SLM) Technique and Radiolabeling of Eluted {sup 90}Y with Biomolecules

    Energy Technology Data Exchange (ETDEWEB)

    Thu, Nguyen Thi; Dong, Duong Van; Cuong, Bui Van; Khoa, Chu Van [Vietnam Atomic Energy Commission (VAEC), Nuclear Research Institute, Dalat (Viet Nam)

    2010-07-01

    In the course of participating in the IAEA-CRP during the last two years, Vietnam has achieved the goal of setting up a {sup 90}Sr/{sup 90}Y generator system based on Supported Liquid Membrane (SLM) technique and also radiolabeling of the eluted {sup 90}Y with antibody, peptides and albumin. A two stage SLM based {sup 90}Sr-{sup 90}Y generator was set up in-house to generate carrier-free {sup 90}Y at different activity levels viz. 5, 20, 50 mCi. The generator system was operated in sequential mode in which 2-ethylhexyl 2-ethylhexyl phosphonic acid (PC88A) based SLM was used in the first stage for the transport {sup 90}Y in 4.0 M nitric acid from source phase where {sup 90}Sr-{sup 90}Y equilibrium mixture is placed in nitric acid medium at pH to 1-2. In the second stage, octyl (phenyl)-N,N-diisobutylcarbamoylmethyl phosphine oxide (CMPO) based SLM was used for the transport of {sup 90}Y selectively to 1.0 M acetic acid which is the best medium for radiolebeling. The eluted {sup 90}Y from the generator was tested for the presence of any traces of {sup 90}Sr using the Extraction Paper Chromatography (EPC) and was found suitable for radiolabeling. The generator system could be upgraded to 100 mCi level successfully due to an expert mission from India through IAEA. The {sup 90}Y product obtained from the generator system was used for radiolabeling of antibody and peptides viz. Rituximab, DOTATATE and albumin particles under different experimental conditions. A new chromatography system could be developed for analyzing {sup 90}Y labeled albumin using the TAE buffer as mobile phase in PC and ITLC.

  18. Development of 90Y-DOTA-nimotuzumab Fab fragment for radioimmunotherapy

    International Nuclear Information System (INIS)

    Alonso Martinez, L.M.; Marylaine Perez-Malo Cruz; Rene Leyva Montana; Calzada Falcon, V.N.; Minely Zamora Barrabi; Alejandro Arbesu Valdivia; Ignacio Hernandez Gonzalez; Mariela Leon Perez

    2014-01-01

    Yttrium-90-( 90 Y) labeled monoclonal antibodies prepared with a chelating agent, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), have been used for radioimmunotherapy of cancer. In the present work, the Fab fragment of anti-EGFR monoclonal antibody nimotuzumab was prepared with high purity, integrity and biological activity. The Fab fragment with high specific recognition of EGFR in NCI-H125 human lung adenocarcinoma cells was derivatized with DOTA-NHS applying a simple procedure. DOTA-nimotuzumab Fab fragment was successfully radiolabeled with 90 Y with high radiochemical yield. The in vitro stability of labeled product was optimal over 24 h in buffered solution at 37 deg C. Biodistribution and pharmacokinetic studies correctly evaluated the in vivo non-tumor uptake, dosage regimen and excretion pathway in normal Wistar rats. (author)

  19. The effect of 90Sr/90Y β-rays on benign prostatic hyperplasia

    International Nuclear Information System (INIS)

    Kong Xiangbo; Ma Qingjie; Gu Xinquan

    2004-01-01

    Objective: To investigate the effect of 90Sr/90Y β-rays on Benign prostatic hyperplasia (BPH). Methods: In order to carry out β intracavitary irradiation, the active area of the applicator was located into prostate gland section of urethra in 37 patients. The dose was controlled 30∼50Gy in each patient and the patients were observed for 3 months. Results: After two weeks 26 cases were remarkably improved, 7 cases were improved and 4 cases were ineffective. There was significant difference on MFR, PVR, I-PSS and volume of prostate gland before and after treatment (P<0.01=. Conclusion: Clinical tests indicate that the 90Sr/90Y prostatic hyperplasia applicators provide a safe, effective ,non-invasive and economical therapeutic method for BPH. It is especially applicable for old and high-risk patients. (authors)

  20. PET/MRI of Hepatic 90Y Microsphere Deposition Determines Individual Tumor Response

    Energy Technology Data Exchange (ETDEWEB)

    Fowler, Kathryn J. [Washington University, Department of Radiology (United States); Maughan, Nichole M. [Washington University, Department of Biomedical Engineering (United States); Laforest, Richard [Washington University, Department of Nuclear Medicine (United States); Saad, Nael E. [Washington University, Department of Radiology (United States); Sharma, Akash [Washington University, Department of Nuclear Medicine (United States); Olsen, Jeffrey; Speirs, Christina K.; Parikh, Parag J., E-mail: parikh@wustl.edu [Washington University, Department of Radiation Oncology (United States)

    2016-06-15

    PurposeThe purpose of our study is to determine if there is a relationship between dose deposition measured by PET/MRI and individual lesion response to yttrium-90 ({sup 90}Y) microsphere radioembolization.Materials and Methods26 patients undergoing lobar treatment with {sup 90}Y microspheres underwent PET/MRI within 66 h of treatment and had follow-up imaging available. Adequate visualization of tumor was available in 24 patients, and contours were drawn on simultaneously acquired PET/MRI data. Dose volume histograms (DVHs) were extracted from dose maps, which were generated using a voxelized dose kernel. Similar contours to capture dimensional and volumetric change of tumors were drawn on follow-up imaging. Response was analyzed using both RECIST and volumetric RECIST (vRECIST) criteria.ResultsA total of 8 hepatocellular carcinoma (HCC), 4 neuroendocrine tumor (NET), 9 colorectal metastases (CRC) patients, and 3 patients with other metastatic disease met inclusion criteria. Average dose was useful in predicting response between responders and non-responders for all lesion types and for CRC lesions alone using both response criteria (p < 0.05). D70 (minimum dose to 70 % of volume) was also useful in predicting response when using vRECIST. No significant trend was seen in the other tumor types. For CRC lesions, an average dose of 29.8 Gy offered 76.9 % sensitivity and 75.9 % specificity for response.ConclusionsPET/MRI of {sup 90}Y microsphere distribution showed significantly higher DVH values for responders than non-responders in patients with CRC. DVH analysis of {sup 90}Y microsphere distribution following treatment may be an important predictor of response and could be used to guide future adaptive therapy trials.

  1. Efficiency calibration of a liquid scintillation counter for 90Y Cherenkov counting

    International Nuclear Information System (INIS)

    Vaca, F.; Garcia-Leon, M.

    1998-01-01

    In this paper a complete and self-consistent method for 90 Sr determination in environmental samples is presented. It is based on the Cherenkov counting of 90 Y with a conventional liquid scintillation counter. The effects of color quenching on the counting efficiency and background are carefully studied. A working curve is presented which allows to quantify the correction in the counting efficiency depending on the color quenching strength. (orig.)

  2. Studying on process for labeling of EDTMP with 90Y using for bone pain palliation

    International Nuclear Information System (INIS)

    Pham Ngoc Dien; Duong Van Dong; Dang Ho Hong Quang; Nguyen Thanh Binh; Bui Van Cuong; Nguyen Dang Khoa; Nguyen Thi Thu; Mai Phuoc Tho; Vo Cam Hoa

    2013-01-01

    This Study describes the method for preparation of labelling compound Ethylene diamine tetramethylene phosphonic acid (EDTMP) with 90 Y. Malignant cancer is one of the most important resulting in human death. Bone metastases in nearly 25% of all cancer patients; so it is useful to develop radiopharmaceuticals for the treatment of bone cancer. Yttrium-90 is high energy (2.3 MeV) beta emitter required with a physical haft life of 2.7 days which has limited bone-seeking properties. Its physical properties make it ideal for therapeutic application, the most energetic beta emission being able to penetrate to 1 cm from the site of deposition in soft tissue with an average range of approximately 4 mm. Theoretically, therefore, it can penetrate all marrow spaces in normal trabecular bone and conceivably even to the centre of large tumours where bone destruction may be extensive. Specific deposition of 90 Y into the skeleton demands its delivery in a chemical form with affinity for bone mineral alone. Compounds with these properties are the phosphonate analogues of polyaminocarboxylic acids, and one in particular EDTMP (ethylen diamine tetra methylene phosphonate) has already been used to target 153 Sm to bone mineral with success. Because of chemical similarities between 90 Y and the rare earths, EDTMP should form stable complexes with 90 Y and carry it specifically to the bone with comparable efficiency. Skeletal uptake of β - emitting radionuclides may be used for bone pain palliation or myeloablation. The physical characteristics of the β - particles required for the two conditions are, however, different, that is, higher energies are favorable for destruction of bone marrow. (author)

  3. Toxicity of inhaled 90Y in fused clay particles in beagle dogs. VI

    International Nuclear Information System (INIS)

    Hobbs, C.H.; Chiffelle, T.L.; Hahn, F.F.; Jones, R.K.; Mauderly, J.L.; McClellan, R.O.; Pickrell, J.A.

    1974-01-01

    Studies on the metabolism, dosimetry, and effects of inhaled 90 Y in fused clay in the Beagle dog are being continued to assess the consequences of inhalation of an energetic beta emitter that has a short effective half-life in the lung. A radiation dose pattern study in which 12 dogs were sacrificed in pairs at 0, 2, 4, 6, 8, and 12 days post-inhalation exposure has been completed. A longevity study in which 89 dogs have been exposed to 90 Y fused clay with initial lung burdens ranging from 80 to 5200 μCi/kg body weight and 12 control dogs were exposed to stable yttrium in fused clay is in progress. The 90 Y was retained in lung with a half-life similar to its physical half-life (64 hours) and with only small quantities translocated to tracheobronchial lymph nodes, skeleton, and liver. The infinite radiation doses to lung, tracheobronchial lymph nodes, skeleton, and liver for an initial lung burden of 100 μCi 90 Y/kg of body weight were estimated to be 1600, 170, 0.54, and 0.38 rads, respectively. Thirty-eight of 39 dogs with doses to lung from 9300 to 70,000 rads have died at 7.5 to 903 days post-exposure. The one surviving dog in this dose range has radiographic evidence of pulmonary fibrosis at 1316 days post-exposure. All the dogs that died had radiation pneumonitis. The dog that died at 903 days post-exposure with a dose to lung of 11,000 rads also had 2 small pulmonary adenomas. Fifty exposed dogs with doses to lung of 1300 to 7900 rads are surviving with no significant abnormalities at 1278 to 1834 days post-exposure and will be studied for the remainder of their lifespan. (U.S.)

  4. Dosimetric comparison of electron beam and 90Sr+90Y applicator for keloids treatment

    International Nuclear Information System (INIS)

    Coelho, Talita S.; Tada, Ariane; Antonio, Patricia L.; Yoriyaz, Helio; Fernandes, Marco A.R.

    2009-01-01

    Studies have been shown that among several methods that have been used for the treatment of keloids the surgical excision followed by the adjuvant radiotherapy presents the lowest relapsed rate of the injury. In this work a comparative dosimetric study has been performed using a 4 MeV electron beam from a Varian Clinac 2100C linear accelerator at the radiotherapy service of the Hospital das Clinicas of UNESP-HC, Botucatu-SP and an Amershan 90 Sr+ 90 Y brachytherapy applicator with 1491 MBq of activity. Percentage depth dose curves from ionization chamber measurements and through Monte Carlo simulation have been obtained and compared. Dose measurements have been obtained using parallel plates ionization chamber (Esradin A12) and extrapolation mini-chamber developed at IPEN. The dose calculations have been obtained using the well-known Monte Carlo radiation transport code MCNP-4C. Maximum dose differences obtained between measured/calculated values for 90 Sr+ 90 Y applicator and for the electron beam were, respectively: 7.8 % and 8.0%. The profiles of the depth and superficial tissue dose distribution produced by the electron beam revealed themselves flatter and more homogeneous than those produced by the 90 Sr+ 90 Y applicator, especially to wider fields, which cannot be obtained with beta therapy applicators because of their geometric limitations. In conclusion this present work has shown that 90 Sr+ 90 Y applicators could be efficient for small and very superficial lesions but in most cases electron beam sources are more adequate especially for large and deeper lesions. (author)

  5. Radiopharmaceutical development based on human blood albumin microspheres and 90Y

    International Nuclear Information System (INIS)

    Petriev, V M; Vlasova, O P; Postnov, A A; Epstein, N B

    2017-01-01

    New radiopharmaceutial (RP) based on human serum albumin microspheres (MSA) and 90 Y was developed for treatment of liver cancer. The optimized synthesis using chelation resulted in approximately 80% yield with high specific activity. The RP developed was tested in mice with inoculated sarcoma-37. In two weeks the tumor size reduced by 43% after the treatment with the dose of 500 μCi injected into the tumor site. (paper)

  6. Development of radioinmunoconjugate 90Y-DOTA-nimotuzumab-Fab for therapy of EGFR over expressing tumors

    International Nuclear Information System (INIS)

    Rodriguez, A. M.; Alonso, L. M.; Gongora, M.; Leyva, R.; Solana, A.

    2015-01-01

    Many monoclonal antibodies conjugated with 1,4,7,10-tetraaza cyclododecane-N, N', N'', N'''-tetraacetic acid (DOTA) and radiolabeled with 90 Y, have been used for radioimmunotherapy. As know IgG molecules are heavy proteins with a molecular weight of approximately 150 kDa. Accordingly, intact IgG antibodies may have significant slow kinetics biodistribution and severely limited properties of tissue penetration. Antibody fragments labeled with radio metals could be promising radiopharmaceuticals for imaging and non-invasive therapy due to its high affinity to the tumor, the lack of effector function and rapid pharmacokinetic. In this work, the nimotuzumab Fab fragment was obtained by cleavage with papain in molar excess. After separating the reaction mixture in three steps using affinity, size exclusion and ion exchange chromatography; the Fab fragment showed high values of purity, integrity and identity. The Fab fragment was derivatized with DOTA and labeled with 90 Y. The radioimmunoconjugate with high radiochemical yield was assessed by in vitro stability with an excess of 50mM DTPA. The development of 90 Y-DOTA-Nimotuzumab-Fab radioimmunoconjugate allows to count on as a potential agent for radioimmunotherapy. (Author)

  7. Peptide receptor radionuclide therapy with {sup 90}Y-DOTATOC in recurrent meningioma

    Energy Technology Data Exchange (ETDEWEB)

    Bartolomei, Mirco; Bodei, Lisa; De Cicco, Concetta; Grana, Chiara Maria; Baio, Silvia Melania; Arico, Demetrio; Paganelli, Giovanni [European Institute of Oncology, Division of Nuclear Medicine, Milan (Italy); Cremonesi, Marta [European Institute of Oncology, Division of Medical Physics, Milan (Italy); Botteri, Edoardo [European Institute of Oncology, Division of Epidemiology and Biostatistics, Milan (Italy); Sansovini, Maddalena [Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Radiometabolic Medicine Division, Meldola (Italy)

    2009-09-15

    Meningiomas are generally benign and in most cases surgery is curative. However, for high-grade histotypes or partially resected tumours, recurrence is fairly common. External beam radiation therapy (EBRT) is usually given in such cases but is not always effective. We assessed peptide receptor radionuclide therapy (PRRT) using {sup 90}Y-DOTATOC in a group of patients with meningioma recurring after standard treatments in all of whom somatostatin receptors were strongly expressed on meningioma cell surfaces. Twenty-nine patients with scintigraphically proven somatostatin subtype 2 receptor-positive meningiomas were enrolled: 14 had benign (grade I), 9 had atypical (grade II) and 6 had malignant (grade III) disease. Patients received intravenous {sup 90}Y-DOTATOC for 2-6 cycles for a cumulative dose in the range of 5-15 GBq. Clinical and neuroradiological evaluations were performed at baseline, during and after PRRT. The treatment was well tolerated in all patients. MRI 3 months after treatment completion showed disease stabilization in 19 of 29 patients (66%) and progressive disease in the remaining 10 (34%). Better results were obtained in patients with grade I meningioma than in those with grade II-III, with median time to progression (from beginning PRRT) of 61 months in the low-grade group and 13 months in the high-grade group. PRRT with {sup 90}Y-DOTATOC can interfere with the growth of meningiomas. The adjuvant role of this treatment, soon after surgery, especially in atypical and malignant histotypes, deserves further investigation. (orig.)

  8. The bremsstrahlung tagged photon beam in Hall B at JLab

    CERN Document Server

    Sober, D I; Longhi, A; Matthews, S K; O'Brien, J T; Berman, B L; Briscoe, W J; Cole, P L; Connelly, J P; Dodge, W R; Murphy, L Y; Philips, S A; Dugger, M K; Lawrence, D; Ritchie, B G; Smith, E S; Lambert, J M; Anciant, E; Audit, G; Auger, T; Marchand, C; Klusman, M; Napolitano, J; Khandaker, M A; Salgado, C W; Sarty, A J

    2000-01-01

    We describe the design and commissioning of the photon tagging beamline installed in experimental Hall B at the Thomas Jefferson National Accelerator Facility (JLab). This system can tag photon energies over a range from 20% to 95% of the incident electron energy, and is capable of operation with beam energies up to 6.1 GeV. A single dipole magnet is combined with a hodoscope containing two planar arrays of plastic scintillators to detect energy-degraded electrons from a thin bremsstrahlung radiator. The first layer of 384 partially overlapping small scintillators provides photon energy resolution, while the second layer of 61 larger scintillators provides the timing resolution necessary to form a coincidence with the corresponding nuclear interaction triggered by the tagged photon. The definitions of overlap channels in the first counter plane and of geometric correlation between the two planes are determined using digitized time information from the individual counters. Auxiliary beamline devices are briefl...

  9. 111In and 90Y labelled peptide radiopharmaceuticals for diagnosis and therapy

    International Nuclear Information System (INIS)

    Obenaus, E.; Crudo, J.L.; Castiglia, S.G. de

    2004-01-01

    Full text: The application of 111In-labelled octreotide to target somatostatin receptors on tumour cells has gained acceptance as a diagnostic procedure for demonstrating neuroendocrine and other SSTR-positive tumors. A further advance in the field of somatostatin analogues is the development of macrocyclic chelators that also bind beta particle emitters like 90Y and 177Lu. [90Y-DOTA, Tyr3] octreotide and [177Lu-DOTA, Tyr3] octreotate are currently being tried as the therapeutic agents. The aim of this work was to label two somatostatin analogues (Tyr3 Octreotide and Lanreotide) with 111In and 90Y using DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) as a chelating agent. DOTA in the form of the tri-t-butyl ester was coupled to the Lys5 (BOC) protected Tyr3octreotide and Lys5 (BOC) protected lanreotide in N,N-dimethylformamide, in a three-step reaction involving conjugation, using HATU and diisopropylethylamine as coupling reagents, de-protection with trifluoroacetic and HPLC purification of the conjugates. The DOTALAN and DOTATOC were labelled with 111In and 90Y and assayed by HPLC. In both cases solutions of gentisic acid in sodium acetate 0.4M pH=5.0 and conjugated peptides were added to the 111In or 90Y chloride. The final solution was heated at 90 deg. C for 25 minutes. We tried different amounts of the two peptide complexes per mCi of 111In/90Y and quality control of the labelled products was performed with the following HPLC system: reverse phase column, flow rate 1ml-min, UV/radiometric detection and a gradient solvent: solvent A: acetonitrile, solvent B: water TFA 0.1%, gradient: 0-3min 100% B, linear increase of eluent A to 50% from 3-13 min, 13-18 min 50% A, 18-20 min linear increase of eluent A to 70%. Serum stability was determined after 4 and 24 hr. incubation of the labeled peptide in human serum at 37 deg. C. After precipitation of proteins with acetonitrile the incubation mixture was analyzed by HPLC. Normal Wistar rats were

  10. Utilization of a novel electrochemical {sup 90}Sr/{sup 90}Y generator for the preparation of {sup 90}Y-labeled RGD peptide dimer in clinically relevant dose

    Energy Technology Data Exchange (ETDEWEB)

    Chakraborty, Sudipta; Chakravarty, Rubel; Pillai, Maroor Raghavan Ambikalmajan; Dash, Ashutosh [Bhabha Atomic Research Centre, Mumbai (India). Radiopharmaceuticals Div.; Sarma, Haladhar Dev [Bhabha Atomic Research Centre, Mumbai (India). Radiation Biology and Health Sciences Div.

    2014-09-01

    The work reported in this paper provides a systematic study towards the development of an optimized strategy for preparation of a clinically relevant dose of {sup 90}Y-labeled dimeric RGD peptide derivative, DOTA-E[c(RGDfK)]{sub 2} [DOTA-(RGD){sub 2}] for in vivo targeted therapy utilizing {sup 90}Y obtained from a novel electrochemical {sup 90}Sr/{sup 90}Y generator. The performance of the generator was evaluated to ensure its suitability for providing {sup 90}Y in adequate quantity and purity required for formulation of clinically relevant dose for PRRT. {sup 90}Y-DOTA-(RGD){sub 2} was synthesized in high yield (86.2 ± 2.5%) and radiochemical purity (98.4 ± 0.5%) using clinically relevant dose (∝ 3.8 GBq) of {sup 90}Y. In vitro stability studies revealed that the radiolabeled conjugate retained its radiochemical purity in normal saline and human serum. Preliminary biodistribution studies carried out in C57/BL6 mice bearing melanoma tumors showed that the preparation exhibited significant tumor uptake (5.30 ± 0.78% of injected activity at 30 min post-injection) with good tumor to background ratio. The optimized radiolabeling protocol seems to be an attractive strategy which is largely viewed as a springboard to realize scope of developing {sup 90}Y labeled cyclic RGD peptides for targeted therapy of tumors over-expressing integrin-α{sub ν}β{sub 3} receptors. (orig.)

  11. Investigation of pharmaceuticals and medical devices containing 90Y extracted from high radioactive liquid waste in spent-fuel reprocessing

    International Nuclear Information System (INIS)

    Hosoma, Takashi

    2012-07-01

    Pharmaceuticals and medical devices containing radioactive 90 Y are realized, approved and placed on the international market where three products are available in Europe and the United States, and one product in Japan. These products are used not for diagnosis but for treatment by internal irradiation. It was estimated from the deliberative report of the approval in Japan that 90 Y was extracted in Europe from high radioactive liquid waste (HALW) yielded in spent-fuel reprocessing. In this report, products placed on the market and physical properties were reviewed, reasons of the realization and conditions to realize succeeding products were estimated, extraction method was compared with other methods, technical subjects, and relevant regulations were investigated. Although a medical device containing radioactive 90 Y has been studied in Japan and one pharmaceutical product was approved, a breakthrough would be necessary to put 90 Y utilization beyond alternative treatments. The breakthrough would become be promising; for example, if conventional treatments could be supported by technical development to deliver 90 Y more sharply to the target with shorter serum half-life. Extraction of 90 Y nuclide from HALW has advantages over thermal neutron irradiation of natural nuclide, a system is envisioned where 90 Sr as a parent nuclide is separated in the reprocessing then transported to and stored in a factory of radiopharmaceuticals followed by 90 Y extraction on demand. (author)

  12. Treatment of advanced pancreatic carcinoma with 90Y-Clivatuzumab Tetraxetan: a phase I single-dose escalation trial.

    Science.gov (United States)

    Gulec, Seza A; Cohen, Steven J; Pennington, Kenneth L; Zuckier, Lionel S; Hauke, Ralph J; Horne, Heather; Wegener, William A; Teoh, Nick; Gold, David V; Sharkey, Robert M; Goldenberg, David M

    2011-06-15

    Humanized antibody hPAM4 specifically binds a mucin glycoprotein expressed in pancreatic adenocarcinomas. This phase I study evaluated a single dose of (90)Y-clivatuzumab tetraxetan ((90)Y-labeled hPAM4) in patients with advanced pancreatic cancer. Twenty-one patients (4 stage III; 17 stage IV) received (111)In-hPAM4 for imaging and serum sampling before (90)Y-hPAM4. Study procedures evaluated adverse events, safety laboratories, computed tomography (CT) scans, biomarkers, pharmacokinetics, radiation dosimetry, and immunogenicity (HAHA). (111)In-hPAM4 showed normal biodistribution with radiation dose estimates to red marrow and solid organs acceptable for radioimmunotherapy and with tumor targeting in 12 patients. One patient withdrew before (90)Y-hPAM4; otherwise, 20 patients received (90)Y doses of 15 (n = 7), 20 (n = 9), and 25 mCi/m(2) (n = 4). Treatment was well tolerated; the only significant drug-related toxicities were (NCI CTC v.3) grade 3 to 4 neutropenia and thrombocytopenia increasing with (90)Y dose. There were no bleeding events or serious infections, and most cytopenias recovered to grade 1 within 12 weeks. Three patients at 25 mCi/m(2) encountered dose-limiting toxicity with grade 4 cytopenias more than 7 days, establishing 20 mCi/m(2) as the maximal tolerated (90)Y dose. Two patients developed HAHA of uncertain clinical significance. Most patients progressed rapidly and with CA19-9 levels increasing within 1 month of therapy, but 7 remained progression-free by CT for 1.5 to 5.6 months, including 3 achieving transient partial responses (32%-52% tumor diameter shrinkage). (90)Y-Clivatuzumab tetraxetan was well tolerated with manageable hematologic toxicity at the maximal tolerated (90)Y dose, and is a potential new therapeutic for advanced pancreatic cancer. ©2011 AACR.

  13. Dosimetry in radionuclide therapies with 90Y-conjugates. The IEO experience

    International Nuclear Information System (INIS)

    Cremonesi, M.; Ferrari, M.; Chinol, M.; Bartolomei, M.; Sacco, E.; Fiorenza, M.; Tosi, G.; Paganelli, G.; Stabin, M. G.

    2000-01-01

    The basis for successful radionuclide therapy is a high and stable uptake of the radiopharmaceutical in the target tissue along with low activity concentration in other normal organs. The contribution of dosimetry in radionuclide therapy is to predict before the treatment the absorbed doses in tumor and normal organs, to identify the critical organs, to minimize any possible toxicity and to evaluate the maximum tolerated dose. In this article is reported the experience concerning pharmacokinetics and dosimetry of two 90 Y-therapeutic protocols: 3-step pretargeting radioimmunotherapy (RIT) according to the biotin-avidin system and receptor mediated radionuclide therapy with the somatostatin analogue (DOTA-D-Phe 1 -Tyr 3 ) octreotide named DOTATOC. For the dosimetric analysis, analogous approaches for the two radiolabeled compounds due to the similar pharmacokinetic characteristics were adopted; the MIRD formalism was applied, taking into account both the physical and the biological characteristics of the radio conjugate and patients' metabolism. In order to determine biological clearance, serial blood samples and complete urine collection were obtained up to 48 hours after injection; to evaluate biodistribution, several whole body scans were acquired. Both therapies showed the advantageous characteristics of a fast blood clearance and a predominantly renal excretion of the radiopharmaceuticals thus lowering the irradiation of the total body. Although pharmacokinetic characteristics were similar, different critical organs were found for the two therapies: in particular, some considerations regarding red marrow, spleen and kidneys were required. The results of the studies indicate that high activities of 90 Y-biotin (3-step RIT) and 90 Y-DOTATOC can be administered with acceptable radiation doses to normal organs

  14. Half-life evaluations for 3H, 90Sr, and 90Y

    International Nuclear Information System (INIS)

    MacMahon, Desmond

    2006-01-01

    A recent paper has reviewed methods for the evaluation of discrepant sets of data and demonstrated the results of applying these methods to the published half-life data of 90 Sr and 137 Cs [MacMahon, T.D., Pearce, A., Harris, P., 2004. Convergence of techniques for the evaluation of discrepant data. Appl. Radiat. Isot. 60, 275-281]. The half-life data for 3 H has been subject to a comprehensive review and critical evaluation by Lucas and Unterweger [2000. Comprehensive review and critical evaluation of the half-life of tritium. J. Res. Natl. Inst. Stand. Technol. 105, 541-549]. The current paper reports the results of applying the various evaluation procedures of MacMahon et al. Convergence of techniques for the evaluation of discrepant data. Appl. Radiat. Isot. 60, 275-281] to the data of Lucas and Unterweger [Comprehensive review and critical evaluation of the half-life of tritium. J. Res. Natl. Inst. Stand. Technol. 105, 541-549], resulting in a recommended half-life of 4497(4) days. MacMahon et al. [Convergence of techniques for the evaluation of discrepant data. Appl. Radiat. Isot. 60, 275-281] highlighted problems in the evaluation of the discrepant half-life data of 90 Sr, in particular the worrying upward trend in the data, where the weighted mean of all the measurements increases, on average, by 35 days each time a new measurement result is added. The current paper reports on further analyses of these data. New measurements of the half-life of 90 Y have been reported by Kossert and Schrader [2004. Standardization by liquid scintillation counting and half-life measurements of 90 Y. Appl. Radiat. Isot. 60, 741]. This has prompted a new evaluation of all available published 90 Y half-life data. The data are fairly consistent, and a value of 64.063(16) h is recommended

  15. The solvent extraction of carrier-free 90Y from 90Sr with crown ethers

    International Nuclear Information System (INIS)

    Chuang, J.T.; Lo, J.G.

    1995-01-01

    A simple solvent extraction method has been developed for the separation of 90 Y from 90 Sr. Crown ether dissolved in chloroform was used as a selective reagent and organic picrate anion was chosen as a counter ion. The effect of various factors on the extraction equilibrium constant of strontium log K ex = 9.15 was obtained from the study of the distribution coefficient versus to crown ether concentration. The separation method was simple, resulted high purity (>99.9%) and quantitative yield, and took less than half an hour. (author) 27 refs.; 4 figs.; 4 tabs

  16. Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers.

    Science.gov (United States)

    Villard, Linda; Romer, Anna; Marincek, Nicolas; Brunner, Philippe; Koller, Michael T; Schindler, Christian; Ng, Quinn K T; Mäcke, Helmut R; Müller-Brand, Jan; Rochlitz, Christoph; Briel, Matthias; Walter, Martin A

    2012-04-01

    Radiopeptide therapy is commonly performed with a single radioisotope. We aimed to compare the effectiveness of somatostatin-based radiopeptide therapy with a single versus a combination of radioisotopes. In a cohort study, patients with metastasized neuroendocrine cancer were treated with repeated cycles of (90)yttrium-labeled tetraazacyclododecane-tetraacetic acid modified Tyr-octreotide ([(90)Y-DOTA]-TOC) or with cycles alternating between [(90)Y-DOTA]-TOC and (177)lutetium-labeled DOTA-TOC ([(177)Lu-DOTA]-TOC) until tumor progression or permanent toxicity. Multivariable Cox regression and competing risk regression were used to study predictors of survival and renal toxicity in patients completing three or more treatment cycles. A total of 486 patients completed three or more treatment cycles; 237 patients received [(90)Y-DOTA]-TOC and 249 patients received [(90)Y-DOTA]-TOC + [(177)Lu-DOTA]-TOC. Patients receiving [(90)Y-DOTA]-TOC + [(177)Lu-DOTA]-TOC had a significantly longer survival than patients receiving [(90)Y-DOTA]-TOC alone (5.51 v 3.96 years; hazard ratio, 0.64; 95% CI, 0.47 to 0.88; P = .006). The rates of severe hematologic toxicities (6.3% v 4.4%; P = .25) and severe renal toxicity (8.9% v 11.2%; P = .47) were comparable in both groups. [(90)Y-DOTA]-TOC + [(177)Lu-DOTA]-TOC was associated with improved overall survival compared with [(90)Y-DOTA]-TOC alone in patients completing three or more cycles of treatment. Contrary to the current practice in radiopeptide therapy, our results suggest an advantage of using a combination of radioisotopes.

  17. Nonexistence of two forms of turbulent bremsstrahlung

    International Nuclear Information System (INIS)

    Kuijpers, J.; Melrose, D.B.

    1985-01-01

    It is shown that the forms of turbulent bremsstrahlung proposed by Tsytovich, Stenflo, and Wilhelmsson and by Nambu do not exist. The proposed mechanisms involve upconversion of ion sound turbulence into Langmuir turbulence, with the ion sound waves being emitted and absorbed resonantly and the Langmuir waves being emitted and absorbed nonresonantly. It is pointed out that a symmetry implicit in a standard QED treatment implies that there is another contribution to turbulent bremsstrahlung in addition to that calculated by Tsytovich, Stenflo, and Wilhelmsson and that the two contributions cancel exactly, leading to the null result. (Our arguments on this point have proved controversial.) Nambu made an approximation inconsistently, and when this approximation is not made, two terms in his analytic treatment cancel exactly. We argue that turbulent bremsstrahlung is related to a radiative correction in which the resonant emission of ion sound turbulence is modified by the nonresonant emission and absorption of Langmuir waves. Physically we interpret the nonexistence of turbulent bremsstrahlung as being due to each emission of a Langmuir quantum being associated with an absorption of an identical Langmuir quantum so that the Langmuir turbulence is unchanged. Proposed astrophysical applications of turbulent bremsstrahlung need to be reconsidered

  18. Depth dose curves from 90Sr+90Y clinical applicators using the thermoluminescent technique

    International Nuclear Information System (INIS)

    Antonio, Patricia L.; Caldas, Linda V.E.; Oliveira, Mercia L.

    2009-01-01

    The 90 Sr+ 90 Y beta-ray sources widely used in brachytherapy applications were developed in the 1950's. Many of these sources, called clinical applicators, are still routinely used in several Brazilian radiotherapy clinics for the treatment of superficial lesions in the skin and eyes, although they are not commercialized anymore. These applicators have to be periodically calibrated, according to international recommendations, because these sources have to be very well specified in order to reach the traceability of calibration standards. In the case of beta-ray sources, the recommended quantity is the absorbed dose rate in water at a reference distance from the source. Moreover, there are other important quantities, as the depth dose curves and the source uniformity for beta-ray plaque sources. In this work, depth dose curves were obtained and studied of five dermatological applicators, using thin thermoluminescent dosimeters of CaSO 4 :Dy and phantoms of PMMA with different thicknesses (between 1.0 mm and 5.0 mm) positioned between each applicator and the TL pellets. The depth dose curves obtained presented the expected attenuation response in PMMA, and the results were compared with data obtained for a 90 Sr+ 90 Y standard source reported by the IAEA, and they were considered satisfactory. (author)

  19. Determination of /sup 90/Sr in milk by solvent extraction of /sup 90/Y

    Energy Technology Data Exchange (ETDEWEB)

    Mitsuhashi, T [National Inst. of Animal Industry, Chiba (Japan); Sakanoue, M

    1977-10-01

    In order to replace the conventional method using violent fuming nitric acid, a new method for the determination of /sup 90/Sr in milk has been developed by using the solvent extraction with bis (2-ethylhexyl) phosphoric acid (HDEHP). The daughter nuclide /sup 90/Y in a radiochemical equilibrium with its parent /sup 90/Sr was extracted with 2:1 HDEHP-toluene from the acid solution (1M HCl) of milk ash sample prepared by dry-ashing. After stripping with 8M HCl, /sup 90/Y, together with stable yttrium added as carrier, was precipitated as oxalate to prepare ..beta..-counting source. The radiochemical purity was confirmed by decay curve. The decontamination of strontium was checked by applying non-dispersive fluorescence x-ray analysis using /sup 133/Ba as irradiating source. Bone samples of cow were also analyzed by the same method and the results were compared with those obtained by other methods. The duplicate crosschecking analyses of finely ground bone samples were carried out to examine the effectiveness of this method. This simple new method was found to be very effective for the routine analysis of /sup 90/Sr in these samples.

  20. Determination of 90Sr in milk by solvent extraction of 90Y

    International Nuclear Information System (INIS)

    Mitsuhashi, Toshihiko; Sakanoue, Masanobu.

    1977-01-01

    In order to replace the conventional method using violent fuming nitric acid, a new method for the determination of 90 Sr in milk has been developed by using the solvent extraction with bis (2-ethylhexyl) phosphoric acid (HDEHP). The daughter nuclide 90 Y in a radiochemical equilibrium with its parent 90 Sr was extracted with 2:1 HDEHP-toluene from the acid solution (1M HCl) of milk ash sample prepared by dry-ashing. After stripping with 8M HCl, 90 Y, together with stable yttrium added as carrier, was precipitated as oxalate to prepare β-counting source. The radiochemical purity was confirmed by decay curve. The decontamination of strontium was checked by applying non-dispersive fluorescence x-ray analysis using 133 Ba as irradiating source. Bone samples of cow were also analyzed by the same method and the results were compared with those obtained by other methods. The duplicate crosschecking analyses of finely ground bone samples were carried out to examine the effectiveness of this method. This simple new method was found to be very effective for the routine analysis of 90 Sr in these samples. (auth.)

  1. Effect of pulmonary irradiation from inhaled 90Y on immunity to Listeria monocytogenes in mice

    International Nuclear Information System (INIS)

    Sanchez, A.; Lundgren, D.L.; McClellan, R.O.

    1976-01-01

    The immunological response of mice subjected to irradiation from particles deposited in the lungs and challenged with Listeria monocytogenes was investigated. Mice, exposed by inhalation to 90 Y (a beta-emitting radionuclide) in relatively insoluble fused aluminosilicate particles, were immunized with L. monocytogenes either before or after exposure. Two additional groups of mice were either immunized or irradiated only. A group of control mice received no irradiation or immunization. The beta radiation dose absorbed by the lungs of each mouse at time of challenge averaged 10,000 rads. Fourteen days after immunization, all mice were challenged with 2 LD 50 doses of L. monocytogenes via the respiratory route. Survival of all immunized mice either with or without exposure to 90 Y varied from 90 to 100% as compared to 10 to 20% for the mice irradiated only and for control mice through 14 days after challenge. Pulmonary clearance of inhaled L. monocytogenes during the first 4 hr after challenge was suppressed in the mice irradiated only but not in those immunized only, or in the immunized and irradiated groups, and control mice. There appeared to be a suppression of proliferation of L. monocytogenes in lungs and spleen in the immunized groups 72 hr after challenge, whereas the lungs and spleens of the mice irradiated only and the control mice had extensive bacterial invasion. It was concluded that the 10,000 rads of beta radiation absorbed by the lungs did not suppress the immune mechanisms of the immunized mice

  2. Thermoluminescent dosimetry of beta radiations of 90 Sr/ 90 Y using ZrO2: Eu

    International Nuclear Information System (INIS)

    Olvera T, L.; Azorin N, J.; Barrera S, M.; Soto E, A.M.; Rivera M, T.

    2005-01-01

    In this work the results of studying the thermoluminescent properties (TL) of the doped zirconium oxide with europium (ZrO 2 : Eu 3+ ) before beta radiations of 90 Sr/ 90 Y are presented. The powders of ZrO 2 : Eu 3+ were obtained by means of the sol-gel technique and they were characterized by means of thermal analysis and by X-ray diffraction. The powders of ZrO 2 : Eu 3+ , previously irradiated with beta particles of 90 Sr/ 90 Y, presented a thermoluminescent curve with two peaks at 204 and 292 C respectively. The TL response of the ZrO 2 : Eu 3+ as function of the absorbed dose was lineal from 2 Gy up to 90 Gy. The fading of the information of the ZrO 2 : Eu 3+ was of 10% the first 2 hours remaining almost constant the information by the following 30 days. The ZrO 2 doped with the (Eu 3+ ) ion it was found more sensitive to the beta radiation that the one of zirconium oxide without doping (ZrO 2 ) obtained by the same method. Those studied characteristics allow to propose to the doped zirconium oxide with europium like thermoluminescent dosemeter for the detection of the beta radiation. (Author)

  3. Development of a dosimetric system for 90Sr + 90Y betatherapy applicators

    International Nuclear Information System (INIS)

    Coelho, Talita Salles

    2010-01-01

    The 90 Sr+ 90 Y applicators, used in betatherapy for prevention of keloids and pterigium, are imported and many times their dosimetric features are shown only in an illustrated form by the manufacturers. The exhaustive routine of the medical physicists in the clinic do not make possible the accomplishment of procedures for the confirmation of these parameters. This work presents the development of a methodology for the dosimetry of 90 Sr+ 90 Y betatherapy applicators. The Monte Carlo code MCNP5 was used for the simulation of the percentage depth dose curves and dose distribution profiles produced by these applicators. The experimental measurements of the radial and axial radiation attenuation, have been done with a mini-extrapolation chamber, thermoluminescent dosimeters and radiographic films. The experimental results have been compared with the simulated values. Both percentage depth dose curves and the radial dose profiles, the theoretical and the experimental ones, have presented good agreement, which may validate the use of the MCNP5 for these simulations, confirming the viability of the usage of this method in procedures of beta emitter sources dosimetry. (author)

  4. Thermoluminescent dosimetry of beta radiations of 90 Sr/ 90 Y using amorphous ZrO2

    International Nuclear Information System (INIS)

    Rivera M, T.; Olvera T, L.; Azorin N, J.; Barrera R, M.; Soto E, A.M.

    2005-01-01

    In this work the results of studying the thermoluminescent properties (Tl) of the zirconium oxide in its amorphous state (ZrO 2 -a) before beta radiations of 90 Sr/ 90 Y are presented. The amorphous powders of the zirconium oxide were synthesized by means of the sol-gel technique. The sol-gel process using alkoxides like precursors, is an efficient method to prepare a matrix of zirconium oxide by hydrolysis - condensation of the precursor to form chains of Zr-H 3 and Zr-O 2 . One of the advantages of this technique is the obtention of gels at low temperatures with very high purity and homogeneity. The powders were characterized by means of thermal analysis and by X-ray diffraction. The powders of ZrO 2 -a, previously irradiated with beta particles of 90 Sr/ 90 Y, presented a thermoluminescent curve with two peaks at 150 and 257 C. The dissipation of the information of the one ZrO 2 -a was of 40% the first 2 hours remaining constant the information for the following 30 days. The reproducibility of the information was of ± 2.5% in standard deviation. The studied characteristics allow to propose to the amorphous zirconium oxide as thermoluminescent dosemeter for the detection of beta radiation. (Author)

  5. Somatostatin-based Radiopeptide Therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in Neuroendocrine Tumors

    OpenAIRE

    Romer A Seiler D Marincek N Brunner P Koller MT Ng QK Maecke HR Muller-Brand J Rochlitz C B

    2014-01-01

    PURPOSE: Somatostatin based radiopeptide treatment is generally performed using the ß emitting radionuclides (90)Y or (177)Lu. The present study aimed at comparing benefits and harms of both therapeutic approaches. METHODS: In a comparative cohort study patients with advanced neuroendocrine tumours underwent repeated cycles of [(90)Y DOTA] TOC or [(177)Lu DOTA] TOC until progression of disease or permanent adverse events. Multivariable Cox regression and competing risks regression were emplo...

  6. An Overview of the Production, Quality Control and Feasibility of Using 90Y as a Therapeutic Radionuclide

    International Nuclear Information System (INIS)

    Venkatesh, M.

    2009-01-01

    90 Y is increasingly accepted world wide as a radionuclide for in-vivo therapy owing to attractive decay features (T1/2 2.67 d; Eβ max 2.28 MeV) and viable production feasibility in high specific activities. 90 Y is most often recommended for treatment of large tumour lesions as the hard β rays are effective in delivering therapeutic dose to large volume. However, possibility of high radiation dose to the critical organs such as bone marrow and kidneys is an important concern that is given due weightage while designing therapy using 90 Y. The best route to avail 90 Y for therapy applications is from 90 Sr, though neutron actiation of natural 89 Y(100% abundance) is feasible. The absorption cross section σ is barely 1.38 b, resulting in low specific activity 90 Y which is useful for limited applications. The possibility of obtaining 90Y through a radionuclide generator as the daughter of a long lived parent 90 Sr (T1/2 28.9 y) is a major advantage that enables access to high specific activity 90 Y. Transporting the 90Y activity to a user institution from a centralized production facility is reasonably feasible and this facilitates its wide spread use. Several generator designs have been developed and reported to access 90 Y. Solvent extraction using a chelating molecule in an organic solvent (0.3M HDEHP/n-dodecane), column chromatography using ion exchange resins (cationic as well as anionic; Dowex-50x8; AG 50x16; Aminex-A5) or inorganic exchanger, membrane based separation using chelating ligand impregnated membranes (CMPO in electrochemical separation are some of the methods reported. Limitations such as elution of 90 Y after initial elution of 90 Sr, availability of 90 Y as a chelated complex which then has to be treated to enable labeling the molecule of interest, possibility of obtaining small quantities of 90 Y owing to radiolytic damages to the separation system components, paucity of special automation gadgets for handling the high activities remotely

  7. Total Lesion Glycolysis and Sequential (90)Y-Selective Internal Radiation Therapy in Breast Cancer Liver Metastases: Preliminary Results.

    Science.gov (United States)

    Bagni, Oreste; Filippi, Luca; Pelle, Giuseppe; Cianni, Roberto; Schillaci, Orazio

    2015-12-01

    To assess the prognostic role of total lesion glycolysis (TLG) in patients with breast cancer liver metastases (BCLM) after sequential lobar (90)Y-radioembolization ((90)Y-RE). Seventeen patients with bilobar BCLM underwent FDG PET/CT and TLG calculation before (90)Y-RE. The hepatic lobe with the highest TLG was treated in the first session. PET was performed 6 weeks postprocedure and decrease in TLG (ΔTLG) in the treated lobe was calculated before the second (90)Y administration. Subjects were divided in two groups (group 1: ΔTLG >50%, group 2: ΔTLG 50% and seven had a ΔTLG value 50% and ΔTLG <50% had a mean OS of 16.4 ± 0.6 and 10.3 ± 0.4 months, respectively (p < 0.001). Cox regression analysis demonstrated hepatic tumor load (p = 0.048) and ΔTLG as the only significant (p = 0.005) predictors of survival. ΔTLG after the first (90)Y administration agrees with final outcome in BCLM patients after separate sequential lobar (90)Y-RE.

  8. Electron and bremsstrahlung penetration and dose calculation

    Science.gov (United States)

    Watts, J. W., Jr.; Burrell, M. O.

    1972-01-01

    Various techniques for the calculation of electron and bremsstrahlung dose deposition are described. Energy deposition, transmission, and reflection coefficients for electrons incident on plane slabs are presented, and methods for their use in electron dose calculations were developed. A method using the straight-ahead approximation was also developed, and the various methods were compared and found to be in good agreement. Both accurate and approximate methods of calculating bremsstrahlung dose were derived and compared. Approximation is found to give a good estimate of dose where the electron spectrum falls off exponentially with energy.

  9. The TAC Radiation Source for Bremsstrahlung Application

    International Nuclear Information System (INIS)

    Demir, N.

    2008-01-01

    The TAC is a project for the first Turkish radiation source and currently design study is produced with funding from the DPT (State Planning Unity). Two main part of the project will be IR-FEL and Bremsstrahlung facility. Each LINAC will provide max. electron energy of 20 MeV. The Bremsstrahlung facility at TAC will consist two of the LINAC module and will be obtained 35 MeV photon energy. This would provide a chance to investigate nuclear structure at this energy range and also some application of photonuclear physics. In this work the main parameter and plans for those of facility will be detailed

  10. Bremsstrahlung from relativistic heavy ions in matter

    DEFF Research Database (Denmark)

    Sørensen, Allan Hvidkjær

    2010-01-01

    The emission of electromagnetic radiation by relativistic bare heavy ions penetrating ordinary matter is investigated. Our main aim is to determine the bremsstrahlung which we define as the radiation emitted when the projectile does not break up. It pertains to collisions without nuclear contact....... As a result of its relative softness, bremsstrahlung never dominates the energy-loss process for heavy ions. As to the emission of electromagnetic radiation in collisions with nuclear break-up, it appears modest when pertaining to incoherent action of the projectile nucleons in noncontact collisions...

  11. Labeling an anti-CD20 monoclonal antibody with 90Y

    International Nuclear Information System (INIS)

    Perera Pintado, Alejandro; Leyva Montaña, René; Prats Capote, Anaís; Góngora Bravo, Magdiel; Alberti Ramírez, Alejandro; León, Mariela; Hernández González, Ignacio; Dorvignit, Denise

    2016-01-01

    Lymphomas are among the 10 leading causes of death, both in Cuba and in the world, with an increasing incidence in recent years. Follicular lymphoma low-grade (indolent) is one of the most common in the Western world, representing 1/3 of all non-Hodgkin lymphomas (NHL). More than 90% of patients present with disseminated disease at diagnosis and generally have a slow evolution and good response to conventional treatment; but radically changed its forecast to relapse, resistance to therapeutic and histologic transformation can occur. The monoclonal antibody therapy has been a promising therapeutic. In this respect CD20 antigen it has been considered one of the most attractive targets in the therapy of follicular B cell lymphoma This is expressed in more than 90% of cases, while not present in stem cells and lines progenitors. Despite the success of immunotherapy, the relapse rate is still considerable. In order to increase the cytotoxic potential of immunotherapy, marked with beta emitting radionuclides alpha particles or monoclonal antibodies are used today. Despite encouraging results in patients with non-Hodgkin lymphomas refractory to other treatments, the extremely high costs of these commercial radiopharmaceuticals have greatly limited its application, even in the first world. A sustainable alternative is the marking of other anti-CD20 monoclonal antibodies, so researchers from several countries have concentrated their efforts on rituximaby other similar antibodies labeled with therapeutic radionuclides, as a possible cost-effectively to more problem. Today in Cuba it has an electrolytic generator 90 Sr- 90 Y Isotope Center, which ensures the availability of the radionuclide. In addition, the chimeric MAb rituximab is applied as part of the therapy of NHL in its health system and, recently, the Center for Molecular Immunology has obtained a chimeric monoclonal anti-CD20 antibody biosimilar rituximab, which is in phase clinical trial; which opens prospects for

  12. Occupational radiation exposure of medical staff performing 90Y-loaded microsphere radioembolization

    International Nuclear Information System (INIS)

    Laffont, Sophie; Ardisson, Valerie; Lenoir, Laurence; Rolland, Yan; Rohou, Tanguy; Edeline, Julien; Pracht, Marc; Sourd, Samuel Le; Lepareur, Nicolas; Garin, Etienne

    2016-01-01

    Radioembolization of liver cancer with 90 Y-loaded microspheres is increasingly used but data regarding hospital staff exposure are scarce. We evaluated the radiation exposure of medical staff while preparing and injecting 90 Y-loaded glass and resin microspheres especially in view of the increasing use of these products. Exposure of the chest and finger of the radiopharmacist, nuclear medicine physician and interventional radiologist during preparation and injection of 78 glass microsphere preparations and 16 resin microsphere preparations was monitored. Electronic dosimeters were used to measure chest exposure and ring dosimeters were used to measure finger exposure. Chest exposure was very low for both products used (<10 μSv from preparation and injection). In our experience, finger exposure was significantly lower than the annual limit of 500 mSv for both products. With glass microspheres, the mean finger exposure was 13.7 ± 5.2 μSv/GBq for the radiopharmacist, and initially 17.9 ± 5.4 μSv/GBq for the nuclear medicine physician reducing to 13.97 ± 7.9 μSv/GBq with increasing experience. With resin microspheres, finger exposure was more significant: mean finger exposure for the radiopharmacist was 295.1 ± 271.9 μSv/GBq but with a reduction with increasing experience to 97.5 ± 35.2 μSv/GBq for the six most recent dose preparations. For administration of resin microspheres, the greatest mean finger exposure for the nuclear medicine physician (the most exposed operator) was 235.5 ± 156 μSv/GBq. Medical staff performing 90 Y-loaded microsphere radioembolization procedures are exposed to safe levels of radiation. Exposure is lower than that from treatments using 131 I-lipiodol. The lowest finger exposure is from glass microspheres. With resin microspheres finger exposure is acceptable but could be optimized in accordance with the ALARA principle, and especially in view of the increasing use of radioembolization. (orig.)

  13. Individualized dosimetry-based activity reduction of {sup 90}Y-DOTATOC prevents severe and rapid kidney function deterioration from peptide receptor radionuclide therapy

    Energy Technology Data Exchange (ETDEWEB)

    Binnebeek, Sofie van; Baete, Kristof; Vanbilloen, Bert; Terwinghe, Christelle; Mortelmans, Luc [University Hospitals Leuven, Nuclear Medicine, Leuven (Belgium); KU Leuven, Department of Imaging and Pathology, Leuven (Belgium); Koole, Michel [University Medical Centre Groningen, Department of Nuclear Medicine, Groningen (Netherlands); Mottaghy, Felix M. [University Hospital Aachen, Department of Nuclear Medicine, Aachen (Germany); Maastricht University Medical Center, Department of Nuclear Medicine, Maastricht (Netherlands); Clement, Paul M. [University Hospitals Leuven, Medical Oncology, Leuven (Belgium); KU Leuven, Laboratory of Experimental Oncology, Leuven (Belgium); Haustermans, Karin [University Hospitals Leuven, Radiation Oncology, Leuven (Belgium); KU Leuven, Department of Oncology, Leuven (Belgium); Cutsem, Eric van; Verslype, Chris [KU Leuven, Department of Oncology, Leuven (Belgium); University Hospitals Leuven, Division of Digestive Oncology, Leuven (Belgium); Verbruggen, Alfons [KU Leuven, Laboratory for Radiopharmacy, Leuven (Belgium); Bogaerts, Kris [KU Leuven, Division of Public Health and Primary Care (I-Biostat), Leuven (Belgium); Deroose, Christophe M. [University Hospitals Leuven, Nuclear Medicine, Leuven (Belgium); KU Leuven, Department of Imaging and Pathology, Leuven (Belgium); UZ Leuven, Nuclear Medicine, Leuven (Belgium)

    2014-06-15

    Assessment of kidney function evolution after {sup 90}Y-DOTATOC peptide receptor radionuclide therapy (PRRT) with capped activity administration based on a 37-Gy threshold of biological effective dose (BED) to the kidney. In a prospective phase II study, patients with metastasized neuroendocrine tumours were evaluated for therapy using 185 MBq {sup 111}In-pentetreotide with amino acid coinfusion. Planar whole-body images were acquired at four time-points after injection and kidney volumes were measured using CT/MRI. BED to the kidneys was estimated using an extended BED formula and biexponential renal clearance. Based on published BED dose-toxicity relationships, we allowed a maximal kidney BED of 37 Gy; if the calculated BED exceeded 37 Gy, treatment activity was reduced accordingly. Kidney function was assessed at baseline and at 18 months, predominantly using {sup 51}Cr-EDTA. The rate of renal function decline was expressed as annual glomerular filtration rate loss (aGFRL). Only 22 of 50 patients reached the 18-months time-point, with most missing patients having died due to disease progression. In the 22 patients who reached 18 months, no rapid kidney function deterioration was observed over the 18 months, aGFRL >33 % was not seen, and only three patients showed an increase of one toxicity grade and one patient an increase of two grades. No significant correlations between kidney volume (p = 0.35), baseline GFR (p = 0.18), risk factors for renal function loss (p = 0.74) and aGFRL were observed. Among the 28 patients who did not reach 18 months, one developed grade 4 kidney toxicity at 15 months after PRRT. Prospective dosimetry using a 37 Gy BED as the threshold for kidney toxicity is a good guide for {sup 90}Y-DOTATOC PRRT and is associated with a low risk of rapid renal function deterioration and evolution to severe nephrotoxicity. (orig.)

  14. Biokinetics and dosimetry in patients administered with 111In-DOTA-Tyr3-octreotide: implications for internal radiotherapy with 90Y-DOTATOC

    International Nuclear Information System (INIS)

    Cremonesi, M.; Ferrari, M.; Maecke, H.R.; Tosi, G.; Zoboli, S.; Chinol, M.; Fiorenza, M.; Paganelli, G.; Stabin, M.G.; Orsi, F.O.; Jermann, E.; Robertson, C.

    1999-01-01

    Recent advances in receptor-mediated tumour imaging have resulted in the development of a new somatostatin analogue, DOTA-dPhe 1 -Tyr 3 -octreotide. This new compound, named DOTATOC, has shown high affinity for somatostatin receptors, ease of labelling and stability with yttrium-90 and favourable biodistribution in animal models. The aim of this work was to evaluate the biodistribution and dosimetry of DOTATOC radiolabelled with indium-111, in anticipation of therapy trials with 90 Y-DOTATOC in patients. Eighteen patients were injected with DOTATOC (10 μg), labelled with 150-185 MBq of 111 In. Blood and urine samples were collected throughout the duration of the study (0-2 days). Planar and single-photon emission tomography images were acquired at 0.5, 3-4, 24 and 48 h and time-activity curves were obtained for organs and tumours. A compartmental model was used to determine the kinetic parameters for each organ. Dose calculations were performed according to the MIRD formalism. Specific activities of >37 GBq/ μmol were routinely achieved. Patients showed no acute or delayed adverse reactions. The residence time for 111 In-DOTATOC in blood was 0.9±0.4 h. The injected activity excreted in the urine in the first 24 h was 73%±11%. The agent localized primarily in spleen, kidneys and liver. The residence times in source organs were: 2.2±1.8 h in spleen, 1.7±1.2 h in kidneys, 2.4±1.9 h in liver, 1.5±0.3 h in urinary bladder and 9.4±5.5 h in the remainder of the body; the mean residence time in tumour was 0.47 h (range: 0.03-6.50 h). Based on our findings, the predicted absorbed doses for 90 Y-DOTATOC would be 7.6±6.3 (spleen), 3.3±2.2 (kidneys), 0.7±0.6 (liver), 2.2±0.3 (bladder), 0.03±0.01 (red marrow) and 10.1 (range: 1.4-31.0) (tumour) mGy/MBq. These results indicate that high activities of 90 Y-DOTATOC can be administered with low risk of myelotoxicity, although with potentially high radiation doses to the spleen and kidneys. Tumour doses were high

  15. Biokinetics and dosimetry in patients administered with {sup 111}In-DOTA-Tyr{sup 3}-octreotide: implications for internal radiotherapy with {sup 90}Y-DOTATOC

    Energy Technology Data Exchange (ETDEWEB)

    Cremonesi, M.; Ferrari, M.; Maecke, H.R.; Tosi, G. [Department of Health Physics, European Institute of Oncology, Milan (Italy); Zoboli, S.; Chinol, M.; Fiorenza, M.; Paganelli, G. [Division of Nuclear Medicine, European Institute of Oncology, via Ripamonti, 435, I-20141-Milan (Italy); Stabin, M.G. [Nuclear Energy Department, Recife, Pernambuco (Brazil); Orsi, F.O. [Department of Radiology, European Institute of Oncology, Milan (Italy); Jermann, E. [Nuclear Medicine Department, University of Basel (Switzerland); Robertson, C. [Department of Epidemiology and Biostatistics, European Institute of Oncology, Milan (Italy)

    1999-08-01

    Recent advances in receptor-mediated tumour imaging have resulted in the development of a new somatostatin analogue, DOTA-dPhe{sup 1}-Tyr{sup 3}-octreotide. This new compound, named DOTATOC, has shown high affinity for somatostatin receptors, ease of labelling and stability with yttrium-90 and favourable biodistribution in animal models. The aim of this work was to evaluate the biodistribution and dosimetry of DOTATOC radiolabelled with indium-111, in anticipation of therapy trials with {sup 90}Y-DOTATOC in patients. Eighteen patients were injected with DOTATOC (10 {mu}g), labelled with 150-185 MBq of {sup 111}In. Blood and urine samples were collected throughout the duration of the study (0-2 days). Planar and single-photon emission tomography images were acquired at 0.5, 3-4, 24 and 48 h and time-activity curves were obtained for organs and tumours. A compartmental model was used to determine the kinetic parameters for each organ. Dose calculations were performed according to the MIRD formalism. Specific activities of >37 GBq/ {mu}mol were routinely achieved. Patients showed no acute or delayed adverse reactions. The residence time for {sup 111}In-DOTATOC in blood was 0.9{+-}0.4 h. The injected activity excreted in the urine in the first 24 h was 73%{+-}11%. The agent localized primarily in spleen, kidneys and liver. The residence times in source organs were: 2.2{+-}1.8 h in spleen, 1.7{+-}1.2 h in kidneys, 2.4{+-}1.9 h in liver, 1.5{+-}0.3 h in urinary bladder and 9.4{+-}5.5 h in the remainder of the body; the mean residence time in tumour was 0.47 h (range: 0.03-6.50 h). Based on our findings, the predicted absorbed doses for {sup 90}Y-DOTATOC would be 7.6{+-}6.3 (spleen), 3.3{+-}2.2 (kidneys), 0.7{+-}0.6 (liver), 2.2{+-}0.3 (bladder), 0.03{+-}0.01 (red marrow) and 10.1 (range: 1.4-31.0) (tumour) mGy/MBq. These results indicate that high activities of {sup 90}Y-DOTATOC can be administered with low risk of myelotoxicity, although with potentially high radiation

  16. Biokinetics and dosimetry in patients administered with [sup 111]In-DOTA-Tyr[sup 3]-octreotide: implications for internal radiotherapy with [sup 90]Y-DOTATOC

    Energy Technology Data Exchange (ETDEWEB)

    Cremonesi, M.; Ferrari, M.; Maecke, H.R.; Tosi, G. (Department of Health Physics, European Institute of Oncology, Milan (Italy)); Zoboli, S.; Chinol, M.; Fiorenza, M.; Paganelli, G. (Division of Nuclear Medicine, European Institute of Oncology, via Ripamonti, 435, I-20141-Milan (Italy)); Stabin, M.G. (Nuclear Energy Department, Recife, Pernambuco (Brazil)); Orsi, F.O. (Department of Radiology, European Institute of Oncology, Milan (Italy)); Jermann, E. (Nuclear Medicine Department, University of Basel (Switzerland)); Robertson, C. (Department of Epidemiology and Biostatistics, European Institute of Oncology, Milan (Italy))

    1999-08-01

    Recent advances in receptor-mediated tumour imaging have resulted in the development of a new somatostatin analogue, DOTA-dPhe[sup 1]-Tyr[sup 3]-octreotide. This new compound, named DOTATOC, has shown high affinity for somatostatin receptors, ease of labelling and stability with yttrium-90 and favourable biodistribution in animal models. The aim of this work was to evaluate the biodistribution and dosimetry of DOTATOC radiolabelled with indium-111, in anticipation of therapy trials with [sup 90]Y-DOTATOC in patients. Eighteen patients were injected with DOTATOC (10 [mu]g), labelled with 150-185 MBq of [sup 111]In. Blood and urine samples were collected throughout the duration of the study (0-2 days). Planar and single-photon emission tomography images were acquired at 0.5, 3-4, 24 and 48 h and time-activity curves were obtained for organs and tumours. A compartmental model was used to determine the kinetic parameters for each organ. Dose calculations were performed according to the MIRD formalism. Specific activities of >37 GBq/ [mu]mol were routinely achieved. Patients showed no acute or delayed adverse reactions. The residence time for [sup 111]In-DOTATOC in blood was 0.9[+-]0.4 h. The injected activity excreted in the urine in the first 24 h was 73%[+-]11%. The agent localized primarily in spleen, kidneys and liver. The residence times in source organs were: 2.2[+-]1.8 h in spleen, 1.7[+-]1.2 h in kidneys, 2.4[+-]1.9 h in liver, 1.5[+-]0.3 h in urinary bladder and 9.4[+-]5.5 h in the remainder of the body; the mean residence time in tumour was 0.47 h (range: 0.03-6.50 h). Based on our findings, the predicted absorbed doses for [sup 90]Y-DOTATOC would be 7.6[+-]6.3 (spleen), 3.3[+-]2.2 (kidneys), 0.7[+-]0.6 (liver), 2.2[+-]0.3 (bladder), 0.03[+-]0.01 (red marrow) and 10.1 (range: 1.4-31.0) (tumour) mGy/MBq. These results indicate that high activities of [sup 90]Y-DOTATOC can be administered with low risk of myelotoxicity, although with potentially high radiation

  17. Separation of 90Y from 90Sr by solvent extraction with ionizable crown ethers

    International Nuclear Information System (INIS)

    Wood, D.J.; Elshani, S.; Du, H.S.; Natale, N.R.; Wai, C.M.

    1993-01-01

    Sym-Dibenzo-16-crown-5-oxyacetic acid and its analogues are selective for the extraction of Y 3+ over Sr 2+ from aqueous solutions into chloroform. The selectivity and the pH range of extraction are influenced by the structure of the ligand. The size of the macrocyclic cavity, the tether length of the lariat, the attachment of alkyl functional groups to the lariat, and the identity of the ionizable group can affect selectivity and extraction efficiency. When the carboxylic acid at the terminal end of the lariat is replaced by a hydroxamic acid, the selectivity for Y 3+ over Sr 2+ is significantly increased. Using these ionizable crown ethers as extractants, 90 Y fractions of greater than 99.9% purity can be obtained in a single solvent extraction step from solutions of 90 Sr. 11 refs., 5 figs., 2 tabs

  18. Treatment of neuroendocrine tumors (NETs) expressing SMT 90Y and 177Lu

    International Nuclear Information System (INIS)

    Oliva González, Juan P.; Baum, Richard

    2016-01-01

    Neuroendocrine tumors (NETs) are a relatively rare and extremely heterogeneous group, essentially characterized by a different metabolism and endocrine histologically pattern. NETs are a challenge for physicians not only for diagnosis but also for early treatment. In addition to this, QT or RT treatments that require a high rate of cell proliferation to be effective, they are not in these tumors as slow growth. The primary treatment of NETs is surgery, either with a curative intent or tumor shrinkage. Peptide Receptors Radiotherapy (RTPR) consists of the administration for therapeutic purposes of Radiolabeled Synthetic Peptides that bind specifically and with high affinity to receptors of tumor cells. The RTPR of TNE with SMT analogues is effective for handling or metastizados inoperable patients. The Conference gives an accurate picture of the treatment of these tumors both 90 Y as 177 Lu. (author)

  19. A data acquisition system for indentification of 90Sr/ 90Y in environmental samples

    International Nuclear Information System (INIS)

    Medin, G.; Brajnik, D.; Starcic, M.; Stanovnik, A.

    1996-01-01

    Often, in the stage of research and development of new techniques for detection of ionizing radiation, elaborate electronic systems are required. In this paper, we describe the relatively complex detector and electronic system used for a relatively simple but nevertheless demanding measurement of the beta emitting radionuclides 90 Sr/ 90 Y in environmental samples. The detection limit of 1 Bq in a thin, disc-shaped sample, was obtained by careful elimination of background. Contribution of other radionuclides in the sample, were eliminated or at least considerably reduced by using a silica aerogel as Cherenkov radiator and thin multiwire chamber in coincidence. Cosmic ray signals were reduced by large scintillation counters in anticoincidence. Finally, persisting RF pick-up signals were eliminated by using the signal from a wire antenna and identical MWPC preamplifier and discriminator for a veto to the master coincidence. For each accepted event, both timing and pulse height information was recorded with a personal computer

  20. Interstitial pituitary irradiation with 90Y for the treatment of acromomegaly

    International Nuclear Information System (INIS)

    Cassar, J.; Doyle, F.H.; Banks, L.M.; Jadresic, A.; Mashiter, K.; Joplin, G.F.

    1981-01-01

    The management of 54 acromegalics referred to us between 1974 and 1978 has been analysed. Twenty-two patients were treated with pituitary implants of yttrium-90 ( 90 Y). Eleven are in complete remission (mean growth hormone (GH) < 11 mlU/l), 8 had improved (mean GH 11-20 mlU/l or 50% less than preoperatively) and 3 were poor responders. Two patients had temporary 6th nerve paresis. Seven patients are on replacement therapy. Thirty- one patients were not implanted for the following reasons with a number of patients having more than one: extension of the tumour into the spehnoid sinus 10, or above the sella 3, partially empty sella 9, internal carotids too close to midline 2, invisible landmarks 1, mild acromegaly 6, poor general health 3, declined investigations or operation 6. It is concluded that pituitary implant of yttrium is an effective and safe form of treatment on carefully selected patients. (author)

  1. Characterization of an extrapolation chamber in a 90Sr/90Y beta radiation field

    International Nuclear Information System (INIS)

    Oramas Polo, I.; Tamayo Garcia, J. A.

    2015-01-01

    The extrapolation chamber is a parallel plate chamber and variable volume based on the Bragg-Gray theory. It determines in absolute mode, with high accuracy the dose absorbed by the extrapolation of the ionization current measured for a null distance between the electrodes. This camera is used for dosimetry of external beta rays for radiation protection. This paper presents the characterization of an extrapolation chamber in a 90 Sr/ 90 Y beta radiation field. The absorbed dose rate to tissue at a depth of 0.07 mm was calculated and is (0.13206±0.0028) μGy. The extrapolation chamber null depth was determined and its value is 60 μm. The influence of temperature, pressure and humidity on the value of the corrected current was also evaluated. Temperature is the parameter that has more influence on this value and the influence of pressure and the humidity is not very significant. Extrapolation curves were obtained. (Author)

  2. A method for energy window optimization for quantitative tasks that includes the effects of model-mismatch on bias: application to Y-90 bremsstrahlung SPECT imaging

    International Nuclear Information System (INIS)

    Rong Xing; Du Yong; Frey, Eric C

    2012-01-01

    Quantitative Yttrium-90 ( 90 Y) bremsstrahlung single photon emission computed tomography (SPECT) imaging has shown great potential to provide reliable estimates of 90 Y activity distribution for targeted radionuclide therapy dosimetry applications. One factor that potentially affects the reliability of the activity estimates is the choice of the acquisition energy window. In contrast to imaging conventional gamma photon emitters where the acquisition energy windows are usually placed around photopeaks, there has been great variation in the choice of the acquisition energy window for 90 Y imaging due to the continuous and broad energy distribution of the bremsstrahlung photons. In quantitative imaging of conventional gamma photon emitters, previous methods for optimizing the acquisition energy window assumed unbiased estimators and used the variance in the estimates as a figure of merit (FOM). However, for situations, such as 90 Y imaging, where there are errors in the modeling of the image formation process used in the reconstruction there will be bias in the activity estimates. In 90 Y bremsstrahlung imaging this will be especially important due to the high levels of scatter, multiple scatter, and collimator septal penetration and scatter. Thus variance will not be a complete measure of reliability of the estimates and thus is not a complete FOM. To address this, we first aimed to develop a new method to optimize the energy window that accounts for both the bias due to model-mismatch and the variance of the activity estimates. We applied this method to optimize the acquisition energy window for quantitative 90 Y bremsstrahlung SPECT imaging in microsphere brachytherapy. Since absorbed dose is defined as the absorbed energy from the radiation per unit mass of tissues in this new method we proposed a mass-weighted root mean squared error of the volume of interest (VOI) activity estimates as the FOM. To calculate this FOM, two analytical expressions were derived for

  3. A method for energy window optimization for quantitative tasks that includes the effects of model-mismatch on bias: application to Y-90 bremsstrahlung SPECT imaging.

    Science.gov (United States)

    Rong, Xing; Du, Yong; Frey, Eric C

    2012-06-21

    Quantitative Yttrium-90 ((90)Y) bremsstrahlung single photon emission computed tomography (SPECT) imaging has shown great potential to provide reliable estimates of (90)Y activity distribution for targeted radionuclide therapy dosimetry applications. One factor that potentially affects the reliability of the activity estimates is the choice of the acquisition energy window. In contrast to imaging conventional gamma photon emitters where the acquisition energy windows are usually placed around photopeaks, there has been great variation in the choice of the acquisition energy window for (90)Y imaging due to the continuous and broad energy distribution of the bremsstrahlung photons. In quantitative imaging of conventional gamma photon emitters, previous methods for optimizing the acquisition energy window assumed unbiased estimators and used the variance in the estimates as a figure of merit (FOM). However, for situations, such as (90)Y imaging, where there are errors in the modeling of the image formation process used in the reconstruction there will be bias in the activity estimates. In (90)Y bremsstrahlung imaging this will be especially important due to the high levels of scatter, multiple scatter, and collimator septal penetration and scatter. Thus variance will not be a complete measure of reliability of the estimates and thus is not a complete FOM. To address this, we first aimed to develop a new method to optimize the energy window that accounts for both the bias due to model-mismatch and the variance of the activity estimates. We applied this method to optimize the acquisition energy window for quantitative (90)Y bremsstrahlung SPECT imaging in microsphere brachytherapy. Since absorbed dose is defined as the absorbed energy from the radiation per unit mass of tissues in this new method we proposed a mass-weighted root mean squared error of the volume of interest (VOI) activity estimates as the FOM. To calculate this FOM, two analytical expressions were

  4. Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours

    International Nuclear Information System (INIS)

    Romer, A.; Seiler, D.; Brunner, P.; Ng, Q.K.T.; Mueller-Brand, J.; Marincek, N.; Walter, M.A.; Koller, M.T.; Maecke, H.R.; Rochlitz, C.; Briel, M.; Schindler, C.

    2014-01-01

    Somatostatin-based radiopeptide treatment is generally performed using the β-emitting radionuclides 90 Y or 177 Lu. The present study aimed at comparing benefits and harms of both therapeutic approaches. In a comparative cohort study, patients with advanced neuroendocrine tumours underwent repeated cycles of [ 90 Y-DOTA]-TOC or [ 177 Lu-DOTA]-TOC until progression of disease or permanent adverse events. Multivariable Cox regression and competing risks regression were employed to examine predictors of survival and adverse events for both treatment groups. Overall, 910 patients underwent 1,804 cycles of [ 90 Y-DOTA]-TOC and 141 patients underwent 259 cycles of [ 177 Lu-DOTA]-TOC. The median survival after [ 177 Lu-DOTA]-TOC and after [ 90 Y-DOTA]-TOC was comparable (45.5 months versus 35.9 months, hazard ratio 0.91, 95 % confidence interval 0.63-1.30, p = 0.49). Subgroup analyses revealed a significantly longer survival for [ 177 Lu-DOTA]-TOC over [ 90 Y-DOTA]-TOC in patients with low tumour uptake, solitary lesions and extra-hepatic lesions. The rate of severe transient haematotoxicities was lower after [ 177 Lu-DOTA]-TOC treatment (1.4 vs 10.1 %, p = 0.001), while the rate of severe permanent renal toxicities was similar in both treatment groups (9.2 vs 7.8 %, p = 0.32). The present results revealed no difference in median overall survival after [ 177 Lu-DOTA]-TOC and [ 90 Y-DOTA]-TOC. Furthermore, [ 177 Lu-DOTA]-TOC was less haematotoxic than [ 90 Y-DOTA]-TOC. (orig.)

  5. Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours.

    Science.gov (United States)

    Romer, A; Seiler, D; Marincek, N; Brunner, P; Koller, M T; Ng, Q K T; Maecke, H R; Müller-Brand, J; Rochlitz, C; Briel, M; Schindler, C; Walter, M A

    2014-02-01

    Somatostatin-based radiopeptide treatment is generally performed using the β-emitting radionuclides (90)Y or (177)Lu. The present study aimed at comparing benefits and harms of both therapeutic approaches. In a comparative cohort study, patients with advanced neuroendocrine tumours underwent repeated cycles of [(90)Y-DOTA]-TOC or [(177)Lu-DOTA]-TOC until progression of disease or permanent adverse events. Multivariable Cox regression and competing risks regression were employed to examine predictors of survival and adverse events for both treatment groups. Overall, 910 patients underwent 1,804 cycles of [(90)Y-DOTA]-TOC and 141 patients underwent 259 cycles of [(177)Lu-DOTA]-TOC. The median survival after [(177)Lu-DOTA]-TOC and after [(90)Y-DOTA]-TOC was comparable (45.5 months versus 35.9 months, hazard ratio 0.91, 95% confidence interval 0.63-1.30, p = 0.49). Subgroup analyses revealed a significantly longer survival for [(177)Lu-DOTA]-TOC over [(90)Y-DOTA]-TOC in patients with low tumour uptake, solitary lesions and extra-hepatic lesions. The rate of severe transient haematotoxicities was lower after [(177)Lu-DOTA]-TOC treatment (1.4 vs 10.1%, p = 0.001), while the rate of severe permanent renal toxicities was similar in both treatment groups (9.2 vs 7.8%, p = 0.32). The present results revealed no difference in median overall survival after [(177)Lu-DOTA]-TOC and [(90)Y-DOTA]-TOC. Furthermore, [(177)Lu-DOTA]-TOC was less haematotoxic than [(90)Y-DOTA]-TOC.

  6. Country report: Cuba. Local Production of 90Y And 188Re Radionuclides and Development of Radiopharmaceuticals for Therapy

    International Nuclear Information System (INIS)

    Xiques, Abmel; Hernández, Ignacio; Leyva, René; Pérez, Marylaine; Alonso, Luis Michel; Zamora, Minelys

    2010-01-01

    During the first period of this CRP we could test an efficient and reliable generator system based on ion-chromatography to obtain 90 Y from its parent radionuclide 90 Sr. This production scheme for 90 Y was outlined in the previous CRP related with the development of generator technologies. Quality parameters such as trace metals that can potentially interfere in the labeling of biomoléculas, 90 Y recovery, 90 Sr/ 90 Y ratio and radiation dose to bed matrix were evaluated. The results showed that high recovery and radionuclidic purity could be obtained for 90 Y during its repeated separation from the 90 Sr cow. No replacement or treatment of the cow were necessary and low waste generation and 90 Sr losses less that 0.1% after each run were also observed during the present study. A Fab’ fragment was enzimatically produced and purified from the monoclonal antibody h-R3 (Nimotuzumab®). The fragment and the parent antibody were successfully conjugated with DOTA and labeled with 90 Y. The radioinmunoconjugate thus obtained also exhibited a good 24 h in-vitro stability in an excess of DTPA. A 90 Y radiocoloid was prepared in a cromic phosphate particle for radiosynoviorthesis with promising results in animal models. Two alumina based 188 W/ 188 Re generators were prepared and their eluates were used in the labeling of hR3-DOTA conjugates. Quality control and in vivo evaluation in comparison with 99m Tc-hR3 showed very good results and similar pattern of distribution and pharmacokinetic and will be used in clinical trials for cancer patients. (author)

  7. Country report: Cuba. Local Production of {sup 90}Y And {sup 188}Re Radionuclides and Development of Radiopharmaceuticals for Therapy

    Energy Technology Data Exchange (ETDEWEB)

    Xiques, Abmel; Hernández, Ignacio; Leyva, René; Pérez, Marylaine; Alonso, Luis Michel; Zamora, Minelys [Centro de Isotopos (CENTIS) (Cuba)

    2010-07-01

    During the first period of this CRP we could test an efficient and reliable generator system based on ion-chromatography to obtain {sup 90}Y from its parent radionuclide {sup 90}Sr. This production scheme for {sup 90}Y was outlined in the previous CRP related with the development of generator technologies. Quality parameters such as trace metals that can potentially interfere in the labeling of biomoléculas, {sup 90}Y recovery, {sup 90}Sr/{sup 90}Y ratio and radiation dose to bed matrix were evaluated. The results showed that high recovery and radionuclidic purity could be obtained for {sup 90}Y during its repeated separation from the {sup 90}Sr cow. No replacement or treatment of the cow were necessary and low waste generation and {sup 90}Sr losses less that 0.1% after each run were also observed during the present study. A Fab’ fragment was enzimatically produced and purified from the monoclonal antibody h-R3 (Nimotuzumab®). The fragment and the parent antibody were successfully conjugated with DOTA and labeled with {sup 90}Y. The radioinmunoconjugate thus obtained also exhibited a good 24 h in-vitro stability in an excess of DTPA. A {sup 90}Y radiocoloid was prepared in a cromic phosphate particle for radiosynoviorthesis with promising results in animal models. Two alumina based {sup 188}W/{sup 188}Re generators were prepared and their eluates were used in the labeling of hR3-DOTA conjugates. Quality control and in vivo evaluation in comparison with {sup 99m}Tc-hR3 showed very good results and similar pattern of distribution and pharmacokinetic and will be used in clinical trials for cancer patients. (author)

  8. Time optimization of 90Sr measurements: Sequential measurement of multiple samples during ingrowth of 90Y

    International Nuclear Information System (INIS)

    Holmgren, Stina; Tovedal, Annika; Björnham, Oscar; Ramebäck, Henrik

    2016-01-01

    The aim of this paper is to contribute to a more rapid determination of a series of samples containing 90 Sr by making the Cherenkov measurement of the daughter nuclide 90 Y more time efficient. There are many instances when an optimization of the measurement method might be favorable, such as; situations requiring rapid results in order to make urgent decisions or, on the other hand, to maximize the throughput of samples in a limited available time span. In order to minimize the total analysis time, a mathematical model was developed which calculates the time of ingrowth as well as individual measurement times for n samples in a series. This work is focused on the measurement of 90 Y during ingrowth, after an initial chemical separation of strontium, in which it is assumed that no other radioactive strontium isotopes are present. By using a fixed minimum detectable activity (MDA) and iterating the measurement time for each consecutive sample the total analysis time will be less, compared to using the same measurement time for all samples. It was found that by optimization, the total analysis time for 10 samples can be decreased greatly, from 21 h to 6.5 h, when assuming a MDA of 1 Bq/L and at a background count rate of approximately 0.8 cpm. - Highlights: • An approach roughly a factor of three more efficient than an un-optimized method. • The optimization gives a more efficient use of instrument time. • The efficiency increase ranges from a factor of three to 10, for 10 to 40 samples.

  9. Long-term effect of 90Y pituitary implantation in acromegaly

    International Nuclear Information System (INIS)

    Jadresic, A.; Jimenez, L.E.; Joplin, G.F.

    1987-01-01

    This report examines the long-term trends in GH levels and pituitary function in a group of 38 acromegalic patients who were selected insofar as we were able to follow them up for more than 10 years after a single dose 90 Y interstitial pituitary irradiation as the sole treatment. Mean serum GH had fallen from 106 to 24 mIU/l within 3-6 months and then slowly declined to 4 mIU/l after 10 years. GH levels of ≤5 mIU/l during a 50 g oral glucose tolerance test were obtained in 8% of patients at 3-6 months and in 18% at 1 year, the cumulative percentage increasing to 53% at 10, and 76% at 14 years. The percentage of patients requiring hormone replacement therapy rose from nil pre-implant to 16% by 3-6 months, and then slowly increased to 39% by 14 years. Serial coned radiographs of the pituitary fossa were available for 32 patients. By 10 years, 16 showed thickening of the dorsum sellae and/or reduction of at least one diameter by 3 mm. Concerning symptoms, all 29 patients whose GH level fell to ≤5 mIU/l showed improvements, 22 becoming asymptomatic. Seven patients with lesser falls in GH levels (from a mean of 193 to a mean of 15 mIU/l) all improved, one becoming asymptomatic. Two showed no variation. These results show that 90 Y pituitary implants have a cumulative effect over the years in inducting remission and hypopituitarism in acromegalic patients, the early decline in GH levels being swifter than from other forms of irradiation. (author)

  10. Long-term effect of /sup 90/Y pituitary implantation in acromegaly

    Energy Technology Data Exchange (ETDEWEB)

    Jadresic, A.; Jimenez, L.E.; Joplin, G.F.

    1987-01-01

    This report examines the long-term trends in GH levels and pituitary function in a group of 38 acromegalic patients who were selected insofar as we were able to follow them up for more than 10 years after a single dose /sup 90/Y interstitial pituitary irradiation as the sole treatment. Mean serum GH had fallen from 106 to 24 mIU/l within 3-6 months and then slowly declined to 4 mIU/l after 10 years. GH levels of less than or equal to 5 mIU/l during a 50 g oral glucose tolerance test were obtained in 8% of patients at 3-6 months and in 18% at 1 year, the cumulative percentage increasing to 53% at 10, and 76% at 14 years. The percentage of patients requiring hormone replacement therapy rose from nil pre-implant to 16% by 3-6 months, and then slowly increased to 39% by 14 years. Serial coned radiographs of the pituitary fossa were available for 32 patients. By 10 years, 16 showed thickening of the dorsum sellae and/or reduction of at least one diameter by 3 mm. Concerning symptoms, all 29 patients whose GH level fell to less than or equal to 5 mIU/l showed improvements, 22 becoming asymptomatic. Seven patients with lesser falls in GH levels (from a mean of 193 to a mean of 15 mIU/l) all improved, one becoming asymptomatic. Two showed no variation. These results show that /sup 90/Y pituitary implants have a cumulative effect over the years in inducting remission and hypopituitarism in acromegalic patients, the early decline in GH levels being swifter than from other forms of irradiation.

  11. Probing few-body systems with bremsstrahlung

    NARCIS (Netherlands)

    Kalantar-Nayestanaki, N; Kruppa, AT; Lovas, RG

    2002-01-01

    A series of bremsstrahlung measurements have been performed with the superconducting cyclotron, AGOR, at KVI. These measurements, on the proton-proton and proton-deuteron systems, aim to investigate the nucleon-nucleon interaction as the nucleons go off their mass shell. Cross sections and analyzing

  12. Probing few-body systems with bremsstrahlung

    NARCIS (Netherlands)

    Kalantar-Nayestanaki, N; Krivec, R; Golli, B; Rosina, M; Sirca, S

    2003-01-01

    A series of bremsstrahlung measurements have been performed with the superconducting cyclotron, AGOR, at KVI. These measurements, on the proton-proton and proton-deuteron systems, aim to investigate the nucleon-nucleon interaction far away from elastic channel. Cross sections and analyzing powers

  13. Probing few-body systems with bremsstrahlung

    NARCIS (Netherlands)

    Kalantar-Nayestanaki, N; Oryu, S; Kamimura, M; Ishikawa, S

    2000-01-01

    A series of bremsstrahlung measurements have been performed with the superconducting cyclotron, AGOR, at KVI. These measurements, on the proton-proton and proton-deuteron systems, aim to investigate the nucleon-nucleon interaction as the nucleons go off their mass shelf. Cross sections and analyzing

  14. Bremsstrahlung in electron-positronium scattering

    International Nuclear Information System (INIS)

    Amusia, M.Ya.; Korol, A.V.; Solovyov, A.V.

    1986-01-01

    The spectrum of radiation formed in the fast nonrelativistic electron scattering on positronium is calculated. It is shown that all the radiation proceeds via virtual positronium deformations during the collision. An essential difference of bremsstrahlung spectra in electron on positronium and electron on hydrogen scattering is demonstrated. (orig.)

  15. Radioembolization of hepatocarcinoma with {sup 90}Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology

    Energy Technology Data Exchange (ETDEWEB)

    Chiesa, C.; Maccauro, M.; Aliberti, G.; Padovano, B.; Seregni, E.; Crippa, F. [Foundation IRCCS Istituto Nazionale Tumori, Nuclear Medicine Division, Milan (Italy); Mira, M.; Negri, A. [University of Milan, Postgraduate Health Physics School, Milan (Italy); Spreafico, C.; Morosi, C.; Civelli, E.; Lanocita, R.; Marchiano, A. [Foundation IRCCS Istituto Nazionale Tumori, Radiology 2, Milan (Italy); Romito, R.; Sposito, C.; Bhoori, S.; Facciorusso, A.; Mazzaferro, V. [Foundation IRCCS Istituto Nazionale Tumori, Surgery 1, Milan (Italy); Camerini, T. [Foundation IRCCS Istituto Nazionale Tumori, Scientific Direction, Milan (Italy); Carrara, M. [Foundation IRCCS Istituto Nazionale Tumori, Health Physics, Milan (Italy); Pellizzari, S. [University La Sapienza, Engineering Faculty, Rome (Italy); Migliorisi, M. [Foundation IRCCS Istituto Nazionale Tumori, Nuclear Medicine Division, Milan (Italy); Foundation IRCCS Istituto Nazionale Tumori, Clinical Engineering, Milan (Italy); De Nile, M.C. [University of Pavia, Physics Faculty, Pavia, Lombardy (Italy)

    2015-10-15

    The aim of this study was to optimize the dosimetric approach and to review the absorbed doses delivered, taking into account radiobiology, in order to identify the optimal methodology for an individualized treatment planning strategy based on {sup 99m}Tc-macroaggregated albumin (MAA) single photon emission computed tomography (SPECT) images. We performed retrospective dosimetry of the standard TheraSphere registered treatment on 52 intermediate (n = 17) and advanced (i.e. portal vein thrombosis, n = 35) hepatocarcinoma patients with tumour burden < 50 % and without obstruction of the main portal vein trunk. Response was monitored with the densitometric radiological criterion (European Association for the Study of the Liver) and treatment-related liver decompensation was defined ad hoc with a time cut-off of 6 months. Adverse events clearly attributable to disease progression or other causes were not attributed to treatment. Voxel dosimetry was performed with the local deposition method on {sup 99m}Tc-MAA SPECT images. The reconstruction protocol was optimized. Concordance of {sup 99m}Tc-MAA and {sup 90}Y bremsstrahlung microsphere biodistributions was studied in 35 sequential patients. Two segmentation methods were used, based on SPECT alone (home-made code) or on coregistered SPECT/CT images (IMALYTICS trademark by Philips). STRATOS trademark absorbed dose calculation was validated for {sup 90}Y with a single time point. Radiobiology was used introducing other dosimetric variables besides the mean absorbed dose D: equivalent uniform dose (EUD), biologically effective dose averaged over voxel values (BED{sub ave}) and equivalent uniform biologically effective dose (EUBED). Two sets of radiobiological parameters, the first derived from microsphere irradiation and the second from external beam radiotherapy (EBRT), were used. A total of 16 possible methodologies were compared. Tumour control probability (TCP) and normal tissue complication probability (NTCP) were

  16. Experimental autoabsorption curve 90Sr in SrCO3. Efficiency calculation to detection of 90Sr, 90Y and 90Sr + 90Y in a beta gas proportional counter

    International Nuclear Information System (INIS)

    Gasco, C.; Alvarez, A.

    1987-01-01

    Strontium-90 has been determined by radiochemical separation techniques in environmental samples. These techniques, of course, cannot separate the two strontium radionuclides from each other of from stable strontium. Consequently the end product of the chemical separation contains all strontium isotopes in SrCO 3 . The beta particules emitted by 90 Sr are absorbed by the SrCO 3 precipitate. This is the main source of error in the activity measurement. It has been prepared sources of 90 Sr in SrCO 3 in order to determinate the counting efficiency and autoabsorption curve. Also detection efficiencies have been calibrated using known activities of 90 Y and equilibrium mixture of 90 Sr+ 90 Y in the same geometry than our samples. The activity of 90 Sr by ingrowth of 90 Y has been calculated by our computer program. (author). 2 figs., 3 refs

  17. Country report: Thailand. Development of Sr-90/ Y-90 Generator and Development of Radiopharmaceuticals Using Y-90

    International Nuclear Information System (INIS)

    Nipavan, Poramatikul

    2010-01-01

    The research project has been conducted at Thailand Institute of Nuclear Technology in accordance to the 1st RCM plan during the IAEA meeting in Warsaw. The objectives of the project include the following 5 specific aims: 1. Development of Sr-90/Y-90 ion-exchange chromatography generator 2. Development of Sr-90/Y-90 extraction chromatography generator 3. Development of quality control technique 4. Development of herapeutic radiopharmaceuticals Y-90 particulates/colloids 5. Development of Re-188 DMSA–bis-phosphonates Currently we have achieved specific aims 1 to 3. The specific aims 4 and 5 are during investigation. For specific aim 4, we are during the process to extract high purity 90 Y from 90 Sr/ 90 Y generator that will yield the starting 90 Y for the production of Y-90 particulates and colloids. For the 5 th specific aim, we are on hold to receive the starting agent, bis- Phosphonates, from Dr. Blower group. Therefore, this progress report will cover our work focusing on specific aims 1 to 3

  18. Country report: Thailand. Development of Sr-90/ Y-90 Generator and Development of Radiopharmaceuticals Using Y-90

    Energy Technology Data Exchange (ETDEWEB)

    Nipavan, Poramatikul [Nuclear Research and Development Group, Thailand Institute of Nuclear Technology (Public Organization), Bangkok (Thailand)

    2010-07-01

    The research project has been conducted at Thailand Institute of Nuclear Technology in accordance to the 1st RCM plan during the IAEA meeting in Warsaw. The objectives of the project include the following 5 specific aims: 1. Development of Sr-90/Y-90 ion-exchange chromatography generator 2. Development of Sr-90/Y-90 extraction chromatography generator 3. Development of quality control technique 4. Development of herapeutic radiopharmaceuticals Y-90 particulates/colloids 5. Development of Re-188 DMSA–bis-phosphonates Currently we have achieved specific aims 1 to 3. The specific aims 4 and 5 are during investigation. For specific aim 4, we are during the process to extract high purity {sup 90}Y from {sup 90}Sr/{sup 90}Y generator that will yield the starting {sup 90}Y for the production of Y-90 particulates and colloids. For the 5{sup th} specific aim, we are on hold to receive the starting agent, bis- Phosphonates, from Dr. Blower group. Therefore, this progress report will cover our work focusing on specific aims 1 to 3.

  19. Tomographic bremsstrahlung imaging with yttrium-90 in the context of radioembolisation of liver tumors; Tomografische Bildgebung mit Yttrium-90-Bremsstrahlung im Rahmen der Radioembolisation von Lebertumoren

    Energy Technology Data Exchange (ETDEWEB)

    Grosser, Oliver Stephan

    2013-04-12

    Establish tomographic Bremsstrahlung SPECT imaging (BSPECT) for the clinical validation of Selective Internal Radiotherapy (SIRT) with Yttrium-90 ({sup 90}Y) labelled microspheres. Various energy ranges (75 ± 3.8 keV; 135 ± 6.8 keV; 167 ± 8.4 keV) and the summation window were studied to see if they were suitable for BSPECT. To this end, clinically available reconstruction techniques were analysed for their suitability for BSPECT. The tomographic examinations were performed on a cylindrical phantom filled with spheres of different diameters d = [28; 35; 40; 50; 60] mm in a non-active waterfilled background. The spheres were filled with identical {sup 90}Y activity concentration (AC). Measurements were conducted at AC = [14.58; 5.20; 1.98; 0.66] MBq/cm{sup 3}. The BSPECT were reconstructed with filtered back-projection (FBP), a 2D Ordered-Subset Expectation Maximisation Algorithm (2D-OSEM) and a 3D Geometric Mean Algorithm (3D-GMA). Evaluation was made visually and on the basis of objective performance parameters such as contrast, signal-to-noise ratio (SNR) and image noise. While the 75 keV ± 3.8 keV window was identified as suitable for the BSPECT, limitations were revealed as to use of different implementations of the Point Spread Function (PSF). It was found for all reconstruction techniques that, at a given sphere diameter, there existed a linear relationship between the AC in the spheres and the reconstructed pulse rate per volume element. The recovery effect was verified for small spheres. The iterative techniques were found to be suitable for the BSPECT at all AC. At low AC, the 3D-GMA exhibited the least noise and the highest SNR. The FBP turned out to be entirely inappropriate for the BSPECT. The narrow energy window in which the bremsstrahlung interferes with the characteristic X-radiation of lead can be used for BSPECT. In this approach, the tomographic data reconstructed with different algorithms exhibited a varying image quality, with the iterative

  20. Bremsstrahlung: an experimentalists personal perspective on the post modern era

    International Nuclear Information System (INIS)

    Quarles, C.A.

    2000-01-01

    In this brief review I will discuss the recent experimental work on the doubly differential cross section, i.e. the photon energy and angular distribution, for electron Bremsstrahlung from thin solid film and gas targets. Since the beginning of the modern era in the study of Bremsstrahlung with the publication of the 1971 paper by Ts eng and Pratt, Professor Pratt has been the dominant influence in Bremsstrahlung research. Most, if not all, experimental research during the modern era has been motivated by the interest in comparing data with the theory of Pratt and his coworkers. As Bremsstrahlung research has moved into its post modern era, new experiments with increasing precision are concentrating on determining under what conditions ordinary Bremsstrahlung theory needs to be supplemented by a contribution from polarization Bremsstrahlung. Efforts to improve the comparison of thin-target experiment with theory have also led to new experimental and modeling work on Bremsstrahlung from thick solid targets. Thick-target Bremsstrahlung is interesting in its own right, but we also want to understand it better since it is the ever-present background in the thin-target experiments and the limiting factor in the effort to distinguish the polarization contribution to the total Bremsstrahlung spectrum. Professor Pratt ushered in the modern era in Bremsstrahlung research and has recently guided the transition into the post modern era. It can be expected that he will continue to have a formative influence on the developments of Bremsstrahlung research into the foreseeable future.

  1. Therapeutic result of radioactive nuclide 90Sr/90Y treatment in patients with benign prostatic hypertrophy (BPH)

    International Nuclear Information System (INIS)

    Chen Hanchao; Li Yuying

    2008-01-01

    Objective: To study the effect of radioactive nuclide 90 Sr/ 90 Y treatment in patients with benign prostatic hypertrophy (BPH). Methods: Sixty patients with BPH were treated with a course of transurethral radioactive nuclide 90 Sr/ 90 Y therapy. Results: The severity of BPH was assessed with four parameters: maximal flow rate (MFR), volume of residual urine (VRU), international prostatic symptom score (IPSS) and volume (size) of prostate. In this series, the total effective rate was 93.33% with no treatment- related mortality. Favorable changes of the parameters after a course of radioactive nuclide therapy were significant. Conclusion: Radioactive nuclide 90 Sr/ 90 Y therapy for patients with BPH was safe, easily performed and quite effective. This procedure is worth popularizing in appropriate patients. (authors)

  2. Radiolabeling optimization and reduced staff radiation exposure for high-dose 90Y-ibritumomab tiuxetan (HD-Zevalin)

    International Nuclear Information System (INIS)

    Papi, Stefano; Martano, Luigi; Garaboldi, Lucia; Rossi, Annalisa; Cremonesi, Marta; Grana, Chiara Maria; Paolucci, Daniele; Sansovini, Maddalena; Paganelli, Giovanni; Chinol, Marco

    2010-01-01

    Introduction: 90 Y-Zevalin labeling may cause severe finger radiation exposure, especially in high-dose protocols (HD-Zevalin), where up to 7.4 GBq could be injected. In this work, we optimized the labeling of HD-Zevalin with special regard to simplicity, speed, safety and radiation protection. Methods: Factors influencing labeling outcome (activity, specific activity, time, final volume, stability) were studied separately. The critical steps of a standard radiolabeling procedure were optimized to reduce finger exposure, developing an alternative labeling procedure and including a different 90 Y supplier. Finger doses were monitored by thermoluminescent dosimeters at each fingertip under anti-X gloves, considering both absolute values and values after normalization to 1.48 GBq. Results: Labeling of 90 Y-Zevalin was safe and reproducible up to 7.4 GBq with a simple and single-step procedure offering good stability for several hours. Radiolabeling specific activity was found critical, being kept at 740 MBq.mg -1 . Radiochemical purity values ≥98% were routinely achieved. The alternative procedure allowed a sensible reduction of finger dose, due to both the different 90 Y vial and the handling. Finger exposure was reduced from 6.6±4.3 to 3.1±0.8 mSv/1.48 GBq in the case of the original 90 Y vial and from 1.5±0.9 to 0.3±0.1 mSv/1.48 GBq using a shielded 90 Y vial. Conclusions: HD-Zevalin can be prepared in a safe and reproducible way, giving high radiochemical purity values, good stability and low finger exposure. This study may improve the safety of nuclear medicine professionals involved in the preparation of Zevalin.

  3. Separation of 90Sr from Purex high level waste and development of a 90Sr-90Y generator

    International Nuclear Information System (INIS)

    Ramanujam, A.; Dhami, P.S.; Chitnis, R.R.; Achuthan, P.V.; Kannan, R.; Gopalakrishnan, V.; Balu, K.

    2000-04-01

    90 Y (T 1/2 =64.2 h) finds several applications in nuclear medicine. It is formed from the decay of 90 Sr which has a long half-life of 28.8 years. 90 Sr can be used as a long-lasting source for the production of carrier-free 90 Y. 90 Sr itself is abundantly available in high level waste (HLW) of PUREX origin. The present studies deal with the separation of pure 90 Sr from HLW and the subsequent separation of 90 Y from 90 Sr. Actinides and some of the fission products like lanthanides, zirconium, molybdenum and cesium were first removed from the HLW using methods based on solvent extraction and ion-exchange studied earlier in our laboratory. The resulting waste solution was used as a feed for the present process. The separation of 90 Sr from HLW was based on radiochemical method which involved a repeated scavenging with ferric hydroxide followed by strontium carbonate precipitation. The separation of 90 Y from 90 Sr was achieved by membrane separation technique. A compact generator is developed for this separation using a commercially available polytetrafluoroethylene (PTFE) membrane, impregnated with indigenously synthesised 2-ethylhexyl 2-ethylhexyl phosphonic acid (KSM-17). Generator system overcomes the drawbacks associated with conventional solvent extraction and ion-exchange based generators. The product is in chloride form and is suitable for complexation studies. After gaining an operating experience of ∼3 years in generating carrier-free 90 Y at 2 mCi level for initial studies in radiotherapeutic applications, the process was scaled up for the production of about 12 mCi of 90 Y to be used for animal studies before its application to patients. Radiochemical and chemical purity of the product was critically assayed by radiometry, ICP-AES, etc. The process is amenable for further scaling up. (author)

  4. {sup 90}Y microspheres prepared by sol-gel method, promising medical material for radioembolization of liver malignancies

    Energy Technology Data Exchange (ETDEWEB)

    Łada, Wiesława, E-mail: w.lada@ichtj.waw.pl [Institute of Nuclear Chemistry and Technology, 03-195 Warsaw, Dorodna 16 (Poland); Iller, Edward [National Centre for Nuclear Research, Radioisotope Centre POLATOM, 05-400 Otwock, Andrzej Sołtan 7 (Poland); Wawszczak, Danuta [Institute of Nuclear Chemistry and Technology, 03-195 Warsaw, Dorodna 16 (Poland); Konior, Marcin, E-mail: marcin.konior@polatom.pl [National Centre for Nuclear Research, Radioisotope Centre POLATOM, 05-400 Otwock, Andrzej Sołtan 7 (Poland); Dziel, Tomasz [National Centre for Nuclear Research, Radioisotope Centre POLATOM, 05-400 Otwock, Andrzej Sołtan 7 (Poland)

    2016-10-01

    A new technology for the production of radiopharmaceutical {sup 90}Y microspheres in the form of spherical yttrium oxide grains obtained by sol-gel method has been described. The authors present and discuss the results of investigations performed in the development of new production technology of yttrium microspheres and determination of their physic-chemical properties. The final product has the structure of spherical yttrium oxide grains with a diameter 25–100 μm, is stable and free from contaminants. Irradiation of 20 mg samples of grains with diameter of 20–50 μm in the thermal neutron flux of 1.7 × 10{sup 14} cm{sup −2} s{sup −1} at the core of MARIA research nuclear reactor allowed to obtain microspheres labelled with the {sup 90}Y isotope on the way of the nuclear reaction {sup 89}Y(n, γ){sup 90}Y. Specific activity of irradiated microspheres has been determined by application of absolute triple to double coincidence ratio method (TDCR) and has been evaluated at 190 MBq/mg Y. {sup 90}Y microspheres prepared by the proposed technique can be regarded as a promising medical material for radioembolization of liver malignancies. - Highlights: • Sol-gel methods for preparation of spherical yttrium trioxide grains have been proposed. • Determination condition for irradiation {sup 89}Y{sub 2}O{sub 3} grains in nuclear reactor • Evaluation of specific activity of {sup 90}Y microspheres • Estimation of {sup 90}Y microspheres as promising medical material for radioembolization.

  5. Prediction of 90Y Radioembolization Outcome from Pretherapeutic Factors with Random Survival Forests.

    Science.gov (United States)

    Ingrisch, Michael; Schöppe, Franziska; Paprottka, Karolin; Fabritius, Matthias; Strobl, Frederik F; De Toni, Enrico N; Ilhan, Harun; Todica, Andrei; Michl, Marlies; Paprottka, Philipp Marius

    2018-05-01

    Our objective was to predict the outcome of 90 Y radioembolization in patients with intrahepatic tumors from pretherapeutic baseline parameters and to identify predictive variables using a machine-learning approach based on random survival forests. Methods: In this retrospective study, 366 patients with primary ( n = 92) or secondary ( n = 274) liver tumors who had received 90 Y radioembolization were analyzed. A random survival forest was trained to predict individual risk from baseline values of cholinesterase, bilirubin, type of primary tumor, age at radioembolization, hepatic tumor burden, presence of extrahepatic disease, and sex. The predictive importance of each baseline parameter was determined using the minimal-depth concept, and the partial dependency of predicted risk on the continuous variables bilirubin level and cholinesterase level was determined. Results: Median overall survival was 11.4 mo (95% confidence interval, 9.7-14.2 mo), with 228 deaths occurring during the observation period. The random-survival-forest analysis identified baseline cholinesterase and bilirubin as the most important variables (forest-averaged lowest minimal depth, 1.2 and 1.5, respectively), followed by the type of primary tumor (1.7), age (2.4), tumor burden (2.8), and presence of extrahepatic disease (3.5). Sex had the highest forest-averaged minimal depth (5.5), indicating little predictive value. Baseline bilirubin levels above 1.5 mg/dL were associated with a steep increase in predicted mortality. Similarly, cholinesterase levels below 7.5 U predicted a strong increase in mortality. The trained random survival forest achieved a concordance index of 0.657, with an SE of 0.02, comparable to the concordance index of 0.652 and SE of 0.02 for a previously published Cox proportional hazards model. Conclusion: Random survival forests are a simple and straightforward machine-learning approach for prediction of overall survival. The predictive performance of the trained model

  6. Dosimetry characterization of the commercial CaF{sub 2} for beta radiation of {sup 90}Sr + {sup 90}Y; Caracterizacao dosimetrica de CaF{sub 2} comercial para radiacao beta de {sup 90}Sr + {sup 90}Y

    Energy Technology Data Exchange (ETDEWEB)

    Oliveira, Mercia L.; Caldas, Linda V.E. [Instituto de Pesquisas Energeticas e Nucleares (IPEN/CNEN-SP), Sao Paulo, SP (Brazil)], e-mail: mlolivei@ipen.br, e-mail: lcaldas@ipen.br

    2003-07-01

    This work studies the dosimetric characteristics of the CaF{sub 2} commercial dosimetry for detection of {sup 90}Sr + {sup 90}Y beta radiation for using in the calibration of flat and concave appliers. Were determined the repetitiousness and linearity of answers of the samples, and their calibration curves.

  7. Use of braking radiation for dose estimates in 90Y therapy

    International Nuclear Information System (INIS)

    Torres, Leonel; Vergara, Alex; García, Leonardo; Coca, Marco A.; Guerrero, Mayka; Calderón, Carlos; Ljungberg, Michael

    2016-01-01

    Objective: The objective of the present work is to standardize and optimize procedures that allow the use of 90 Y braking images for dosimetric estimations during the therapy of malignant diseases. Materials and Methods: Acquisition parameters such as the selection of the collimator and the definition of the energy windows, as well as the calibration factor for the SPECT MEDISO Nucline ™ Spirit DH-V system were estimated. Methods were evaluated for dispersion correction, attenuation, collimator interactions (septal penetration and degradation of information with distance). Simulations were performed using the Monte Carlo method, using SIMIND software v5.0. Results: The optimum conditions of position-width of energetic window and collimator to be used were determined from the relation between total photons and primary photons (T / P), calculated with the SIMIND. The sensitivity of the system was estimated for the selected collimator (HEGP), which resulted in the range of 2.1-3.0 cps / MBq. It was standardized the procedure for the use of transmission maps obtained from TAC images for the correction of the attenuation of flat images. For the quantification of SPECT studies we used iterative reconstruction algorithms, using the OSEM-ESSE method (Ordered Subset Expectation Maximization - Effective Source Scatter Estimation).

  8. Study On The Preparation Of 90Y-DTPA-Rituximab For Non-Hodgkin Lymphoma Treatment

    International Nuclear Information System (INIS)

    Nguyen Thi Thu; Duong Van Dong; Bui Van Cuong; Vo Thi Cam Hoa; Chu Van Khoa; Phan Quoc Thong

    2011-01-01

    Yttrium is one of the most useful radionuclides for radioimmunotherapeutic applications, especially labelling with monoclonal antibodies. Rituximab was bound to the DTPA chelating agent using Hnatowich methods. Cyclic anhydride DTPA (cDTPAa, 0.1 mg/ml) was dissolved in chloroform and was degassed under a stream of nitrogen for 30 minutes. Rituximab solution in 0.05 M bicarbonate buffer was immediately added and mixed for one minute at room temperature. The antibody Rituximab at different concentration (5 mg/ml and 10 mg/ml) was coupled with the cDTPAa, at molar ratios (cDTPAa : Rituximab) of 1:1, 3:1, 5:1, 10:1 and 20:1. The conjugation of DTPA-Rituximab mixture was labelled with Y-90, then using Sephadex G25 in order to determine coupling efficiency. Coupling efficiency at a 3:1 mole ratio was 70%. After purification, the conjugation DTPA-Rituximab was labeled with Y-90 in 0.5 M acetate buffer, pH 5, at room temperature. The labeling yield was about 99%. The radiochemical purity of 90 Y-DTPA-Rituximab was more than 98 % which determined by ITLC in 0.1 M acetate at pH 6 as mobile phase. The radiopharmaceuticals have been test for sterility, apyrogenicity and biodistribution. This is a potential radiopharmaceutical for clinical application in therapeutic Non Hodgkin Lymphoma treatments. (author)

  9. Technology of DTPA and immunoglobulins conjugation and their attachment to 90Y and 177Lu radionuclides

    International Nuclear Information System (INIS)

    Rekova, M.; Jedinakova-Krizova, V.

    2010-01-01

    The aim of the study of labeling of ligand-antibody conjugates was to find optimal conditions of preparing of these conjugates and appropriate radioactivity of selected nuclide for applications in nuclear medicine. Conjugation of the γ-immunoglobulin G (human or bovine IgG, polyclonal antibodies) and bifunctional chelating agent, diethylenetriaminepentaacetic acid dianhydride (cDTPAA), was carried out. Various values of the cDTPAA/antibody ratio, the weight concentration of polyclonal or monoclonal antibodies (MEM-97) and buffers were used. Further, the labeling conditions of the DTPA-IgG conjugate by radionuclides 90 Y and 177 Lu were optimized, and the labeling yield and the conjugation ratio of prepared radionuclide-DTPA-IgG conjugates was determined. Optimal incubation time of the immunoglobulin conjugation was obtained at 30 min from mixing of individual components. The labeling yield of radionuclide-DTPA-antibody conjugate higher than 95% was achieved. Higher values of conjugation ratio of radionuclide-DTPA-antibody conjugate were achieved in 0.1 mol L -1 carbonate buffer, pH 8.5, and the 0.1 mol L -1 carbonate buffer is suitable for studied conjugation systems. This study showed that the labeling yield as well as the conjugation ratio of tested systems depend on the amount of antibody substance, bifunctional chelating agent/antibody molar ratio and pH value of the buffer used. (author)

  10. Phosphate Suspension Chromium (III) radiolabelled with 32P and 90Y

    International Nuclear Information System (INIS)

    Cruz Arencibia, Jorge; Turiño Pérez, David; Cruz Morales, Amed; Morín Zorrilla, José; Taylor Delgado, Tamara; García Rodríguez, Enrique; Baganet Cobas, Aymara

    2016-01-01

    Chronic synovitis is a manifestation common joint of rheumatoid arthritis, hemophilia and other systemic diseases. The modalities of treatment of this complication radiosynoviorthesis stands out for its good response, ease of implementation and lower total cost. In the United States, Europe and some countries in Latin America they are used to this different radioactive colloids and suspensions. In Cuba it was developed and is approved suspension Chromic Phosphate 32 P-labeled. At work the consistency of the production process of this suspension is examined. As a result of the evaluation was found that the suspension is characterized by a radiochemical purity of 94 ± 1% and particle size predominantly of 91 ± 3 between 0.2-10 microns. The results achieved in regular production and application to patients with rheumatic diseases and hemophiliacs, with follow-up to one year prove their efficacy and safety, the latter associated with low leakage articular detected and the absence of adverse reactions. Also at work the results achieved in the development of a technology for the production of suspension Phosphate Chromium (III) labeled with 90 Y, similarly to existing 32 P composition is exposed, and properties even more favorable, in particular radiochemical purity of 97%, favoring the registration of a radiopharmaceutical with better technical and economic characteristics, which must ensures the use of this form of treatment in the country. (author)

  11. Diffractive corrections to the muon Bremsstrahlung

    International Nuclear Information System (INIS)

    Kel'ner, S.R.; Fedotov, A.M.

    1999-01-01

    The corrections to the muon Bremsstrahlung cross section due to diffraction of hard photons on nuclei are obtained. In this process the momentum is transmitted to a nucleus not by a charged particle but by the photon the interaction of which with the nucleus can be considered as diffraction on weakly absorbing ball. The amplitude of the process interferes with the usual Bremsstrahlung amplitude, therefore in the cross section together with the diffraction correction the interference term also appears, possessing different sings for μ + and μ - . The photon emission cross section also depends on the sing of muon charge and for muon energy about 10 TeV the difference between the cross section may reach 10%. The corrections to the radiation energy loss are also calculated [ru

  12. Gluon Bremsstrahlung in Weakly-Coupled Plasmas

    International Nuclear Information System (INIS)

    Arnold, Peter

    2009-01-01

    I report on some theoretical progress concerning the calculation of gluon bremsstrahlung for very high energy particles crossing a weakly-coupled quark-gluon plasma. (i) I advertise that two of the several formalisms used to study this problem, the BDMPS-Zakharov formalism and the AMY formalism (the latter used only for infinite, uniform media), can be made equivalent when appropriately formulated. (ii) A standard technique to simplify calculations is to expand in inverse powers of logarithms ln(E/T). I give an example where such expansions are found to work well for ω/T≥10 where ω is the bremsstrahlung gluon energy. (iii) Finally, I report on perturbative calculations of q.

  13. Quantum-mechanical suppression of bremsstrahlung

    Energy Technology Data Exchange (ETDEWEB)

    Becker-Szendy, R.; Keller, L.; Niemi, G.; Perl, M.; Rochester, L. [Stanford Univ., CA (United States); Anthony, P. [Stanford Univ., CA (United States)]|[Lawrence Livermore National Lab., CA (United States); Bosted, P. [American Univ., Washington, DC (United States); Cavalli-Sforza, M.; Kelley, L.; Klein, S. [Univ. of California, Santa Cruz, CA (United States)] [and others

    1994-12-01

    The authors have studied quantum-mechanical suppression of bremsstrahlung of low-energy 1-500 MeV photons from high-energy 25 GeV electrons. They have measured the LPM effect, where multiple scattering of the radiating electron destroys coherence required for the emission of low-energy photons, and the dielectric effect, where the emitted photon traveling in the radiator medium interferes with itself. For the experiment, the collaboration developed a novel method of extracting a parasitic low-intensity high-energy electron beam into the fixed target area during normal SLC operation of the accelerator. The results agree quantitatively with Migdal`s calculation of the LPM effect. Surface effects, for which there is no satisfactory theoretical prediction, are visible at low photon energies. For very thin targets, the suppression disappears, as expected. Preliminary results on dielectric suppression of bremsstrahlung are in qualitative agreement with the expectation.

  14. 'Atomic Bremsstrahlung': Retrospectives, current status and perspectives

    International Nuclear Information System (INIS)

    Amusia, M.Ya.

    2006-01-01

    We describe here the 'Atomic bremsstrahlung' (AB)-emission of continuous spectrum electromagnetic radiation, which is generated in collisions of particles that have internal deformable structure that includes positively and negatively charged constituents. The deformation of one or both colliding partners induces multiple, mainly dipole, time-dependent electrical moments that become a source of radiation. The history of AB invention is presented and its unusual in comparison to ordinary bremsstrahlung (OB) properties, are discussed. As examples, fast electron atom, non-relativistic and relativistic collisions are considered. Attention is given to ion-atom and atom-atom collisions. Specifics of 'elastic' and 'inelastic' (i.e. radiation accompanied by destruction of collision partners) AB will be mentioned. Attention will be given to possible manifestation of AB in nature and in some exotic systems, for instance scattering of electrons upon muonic hydrogen. Some cooperative effects connected to AB will be considered. New classical schemes similar to AB will be presented

  15. Clinical results of radionuclide therapy of neuroendocrine tumours with {sup 90}Y-DOTATATE and tandem {sup 90}Y/{sup 177}Lu-DOTATATE: which is a better therapy option?

    Energy Technology Data Exchange (ETDEWEB)

    Kunikowska, Jolanta; Krolicki, Leszek [Medical University of Warsaw, Nuclear Medicine Department, Warsaw (Poland); Hubalewska-Dydejczyk, Alicja; Sowa-Staszczak, Anna [Collegium Medicum Cracow, Cracow (Poland); Mikolajczak, Renata; Pawlak, Dariusz [Institute of Atomic Energy POLATOM, Swierk-Otwock (Poland)

    2011-10-15

    Peptide receptor radionuclide therapy (PRRT) using radiolabelled somatostatin analogues is a treatment option for patients with disseminated neuroendocrine tumours (NET). A combination treatment using the high-energy {sup 90}Y beta emitter for larger lesions and the lower energy {sup 177}Lu for smaller lesions has been postulated in the literature.The aim of the study was to evaluate combined {sup 90}Y/{sup 177}Lu-DOTATATE therapy in comparison to {sup 90}Y-DOTATATE alone. Fifty patients with disseminated NET were included in the study prospectively and divided into two groups: group A (n = 25) was treated with {sup 90}Y-DOTATATE, whereas group B (n = 25) received the 1:1 {sup 90}Y/{sup 177}Lu-DOTATATE. The administered activity was based on 3.7 GBq/m{sup 2} body surface area in three to five cycles, with amino acid infusion for nephroprotection. The median overall survival time in group A was 26.2 months while in group B median survival was not reached. Overall survival was significantly higher in group B (p = 0.027). Median event-free survival time in group A was 21.4 months and in group B 29.4 months (p > 0.1). At the 12-month follow-up, comparison of group A vs group B showed stable disease (SD) in 13 vs 16 patients, disease regression (RD) in 5 vs 3 patients and disease progression (PD) in 3 vs 4 patients; 4 and 2 patients died, respectively. The 24-month follow-up results were SD in nine vs ten patients, RD in one patient vs none and PD in four patients in both groups; three and four patients died, respectively. Side effects were rare and mild. The results indicate that therapy with tandem radioisotopes ({sup 90}Y/{sup 177}Lu-DOTATATE) provides longer overall survival than with a single radioisotope ({sup 90}Y-DOTATATE) and the safety of both methods is comparable. (orig.)

  16. Modeling the bremsstrahlung emission from converters

    CERN Document Server

    Mirea, M; Clapier, F; Hassaïne, M; Ibrahim, F; Müller, A C; Pauwels, N; Proust, J; Verney, D; Antoni, R; Bourgeois, L; Kandri-Rody, S

    2001-01-01

    The bremsstrahlung angular and energy theoretical distributions delivered from W and UCx thick converters are reported. This study is focussed on initial kinetic energies of the electron beam included in the range 30-60 MeV, suitable for the production of large radiative yields able to induce the $^{238}$U fission. These results offer the possibility to evaluate the required shielding for a neutron rich nuclei source.

  17. Bremsstrahlung doses from natural uranium ingots

    International Nuclear Information System (INIS)

    Anderson, J. L.; Hertel, N. E.

    2005-01-01

    In the past, some privately owned commercial facilities in the United States were involved in producing or processing radioactive materials used in the production of atomic weapons. Seven different geometrical objects, representative of the configurations of natural uranium metal potentially encountered by workers at these facilities, are modelled to determine gamma ray and Bremsstrahlung dose rates. The dose rates are calculated using the MCNP5 code and also by using the MICROSHIELD point-kernel code. Both gamma ray and Bremsstrahlung dose rates are calculated and combined to obtain a total dose rate. The two methods were found to be in good agreement despite differences in modelling assumptions and method differences. Computed total dose rates on the surface of these objects ranged from ∼51-84 μSv h -1 and 17-95 μSv h -1 using the MCNP5 and the MICROSHIELD modeling, respectively. The partitioning of the computed dose rates between gamma rays and Bremsstrahlung were the same order of magnitude for each object. (authors)

  18. Bremsstrahlung doses from natural uranium ingots.

    Science.gov (United States)

    Anderson, Jeri L; Hertel, Nolan E

    2005-01-01

    In the past, some privately owned commercial facilities in the United States were involved in producing or processing radioactive materials used in the production of atomic weapons. Seven different geometrical objects, representative of the configurations of natural uranium metal potentially encountered by workers at these facilities, are modelled to determine gamma ray and bremsstrahlung dose rates. The dose rates are calculated using the MCNP5 code and also by using the MICROSHIELD point-kernel code. Both gamma ray and bremsstrahlung dose rates are calculated and combined to obtain a total dose rate. The two methods were found to be in good agreement despite differences in modelling assumptions and method differences. Computed total dose rates on the surface of these objects ranged from approximately 51-84 microSv h(-1) and 17-95 microSv h(-1) using the MCNP5 and the MICROSHIELD modeling, respectively. The partitioning of the computed dose rates between gamma rays and bremsstrahlung were the same order of magnitude for each object.

  19. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study

    International Nuclear Information System (INIS)

    Bodei, Lisa; Zoboli, Stefania; Grana, Chiara; Bartolomei, Mirco; Rocca, Paola; Caracciolo, Maurizio; Chinol, Marco; Paganelli, Giovanni; Cremonesi, Marta; Maecke, Helmut R.

    2003-01-01

    The aim of this study was to determine the maximum tolerated dose of 90 Y-DOTATOC per cycle administered in association with amino acid solution as kidney protection in patients with somatostatin receptor-positive tumours. Forty patients in eight groups received two cycles of 90 Y-DOTATOC, with activity increased by 0.37 GBq per group, starting at 2.96 and terminating at 5.55 GBq. All patients received lysine ± arginine infusion immediately before and after therapy. Forty-eight percent developed acute grade I-II gastrointestinal toxicity (nausea and vomiting) after amino acid infusion whereas no acute adverse reactions occurred after 90 Y-DOTATOC injection up to 5.55 GBq/cycle. Grade III haematological toxicity occurred in three of seven (43%) patients receiving 5.18 GBq, which was defined as the maximum tolerable activity per cycle. Objective therapeutic responses occurred. Five GBq per cycle is the recommended dosage of 90 Y-DOTATOC when amino acids are given to protect the kidneys. Although no patients developed acute kidney toxicity, delayed kidney toxicity remains a major concern, limiting the cumulative dose to 25 Gy. The way forward with this treatment would seem to be to identify more effective renal protective agents, in order to be able to increase the cumulative injectable activity and hence tumour dose. (orig.)

  20. Dosimetric comparison of {sup 90}Y, {sup 32}P, and {sup 186}Re radiocolloids in craniopharyngioma treatments

    Energy Technology Data Exchange (ETDEWEB)

    Sadeghi, Mahdi; Karimi, Elham; Hosseini, S. Hamed [Agricultural, Medical and Industrial Research School, Nuclear Science and Technology Research Institute, P.O. Box 31485/498, Karaj (Iran, Islamic Republic of); Faculty of Engineering, Research and Science Campus, Islamic Azad University, P.O. Box 14155/4933, Tehran (Iran, Islamic Republic of)

    2009-11-15

    Purpose: In the radionuclide treatment of some forms of brain tumors such as craniopharyngiomas, the selection of the appropriate radionuclide for therapy is a key element in treatment planning. The aim was to study the influence by considering the beta-emitter radionuclide dose rate in an intracranial cyst. Methods: Dosimetry was performed using the MCNP4C radiation transport code. Analytical dosimetry was additionally performed using the Loevinger and the Berger formulas in the MATLAB software. Each result was compared under identical conditions. The advantages and disadvantages of using {sup 90}Y versus {sup 32}P and {sup 186}Re were investigated. Results: The dose rate at the inner surface of the cyst wall was estimated to be 400 mGy/h for a 1 MBq/ml concentration of {sup 90}Y. Under identical conditions of treatment, the corresponding dose rates were 300 mGy/h for {sup 32}P and 160 mGy/h for {sup 186}Re. For a well-defined cyst radius and identical wall thickness, higher dose rates resulted for {sup 90}Y. Conclusions: To achieve the same radiological burden, the required amount of physical activity of injectable solution is lower for {sup 32}P. This is found to be a consequence of both the radionuclide physical half-life and the pattern of energy deposition from the emitted radiation. According to the half-life and dose-rate results, {sup 90}Y would be a good substitute for {sup 32}P.

  1. Dosimetry characterization of the commercial CaF2 for beta radiation of 90Sr + 90Y

    International Nuclear Information System (INIS)

    Oliveira, Mercia L.; Caldas, Linda V.E.

    2003-01-01

    This work studies the dosimetric characteristics of the CaF 2 commercial dosimetry for detection of 90 Sr + 90 Y beta radiation for using in the calibration of flat and concave appliers. Were determined the repetitiousness and linearity of answers of the samples, and their calibration curves

  2. Gold nanorod-mediated hyperthermia enhances the efficacy of HPMA copolymer-90Y conjugates in treatment of prostate tumors

    International Nuclear Information System (INIS)

    Buckway, Brandon; Frazier, Nick; Gormley, Adam J.; Ray, Abhijit; Ghandehari, Hamidreza

    2014-01-01

    Introduction: The treatment of prostate cancer using a radiotherapeutic 90 Y labeled N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer can be enhanced with localized tumor hyperthermia. An 111 In labeled HPMA copolymer system for single photon emission computerized tomography (SPECT) was developed to observe the biodistribution changes associated with hyperthermia. Efficacy studies were conducted in prostate tumor bearing mice using the 90 Y HPMA copolymer with hyperthermia. Methods: HPMA copolymers containing 1, 4, 7, 10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) were synthesized by reversible addition-fragmentation transfer (RAFT) copolymerization and subsequently labeled with either 111 In for imaging or 90 Y for efficacy studies. Radiolabel stability was characterized in vitro with mouse serum. Imaging and efficacy studies were conducted in DU145 prostate tumor bearing mice. Imaging was performed using single photon emission computerized tomography (SPECT). Localized mild tumor hyperthermia was achieved by plasmonic photothermal therapy using gold nanorods. Results: HPMA copolymer-DOTA conjugates demonstrated efficient labeling and stability for both radionuclides. Imaging analysis showed a marked increase of radiolabeled copolymer within the hyperthermia treated prostate tumors, with no significant accumulation in non-targeted tissues. The greatest reduction in tumor growth was observed in the hyperthermia treated tumors with 90 Y HPMA copolymer conjugates. Histological analysis confirmed treatment efficacy and safety. Conclusion: HPMA copolymer-DOTA conjugates radiolabeled with both the imaging and treatment radioisotopes, when combined with hyperthermia can serve as an image guided approach for efficacious treatment of prostate tumors

  3. Depth dose distribution in the water for clinical applicators of 90Sr + 90Y, with a extrapolation mini chamber

    International Nuclear Information System (INIS)

    Antonio, Patricia de Lara; Caldas, Linda V.E.; Oliveira, Mercia L.

    2009-01-01

    This work determines the depth dose in the water for clinical applicators of 90 Sr + 90 Y, using a extrapolation mini chamber developed at the IPEN, Sao Paulo, Brazil, and different thickness acrylic plates. The obtained results were compared with the international recommendations and were considered satisfactory

  4. Personnel dose reduction in 90Y microspheres liver-directed radioembolization: from interventional radiology suite to patient ward.

    Science.gov (United States)

    Law, Martin; Wong, K K; Tso, W K; Lee, Victor; Luk, M Y; Tong, C C; Chu, Ferdinand

    2017-03-01

    To describe a method to reduce the external radiation exposure emitted from the patient after liver-directed radioembolization using 90 Y glass microspheres, to quantitatively estimate the occupational dose of medical personnel providing patient care to the patient radioembolized with the use of the method and to discuss radiation exposure to patients who are adjacent if the patient radioembolized needs hospitalization. A lead-lined blanket of lead equivalence of 0.5 mm was used to cover the patient abdomen immediately after the 90 Y radioembolization procedure, in order to reduce the radiation emitted from the patient. The interventional radiologist used a rod-type puncture site compressor for haemostasis to avoid direct contact with possible residual radioactivity at the puncture site. Dose rates were measured at the interventional radiologist chest and hand positions during puncture site pressing for haemostasis with and without the use of the blanket. The measurement results were applied to estimate the occupational dose of colleagues performing patient care to the patient radioembolized. The exposure to patients adjacent in the ward was estimated if the patient radioembolized was hospitalized. The radiation exposures measured at the radiologist chest and hand positions have been significantly reduced with the lead-lined blanket in place. The radiologist, performing puncture site pressing at the end of radioembolization procedure, would receive an average hand dose of 1.95 μSv and body dose under his own lead apron of 0.30 μSv for an average 90 Y microsphere radioactivity of 2.54 GBq. Other medical personnel, nurses and porters, would receive occupational doses corresponding to an hour of background radiation. If the patient radioembolized using 90 Y needs hospitalization in a common ward, using the lead-lined blanket to cover the abdomen of the patient and keeping a distance of 2 m from the patient who is adjacent would reduce the exposure by 0

  5. Gastric injury from 90Y to left hepatic lobe tumors adjacent to the stomach: fact or fiction?

    International Nuclear Information System (INIS)

    Gates, Vanessa L.; Hickey, Ryan; Marshall, Karen; Williams, Melissa; Salzig, Krystina; Lewandowski, Robert J.; Salem, Riad

    2015-01-01

    Radioembolization with 90 Y microspheres is a locoregional radiation therapy for unresectable hepatic neoplasm. Non-target delivery of 90 Y microspheres resulting in gastrointestinal (GI) symptoms is a recognized complication; there is minimal knowledge regarding the radiation effect to the gastric wall from left hepatic lobe 90 Y treatments. Our aim was to study the incidence of GI complications when the target tissue (hepatic parenchyma ± tumor) is in close proximity to the gastric wall. We hypothesized that liver (tumor) to stomach proximity does not correlate with increased toxicity. Between November 2011 and September 2013, we studied all patients who underwent left lobe radioembolization with 90 Y glass microspheres. With Institutional Review Board (IRB) approval, we retrospectively reviewed MRI/CT images of these patients, identifying a subset of patients with the left hepatic lobe <1 cm from the gastric wall. Patients were seen in clinic 1 month posttreatment and subsequently at 3-month intervals. Short- and long-term gastric adverse events were tabulated. Ninety-seven patients successfully underwent left hepatic lobe 90 Y microsphere radioembolization in which the average distance from the liver to the stomach wall was 1.0 ± 2.8 mm. The average dose for patients who received radioembolization to the left hepatic lobe was 109 ± 57 Gy. Fifty patients had tumor within 1 cm of the gastric wall. The average dose for patients who received radioembolization to the left hepatic lobe with tumor within 1 cm of the gastric wall was 121 ± 41 Gy. There were no reportable or recordable medical events. Of the patients, 34 % reported abdominal pain that was grade 1-2; 65 % of the patients reported no abdominal pain. None of the 97 patients developed a clinically evident GI ulcer. Patients with left lobe tumors adjacent to or abutting the stomach do not exhibit acute or chronic radiation effects following radioembolization with glass microspheres. (orig.)

  6. Activity measurements of {sup 18}F and {sup 90}Y with commercial radionuclide calibrators for nuclear medicine in Switzerland

    Energy Technology Data Exchange (ETDEWEB)

    Caffari, Yvan, E-mail: Yvan.Caffari@chuv.c [Institut de Radiophysique Appliquee, Grand-Pre 1, 1007 Lausanne (Switzerland); Spring, Philippe; Bailat, Claude; Nedjadi, Youcef; Bochud, Francois [Institut de Radiophysique Appliquee, Grand-Pre 1, 1007 Lausanne (Switzerland)

    2010-07-15

    The activity of radiopharmaceuticals in nuclear medicine is measured before patient injection with radionuclide calibrators. In Switzerland, the general requirements for quality controls are defined in a federal ordinance and a directive of the Federal Office of Metrology (METAS) which require each instrument to be verified. A set of three gamma sources (Co-57, Cs-137 and Co-60) is used to verify the response of radionuclide calibrators in the gamma energy range of their use. A beta source, a mixture of {sup 90}Sr and {sup 90}Y in secular equilibrium, is used as well. Manufacturers are responsible for the calibration factors. The main goal of the study was to monitor the validity of the calibration factors by using two sources: a {sup 90}Sr/{sup 90}Y source and a {sup 18}F source. The three types of commercial radionuclide calibrators tested do not have a calibration factor for the mixture but only for {sup 90}Y. Activity measurements of a {sup 90}Sr/{sup 90}Y source with the {sup 90}Y calibration factor are performed in order to correct for the extra-contribution of {sup 90}Sr. The value of the correction factor was found to be 1.113 whereas Monte Carlo simulations of the radionuclide calibrators estimate the correction factor to be 1.117. Measurements with {sup 18}F sources in a specific geometry are also performed. Since this radionuclide is widely used in Swiss hospitals equipped with PET and PET-CT, the metrology of the {sup 18}F is very important. The {sup 18}F response normalized to the {sup 137}Cs response shows that the difference with a reference value does not exceed 3% for the three types of radionuclide calibrators.

  7. Intra-arterial treatment with 90Y microspheres for hepatocellular carcinoma: 4 years experience at the Ghent University Hospital

    International Nuclear Information System (INIS)

    Lambert, Bieke; Mertens, Jeroen; Oltenfreiter, Ruth; Sturm, Emiel; Defreyne, Luc; Smeets, Peter; Troisi, Roberto; Vlierberghe, Hans van

    2011-01-01

    We report on our experience in terms of eligibility, safety, response and survival for treatment of hepatocellular carcinoma (HCC) with 90 Y microspheres. Secondly, we investigated the urinary excretion of 90 Y following treatment. We retrospectively reviewed all HCC patients referred to our department for 90 Y microsphere treatment. We recorded reasons for not proceeding to actual treatment. In case treatment was performed, we assessed the tolerance (Common Terminology Criteria for Adverse Events v3.0, CTCAE v3.0), the response [modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria] and long-term survival (Kaplan-Meier). The urinary excretion was estimated by 12-h urine collections post-injection for analysis in a gamma counter. Forty-three HCC patients were referred for radioembolization. Fourteen patients were excluded, mainly due to unfavourable 99m Tc-macroaggregated albumin (MAA) distribution. Twenty-nine patients were treated with 90 Y microspheres (TheraSphere, mean activity 2.17 GBq). In four patients severe clinical adverse events were encountered, however only in one case clearly related to the therapy. Twenty patients were assessable by mRECIST: complete response in 15%, partial response in 35%, stable disease in 30% and progression in 20% were observed. A median survival of 12.3 months (95% confidence interval 9.4-15.2) was estimated. Concerning the substudy on urinary excretion, only 0.0025% of the administered activity was excreted in the urine within the first 12 h following TheraSphere. Following a strict workup before admitting patients to radioembolization with TheraSphere, we found good clinical tolerance in the vast majority of patients. Radiological response assessment yielded an overall response rate of 50%, when evaluated early following treatment. Urine analysis showed consistently only low activities of 90 Y excreted in the urine. (orig.)

  8. Intra-arterial treatment with {sup 90}Y microspheres for hepatocellular carcinoma: 4 years experience at the Ghent University Hospital

    Energy Technology Data Exchange (ETDEWEB)

    Lambert, Bieke; Mertens, Jeroen; Oltenfreiter, Ruth [Ghent University Hospital, Department of Nuclear Medicine, Ghent (Belgium); Sturm, Emiel; Defreyne, Luc [Ghent University Hospital, Department of Vascular and Interventional Radiology, Ghent (Belgium); Smeets, Peter [Ghent University Hospital, Department of Radiology, Ghent (Belgium); Troisi, Roberto [Ghent University Hospital, Department of Hepatobiliary Surgery and Liver Transplantation, Ghent (Belgium); Vlierberghe, Hans van [Ghent University Hospital, Department of Gastroenterology and Hepatology, Ghent (Belgium)

    2011-12-15

    We report on our experience in terms of eligibility, safety, response and survival for treatment of hepatocellular carcinoma (HCC) with {sup 90}Y microspheres. Secondly, we investigated the urinary excretion of {sup 90}Y following treatment. We retrospectively reviewed all HCC patients referred to our department for {sup 90}Y microsphere treatment. We recorded reasons for not proceeding to actual treatment. In case treatment was performed, we assessed the tolerance (Common Terminology Criteria for Adverse Events v3.0, CTCAE v3.0), the response [modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria] and long-term survival (Kaplan-Meier). The urinary excretion was estimated by 12-h urine collections post-injection for analysis in a gamma counter. Forty-three HCC patients were referred for radioembolization. Fourteen patients were excluded, mainly due to unfavourable {sup 99m}Tc-macroaggregated albumin (MAA) distribution. Twenty-nine patients were treated with {sup 90}Y microspheres (TheraSphere, mean activity 2.17 GBq). In four patients severe clinical adverse events were encountered, however only in one case clearly related to the therapy. Twenty patients were assessable by mRECIST: complete response in 15%, partial response in 35%, stable disease in 30% and progression in 20% were observed. A median survival of 12.3 months (95% confidence interval 9.4-15.2) was estimated. Concerning the substudy on urinary excretion, only 0.0025% of the administered activity was excreted in the urine within the first 12 h following TheraSphere. Following a strict workup before admitting patients to radioembolization with TheraSphere, we found good clinical tolerance in the vast majority of patients. Radiological response assessment yielded an overall response rate of 50%, when evaluated early following treatment. Urine analysis showed consistently only low activities of {sup 90}Y excreted in the urine. (orig.)

  9. Gastric injury from {sup 90}Y to left hepatic lobe tumors adjacent to the stomach: fact or fiction?

    Energy Technology Data Exchange (ETDEWEB)

    Gates, Vanessa L.; Hickey, Ryan; Marshall, Karen; Williams, Melissa; Salzig, Krystina; Lewandowski, Robert J. [Robert H. Lurie Comprehensive Cancer Center, Department of Radiology, Section of Interventional Radiology, Northwestern Memorial Hospital, Chicago, IL (United States); Salem, Riad [Robert H. Lurie Comprehensive Cancer Center, Department of Radiology, Section of Interventional Radiology, Northwestern Memorial Hospital, Chicago, IL (United States); Northwestern University, Department of Medicine, Division of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL (United States)

    2015-12-15

    Radioembolization with {sup 90}Y microspheres is a locoregional radiation therapy for unresectable hepatic neoplasm. Non-target delivery of {sup 90}Y microspheres resulting in gastrointestinal (GI) symptoms is a recognized complication; there is minimal knowledge regarding the radiation effect to the gastric wall from left hepatic lobe {sup 90}Y treatments. Our aim was to study the incidence of GI complications when the target tissue (hepatic parenchyma ± tumor) is in close proximity to the gastric wall. We hypothesized that liver (tumor) to stomach proximity does not correlate with increased toxicity. Between November 2011 and September 2013, we studied all patients who underwent left lobe radioembolization with {sup 90}Y glass microspheres. With Institutional Review Board (IRB) approval, we retrospectively reviewed MRI/CT images of these patients, identifying a subset of patients with the left hepatic lobe <1 cm from the gastric wall. Patients were seen in clinic 1 month posttreatment and subsequently at 3-month intervals. Short- and long-term gastric adverse events were tabulated. Ninety-seven patients successfully underwent left hepatic lobe {sup 90}Y microsphere radioembolization in which the average distance from the liver to the stomach wall was 1.0 ± 2.8 mm. The average dose for patients who received radioembolization to the left hepatic lobe was 109 ± 57 Gy. Fifty patients had tumor within 1 cm of the gastric wall. The average dose for patients who received radioembolization to the left hepatic lobe with tumor within 1 cm of the gastric wall was 121 ± 41 Gy. There were no reportable or recordable medical events. Of the patients, 34 % reported abdominal pain that was grade 1-2; 65 % of the patients reported no abdominal pain. None of the 97 patients developed a clinically evident GI ulcer. Patients with left lobe tumors adjacent to or abutting the stomach do not exhibit acute or chronic radiation effects following radioembolization with glass

  10. Beta induced Bremsstrahlung dose rate in concrete shielding

    International Nuclear Information System (INIS)

    Manjunatha, H.C.

    2013-01-01

    Dosimetric study of beta-induced Bremsstrahlung in concrete is importance in the field of radiation protection. The efficiency, intensity and dose rate of beta induced Bremsstrahlung by 113 pure beta nuclides in concrete shielding is computed. The Bremsstrahlung dosimetric parameters such as the efficiency (yield), Intensity and dose rate of Bremsstrahlung are low for 199 Au and high for 104 Tc in concrete. The efficiency, Intensity and dose rate of Bremsstrahlung increases with maximum energy of beta nuclide (Emax) and modified atomic number (Zmod) of the target. The estimated Bremsstrahlung efficiency, Intensity and dose rate are useful in the calculations photon track-length distributions. These parameters are useful to determine the quality and quantity of the radiation (known as the source term). Precise estimation of this source term is very important in planning of radiation shielding. (author)

  11. Accumulation of Sr90-Y90 by the developing spawn and larvae of Coregonus lavaretus L

    International Nuclear Information System (INIS)

    Kulikov, N.V.; Ozhegov, L.N.

    1976-01-01

    The results are given of laboratory experiments aimed at studying accumulation of Sr-90 and its daughter product Y-90 in the spawn and larvae of whitefish, a representative of autumn spawning fish species. The results are of interest for predicting possible consequences of radioactive contamination of water bodies and introduction of limits for permissible concentration of radioactive substances in aqueous medium. The accumulation coefficient of Sr-90 in the spawn reaches its maximum after the first twenty four hours of the experiment. Subsequently throughout the incubation period the accumulation coefficient (AC) of radionuclide does not undergo any changes being about 3. Besides it has been established that the equilibrium distribution of Sr-90 in whitefish spawn and the surrounding solution occurs during the first two hours. Unlike Sr-90 the accumulation of Y-90 occurs during the whole incubation period and results in the AC value of 80 by the end of the spawn incubation. The experiments aimed at determining the strength of radionuclide fixation by whitefish spawn and larvae revealed that both radionuclides in the spawn are rather mobile. Strontium separates fully from it during the first twenty four hours and yttrium marked by higher fixation strength transfers completely from the spawn into surrounding aqueous medium by the end of the experiment. In larvae the radionuclides are fixed stroger than in the spawn. The approximate radiation doses of embryos by the time of their hatching have been estimated. The estimates indicate that the total radiation dose of the spawn developing in aqueous solution of Sr-90 - Y-90 with 1.1 curie/0 -5 concentration is about 500 radl

  12. Resonance double magnetic bremsstrahlung in a strong magnetic field

    International Nuclear Information System (INIS)

    Fomin, P.I.; Kholodov, R.I.

    2003-01-01

    The possibility of resonance double magnetic bremsstrahlung in the approximation of weakly excited electron states in a strong external magnetic field is analyzed. The differential probability of this process in the Breit-Wigner form is obtained. The probability of double magnetic bremsstrahlung (second-order process of perturbation theory) is compared with the probability of magnetic bremsstrahlung (first-order process of perturbation theory)

  13. Cellular and molecular properties of 90Y-labeled cetuximab in combination with radiotherapy on human tumor cells in vitro

    International Nuclear Information System (INIS)

    Saki, M.; Toulany, M.; Rodemann, H.P.; Sihver, W.; Zenker, M.; Heldt, J.M.; Mosch, B.; Pietzsch, H.J.; Steinbach, J.; Baumann, M.

    2012-01-01

    Purpose: Anti-EGFR antibody cetuximab (C225) is used in combination with radiotherapy of head and neck squamous cell carcinoma (HNSCC) patients. We investigated whether conjugation of cetuximab with trans-cyclohexyl-diethylene-triamine-pentaacetic acid (CHX-A''-DTPA) and radiolabeling with 90 Yttrium affect the molecular and cellular function of cetuximab and improve its combined effect with external-beam irradiation (EBI). Methods: The following cell lines were used: HNSCC UT5, SAS, FaDu, as well as A43, Chinese hamster ovary cells (CHO), and human skin fibroblast HSF7. Binding affinity and kinetics, specificity, retention, and the combination of 90 Y-cetuximab with EBI were evaluated. Results: Control cetuximab and CHX-A''-DTPA-cetuximab blocked the proliferation activity of UT5 cells. In combination with EBI, CHX-A''-DTPA-cetuximab increased the radiosensitivity of UT5 to a similar degree as control cetuximab did. In contrast, in SAS and HSF7 cells neither proliferation nor radiosensitivity was affected by either of the antibodies. Binding [ 90 Y]Y-CHX-A''-DTPA-cetuximab ( 90 Y-cetuximab) to EGFR in HNSCC cells occurred time dependently with a maximum binding at 24 h. Retention of 90 Y-cetuximab was similar in both HNSCC cell lines; 24 h after treatment, approximately 90% of bound activity remained in the cell layer. Competition assays, using cell membranes in the absence of an internalized fraction of cetuximab, showed that the cetuximab affinity is not lost as a result of conjugation with CHX-A''-DTPA. Cetuximab and CHX-A''-DTPA-cetuximab blocked EGF-induced Y1068 phosphorylation of EGFR. The lack of an effect of cetuximab on EGF-induced Akt and ERK1/2 phosphorylation and the inhibition of irradiation (IR)-induced Akt and ERK1/2 phosphorylation by cetuximab were not affected by DTPA conjugation. 90 Y-cetuximab in combination with EBI resulted in a pronounced inhibition of colony formation of HNSCC cells. Conclusions: Conjugation of CHX-A''-DTPA to cetuximab

  14. Dosimetry of a 90Y-hydroxide liquid brachytherapy treatment approach to canine osteosarcoma using PET/CT

    International Nuclear Information System (INIS)

    Zhou, Jien Jie; Gonzalez, Arnulfo; Lenox, Mark W.; Fossum, Theresa W.; Frank, R. Keith; Simon, Jaime; Stearns, Stan; Ruoff, Catherine M.; Wendt, Richard E.; Akabani, Gamal

    2015-01-01

    A new treatment strategy based on direct injections of 90 Y-hydroxide into the tumor bed in dogs with osteosarcoma was studied. Direct injections of the radiopharmaceutical into the tumor bed were made according to a pretreatment plan established using 18 F-FDG images. Using a special drill, cannulas were inserted going through tissue, tumor and bone. Using these cannulas, direct injections of the radiopharmaceutical were made. The in vivo biodistribution of 90 Y-hydroxide and the anatomical tumor bed were imaged using a time-of-flight (TOF) PET/CT scanner. The material properties of the tissues were estimated from corresponding CT numbers using an electron-density calibration. Radiation absorbed dose estimates were calculated using Monte Carlo methods where the biodistribution of the pharmaceutical from PET images was sampled using a collapsing 3-D rejection technique. Dose distributions in the tumor bed and surrounding tissues were calculated, showing significant heterogeneity with multiple hot spots at injection sites. Dose volume histograms showed that approximately 33.9% of bone and tumor and 70.2% of bone marrow and trabecular bone received an absorbed dose over 200 Gy; approximately 3.2% of bone and tumor and 31.0% of bone marrow and trabecular bone received a total dose of over 1000 Gy. - Graphical abstract: Treatment of canine osteosarcoma using 90 Y-hydroxide using localized liquid brachytherapy. A 3-D co-registered PET/CT image showing the distribution of 90 Y in the left tibia of a dog with osteosarcoma. Multiple high activity hotspots are shown within bone marrow and isolated hotspots within the tumor bed, corresponding to the sites of administration. Absorbed doses were estimated to be as high as 2000 Gy to tumor. - Highlights: • A liquid brachytherapy treatment of canine osteosarcoma using 90 Y hydroxyapatite is presented. • Dosimetry of 90 Y hydroxyapatite liquid brachytherapy was carried out using PET-CT. • Activity distribution correlated

  15. Computed tomography hepatic arteriography has a hepatic falciform artery detection rate that is much higher than that of digital subtraction angiography and 99mTc-MAA SPECT/CT: Implications for planning 90Y radioembolization?

    Energy Technology Data Exchange (ETDEWEB)

    Burgmans, M.C., E-mail: mburgmans@hotmail.com [Department of Diagnostic Radiology, Singapore General Hospital, Outram Road, Singapore 169608 (Singapore); Too, C.W., E-mail: too.chow.wei@singhealth.com.sg [Department of Diagnostic Radiology, Singapore General Hospital, Outram Road, Singapore 169608 (Singapore); Kao, Y.H., E-mail: yung.h.kao@gmail.com [Department of Nuclear Medicine and PET, Singapore General Hospital, Outram Road, Singapore 169608 (Singapore); Goh, A.S.W., E-mail: anthony.goh.s.w@sgh.com.sg [Department of Nuclear Medicine and PET, Singapore General Hospital, Outram Road, Singapore 169608 (Singapore); Chow, P.K.H., E-mail: gsupc@singnet.com.sg [Department of General Surgery, Singapore General Hospital, Outram Road, Singapore 169608 (Singapore); Office of Clinical Sciences, Duke-NUS Graduate Medical School Singapore, 8 College Road, Singapore 169857 (Singapore); Department of Surgical Oncology, National Cancer Center Singapore, 11 Hospital Drive, Singapore 169610 (Singapore); Tan, B.S., E-mail: tan.bien.soo@sgh.com.sg [Department of Diagnostic Radiology, Singapore General Hospital, Outram Road, Singapore 169608 (Singapore); Tay, K.H., E-mail: tay.kiang.hiong@sgh.com.sg [Department of Diagnostic Radiology, Singapore General Hospital, Outram Road, Singapore 169608 (Singapore); Lo, R.H.G., E-mail: richard.lo.h.g@sgh.com.sg [Department of Diagnostic Radiology, Singapore General Hospital, Outram Road, Singapore 169608 (Singapore)

    2012-12-15

    Purpose: To compare the hepatic falciform artery (HFA) detection rates of digital subtraction angiography (DSA), computed tomography hepatic arteriography (CTHA) and 99mTc-macroaggregated albumin (99mTc-MAA) single photon emission computed tomography with integrated CT (SPECT/CT) and to correlate HFA patency with complication rates of yttrium-90 (90Y) radioembolization. Material and methods: From August 2008 to November 2010, 79 patients (range 23–83 years, mean 62.3 years; 67 male) underwent pre-treatment DSA, CTHA and 99mTc-MAA scintigraphy (planar/SPECT/CT) to assess suitability for radioembolization with 90Y resin microspheres. Thirty-seven patients were excluded from the study, because CTHA was performed with a catheter position that did not result in opacification of the liver parenchyma adjacent to the falciform ligament. DSA, CTHA and 99mTc-MAA SPECT/CT images and medical records were retrospectively reviewed. Results: A patent HFA was detected in 22 of 42 patients (52.3%). The HFA detection rates of DSA, CTHA and 99mTc-MAA SPECT/CT were 11.9%, 52.3% and 13.3%, respectively (p < 0.0001). An origin from the segment 4 artery was seen in 51.7% of HFAs. Prophylactic HFA coil-embolization prior to 90Y microspheres infusion was performed in 2 patients. Of the patients who underwent radioembolization with a patent HFA, none developed supra-umbilical radiation dermatitis. One patient experienced epigastric pain attributed to post-embolization syndrome and was managed conservatively. Conclusion: The HFA detection rate of CTHA is superior to that of DSA and 99mTc-MAA SPECT/CT. Complications related to non-target radiation of the HFA vascular territory rarely occur, even in patients undergoing radioembolization with a patent HFA.

  16. Computed tomography hepatic arteriography has a hepatic falciform artery detection rate that is much higher than that of digital subtraction angiography and 99mTc-MAA SPECT/CT: Implications for planning 90Y radioembolization?

    International Nuclear Information System (INIS)

    Burgmans, M.C.; Too, C.W.; Kao, Y.H.; Goh, A.S.W.; Chow, P.K.H.; Tan, B.S.; Tay, K.H.; Lo, R.H.G.

    2012-01-01

    Purpose: To compare the hepatic falciform artery (HFA) detection rates of digital subtraction angiography (DSA), computed tomography hepatic arteriography (CTHA) and 99mTc-macroaggregated albumin (99mTc-MAA) single photon emission computed tomography with integrated CT (SPECT/CT) and to correlate HFA patency with complication rates of yttrium-90 (90Y) radioembolization. Material and methods: From August 2008 to November 2010, 79 patients (range 23–83 years, mean 62.3 years; 67 male) underwent pre-treatment DSA, CTHA and 99mTc-MAA scintigraphy (planar/SPECT/CT) to assess suitability for radioembolization with 90Y resin microspheres. Thirty-seven patients were excluded from the study, because CTHA was performed with a catheter position that did not result in opacification of the liver parenchyma adjacent to the falciform ligament. DSA, CTHA and 99mTc-MAA SPECT/CT images and medical records were retrospectively reviewed. Results: A patent HFA was detected in 22 of 42 patients (52.3%). The HFA detection rates of DSA, CTHA and 99mTc-MAA SPECT/CT were 11.9%, 52.3% and 13.3%, respectively (p < 0.0001). An origin from the segment 4 artery was seen in 51.7% of HFAs. Prophylactic HFA coil-embolization prior to 90Y microspheres infusion was performed in 2 patients. Of the patients who underwent radioembolization with a patent HFA, none developed supra-umbilical radiation dermatitis. One patient experienced epigastric pain attributed to post-embolization syndrome and was managed conservatively. Conclusion: The HFA detection rate of CTHA is superior to that of DSA and 99mTc-MAA SPECT/CT. Complications related to non-target radiation of the HFA vascular territory rarely occur, even in patients undergoing radioembolization with a patent HFA.

  17. Weibel instability due to inverse bremsstrahlung absorption

    International Nuclear Information System (INIS)

    Bendib, A.; Bendib, K.; Bendib, A.; Bendib, K.; Sid, A.; Bendib, K.

    1997-01-01

    A new Weibel source due to the inverse bremsstrahlung absorption is presented. It has been shown that in homogeneous plasmas, this mechanism may drive strong collisionless Weibel modes with growth rates of order of γ∼10 11 s -1 and negligible group velocities. In the laser-produced plasmas, for short laser wavelengths (λ L 10 14 W/cm 2 ), this Weibel source is most efficient as the ones due to the heat flux and the plasma expansion. The useful scaling law of the convective e-foldings, with respect to the laser and the plasma parameters, is also derived. copyright 1997 The American Physical Society

  18. Safety of {sup 90}Y Radioembolization in Patients Who Have Undergone Previous External Beam Radiation Therapy

    Energy Technology Data Exchange (ETDEWEB)

    Lam, Marnix G.E.H. [Division of Interventional Radiology, Stanford University School of Medicine, Stanford, California (United States); Department of Radiology and Nuclear Medicine, University Medical Center Utrecht (Netherlands); Abdelmaksoud, Mohamed H.K. [Division of Interventional Radiology, Stanford University School of Medicine, Stanford, California (United States); Chang, Daniel T.; Eclov, Neville C.; Chung, Melody P.; Koong, Albert C. [Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California (United States); Louie, John D. [Division of Interventional Radiology, Stanford University School of Medicine, Stanford, California (United States); Sze, Daniel Y., E-mail: dansze@stanford.edu [Division of Interventional Radiology, Stanford University School of Medicine, Stanford, California (United States)

    2013-10-01

    Purpose: Previous external beam radiation therapy (EBRT) is theoretically contraindicated for yttrium-90 ({sup 90}Y) radioembolization (RE) because the liver has a lifetime tolerance to radiation before becoming vulnerable to radiation-induced liver disease. We analyzed the safety of RE as salvage treatment in patients who had previously undergone EBRT. Methods and Materials: Between June 2004 and December 2010, a total of 31 patients who had previously undergone EBRT were treated with RE. Three-dimensional treatment planning with dose–volume histogram (DVH) analysis of the liver was used to calculate the EBRT liver dose. Liver-related toxicities including RE-induced liver disease (REILD) were reviewed and classified according to Common Terminology Criteria for Adverse Events version 4.02. Results: The mean EBRT and RE liver doses were 4.40 Gy (range, 0-23.13 Gy) and 57.9 Gy (range, 27.0-125.9 Gy), respectively. Patients who experienced hepatotoxicity (≥grade2; n=12) had higher EBRT mean liver doses (7.96 ± 8.55 Gy vs 1.62 ± 3.39 Gy; P=.037), the only independent predictor in multivariate analysis. DVH analysis showed that the fraction of liver exposed to ≥30 Gy (V30) was the strongest predictor of hepatotoxicity (10.14% ± 12.75% vs 0.84% ± 3.24%; P=.006). All patients with V30 >13% experienced hepatotoxicity. Fatal REILD (n=2) occurred at the 2 highest EBRT mean liver doses (20.9 Gy and 23.1 Gy) but also at the highest cumulative liver doses (91.8 Gy and 149 Gy). Conclusions: Prior exposure of the liver to EBRT may lead to increased liver toxicity after RE treatment, depending on fractional liver exposure and dose level. The V30 was the strongest predictor of toxicity. RE appears to be safe for the treatment of hepatic malignancies only in patients who have had limited hepatic exposure to prior EBRT.

  19. Determination of Radiation Absorbed Dose to Primary Liver Tumors and Normal Liver Tissue Using Post Radioembolization 90Y PET

    Directory of Open Access Journals (Sweden)

    Shyam Mohan Srinivas

    2014-10-01

    Full Text Available Background: Radioembolization with Yttrium-90 (90Y microspheres is becoming a more widely used transcatheter treatment for unresectable hepatocellular carcinoma (HCC. Using post-treatment 90Y PET/CT scans,the distribution of microspheres within the liver can be determined and quantitatively assessesed . We studied the radiation dose of 90Y delivered to liver and treated tumors.Methods: This retrospective study of 56 patients with HCC, including analysis of 98 liver tumors, measured and correlated the dose of radiation delivered to liver tumors and normal liver tissue using glass microspheres (TheraSpheres® to the frequency of complications with mRECIST. 90Y PET/CT and triphasic liver CT scans were used to contour treated tumor and normal liver regions and determine their respective activity concentrations. An absorbed dose factor was used to convert the measured activity concentration (Bq/mL to an absorbed dose (Gy.Results: The 98 studied tumors received a mean dose of 169 Gy (mode 90-120 Gy;range 0-570 Gy. Tumor response by mRECIST criteria was performed for 48 tumors that had follow up scans. There were 21 responders (mean dose 215 Gy and 27 nonresponders (mean dose 167 Gy. The association between mean tumor absorbed dose and response suggests a trend but did not reach statistical significance (p=0.099. Normal liver tissue received a mean dose of 67 Gy (mode 60-70 Gy; range 10-120 Gy. There was a statistically significant association between absorbed dose to normal liver and the presence of two or more severe complications (p=0.036.Conclusion: Our cohort of patients showed a possible dose response trend for the tumors. Collateral dose to normal liver is nontrivial and can have clinical implications. These methods help us understand whether patient adverse events, treatment success, or treatment failure can be attributed to the dose which the tumor or normal liver received.

  20. Comparative effects of inhaled relatively insoluble forms of 90Y, 144Ce, and 90Sr on canine peripheral lymphocyte function

    International Nuclear Information System (INIS)

    Benjamin, S.A.; Jones, R.K.; Snipes, M.B.; Lustgarten, C.S.

    1976-01-01

    Dogs that have inhaled relatively insoluble forms of either alpha- or beta-emitting radionuclides manifest a peripheral lymphopenia, the development and course of which depends on both total dose and dose rate. The remaining peripheral lymphocytes in dogs exposed to longer lived beta-emitting radionuclides showed a depressed function as measured by the ability to respond to plant mitogens in vitro. This experiment was designed to evaluate the effect of dose rate on peripheral lymphocyte function by exposing dogs to aerosols of radionuclides with varied effective half-lives in the lung: 90 Y (2.6 days), 144 Ce (170 days), and 90 Sr (650 days). Three groups of four adult beagle dogs each were exposed by inhalation to 90 Y, 144 Ce, or 90 Sr in fused-clay particles. Two controls were matched with each group. Initial lung burdens and initial dose rates to the lung were 520 to 610 μCi/kg of body weight and 2200 to 2600 rads/day in the 90 Y group, 33 to 60 μCi/kg and 200 to 350 rads/day in the 144 Ce group, and 25 to 32 μCi/kg and 130 to 170 rads/day in the 90 Sr group. Hematologic parameters and lymphocyte function as measured by the ability of lymphocytes to respond to plant mitogen stimulation were evaluated on a weekly or biweekly basis for 8 weeks after exposure and on a monthly basis thereafter. The 90 Y-exposed dogs showed a marked lymphopenia within 1 week with a return to control levels by 20 weeks after exposure. The remaining peripheral lymphocytes, however, showed no functional changes in these dogs. Animals exposed to 144 Ce or 90 Sr developed a progressive and persisent lymphopenia and showed functional depression of the remaining lymphocytes as well. The relationships among dose pattern, lymphopenia, and lymphocyte-function depression are discussed

  1. Bremsstrahlung converter debris shields: test and analysis

    International Nuclear Information System (INIS)

    Reedy, E.D. Jr.; Perry, F.C.

    1983-10-01

    Electron beam accelerators are commonly used to create bremsstrahlung x-rays for effects testing. Typically, the incident electron beam strikes a sandwich of three materials: (1) a conversion foil, (2) an electron scavenger, and (3) a debris shield. Several laboratories, including Sandia National Laboratories, are developing bremsstrahlung x-ray sources with much larger test areas (approx. 200 to 500 cm 2 ) than ever used before. Accordingly, the debris shield will be much larger than before and subject to loads which could cause shield failure. To prepare for this eventuality, a series of tests were run on the Naval Surface Weapons Center's Casino electron beam accelerator (approx. 1 MeV electrons, 100 ns FWHM pulse, 45 kJ beam energy). The primary goal of these tests was to measure the stress pulse which loads a debris shield. These measurements were made with carbon gages mounted on the back of the converter sandwich. At an electron beam fluence of about 1 kJ/cm 2 , the measured peak compressive stress was typically in the 1 to 2 kbar range. Measured peak compressive stress scaled in a roughly linear manner with fluence level as the fluence level was increased to 10 kJ/cm 2 . The duration of the compressive pulse was on the order of microseconds. In addition to the stress wave measurements, a limited number of tests were made to investigate the type of damage generated in several potential shield materials

  2. Preparation of silica coated and 90Y-radiolabeled β-NaYF4 upconverting nanophosphors for multimodal tracing

    Science.gov (United States)

    Najmr, Stan; Lu, Tianfeng; Keller, Austin W.; Zhang, Mingyue; Lee, Jennifer D.; Makvandi, Mehran; Pryma, Daniel A.; Kagan, Cherie R.; Murray, Christopher B.

    2018-06-01

    Rare-earth (RE) compounds have been actively pursued for therapeutic and diagnostic applications due to their ability to upconvert near infrared light into the UV–vis range. Through nanoengineering and bottom-up synthesis, additional functionality can be added to these upconverting systems. Herein, we report the synthesis of 90Y-doped β-NaYF4:Er, Yb upconverting nanophosphors (UCNPs) to enable β-particle emission and upconversion by the same UCNP. To homogenously incorporate the radionuclides, we employ a hydroxide metathesis method to produce the RE precursor required for the solvothermal synthesis of monodisperse UCNPs. Once incorporated, we find that the β-emitting 90Y dopants do not influence the energy pathways required for upconversion, enabling simultaneous radio- and optical-tracing. The resulting large (>100 nm in height and width), anisotropic, 90Y-radiolabeled β-NaYF4 UCNPs are then coated with silica using a modified, micelle-driven Stöber process to enable their dispersion in polar solvents. Doing so highlights the importance of surfactant (Igepal CO-520) and silica source (tetraethyl orthosilicate) interactions to the continuity of the silica shell and makes the vast library of silica surface chemistry and functionality accessible to upconverting radiotracers.

  3. Development and biological evaluation of {sup 90}Y-BPAMD as a novel bone seeking therapeutic agent

    Energy Technology Data Exchange (ETDEWEB)

    Rabiei, Ali; Shamsaei, Mojtaba [Amir Kabir University of Technology, Tehran (Iran, Islamic Republic of). Energy Engineering and Physics Dept.; Yousefnia, Hassan; Zolghadri, Samaneh; Jalilian, Amir Reza [Nuclear Science and Technology Research Institute (NSTRI), Tehran (Iran, Islamic Republic of); Enayati, Razieh [Islamic Azad Univ. (IAU), Tehran (Iran, Islamic Republic of). Faculty of Engineering

    2016-07-01

    Nowadays, the bone-seeking radiopharmaceuticals play an important role in the treatment of the bone-related pathologies. Whereas various phosphonate ligands have already been identified, a DOTA-based bisphosphonate, 4-{[(bis(phosphonomethyl))carbamoyl]methyl}-7,10-bis(carboxymethyl) -1,4,7,10-tetraazacyclododec-1-yl (BPAMD) with better characteristics has recently been synthesized. In this study, {sup 90}Y-BPAMD was developed with radiochemical purity >98% and the specific activity of 3.52 TBq/mmol in the optimized conditions as a new bone-seeking therapeutic agent. The complex demonstrated significant stability at room temperature and in human serum even after 48 h. At even low amount of hydroxyapatite (5 mg), more than 90% binding to hydroxyapatite was observed. Biodistribution studies after injection of the complex into the Syrian rats showed major accumulation of the labelled compound in the bone tissue and an insignificant uptake in the other organs all the times after injection. Generally, {sup 90}Y-BPAMD demonstrated interesting characteristics compared to the other {sup 90}Y bone-seeking agents and even {sup 166}Ho-BPAMD, and can be considered as a new bone-seeking candidate for therapeutic applications.

  4. Investigation on the influence of metal ion impurities on the complexation behavior of generator produced {sup 90}Y with bifunctional chelators

    Energy Technology Data Exchange (ETDEWEB)

    Pandey, Usha; Gamre, Naresh; Dash, Ashutosh [Isotope Applications and Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai (India)

    2014-05-01

    The {sup 90}Sr/ {sup 90}Y generator is the exclusive source of 'no carrier added' {sup 90}Y for targeted therapy. However, the concomitant presence of trace metals diminishes the complexation of {sup 90}Y with bifunctional chelators (BFCs). A systematic investigation was performed to evaluate the influence of trace metals on the complexation of {sup 90}Y (from an electrochemical generator) with BFCs such as p-SCN-Bn-PCTA, p-SCN-Bn-DTPA and p-SCN-Bn-DOTA. Our study indicates that while p-SCN-Bn-DTPA was least affected by most of the trace metals studied, p-SCN-Bn-PCTA was most sensitive to their presence and hence could be the ligand of choice for assessing the chemical purity of generator derived {sup 90}Y. (author)

  5. Country report: Brazil. Development of Radiopharmaceuticals Based on {sup 188}Re and {sup 90}Y for Radionuclide Therapy at IPEN-CNEN/SP

    Energy Technology Data Exchange (ETDEWEB)

    Osso, Jr., J. A.; Barrio, G.; Dias, C. R.B.R.; Brambilla, T. P.; Dantas, D. M.; Suzuki, K. N.; Barboza, M. F.S.; Bortoleti, E.; Fukumori, N. T.; Mengatti, J. [Radiopharmacy Center – Institute of Energetic and Nuclear Research – IPE N-CNEN/SP, São Paulo – Brazil (Brazil)

    2010-07-01

    The overall objective of this CRP is to develop radiopharmaceuticals for targeted therapy using {sup 188}Re and {sup 90}Y and to study the performance of generators with long lived parent radionuclides as well as to validate the QC control procedures for estimating the purity of generator eluents. The CRP is expected to enhance the capability in production of {sup 90}Y and {sup 188}Re radiopharmaceuticals to meet the increasing demand of therapeutic products for clinical applications, in particular in Brazil. In this period efforts were made towards the assembling of {sup 90}Sr-{sup 90}Y generators, quality control of {sup 90}Y, the labelling of DMSA(V) and anti-CD20 with {sup 188}Re and the labelling of Hydroxiapatite(HA) with {sup 90}Y. (author)

  6. Vector dark matter annihilation with internal bremsstrahlung

    Energy Technology Data Exchange (ETDEWEB)

    Bambhaniya, Gulab, E-mail: gulab@prl.res.in [Physical Research Laboratory, Ahmedabad 380009 (India); Kumar, Jason, E-mail: jkumar@hawaii.edu [Department of Physics & Astronomy, University of Hawaii, Honolulu, HI 96822 (United States); Marfatia, Danny, E-mail: dmarf8@hawaii.edu [Department of Physics & Astronomy, University of Hawaii, Honolulu, HI 96822 (United States); Nayak, Alekha C., E-mail: acnayak@iitk.ac.in [Department of Physics, Indian Institute of Technology, Kanpur 208016 (India); Tomar, Gaurav, E-mail: tomar@prl.res.in [Physical Research Laboratory, Ahmedabad 380009 (India)

    2017-03-10

    We consider scenarios in which the annihilation of self-conjugate spin-1 dark matter to a Standard Model fermion–antifermion final state is chirality suppressed, but where this suppression can be lifted by the emission of an additional photon via internal bremsstrahlung. We find that this scenario can only arise if the initial dark matter state is polarized, which can occur in the context of self-interacting dark matter. In particular, this is possible if the dark matter pair forms a bound state that decays to its ground state before the constituents annihilate. We show that the shape of the resulting photon spectrum is the same as for self-conjugate spin-0 and spin-1/2 dark matter, but the normalization is less heavily suppressed in the limit of heavy mediators.

  7. Coulomb correction calculations of pp Bremsstrahlung

    International Nuclear Information System (INIS)

    Katsogiannis, A.; Amos, K.; Jetter, M.; von Geramb, H.V.

    1994-01-01

    The effects of the Coulomb interaction upon the photon cross section and analyzing power from pp Bremsstrahlung have been studied in detail. Off-shell properties of the Coulomb T matrices have been considered but the associated, Coulomb modified, hadronic T matrices are important elements in any analyses of low energy, forward proton scattering data. At the lowest energy considered (5 MeV), the full calculations gave cross sections that were half the size of those found without Coulomb effects or with a simple model approximation to them. With increasing energy, the cross sections varied to those characteristic of magnetic interaction dominance and the specific differences due to Coulomb effects diminished. 47 refs., 7 figs

  8. Gluon bremsstrahlung and elastic scattering of hadrons

    International Nuclear Information System (INIS)

    Povh, B.

    2001-01-01

    The differential and the total cross sections in high energy hadron-proton interactions give a beautiful insight in the low Q 2 structure of the nucleon. The cross section is composed of two parts: a large energy independent part corresponding to the interaction of the valence quark with the target without gluon radiation and an energy dependent part caused by gluon bremsstrahlung. The gluons are located at small transverse distances of about 0.3 fm from the valence quarks. The model with two scales, the size of the hadron (R 2 ∼ 1 fm 2 ) and the size of the gluonic cloud (r 0 2 ∼ 0.1 fm 2 ), correctly predicts the total and the differential cross sections and the behaviour of diffractive dissociation in hadronic and deep inelastic events. (orig.)

  9. Zeff measurements in ATF using visible bremsstrahlung

    International Nuclear Information System (INIS)

    Morita, S.; Richards, R.K.; Horton, L.D.; Isler, R.C.; Crume, E.C. Jr.; Murakami, M.

    1991-04-01

    Measurements of the effective charge Z eff in plasmas with electron cyclotron heating (ECH) and neutral beam injection (NBI) in the Advanced Toroidal Facility (ATF) have been carried out using visible bremsstrahlung. The electron temperature needed for the analysis is calculated from the measured stored energy and electron density. The value of Z eff varies widely depending on experimental conditions. In ECH plasmas it is between 2 and 8. In NBI plasmas, which are subject to radiation collapse, Z eff is between 3 and 5 at the time the stored energy reaches a maximum. However, Z eff is less than 2.5 in quasi-steady medium-density plasmas and is close to 1.2 in the highest-density plasmas, where the average electron density bar n e is of the order of 10 14 cm -3 . 12 refs., 29 figs., 1 tab

  10. Investigation on the influence of metal ion impurities on the complexation behavior of generator produced {sup 90}Y with different bifunctional chelators

    Energy Technology Data Exchange (ETDEWEB)

    Pandey, Usha; Gamre, Naresh; Chakravarty, Rubel; Pillai, Maroor Raghavan Ambikalmajan; Dash, Ashutosh [Bhabha Atomic Research Centre, Trombay, Mumbai (India). Radiopharmaceuticals Div.

    2014-07-01

    While the {sup 90}Sr/{sup 90}Y generator is the exclusive source of obtaining 'no carrier added' {sup 90}Y for targeted therapy, the presence of trace metals in the radiolabeling solutions poses a serious challenge owing to their ability to diminish the {sup 90}Y complexation yields with bifunctional chelators (BFCs). p-SCN-Bn-PCTA is a novel ligand having faster complexation kinetics with a number of radiometals. In this work, a systematic investigation was performed to evaluate the chelating ability of p-SCN-Bn-PCTA for {sup 90}Y and the influence of trace metal ions on it's complexation with {sup 90}Y in comparison to p-SCN-Bn-DTPA and p-SCN-Bn-DOTA using {sup 90}YCl{sub 3} obtained from an electrochemical generator. Results from our study indicate that while p-SCN-Bn-PCTA gave very good radiolabeling yields with {sup 90}Y when the reaction was carried out by heating for few minutes, it was most sensitive to the presence of trace metals, especially Fe(III). An independent and useful observation is that p-SCN-Bn-PCTA could be considered as the ligand of choice for assessing the chemical purity of generator derived {sup 90}Y.

  11. High energy bremsstrahlung in an intense laser field

    International Nuclear Information System (INIS)

    Schlessinger, L.; Wright, J.A.

    1980-02-01

    The cross section for bremsstrahlung emission and absorption by electrons in an intense laser field has been calculated in the Born approximation for the electron-ion potential. Typical numerical results are presented as a function of the ratio of the electron guiver energy to its energy and the ratio of the bremsstrahlung energy to the electron energy. The intense field correction factor for the rate of bremsstrahlung emission and absorption for electrons with a Boltzmann distribution of energies has been calculated. Numerical results for the correction factor are presented for the Boltzmann case as a function of the ratio of the electron quiver energy to its thermal energy and the ratio of the bremsstrahlung energy to the thermal energy. For typical laser fusion parameters, this correction factor which is the ratio of the thermal bremsstrahlung emission rate in the intense laser field to the rate at zero field can be quite significant. For a laser of wavelength 1.06 μm at an intensity of 3 x 10 15 w/cm 2 and an electron temperature of 1 keV, the correction factor varies from 0.98 at a bremsstrahlung energy of 100 V to greater than 5 at a bremsstrahlung energy of 10 keV

  12. Anti-CD45 radioimmunotherapy with 90Y but not 177Lu is effective treatment in a syngeneic murine leukemia model.

    Directory of Open Access Journals (Sweden)

    Johnnie J Orozco

    Full Text Available Radioimmunotherapy (RIT for treatment of hematologic malignancies has primarily employed monoclonal antibodies (Ab labeled with 131I or 90Y which have limitations, and alternative radionuclides are needed to facilitate wider adoption of RIT. We therefore compared the relative therapeutic efficacy and toxicity of anti-CD45 RIT employing 90Y and 177Lu in a syngeneic, disseminated murine myeloid leukemia (B6SJLF1/J model. Biodistribution studies showed that both 90Y- and 177Lu-anti-murine CD45 Ab conjugates (DOTA-30F11 targeted hematologic tissues, as at 24 hours 48.8 ± 21.2 and 156 ± 14.6% injected dose per gram of tissue (% ID/g of 90Y-DOTA-30F11 and 54.2 ± 9.5 and 199 ± 11.7% ID/g of 177Lu-DOTA-30F11 accumulated in bone marrow (BM and spleen, respectively. However, 90Y-DOTA-30F11 RIT demonstrated a dose-dependent survival benefit: 60% of mice treated with 300 µCi 90Y-DOTA-30F11 lived over 180 days after therapy, and mice treated with 100 µCi 90Y-DOTA-30F11 had a median survival 66 days. 90Y-anti-CD45 RIT was associated with transient, mild myelotoxicity without hepatic or renal toxicity. Conversely, 177Lu- anti-CD45 RIT yielded no long-term survivors. Thus, 90Y was more effective than 177Lu for anti-CD45 RIT of AML in this murine leukemia model.

  13. Nonlinear effects on bremsstrahlung emission in dusty plasmas

    International Nuclear Information System (INIS)

    Kim, Young-Woo; Jung, Young-Dae

    2004-01-01

    Nonlinear effects on the bremsstrahlung process due to ion-dust grain collisions are investigated in dusty plasmas. The nonlinear screened interaction potential is applied to obtain the Fourier coefficients of the force acting on the dust grain. The classical trajectory analysis is applied to obtain the differential bremsstrahlung radiation cross section as a function of the scaled impact parameter, projectile energy, photon energy, and Debye length. The result shows that the nonlinear effects suppress the bremsstrahlung radiation cross section due to collisions of ions with positively charged dust grains. These nonlinear effects decrease with increasing Debye length and temperature, and increase with increasing radiation photon energy

  14. Hepatic Toxicity After Radioembolization of the Liver Using {sup 90}Y-Microspheres: Sequential Lobar Versus Whole Liver Approach

    Energy Technology Data Exchange (ETDEWEB)

    Seidensticker, Ricarda; Seidensticker, Max; Damm, Robert; Mohnike, Konrad [Universitaetsklinikum Magdeburg, Klinik fuer Radiologie and Nuklearmedizin (Germany); Schuette, Kerstin; Malfertheiner, Peter [Universitaetsklinikum Magdeburg, Klinik fuer Gastroenterologie, Hepatologie und Infektiologie (Germany); Buskirk, Mark Van [Data Reduction (United States); Pech, Maciej; Amthauer, Holger; Ricke, Jens, E-mail: jens.ricke@med.ovgu.de [Universitaetsklinikum Magdeburg, Klinik fuer Radiologie and Nuklearmedizin (Germany)

    2012-10-15

    Purpose: {sup 90}Y-radioembolization (RE) is a promising technique for delivering high doses of radiation to liver tumors but may result in compromise of liver function. To gain further perspective, we evaluated the toxicity rates of sequential lobar versus 'whole liver' {sup 90}Y-radioembolization. Methods: Thirty-four patients with liver malignancy in noncirrhotic livers were included; {sup 90}Y-radioembolization was performed as either whole liver or sequential lobar treatment in 17 patients each. Standard clinical and liver specific laboratory parameters as well as MR imaging before treatment and at follow-up (6 and 12 weeks) after radioembolization were evaluated for toxicity using the Common Terminology Criteria for Adverse Events (CTCAE). Volumetry of the liver, tumor, and spleen and measurement of portal vein diameter also were performed. Results: Three months after whole liver RE, 14 liver-related grade 3/4 events were recorded versus 2 events after sequential lobar treatment (P < 0.05). Three patients treated with whole liver RE suffered from radioembolization-induced liver disease (REILD). Pathological increases in bilirubin at 3 months were observed for the whole liver group only (52.3 vs. 18.7 {mu}mol/l, P = 0.012). Total liver volume did not change significantly in either group, but shrinkage of the initially treated hepatic lobe with compensatory hypertrophy of the subsequently treated lobe was observed in the sequential lobar group (P < 0.05). Portal vein diameter increased significantly in whole liver-treated patients only (+17% vs. +6.6%, P = 0.043). Conclusions: Noncirrhotic patients undergoing sequential lobar radioembolization had less hepatic toxicity compared to whole liver embolization. The sequential approach should be the preferred strategy.

  15. Absorbed doses to the main parts of eyeball due to use 90Sr + 90Y ophthalmic applicator

    International Nuclear Information System (INIS)

    Chen Lishu

    1993-05-01

    The ophthalmic radiotherapy dosimetry and some affecting factors are introduced. The distributions of absorbed doses to the main parts of a fresh eyeball such as the cornea, sclera, lens and anterior chamber, during the radiotherapy by using a 90 Sr + 90 Y ophthalmic applicator are presented. An tissue-equivalent extrapolation ionization chamber was used in the dose measurement. The reasonable doses during ophthalmic radiotherapy for different depths have been obtained. Therefore, the absorbed dose to the lens, the most sensitive organ, can be given. These data are useful for radiation protection in ophthalmic radiotherapy

  16. 90Y/90 Sr electron induced damages in an essential eucalyptus oil related to the absorbed dose

    International Nuclear Information System (INIS)

    Heredia Cardona, J.A.; Diaz Rizo, O.; Martinez Luzardo, F.; Quert, R.

    2007-01-01

    A good irradiation geometry was achieved in order to carry out the irradiation of an essential eucalyptus oil with a 90 Y/ 90 Sr electron source. The Monte Carlo simulation code MCNP-4C was employed to determine the absorbed doses in this particular experimental configuration. It also helped us to understand which electrons (from an energetic point of view) were responsible for the damages. In order to identify the induced damages, the irradiated samples were studied by mass spectrometry. The obtained results were related to the absorbed doses determined by the computational simulation

  17. S values at voxels level for 188Re and 90Y calculated with the MCNP-4C code

    International Nuclear Information System (INIS)

    Coca Perez, Marco Antonio; Torres Aroche, Leonel Alberto; Cornejo, Nestor; Martin Hernandez, Guido

    2003-01-01

    The main objective of this work was estimate the voxels S values for 188 Re at cubical geometry using the MCNP-4C code for the simulation of radiation transport and energy deposition. Mean absorbed dose to target voxels per radioactive decay in a source voxels were estimated and reported for 188 Re and Y 90 . A comparison of voxels S values computed with the MCNP code the data reported in MIRD pamphlet 17 for 90 Y was performed in order to evaluate our results

  18. Evaluation of 2 amino acid protocols for kidney protection in patients treated with 90Y-DOTATOC for neuroendocrine tumors

    International Nuclear Information System (INIS)

    Arveschoug, A.K.; Kramer, S.M.J.; Iversen, P.; Froekiaer, J.; Groenbaek, H.

    2015-01-01

    Full text of publication follows. Background: peptide receptor radionuclide therapy (PRRT) is an established treatment for progressive neuroendocrine tumours (NET). Nephrotoxicity is the limiting factor using 90 Y-DOTATOC. Although administration of amino acids lowers the radioactive dose to the kidneys, delayed renal damage is a concern following therapy. Studies have indicated that prolonging the infusion of amino acids offers improved kidney protection. The intermittent infusion of amino acids up two days after PRRT has also been shown to further reduce renal uptake of radioactivity in pilot studies. Aim: We evaluated whether differences could be detected in GFR in patients treated with two different protocols for kidney protection using commercially available (Vamin-18) amino acid mixture (AAM); a standard protocol with 2 litres of AAM infused over 4 hours or a 24-hour infusion protocol with 3 litres of AAM. Material and method: GFR in 18 patients treated with infusion of 2 litres AAM of 4 hours was compared with GFR in 13 patients treated with 3 litres of AAM over 24 hours at 3 months, 6 months and 12 months after therapy with 90 Y DOTATOC. The majority of patients received the standard treatment of 3.7 GBq/m 2 90 Y DOTATOC every 8-10 weeks. The glomerular filtration rate (GFR) was estimated using the 51 Cr-EDTA plasma clearance by a single sample technique according to Groth and Aasted. Results: pre-existing risk factors associated with kidney failure were seen in 84 % of the patients. Other identified risk factors associated with kidney failure were former treatment with 90 Y-DOTATOC and/or chemotherapy, hypertension and diabetes. In the whole group of patients a significant fall in renal function was seen up to twelve months after PRRT. The median loss of kidney function was 30 ml/min/1.73m 2 (27 %) 12 months after treatment compared to pre-therapeutic values. Although no significant statistical difference was found comparing the two amino acid protocols

  19. Development of a dosimetric system for {sup 90}Sr + {sup 90}Y betatherapy applicators; Desenvolvimento de um sistema de dosimetria para aplicadores de betaterapia de {sup 90}Sr + {sup 90}Y

    Energy Technology Data Exchange (ETDEWEB)

    Coelho, Talita Salles

    2010-07-01

    The {sup 90}Sr+{sup 90}Y applicators, used in betatherapy for prevention of keloids and pterigium, are imported and many times their dosimetric features are shown only in an illustrated form by the manufacturers. The exhaustive routine of the medical physicists in the clinic do not make possible the accomplishment of procedures for the confirmation of these parameters. This work presents the development of a methodology for the dosimetry of {sup 90}Sr+{sup 90}Y betatherapy applicators. The Monte Carlo code MCNP5 was used for the simulation of the percentage depth dose curves and dose distribution profiles produced by these applicators. The experimental measurements of the radial and axial radiation attenuation, have been done with a mini-extrapolation chamber, thermoluminescent dosimeters and radiographic films. The experimental results have been compared with the simulated values. Both percentage depth dose curves and the radial dose profiles, the theoretical and the experimental ones, have presented good agreement, which may validate the use of the MCNP5 for these simulations, confirming the viability of the usage of this method in procedures of beta emitter sources dosimetry. (author)

  20. Thermoluminescent dosimetry of beta radiations of {sup 90} Sr/ {sup 90} Y using amorphous ZrO{sub 2}; Dosimetria termoluminiscente de radiaciones beta de {sup 90} Sr/ {sup 90} Y usando ZrO{sub 2} amorfo

    Energy Technology Data Exchange (ETDEWEB)

    Rivera M, T. [CICATA-Legaria, IPN, Legaria Num. 694, 11500 Mexico D.F. (Mexico); Olvera T, L.; Azorin N, J.; Barrera R, M.; Soto E, A.M. [UAM-I, 09340 Mexico D.F. (Mexico)

    2005-07-01

    In this work the results of studying the thermoluminescent properties (Tl) of the zirconium oxide in its amorphous state (ZrO{sub 2}-a) before beta radiations of {sup 90} Sr/ {sup 90} Y are presented. The amorphous powders of the zirconium oxide were synthesized by means of the sol-gel technique. The sol-gel process using alkoxides like precursors, is an efficient method to prepare a matrix of zirconium oxide by hydrolysis - condensation of the precursor to form chains of Zr-H{sub 3} and Zr-O{sub 2}. One of the advantages of this technique is the obtention of gels at low temperatures with very high purity and homogeneity. The powders were characterized by means of thermal analysis and by X-ray diffraction. The powders of ZrO{sub 2}-a, previously irradiated with beta particles of {sup 90} Sr/{sup 90} Y, presented a thermoluminescent curve with two peaks at 150 and 257 C. The dissipation of the information of the one ZrO{sub 2}-a was of 40% the first 2 hours remaining constant the information for the following 30 days. The reproducibility of the information was of {+-} 2.5% in standard deviation. The studied characteristics allow to propose to the amorphous zirconium oxide as thermoluminescent dosemeter for the detection of beta radiation. (Author)

  1. Thermoluminescent dosimetry of beta radiations of {sup 90} Sr/ {sup 90} Y using ZrO{sub 2}: Eu; Dosimetria termoluminiscente de radiaciones beta de {sup 90} Sr/ {sup 90} Y usando ZrO{sub 2}: Eu

    Energy Technology Data Exchange (ETDEWEB)

    Olvera T, L.; Azorin N, J.; Barrera S, M.; Soto E, A.M. [UAM-I, 09340 Mexico D.F. (Mexico); Rivera M, T. [CICATA-IPN, Legaria 694, 11500 Mexico D.F. (Mexico)

    2005-07-01

    In this work the results of studying the thermoluminescent properties (TL) of the doped zirconium oxide with europium (ZrO{sub 2}: Eu{sup 3+}) before beta radiations of {sup 90}Sr/ {sup 90}Y are presented. The powders of ZrO{sub 2}: Eu{sup 3+} were obtained by means of the sol-gel technique and they were characterized by means of thermal analysis and by X-ray diffraction. The powders of ZrO{sub 2}: Eu{sup 3+}, previously irradiated with beta particles of {sup 90}Sr/ {sup 90}Y, presented a thermoluminescent curve with two peaks at 204 and 292 C respectively. The TL response of the ZrO{sub 2}: Eu{sup 3+} as function of the absorbed dose was lineal from 2 Gy up to 90 Gy. The fading of the information of the ZrO{sub 2}: Eu{sup 3+} was of 10% the first 2 hours remaining almost constant the information by the following 30 days. The ZrO{sub 2} doped with the (Eu{sup 3+}) ion it was found more sensitive to the beta radiation that the one of zirconium oxide without doping (ZrO{sub 2}) obtained by the same method. Those studied characteristics allow to propose to the doped zirconium oxide with europium like thermoluminescent dosemeter for the detection of the beta radiation. (Author)

  2. Stabilization effect of Weibel modes due to inverse bremsstrahlung ...

    Indian Academy of Sciences (India)

    2016-11-04

    Nov 4, 2016 ... In this work, the Weibel instability due to inverse bremsstrahlung absorption in laser fusion plasma ... pling of self-generated magnetic field with the laser wave field. This is ... To describe fully ionized plasma where the interac-.

  3. Dynamic bremsstrahlung from relativistic particles scattered by atom

    International Nuclear Information System (INIS)

    Astapenko, V.A.; Bujmistrov, V.M.; Krotov, Yu.A.; Mikhajlov, L.K.; Trakhtenberg, L.I.

    1985-01-01

    The bremsstrahlung cross section for a relativistic particle scattered by an atom is calculated. In contrast to the screening approximation usually employed, the influence of the atomic electron on the bremsstrahlung is taken into account exactly, viz., the atomic electron is considered as a moving particle interacting with the electromagnetic field and not only as the source of a static external field. Consequently, along with the static term which leads to the Bethe-Heitw,ler formula, a ne dynamic, term appears in the transition amplitude. The corresponding cross section, the dynamic bremsstrahlung cross section, in certain frequensy ranges and certain ranges of the directions of photon emission exceeds considerably the static bremsstrahlung cross section

  4. Measurement of the bremsstrahlung spectra generated from thick ...

    Indian Academy of Sciences (India)

    with those predicted by Monte-Carlo (MC) calculations using PENELOPE code. A close ... done on bremsstrahlung cross-section measurements and many theories have been given for ..... This probability is expected to be maximum for elastic.

  5. Preparation and radiolabeling of humanized anti-HER1 monoclonal antibody nimotuzumab Fab' fragment with 68Ga and 90Y

    International Nuclear Information System (INIS)

    Alonso Martinez, L. M.; Xiques Castillo, A.; Leyva Montanna, R.; Perez-Malo Cruz, M.; Zamora Barrabi, M.; Manresa Sanchez, Y.

    2013-01-01

    Antibody-based targeted delivery of radioisotopes to malignant tissues is a promising approach in cancer diagnostics and therapy. However, intact antibody molecules are large glycoproteins (∼150 kDa) that have limited application in molecular imaging and therapy due to their relatively slow clearance from the circulation leading to a high background signal rather both cases the sensitivity can be increased with the use of enzymatically produced Fab' fragments. In this work, the ability to get labeled with 62 Ga and 90 Y of a monoclonal antibody (mAb) Fab' fragment against the transmembrane receptor tyrosine kinase HER-1 was studied for future applications in PET imaging and radioimmunotherapy of tumors. In order to obtain the Fab' fragment the mAb was cleaved with pepsin in molar excess. After separating the reaction mixture in two steps using affinity and ion-exchange chromatography, the Fab' fragment was finally obtained by reduction of the F(ab') 2 with a molar excess of 2-mercaptoethanol followed by a size exclusion purification step. The Fab' fragment was derivatized with 1,4,7,10-tetraaza cyclododecane-1,4,7,10-tetraacetic acid mono N-hydroxysuccinimide commercial ester (DOTA-NHS-ester) applying a simple procedure and the number of DOTA groups linked to Fab' were determinate. The labeling of the conjugate with 68 Ga and 90 Y from 'in-house generators yielded radiochemically pure probes that can become a suitable radioimmunoconjugated in a near future. (Author)

  6. The exploration of nursing care for patients with benign prostatic hyperplasia treated using 90Sr-90Y

    International Nuclear Information System (INIS)

    Xiao Lizhen; Bai Xuemei; Zhang Bihui; Yang Xiaoling

    2004-01-01

    An exploration of nursing care for patients with benign prostatic hyperplasia (BPH) treated using 90 Sr- 90 Y through the rectum was carried out . The treatment result and nursing experience in 90 cases were reported in this paper. Before the therapy nurses explained the method and principle of this treatment to the patients for the sake of increasing their confidence and to help them complete the treatment course successfully. During the radiotherapy, nurses practiced strictly radiation protection principles and operating instructions. They assisted the patients to have a healthy life style and good diet . The result of treatment indicated that the total effectiveness rate was 96.7%. The symptoms of lower urinary obstruction were improved evidently and the life quality of the patients elevated. Observation of clinical system confirmed that 90 Sr- 90 Y may be a new treatment method of BPH with benefits of safe irradiation dos, easy operation, non-traumatization, painlessness, and remarkable curative effects. However, it should be stressed that nursing care plays a pivotal role in the treatment result. (authors)

  7. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival.

    Science.gov (United States)

    Salem, Riad; Lewandowski, Robert J; Atassi, Bassel; Gordon, Stuart C; Gates, Vanessa L; Barakat, Omar; Sergie, Ziad; Wong, Ching-Yee O; Thurston, Kenneth G

    2005-12-01

    To present safety and efficacy results obtained in treatment of a cohort of patients with unresectable hepatocellular carcinoma (HCC) with use of 90Y microspheres (TheraSphere). Forty-three consecutive patients with HCC were treated with 90Y microspheres over a 4-year period. Patients were treated by liver segment or lobe on one or more occasions based on tumor distribution, liver function, and vascular flow dynamics. Patients were followed for adverse events, objective tumor response, and survival. Patients were stratified into three risk groups according to method of treatment and risk stratification (group 0, segmental; group 1, lobar low-risk; group 2, lobar high-risk) and Okuda and Child-Pugh scoring systems. Based on follow-up data from 43 treated patients, 20 patients (47%) had an objective tumor response based on percent reduction in tumor size and 34 patients (79%) had a tumor response when percent reduction and/or tumor necrosis were used as a composite measure of tumor response. There was no statistical difference among the three risk groups with respect to tumor response. Survival times from date of diagnosis were different among the risk groups (P TheraSpheres) provides a safe and effective method of treatment for a broad spectrum of patients presenting with unresectable HCC. Further investigation is warranted.

  8. {sup 18}F-FDG PET/CT predicts survival after {sup 90}Y transarterial radioembolization in unresectable hepatocellular carcinoma

    Energy Technology Data Exchange (ETDEWEB)

    Jreige, Mario; Mitsakis, Periklis; Gucht, Axel van der; Pomoni, Anastasia; Silva-Monteiro, Marina; Boubaker, Ariane; Nicod-Lalonde, Marie; Prior, John O.; Schaefer, Niklaus [Lausanne University Hospital, Department of Nuclear Medicine and Molecular Imaging, Lausanne (Switzerland); Gnesin, Silvano [Lausanne University Hospital, Institute of Radiation Physics, Lausanne (Switzerland); Duran, Rafael; Denys, Alban [Lausanne University Hospital, Department of Radiodiagnostic and Interventional Radiology, Lausanne (Switzerland)

    2017-07-15

    To compare the value of pretreatment functional and morphological imaging parameters for predicting survival in patients undergoing transarterial radioembolization using yttrium-90 ({sup 90}Y-TARE) for unresectable hepatocellular carcinoma (uHCC). We analysed data from 48 patients in our prospective database undergoing {sup 90}Y-TARE treatment for uHCC (31 resin, 17 glass). All patients underwent {sup 18}F-FDG PET/CT and morphological imaging (CT and MRI scans) as part of a pretherapeutic work-up. Patients did not receive any treatment between these imaging procedures and {sup 90}Y-TARE. Kaplan-Meier estimates of progression-free survival (PFS) and overall survival (OS) were used to assess the prognostic value of {sup 18}F-FDG PET/CT metabolic parameters, including SUV{sub max}, tumour-to-liver (T/L) uptake ratio and SUV{sub mean} of healthy liver, and morphological data, including number and size of lesions, portal-venous infiltration (PVI). Relevant prognostic factors for HCC including Child-Pugh class, Barcelona Clinic Liver Cancer (BCLC) stage, tumour size, PVI and serum AFP level were compared with metabolic parameters in univariate and multivariate analyses. The median follow-up in living patients was 16.2 months (range 11.4-50.1 months). Relapse occurred in 34 patients (70.8%) at a median of 7.4 months (range 1.4-27.9 months) after {sup 90}Y-TARE, and relapse occurred in 24 of 34 patients (70.8%) who died from their disease at a median of 8.1 months (range 2.2-35.2 months). Significant prognostic markers for PFS were the mean and median lesion SUV{sub max} (both P = 0.01; median PFS 10.2 vs. 7.4 months), and significant prognostic markers for OS were the first quarter (Q1) cut-off values for lesion SUV{sub max} and T/L uptake ratio (both P = 0.02; median OS 30.9 vs. 9 months). The multivariate analysis confirmed that lesion SUV{sub max} and T/L uptake ratio were independent negative predictors of PFS (hazard ratio, HR, 2.7, 95% CI 1.2-6.1, P = 0.02, for mean

  9. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers.

    Science.gov (United States)

    Imhof, Anna; Brunner, Philippe; Marincek, Nicolas; Briel, Matthias; Schindler, Christian; Rasch, Helmut; Mäcke, Helmut R; Rochlitz, Christoph; Müller-Brand, Jan; Walter, Martin A

    2011-06-10

    To investigate response, survival, and safety profile of the somatostatin-based radiopeptide (90)yttrium-labeled tetraazacyclododecane-tetraacetic acid modified Tyr-octreotide ([(90)Y-DOTA]-TOC) in neuroendocrine cancers. In a clinical phase II single-center open-label trial, patients with neuroendocrine cancers were treated with repeated cycles of [(90)Y-DOTA]-TOC. Each cycle consisted of a single intravenous injection of 3.7GBq/m(2) body-surface [(90)Y-DOTA]-TOC. Additional cycles were withheld in case of tumor progression and/or permanent toxicity. Overall, 1,109 patients received 2,472 cycles of [(90)Y-DOTA]-TOC (median, two; range, one to 10 cycles per patient). Of the 1,109 patients, 378 (34.1%) experienced morphologic response; 172 (15.5%), biochemical response; and 329 (29.7%), clinical response. During a median follow-up of 23 months, 491 patients (44.3%) died. Longer survival was correlated with each: morphologic (hazard ratio [HR], 0.46; 95% CI, 0.38 to 0.56; median survival, 44.7 v 18.3 months; P TOC treatment in a large cohort. Response to [(90)Y-DOTA]-TOC is associated with longer survival. Somatostatin receptor imaging is predictive for both survival after [(90)Y-DOTA]-TOC treatment and occurrence of renal toxicity.

  10. The somatostatin receptor-targeted radiotherapeutic [{sup 90}Y-DOTA-dPhe{sup 1},Tyr{sup 3}]octreotide ({sup 90}Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours

    Energy Technology Data Exchange (ETDEWEB)

    Stolz, B.; Weckbecker, G.; Smith-Jones, P.M.; Albert, R.; Raulf, F.; Bruns, C. [Novartis Pharma AG, Basel (Switzerland)

    1998-07-01

    Somatostatin receptor-expressing tumours are potential targets for therapy with radiolabelled somatostatin analogues. We have synthesized a number of such analogues in the past and identified [DOTA-dPhe{sup 1}, Tyr{sup 3}]octreotide (SMT 487) as the most promising candidate molecule because of its advantageous properties in cellular and in vivo tumour models. In the current paper we describe the radiotherapeutic effect of yttrium-90 labelled SMT 487 in Lewis rats bearing the somatostatin receptor-positive rat pancreatic tumour CA 20948. SMT 487 binds with nanomolar affinity to both the human and the rat somatostatin receptor subtype 2 (sst{sub 2}) (human sst{sub 2} IC{sub 50}=0.9 nM, rat sst{sub 2} IC{sub 50}=0.5 nM). In vivo, {sup 90}Y-SMT 487 distributed rapidly to the sst{sub 2} expressing CA 20948 rat pancreatic tumour, with a tumour-to-blood ratio of 49.15 at 24 h post injection. A single intravenous administration of 10 mCi/kg {sup 90}Y-SMT 487 resulted in a complete remission of the tumours in five out of seven CA 20948 tumour-bearing Lewis rats. No regrowth of the tumours occurred 8 months post injection. Control animals that were treated with 30 {mu}g/kg of unlabelled SMT 487 had to be sacrificed 10 days post injection due to excessive growth or necrotic areas on the tumour surface. Upon re-inoculation of tumour cells into those rats that had shown complete remission, the tumours disappeared after 3-4 weeks of moderate growth without any further treatment. The present study shows for the first time the curative potential of {sup 90}Y-SMT 487-based radiotherapy for somatostatin receptor-expressing tumours. Clinical phase I studies with yttrium-labelled SMT 487 have started in September 1997. (orig.) With 4 figs., 2 tabs., 29 refs.

  11. Analytic approximate radiation effects due to Bremsstrahlung

    Energy Technology Data Exchange (ETDEWEB)

    Ben-Zvi I.

    2012-02-01

    The purpose of this note is to provide analytic approximate expressions that can provide quick estimates of the various effects of the Bremsstrahlung radiation produced relatively low energy electrons, such as the dumping of the beam into the beam stop at the ERL or field emission in superconducting cavities. The purpose of this work is not to replace a dependable calculation or, better yet, a measurement under real conditions, but to provide a quick but approximate estimate for guidance purposes only. These effects include dose to personnel, ozone generation in the air volume exposed to the radiation, hydrogen generation in the beam dump water cooling system and radiation damage to near-by magnets. These expressions can be used for other purposes, but one should note that the electron beam energy range is limited. In these calculations the good range is from about 0.5 MeV to 10 MeV. To help in the application of this note, calculations are presented as a worked out example for the beam dump of the R&D Energy Recovery Linac.

  12. Bremsstrahlung X rays from Jovian auroral electrons

    International Nuclear Information System (INIS)

    Barbosa, D.D.

    1990-01-01

    The spectrum of X rays from the planet Jupiter is calculated according to an auroral electron beam model. The electrons are assumed to be accelerated by a field-aligned potential drop and penetrate into the atmosphere as a Maxwellian beam of primaries which are scattered, degraded in energy, and merged with a population of ionization secondaries having a power law energy distribution. The soft X rays observed by the Einstein Observatory satelltie are due to bremsstrahlung from the sedondary electrons in the H 2 atmosphere. A good match to the X ray data is obtained if the power law spectral index of the secondary electrons, γ e , is ≅ 2, yielding a power law slope for the photon flux γ X = γ e + 1 ≅ 3. The X ray intensity is best reconciled with a beam of primaries having a characteristic energy 30-100 keV and penetrating the homopause with an auroral energy flux typically of 10-20 ergs cm -2 s -1 but no greater than 50 ergs cm -2 s -1

  13. Analytic approximate radiation effects due to Bremsstrahlung

    International Nuclear Information System (INIS)

    Ben-Zvi, I.

    2012-01-01

    The purpose of this note is to provide analytic approximate expressions that can provide quick estimates of the various effects of the Bremsstrahlung radiation produced relatively low energy electrons, such as the dumping of the beam into the beam stop at the ERL or field emission in superconducting cavities. The purpose of this work is not to replace a dependable calculation or, better yet, a measurement under real conditions, but to provide a quick but approximate estimate for guidance purposes only. These effects include dose to personnel, ozone generation in the air volume exposed to the radiation, hydrogen generation in the beam dump water cooling system and radiation damage to near-by magnets. These expressions can be used for other purposes, but one should note that the electron beam energy range is limited. In these calculations the good range is from about 0.5 MeV to 10 MeV. To help in the application of this note, calculations are presented as a worked out example for the beam dump of the R and D Energy Recovery Linac.

  14. Bremsstrahlung convertors: materials design and development

    International Nuclear Information System (INIS)

    Allred, R.E.

    1976-03-01

    An improved bremsstrahlung convertor for use at high electron beam energies was developed. The convertor consists of three main components: (1) conversion foil; (2) electron scavenger; and (3) impulse shield. Structural failures of the impulse shield were experimentally determined to be caused by shock wave interactions. Convertor materials and design modifications were aimed at attenuation of the magnitude of the shock and maximization of energy absorption by the convertor materials. Techniques proven successful included the introduction of porosity into electron scavenger and impulse shield materials, the use of a standoff between the conversion foil and the electron scavenger, the insertion of a gap between the scavenger and impulse shield, and the use of advanced composite materials for the impulse shield. These modifications have increased the convertor operating range from 4 cal/gm Au to over 8 cal/gm Au. Kevlar 49 reinforced-resin composites have proven to have the best combination of strength, stiffness, toughness, and x-ray transport properties for use as bremmstrahlung convertor impulse shields

  15. Gravitational bremsstrahlung in ultra-planckian collisions

    CERN Document Server

    Gal'tsov, Dmitry; Tomaras, Theodore N

    2013-01-01

    A classical computation of gravitational bremsstrahlung in ultra-planckian collisions of massive point particles is presented in an arbitrary number d of toroidal or non-compact extra dimensions. Our method generalizes the post-linear formalism of General Relativity to the multidimensional case. The total emitted energy, as well as its angular and frequency distribution are discussed in detail. In terms of the gravitational radius r_S of the collision energy, the impact parameter b and the Lorentz factor in the CM frame, the leading order radiation efficiency in the Lab frame is shown to be of order (r_S/b)^{3(d+1)} gamma_{cm} for d=0, 1 and of order (r_S/b)^{3(d+1)} gamma_{cm}^{2d-3} for d>1, up to a known d-dependent coefficient and a ln gamma_{cm} factor for d=2, while the characteristic frequency of the radiation is gamma/b. The contribution of the low frequency part of the radiation (soft gravitons) to the total radiated energy is shown to be negligible for all values of d. The domain of validity of the ...

  16. Country report: Pakistan. Second Research Co-ordination Meeting on Development of Radiopharmaceuticals Based on 188Re and 90Y for Radionuclide Therapy, 22-26 March 2010, Vienna

    International Nuclear Information System (INIS)

    Mansur, M.S.; Mushtaq, A.

    2010-01-01

    Various experiments were carried out for the separation of 90 Y from 90 Sr using colloid formation behavior of 90 Y in basic pH range. When the acidic solution of 90 Sr/ 90 Y was treated with NaOH and passed through a small glass wool column, more than 95% 90 Y was retained on glass wool, which was further washed with 0.1 M NaOH. The 90 Y was extracted in 1 M HCl. Radionuclidic purity was determined by half life measurement. The contamination of parent was less than 0.0001%. Similarly when the colloid was passed through membrane filter more than 95% 90 Y was retained which was recovered by 1 M HCl. The contamination of 90 Sr was less than 0.0001%. The stock solution of 90 Sr/ 90 Y in NH 4 OH/NaOH was again passed through Millipore filter paper or glass wool after one week. The retention of 90Y was insignificant. The equilibrium mixture of 90 Sr/ 90 Y was acidified with HCl and again precipitated with addition of NH 4 OH or NaOH. The basic solution was passed through the Millipore filter or glass wool. More than 90% activity of 90 Y was retained, which was finally extracted in 1 M HCl It was concluded that for recovery of 90 Y from 90 Sr by colloid formation, the acidic solution of 90 Sr/ 90 Y shall be freshly precipitated by NH 4 OH or NaOH. It was also observed that the adsorption of 90 Y was quite high when the 90 Sr solution was left in a glass vial for the growth of 90 Y. However it can be easily extracted after keeping it in boiling water bath for few minutes. The separated 90 Y via colloid formation was used for the labeling of EDTMP. Labeling efficiency of 90 Y-EDTMP was more than 98%

  17. Development of Technology for the Preparation of 90Sr/90Y Generators at the Radiopharmacy Directory of IPEN/CNEN-SP

    International Nuclear Information System (INIS)

    Barrio, Graciela

    2010-01-01

    90 Y (T /2 = 2,67 d; Eβmax = 2,28 MeV) is a radionuclide with efficacy established for various cancer therapies, labeling biomolecules and treating of radiosinovectomy. Due to its nuclear properties, is obtained through the decay of 90 Sr T /2 = 28 y in the form of a generator. Several types of 90 Sr/ 90 Y generators were developed, and the most employed are the cation exchange resins, where Sr and Y are adsorbed and 90 Y is selectively eluted with acetate or EDTA. The disadvantage of this type of generator is the radiolysis, which degrades its use. The electrochemical generator is a proposed solution because there is no significant effect of radiation. In this concept, the difference between the electrochemical potentials of the elements Sr and Y is used to obtain a rapid separation of 90 Y from 90 Sr. The production of 90 Y via colloid formation is the simplest method for the separation, based on the colloid formation of Y in high alkaline pH, which can be filtered and separated from Sr, and subsequently dissolved in HCl. The objective of this work was the development of technologies for the preparation of 90 Sr/ 90 Y generators, and three technologies were developed: generators using cation resins columns, generators through colloid formation and electrochemical generators. Radionuclidic quality control of 90 Y was also evaluated by liquid scintillation, radionuclide identity, extraction paper chromatography (EPC) using complexing agents for 90 Y and by Optical Emission Spectrometry with Inductively Coupled Plasma (ICP-OES). The results showed that generators using cation resins have the best results related to the elution efficiency (∼83%), the reproducibility and radionuclidic purity. The electrochemical generator showed a potential for development, having the advantage of not suffering the effects of radiolysis of the pair 90 Sr/ 90 Y as the resin. A comparison and evaluation of the methods of the radionuclidic quality control showed that the EPC is very

  18. Localized internal radiotherapy with 90Y particles embedded in a new thermosetting alginate gel: a feasibility study in pigs.

    Science.gov (United States)

    Holte, Oyvind; Skretting, Arne; Bach-Gansmo, Tore; Hol, Per Kristian; Johnsrud, Kjersti; Tønnesen, Hanne Hjorth; Karlsen, Jan

    2006-02-01

    Internal radiotherapy requires the localization of the radionuclide to the site of action. A new injectable alginate gel formulation intended to undergo immediate gelation in tissues and capable of encapsulating radioactive particles containing 90Y was investigated. The formulation was injected intramuscularly, into the bone marrow compartment of the femur and intravenously, respectively, in pigs. The distribution of radioactivity in various tissues was determined. Following intramuscular injection, more than 90% of the radioactivity was found at the site of injection. Following injection into bone marrow, 30-40% of the radioactivity was retained at the site of injection, but a considerable amount of radioactivity was also detected in the lungs (35-45%) and the liver (5-18%). Following intravenous injection, 80-90% of the radioactivity was found in the lungs. The present formulation appears suitable for localized radiotherapy in organs and tissues having low perfusion.

  19. 90Sr- 90Y and 89Sr beta radioactivity measurement in milk samples using a proportional counter

    International Nuclear Information System (INIS)

    Mananes, A.; Perez Santos, C.; Martinez Churiaque, F.

    1987-01-01

    A thin window glas flow proportional counter is used to measure the 90 Sr- 90 Y and 89 Sr beta radioactivity in milk samples. A chemical procedure is used to separate strontium-yttrium from the other radionuclides present in milk. A calculation of the total efficiency of the system is performed which includes an empirical estimation of the backscattering factor. The calibration of the whole process allows the determination of the 90 Sr activity within 10% relative error in spite of uncertainties in the recovery yields of strontium and yttrium. No 89 Sr activity has been detected, and the mean value obtained for the 90 Sr activity in nine milk samples of Cantabria is 0.115 Bq/1 with a minimum detectable activity of 0.0105 Bq. (author) 18 refs

  20. S values at voxels level for 188Re and 90Y calculated with the MCNP-4C code

    International Nuclear Information System (INIS)

    Coca, M.A.; Torres, L.A.; Cornejo, N.; Martin, G.

    2008-01-01

    Full text: MIRD formalism at voxel level has been suggested as an optional methodology to perform internal radiation dosimetry calculation during internal radiation therapy in Nuclear Medicine. Voxel S values for Y 90 , 131 I, 32 P, 99m Tc and 89 Sr have been published to different sizes. Currently, 188 Re has been proposed as a promising radionuclide for therapy due to its physical features and availability from generators. The main objective of this work was to estimate the voxel S values for 188 Re at cubical geometry using the MCNP-4C code for the simulations of radiation transport and energy deposition. Mean absorbed dose to target voxels per radioactive decay in a source voxel were estimated and reported for 188 Re and Y 90 . A comparison of voxel S values computed with the MCNP code and the data reported in MIRD Pamphlet 17 for 90 Y was performed in order to evaluate our results. (author)

  1. Large-scale purification of 90Sr from nuclear waste materials for production of 90Y, a therapeutic medical radioisotope.

    Science.gov (United States)

    Wester, Dennis W; Steele, Richard T; Rinehart, Donald E; DesChane, Jaquetta R; Carson, Katharine J; Rapko, Brian M; Tenforde, Thomas S

    2003-07-01

    A major limitation on the supply of the short-lived medical isotope 90Y (t1/2 = 64 h) is the available quantity of highly purified 90Sr generator material. A radiochemical production campaign was therefore undertaken to purify 1,500 Ci of 90Sr that had been isolated from fission waste materials. A series of alkaline precipitation steps removed all detectable traces of 137Cs, alpha emitters, and uranium and transuranic elements. Technical obstacles such as the buildup of gas pressure generated upon mixing large quantities of acid with solid 90Sr carbonate were overcome through safety features incorporated into the custom-built equipment used for 90Sr purification. Methods are described for analyzing the chemical and radiochemical purity of the final product and for accurately determining by gravimetry the quantities of 90Sr immobilized on stainless steel filters for future use.

  2. Large-scale purification of 90Sr from nuclear waste materials for production of 90Y, a therapeutic medical radioisotope

    International Nuclear Information System (INIS)

    Wester, D.W.; Steele, R.T.; Rinehart, D.E.; DesChane, J.R.; Carson, K.J.; Rapko, B.M.; Tenforde, T.S.

    2003-01-01

    A major limitation on the supply of the short-lived medical isotope 90 Y (t 1/2 =64 h) is the available quantity of highly purified 90 Sr generator material. A radiochemical production campaign was therefore undertaken to purify 1500 Ci of 90 Sr that had been isolated from fission waste materials. A series of alkaline precipitation steps removed all detectable traces of 137 Cs, alpha emitters, and uranium and transuranic elements. Technical obstacles such as the buildup of gas pressure generated upon mixing large quantities of acid with solid 90 Sr carbonate were overcome through safety features incorporated into the custom-built equipment used for 90 Sr purification. Methods are described for analyzing the chemical and radiochemical purity of the final product and for accurately determining by gravimetry the quantities of 90 Sr immobilized on stainless steel filters for future use

  3. Positron-emitting resin microspheres as surrogates of 90Y SIR-Spheres: a radiolabeling and stability study

    International Nuclear Information System (INIS)

    Avila-Rodriguez, Miguel A.; Selwyn, Reed G.; Hampel, Joseph A.; Thomadsen, Bruce R.; DeJesus, Onofre T.; Converse, Alexander K.; Nickles, Robert J.

    2007-01-01

    Commercially available resin microspheres and SIR-Spheres were labeled with metallic positron emitters and evaluated as positron emission tomography (PET) imaging surrogates of 90 Y SIR-Spheres. Radiolabeling was performed using a batch method, and in vitro stability over 24 h was evaluated in saline at physiological pH at 37 o C. The activity per microsphere distribution, as evaluated by autoradiography, showed the activity per microsphere to be proportional to the square radius of the spheres, suggesting surface binding. The in vivo stability of radiolabeling was evaluated in rats by micro-PET imaging after the intravenous injection of labeled microspheres. The different resin microspheres and radionuclides evaluated in this study all showed good radiolabeling efficiency and in vitro stability. However, only resins labeled with 86 Y and 89 Zr proved to have the in vivo stability required for clinical applications

  4. EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomab tiuxetan (Zevalin)

    International Nuclear Information System (INIS)

    Tennvall, Jan; Fischer, Manfred; Brans, Boudewijn; Bischof Delaloye, Angelika; Bombardieri, Emilio; Bodei, Lisa; Giammarile, Francesco; Lassmann, Michael; Oyen, Wim

    2007-01-01

    In January 2004, EMEA approved 90 Y-radiolabelled ibritumomab tiuxetan, Zevalin, in Europe for the treatment of adult patients with rituximab-relapsed or -refractory CD20+ follicular B-cell non-Hodgkin's lymphoma. The number of European nuclear medicine departments using Zevalin is continuously increasing, since the therapy is often considered successful. The Therapy, Oncology and Dosimetry Committees have worked together in order to define some EANM guidelines on the use of Zevalin, paying particular attention to the problems related to nuclear medicine. The purpose of this guideline is to assist the nuclear medicine physician in treating and managing patients who may be candidates for radio-immunotherapy. The guideline also stresses the need for close collaboration with the physician(s) treating the patient for the underlying disease. (orig.)

  5. Tumor-targeting properties of 90Y- and 177Lu-labeled α-melanocyte stimulating hormone peptide analogues in a murine melanoma model

    International Nuclear Information System (INIS)

    Miao Yubin; Hoffman, Timothy J.; Quinn, Thomas P.

    2005-01-01

    The purpose of this study was to compare the tumor-targeting properties of 90 Y-DOTA-Re(Arg 11 )CCMSH and 177 Lu-DOTA-Re(Arg 11 )CCMSH in a murine melanoma mouse model. Methods: The in vitro properties of cellular internalization and retention of 90 Y-DOTA-Re(Arg 11 )CCMSH and 177 Lu-DOTA-Re(Arg 11 )CCMSH were studied in B16/F1 murine melanoma cells. The pharmacokinetics of 90 Y-DOTA-Re(Arg 11 )CCMSH and 177 Lu-DOTA-Re(Arg 11 )CCMSH were determined in B16/F1 melanoma-bearing C57 mice. Results: 90 Y-DOTA-Re(Arg 11 )CCMSH and 177 Lu-DOTA-Re(Arg 11 )CCMSH exhibited fast cellular internalization and extended cellular retention in B16/F1 cells. High receptor-mediated tumor uptake and retention coupled with fast whole-body clearance of 90 Y-DOTA-Re(Arg 11 )CCMSH and 177 Lu-DOTA-Re(Arg 11 )CCMSH were demonstrated in B16/F1 tumor-bearing C57 mice. The tumor uptakes of 90 Y-DOTA-Re(Arg 11 )CCMSH and 177 Lu-DOTA-Re(Arg 11 )CCMSH were 25.70±4.64 and 14.48±0.85 %ID/g at 2 h, and 14.09±2.73 and 17.68±3.32 %ID/g at 4 h postinjection. There was little activity accumulated in normal organs except for kidney. Conclusions: High tumor-targeting properties of 90 Y-DOTA-Re(Arg 11 )CCMSH and 177 Lu-DOTA-Re(Arg 11 )CCMSH highlighted their potential as radiopharmaceuticals for targeted radionuclide therapy of melanoma in further investigations

  6. Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus 90Y-radioembolization for hepatocellular carcinoma

    International Nuclear Information System (INIS)

    Ludwig, Johannes M.; Xing, Minzhi; Zhang, Di; Kim, Hyun S.

    2017-01-01

    To investigate comparative effectiveness of drug-eluting bead transarterial chemoembolization (DEB-TACE) versus Yttrium-90 ( 90 Y)-radioembolization for hepatocellular carcinoma (HCC). Studies comparing conventional (c)TACE versus 90 Y-radioembolization or DEB-TACE for HCC treatment were identified using PubMed/Medline, Embase, and Cochrane databases. The adjusted indirect meta-analytic method for effectiveness comparison of DEB-TACE versus 90 Y-radioembolization was used. Wilcoxon rank-sum test was used to compare baseline characteristics. A priori defined sensitivity analysis of stratified study subgroups was performed for primary outcome analyses. Publication bias was tested by Egger's and Begg's tests. Fourteen studies comparing DEB-TACE or 90 Y-radioembolization with cTACE were included. Analysis revealed a 1-year overall survival benefit for DEB-TACE over 90 Y-radioembolization (79 % vs. 54.8 %; OR: 0.57; 95 %CI: 0.355-0.915; p = 0.02; I-squared: 0 %; p > 0.5), but not for the 2-year (61 % vs. 34 %; OR: 0.65; 95%CI: 0.294-1.437; p = 0.29) and 3-year survival (56.4 % vs. 20.9 %; OR: 0.713; 95 % CI: 0.21-2.548; p = 0.62). There was significant heterogeneity in the 2- and 3-year survival analyses. The pooled median overall survival was longer for DEB-TACE (22.6 vs. 14.7 months). There was no significant difference in tumour response rate. DEB-TACE and 90 Y-radioembolization are efficacious treatments for patients suffering from HCC; DEB-TACE demonstrated survival benefit at 1-year compared to 90 Y-radioembolization but direct comparison is warranted for further evaluation. (orig.)

  7. Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus {sup 90}Y-radioembolization for hepatocellular carcinoma

    Energy Technology Data Exchange (ETDEWEB)

    Ludwig, Johannes M.; Xing, Minzhi [Yale School of Medicine, Division of Interventional Radiology, Department of Radiology and Biomedical Imaging, New Haven, CT (United States); Zhang, Di [University of Pittsburgh Graduate School of Public Health, Department of Biostatistics, Pittsburgh, PA (United States); Kim, Hyun S. [Yale School of Medicine, Division of Interventional Radiology, Department of Radiology and Biomedical Imaging, New Haven, CT (United States); Yale School of Medicine, Yale Cancer Center, New Haven, CT (United States)

    2017-05-15

    To investigate comparative effectiveness of drug-eluting bead transarterial chemoembolization (DEB-TACE) versus Yttrium-90 ({sup 90}Y)-radioembolization for hepatocellular carcinoma (HCC). Studies comparing conventional (c)TACE versus {sup 90}Y-radioembolization or DEB-TACE for HCC treatment were identified using PubMed/Medline, Embase, and Cochrane databases. The adjusted indirect meta-analytic method for effectiveness comparison of DEB-TACE versus {sup 90}Y-radioembolization was used. Wilcoxon rank-sum test was used to compare baseline characteristics. A priori defined sensitivity analysis of stratified study subgroups was performed for primary outcome analyses. Publication bias was tested by Egger's and Begg's tests. Fourteen studies comparing DEB-TACE or {sup 90}Y-radioembolization with cTACE were included. Analysis revealed a 1-year overall survival benefit for DEB-TACE over {sup 90}Y-radioembolization (79 % vs. 54.8 %; OR: 0.57; 95 %CI: 0.355-0.915; p = 0.02; I-squared: 0 %; p > 0.5), but not for the 2-year (61 % vs. 34 %; OR: 0.65; 95%CI: 0.294-1.437; p = 0.29) and 3-year survival (56.4 % vs. 20.9 %; OR: 0.713; 95 % CI: 0.21-2.548; p = 0.62). There was significant heterogeneity in the 2- and 3-year survival analyses. The pooled median overall survival was longer for DEB-TACE (22.6 vs. 14.7 months). There was no significant difference in tumour response rate. DEB-TACE and {sup 90}Y-radioembolization are efficacious treatments for patients suffering from HCC; DEB-TACE demonstrated survival benefit at 1-year compared to {sup 90}Y-radioembolization but direct comparison is warranted for further evaluation. (orig.)

  8. Somatostatin-based radiopeptide therapy with [{sup 177}Lu-DOTA]-TOC versus [{sup 90}Y-DOTA]-TOC in neuroendocrine tumours

    Energy Technology Data Exchange (ETDEWEB)

    Romer, A.; Seiler, D.; Brunner, P.; Ng, Q.K.T.; Mueller-Brand, J. [University Hospital Basel, Institute of Nuclear Medicine, Basel (Switzerland); Marincek, N.; Walter, M.A. [University Hospital Basel, Institute of Nuclear Medicine, Basel (Switzerland); University Hospital Bern, Institute of Nuclear Medicine, Bern (Switzerland); Koller, M.T. [University Hospital Basel, Basel Institute for Clinical Epidemiology and Biostatistics, Basel (Switzerland); Maecke, H.R. [University Hospital Basel, Division of Radiochemistry, Basel (Switzerland); Rochlitz, C. [University Hospital Basel, Department of Oncology, Basel (Switzerland); Briel, M. [University Hospital Bern, Institute of Nuclear Medicine, Bern (Switzerland); University Hospital Basel, Basel Institute for Clinical Epidemiology and Biostatistics, Basel (Switzerland); McMaster University, Department of Clinical Epidemiology and Biostatistics, Hamilton (Canada); Schindler, C. [University of Basel, Swiss Tropical and Public Health Institute, Basel (Switzerland)

    2014-02-15

    Somatostatin-based radiopeptide treatment is generally performed using the β-emitting radionuclides {sup 90}Y or {sup 177}Lu. The present study aimed at comparing benefits and harms of both therapeutic approaches. In a comparative cohort study, patients with advanced neuroendocrine tumours underwent repeated cycles of [{sup 90}Y-DOTA]-TOC or [{sup 177}Lu-DOTA]-TOC until progression of disease or permanent adverse events. Multivariable Cox regression and competing risks regression were employed to examine predictors of survival and adverse events for both treatment groups. Overall, 910 patients underwent 1,804 cycles of [{sup 90}Y-DOTA]-TOC and 141 patients underwent 259 cycles of [{sup 177}Lu-DOTA]-TOC. The median survival after [{sup 177}Lu-DOTA]-TOC and after [{sup 90}Y-DOTA]-TOC was comparable (45.5 months versus 35.9 months, hazard ratio 0.91, 95 % confidence interval 0.63-1.30, p = 0.49). Subgroup analyses revealed a significantly longer survival for [{sup 177}Lu-DOTA]-TOC over [{sup 90}Y-DOTA]-TOC in patients with low tumour uptake, solitary lesions and extra-hepatic lesions. The rate of severe transient haematotoxicities was lower after [{sup 177}Lu-DOTA]-TOC treatment (1.4 vs 10.1 %, p = 0.001), while the rate of severe permanent renal toxicities was similar in both treatment groups (9.2 vs 7.8 %, p = 0.32). The present results revealed no difference in median overall survival after [{sup 177}Lu-DOTA]-TOC and [{sup 90}Y-DOTA]-TOC. Furthermore, [{sup 177}Lu-DOTA]-TOC was less haematotoxic than [{sup 90}Y-DOTA]-TOC. (orig.)

  9. Calibration and validation of a quality assurance system for {sup 90}Sr/{sup 90}Y radiation source trains

    Energy Technology Data Exchange (ETDEWEB)

    Rosenthal, P [Department of Radiation Therapy and Oncology, Freie Universitaet Berlin, Benjamin Franklin University Medical Centre, Hindenburgdamm 30, D-12200 Berlin (Germany); Weber, W [Novoste GmbH, Huettenallee 237 c, D-47800 Krefeld (Germany); Foerster, A [Department of Radiation Therapy and Oncology, Freie Universitaet Berlin, Benjamin Franklin University Medical Centre, Hindenburgdamm 30, D-12200 Berlin (Germany); Orth, O [Department of Radiation Therapy and Oncology, Freie Universitaet Berlin, Benjamin Franklin University Medical Centre, Hindenburgdamm 30, D-12200 Berlin (Germany); Koehler, B [Department of Radiation Therapy and Oncology, Freie Universitaet Berlin, Benjamin Franklin University Medical Centre, Hindenburgdamm 30, D-12200 Berlin (Germany); Seiler, F [Department of Radiation Therapy and Oncology, Freie Universitaet Berlin, Benjamin Franklin University Medical Centre, Hindenburgdamm 30, D-12200 Berlin (Germany)

    2003-03-07

    A quality assurance system (OPTIDOS, PTW-Freiburg) developed for dose rate verification of {sup 90}Sr/{sup 90}Y radiation source trains (RSTs) was calibrated and validated. These source trains are used in the 5-F-BetaCath{sup TM} system (Novoste Corp.) for the treatment of endovascular diseases. The calibration factor of the OPTIDOS system was obtained empirically and is valid for {sup 90}Sr/{sup 90}Y dose rate measurements at the specification point which is located at 2 mm distance from the source axis. A total of 187 OPTIDOS dose rate verifications of the 5-F-BetaCath{sup TM} system were performed in different hospitals. The histogram of the deviation between the manufacturer's dose rate specification and the dose rate measured using the OPTIDOS dosimetry system is Gaussian shaped with {+-}3% relative width and a mean shift of about +2% with respect to the corresponding dose rate specification. Additionally, 128 OPTIDOS dose rate verifications of the new jacketed RST (3.5-F-BetaCath{sup TM}, Novoste Corp.) were performed using the same calibration factor as derived for the 5-F-BetaCath{sup TM} system. Distribution of the deviation between the certified and the measured dose rate is nearly identical in comparison to the histogram of the 5-F-BetaCath{sup TM} system. The mean value of the deviations is shifted by -1.5% with respect to the certified dose rate. In order to compare the results of the calibrated OPTIDOS dosimetry system with a standard measuring method, separate dose rate measurements were performed using electron accelerator calibrated radiochromic films in which calibration is traceable to PTB (Physikalisch Technische Bundesanstalt, Germany). Deviation between both the methods is less than 3.1%. These results confirm that the calibrated OPTIDOS dosimetry system can be considered suitable for quality assurance of both types of RST used in the BetaCath{sup TM} systems.

  10. Differential bremsstrahlung and pair production cross sections at high energies

    International Nuclear Information System (INIS)

    Olsen, Haakon A.

    2003-01-01

    Detailed differential cross sections for high energy bremsstrahlung and pair production are derived with specific attention to the differences between the two processes, which are considerable. For the integrated cross sections, which are the only cross sections specifically known until now, the final state integration theorem guarantees that the exact cross section formulas can be exchanged between bremsstrahlung and pair production by the same substitution rules as for the Born-approximation Bethe-Heitler cross sections, for any amount of atomic screening. In fact the theorem states that the Coulomb corrections to the integrated bremsstrahlung and pair production cross sections are identical for any amount of screening. The analysis of the basic differential cross sections leads to fundamental physical differences between bremsstrahlung and pair production. Coulomb corrections occur for pair production in the strong electric field of the atom for 'large' momentum transfer of the order of mc. For bremsstrahlung, on the other hand, the Coulomb corrections take place at a 'large' distance from the atom of the order of ((ℎ/2π)/mc)ε, with a 'small' momentum transfer mc/ε, where ε is the initial electron energy in units of mc 2 . And the Coulomb corrections can be large, of the order of larger than (Z/137) 2 , which is considerably larger than the integrated cross section corrections

  11. Study of bremsstrahlung photons in bulk target using MCNP code

    Directory of Open Access Journals (Sweden)

    S. Sangaroon

    2017-11-01

    Full Text Available The aim of this research was to study the feasibility of bremsstrahlung photon production in target bombarded by 1 GeV electrons. The calculations were performed by the Monte Carlo code MCNP. Six target materials with densities between 2 and 20 g/cm3 were studied. The bremsstrahlung photon flux is high for the target density above 8 g/cm3. Copper is the best target for 1 GeV electron beam due to high bremsstrahlung photon production, low scattering and low transmission electron flux. The copper target was altered to have different thicknesses between 0.01 and 2.5 cm. The results showed that the bremsstrahlung photon flux significantly increased when the target thickness increased from 0.01 to 1.5 cm. The angular distribution of the bremsstrahlung photons with angles between 0 and 120 degrees was determined for copper target. The maximum angle of the photon scattering was about 20 degree.

  12. Shielding calculation for bremsstrahlung from β-emitters

    International Nuclear Information System (INIS)

    Ichimiya, Tsutomu

    1990-01-01

    Accompanying the revision of radiation injury prevention law, the shielding calculation method for photon corresponding to the dose equivalent was shown. However, regarding the electron from β decay nuclide and bremsstrahlung caused by shielding material, the shielding calculation method corresponding to the 1 cm dose equivalent has not been reported, hence, in this report, the spectrum of β-ray is calculated and the 1 cm dose equivalent transmission rate of the bremsstrahlung was calculated for three kinds of shielding materials (iron, lead, concrete). As the result of consideration, it is sufficient to think about the bremsstrahlung due to negative electron emission accompanying β-decay. In β-decay, electrons which constitute the continuous spectrum with maximum energy are emitted. The shape of the spectrum differs with nuclides. The maximum energy of β-ray of generally used nuclides is mostly below 3MeV and, besides, the electron ray itself is easily shielded, while the strength of bremsstrahlung depends on the atomic number of shielding materials and its generating mechanism is complicated. In this report, the actual shielding calculation method for bremsstrahlung is shown with regard to the most frequently used β-decay nuclides. (M.T.)

  13. Preparation and biological evaluation of 111In-, 177Lu- and 90Y-labeled DOTA analogues conjugated to B72.3

    International Nuclear Information System (INIS)

    Mohsin, Huma; Fitzsimmons, Jonathan; Shelton, Tiffani; Hoffman, Timothy J.; Cutler, Cathy S.; Lewis, Michael R.; Athey, Phillip S.; Gulyas, Gyongyi; Kiefer, Garry E.; Frank, R. Keith; Simon, Jaime; Lever, Susan Z.; Jurisson, Silvia S.

    2007-01-01

    Three 1,4,7,10-tetraazacyclododecane-N,N',N '' ,N '' '-tetraacetic acid (DOTA) analogues were evaluated for relative in vivo stability when radiolabeled with 111 In, 90 Y and 177 Lu and conjugated to the monoclonal antibody B72.3. The DOTA analogues evaluated were 'NHS-DOTA' [N-hydroxysuccinimdyl (NHS) group activating one carboxylate], 'Arm-DOTA' (also known as MeO-DOTA; with a p-NCS, o-MeO-benzyl moiety on the methylene group of one acetic acid arm) and 'Back-DOTA' (with a p-NCS-benzyl moiety on a backbone methylene group of the macrocycle). The B72.3 was conjugated to the DOTA analogues to increase the retention time of the radioloabeled conjugates in vivo in mice. The serum stability of the various radiometalated DOTA conjugates showed them to have good stability out to 168 h (all >95% except 111 In-NHS-DOTA-B72.3, which was 91% stable). Hydroxyapatite stability for the 111 In and 177 Lu DOTA-conjugates was >95% at 168 h, while the 90 Y DOTA-conjugates were somewhat less stable (between 90% and 95% at 168 h). The biodistribution studies of the radiometalated DOTA-conjugates showed that no significant differences were observed for the 111 In and 177 Lu analogues; however, the 90 Y analogues showed lower stabilities, as evidenced by their increased bone uptake relative to the other two [2-20% injected dose per gram (% ID/g) for 90 Y and 2-8% ID/g for 111 In and 177 Lu]. The lower stability of the 90 Y analogues could be due to the higher beta energy of 90 Y and/or to the larger ionic radius of Y 3+ . Based on the bone uptake observed, the 177 Lu-NHS-DOTA-B72.3 had slightly lower stability than the 177 Lu-Arm-DOTA-B72.3 and 177 Lu-Back-DOTA-B72.3, but not significantly at all time points. For 90 Y, the analogue showing the lowest stability based on bone uptake was 90 Y-Arm-DOTA-B72.3, perhaps because of the metal's larger ionic radius and potential steric interactions minimizing effective complexation. The 111 In analogues all showed similar biological

  14. Inflammation-induced synergetic enhancement of nanoparticle treatments with DOXIL{sup ®} and {sup 90}Y-Lactosome for orthotopic mammary tumor

    Energy Technology Data Exchange (ETDEWEB)

    Kurihara, Kensuke; Ueda, Motoki [Graduate School of Medicine, Kyoto University, Department of Diagnostic Imaging and Nuclear Medicine (Japan); Hara, Isao [Shimadzu Corporation, Technology Research Laboratory (Japan); Hara, Eri [Kyoto University Hospital, Department of Experimental Therapeutics, Institute for Advancement of Clinical and Translational Science (Japan); Sano, Kohei [Graduate School of Medicine, Kyoto University, Department of Diagnostic Imaging and Nuclear Medicine (Japan); Makino, Akira [University of Fukui, Division of Molecular Imaging, Biomedical Imaging Research Center (Japan); Ozeki, Eiichi [Shimadzu Corporation, Technology Research Laboratory (Japan); Yamamoto, Fumihiko [Tohoku Pharmaceutical University, Department of Radiopharmacy (Japan); Saji, Hideo [Kyoto University, Department of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences (Japan); Togashi, Kaori [Graduate School of Medicine, Kyoto University, Department of Diagnostic Imaging and Nuclear Medicine (Japan); Kimura, Shunsaku, E-mail: shun@scl.kyoto-u.ac.jp [Kyoto University, Department of Material Chemistry, Graduate School of Engineering (Japan)

    2016-05-15

    Polymeric micelles (Lactosome) in the size of 20–30 nm were labeled with radionuclides of {sup 111}In ({sup 111}In-DOTA-Lactosome) for SPECT imaging and {sup 90}Y ({sup 90}Y-DOTA-Lactosome) for β-ray irradiation for mammary tumor in mice. The tumor site at the femoral right leg grafted with 4T1 cells was clearly imaged at 24 h after the intravenous injection. Biodistribution revealed that the half-life time of {sup 111}In-DOTA-Lactosome was 11 h, which enabled the nanoparticle selectively accumulated in tumor site due to the enhanced permeability and retention (EPR) effect. The anti-tumor therapeutic effect of {sup 90}Y-DOTA-Lactosome was observed depending on the dose frequency and amount. Under the condition of the percutaneous ethanol injection treatment, the therapeutic effect of {sup 90}Y-DOTA-Lactosome was enhanced due to the super EPR effect. Owing to the super EPR effect, co-administration of {sup 90}Y-DOTA-Lactosome and DOXIL{sup ®} inhibited the tumor growth during 15 days with their administrations.

  15. Electron collision effects on the bremsstrahlung emission in Lorentzian plasmas

    International Nuclear Information System (INIS)

    Jung, Young-Dae; Kato, Daiji

    2009-06-01

    The electron-electron collision effects on the electron-ion bemsstranhlung process are investigated in warm Lorentzian plasmas. The effective electron-ion interaction potential is obtained by including the far-field terms caused by the electron-electron collisions with the effective Debye length in Lorentzian plasmas. The bremsstranhlung radiation cross section is obtained as a function of the electron energy, photon energy, collision frequency, spectral index, and Debye length using the Born approximation for the initial and final states of the projectile electron. It is shown that the non-Maxwellian character suppresses the bremsstrahlung radiation cross section. It is also shown that the electron-electron collision effect enhances the bremsstrahlung emission spectrum. In addition, the bremsstrahlung radiation cross section decreases with an increase of the plasma temperature. (author)

  16. Bremsstrahlung emission probability in the α decay of 210Po

    International Nuclear Information System (INIS)

    Boie, Hans-Hermann

    2009-01-01

    A high-statistics measurement of bremsstrahlung emitted in the α decay of 210 Po has been performed. The measured differential emission probabilities, which could be followed up to γ-energies of ∝ 500 keV, allow for the first time for a serious test of various model calculations of the bremsstrahlung accompanied α decay. It is shown that corrections to the α-γ angular correlation due to the interference between the electric dipole and quadrupole amplitudes and due to the relativistic character of the process have to be taken into account. With the experimentally derived angular correlation the measured energydifferential bremsstrahlung emission probabilities show excellent agreement with the fully quantum mechanical calculation. (orig.)

  17. Suppression of bremsstrahlung and pair production due to environmental factors

    International Nuclear Information System (INIS)

    Klein, Spencer

    1999-01-01

    The environment in which bremsstrahlung and pair creation occurs can strongly affect cross sections for these processes. Because ultrarelativistic electromagnetic interactions involve very small longitudinal momentum transfers, the reactions occur gradually, spread over long distances. During this time, even relatively weak factors can accumulate enough to disrupt the interaction. In the Landau-Pomeranchuk-Migdal effect, multiple scattering reduces the bremsstrahlung and pair production cross section. This review will discuss this and a variety of other factors that can suppress bremsstrahlung and pair production, as well as related effects involving beamstrahlung and QCD processes. After surveying different theoretical approaches, experimental measurements will be covered. Recent accurate measurements by the SLAC E-146 Collaboration will be highlighted, along with several recent theoretical works relating to the experiment. (c) 1999 The American Physical Society

  18. Zeff from spectroscopic bremsstrahlung measurements at ASDEX Upgrade and JET

    International Nuclear Information System (INIS)

    Meister, H.; Fischer, R.; Horton, L.D.; Maggi, C.F.; Nishijima, D.; Giroud, C.; Zastrow, K.-D.; Zaniol, B.

    2004-01-01

    The effective ionic charge Z eff is a means to assess the impurity content of a fusion plasma. It can be derived from measurements of bremsstrahlung intensity. These have been extended at ASDEX Upgrade by the usage of the sight lines for the charge exchange recombination diagnostic. Together with a previously installed sight line array, it is now possible to routinely determine the bremsstrahlung intensity over the whole minor radius purely from spectroscopic measurements. In a tokamak where the plasma facing components are made up of various materials, this is necessary to check if measurements are contaminated by line radiation. The bremsstrahlung background of the respective spectra is determined using Bayesian probability theory, giving consistent and improved error statistics. Using the information for electron temperature and density profiles, the Z eff profile is determined by an integrated method. The same approach to assess the Z eff profile has been demonstrated to be successful also at the JET tokamak

  19. Partial decay energy of 51Cr from inner bremsstrahlung spectrum

    International Nuclear Information System (INIS)

    Sanjeeviah, H.; Sanjeevaiah, B.

    1980-01-01

    The inner bremsstrahlung spectrum accompanying orbital electron capture decay of 51 Cr to the first excited state in 51 V was measured in coincidence with 320 keV gamma rays. From the Jauch plot of the spectrum the partial decay energy was deduced to be 433 +- 18 keV in good agreement with the previously measured value and the accepted mass difference. The overall shape factor of the inner bremsstrahlung spectrum was found to be a constant X(1.1 +- 0.1). (author)

  20. The Stonehenge technique. A method for aligning coherent bremsstrahlung radiators

    International Nuclear Information System (INIS)

    Livingston, Ken

    2009-01-01

    This paper describes a technique for the alignment of crystal radiators used to produce high energy, linearly polarized photons via coherent bremsstrahlung scattering at electron beam facilities. In these experiments the crystal is mounted on a goniometer which is used to adjust its orientation relative to the electron beam. The angles and equations which relate the crystal lattice, goniometer and electron beam direction are presented here, and the method of alignment is illustrated with data taken at MAMI (the Mainz microtron). A practical guide to setting up a coherent bremsstrahlung facility and installing new crystals using this technique is also included.

  1. The Stonehenge technique. A method for aligning coherent bremsstrahlung radiators

    Energy Technology Data Exchange (ETDEWEB)

    Livingston, Ken [Department of Physics and Astronomy, University of Glasgow, Glasgow G12 8QQ (United Kingdom)], E-mail: k.livingston@physics.gla.ac.uk

    2009-05-21

    This paper describes a technique for the alignment of crystal radiators used to produce high energy, linearly polarized photons via coherent bremsstrahlung scattering at electron beam facilities. In these experiments the crystal is mounted on a goniometer which is used to adjust its orientation relative to the electron beam. The angles and equations which relate the crystal lattice, goniometer and electron beam direction are presented here, and the method of alignment is illustrated with data taken at MAMI (the Mainz microtron). A practical guide to setting up a coherent bremsstrahlung facility and installing new crystals using this technique is also included.

  2. The Stonehenge technique. A method for aligning coherent bremsstrahlung radiators

    Science.gov (United States)

    Livingston, Ken

    2009-05-01

    This paper describes a technique for the alignment of crystal radiators used to produce high energy, linearly polarized photons via coherent bremsstrahlung scattering at electron beam facilities. In these experiments the crystal is mounted on a goniometer which is used to adjust its orientation relative to the electron beam. The angles and equations which relate the crystal lattice, goniometer and electron beam direction are presented here, and the method of alignment is illustrated with data taken at MAMI (the Mainz microtron). A practical guide to setting up a coherent bremsstrahlung facility and installing new crystals using this technique is also included.

  3. Molecular response assessed by {sup 68}Ga-DOTANOC and survival after {sup 90}Y microsphere therapy in patients with liver metastases from neuroendocrine tumours

    Energy Technology Data Exchange (ETDEWEB)

    Filippi, Luca; Salvatori, Rita; Bagni, Oreste [Santa Maria Goretti Hospital, Department of Nuclear Medicine, Latina (Italy); Scopinaro, Francesco [Sant' Andrea Hospital, Department of Nuclear Medicine, Rome (Italy); Pelle, Giuseppe; Cianni, Roberto [Santa Maria Goretti Hospital, Department of Interventional Radiology, Latina (Italy); Schillaci, Orazio [University Tor Vergata, Department of Biomedicine and Prevention, Rome (Italy)

    2016-03-15

    We investigated the prognostic role of {sup 68}Ga-DOTANOC in patients affected by hepatic metastases from neuroendocrine tumours (NET) undergoing {sup 90}Y radioembolization ({sup 90}Y-RE). A group of 15 consecutive patients with unresectable NET liver metastases underwent {sup 68}Ga-DOTANOC PET at baseline and 6 weeks after {sup 90}Y-RE. Molecular response was defined as a reduction of >50 % in the tumour-to-spleen ratio (ΔT/S). The patients were divided into two groups (responders with ΔT/S >50 % and nonresponders with ΔT/S <50 %) Patients were followed up by imaging and laboratory tests every 3 months until death or for at least 36 months following {sup 90}Y-RE. Statistical analysis was performed to identify factors predicting overall survival (OS) and progression-free survival (PFS). A decrease in T/S ratio was seen in all patients on {sup 68}Ga-DOTANOC PET scans performed after {sup 90}Y-RE. Nine patients were classified as responders and six as nonresponders. The mean OS in all patients was 31.0 months. Responders had a significantly (p < 0.001) longer OS (mean 36.0 ± 2.5 months) and PFS (mean 29.7 ± 3.4 months) than nonresponders. In a multivariate analysis, none of the other examined variables including age, unilobar vs. bilobar locations, bilirubin levels, radiological response or the presence of extrahepatic disease significantly predicted patient outcome. Molecular response assessed with {sup 68}Ga-DOTANOC PET might be a useful predictor of survival in patients affected by NET liver metastases treated with {sup 90}Y-RE. (orig.)

  4. Electrochemical separation of 90-yttrium in the electrochemical 90Sr/90Y generator and its use for radiolabelling of DOTA-conjugated somatostatin analog [DOTA0, Tyr3] octreotate

    Directory of Open Access Journals (Sweden)

    Petrović Đorđe Ž.

    2012-01-01

    Full Text Available Radiopharmaceuticals based on 90Y are widely used in the treatment of malignant deseases. In order to meet the requirements for their future application, a 90Sr/90Y generator was developed and 90Y eluted from this locally produced generator was used for the radiolabelling of the DOTA-conjugated somatostatin analog [DOTA0,Tyr3] octreotate and the preparation of [90Y-DOTA0,Tyr3] octreotate (90Y-DOTATATE for peptide receptore radionuclide therapy. 90Sr/90Y generator was based on the electrochemical separation of 90Y from 90Sr in a two-cycle electrolysis procedure. Three electrode cells were used to perform both electrolyses. In both cycles, working electrodes were kept on constant potential. The pH of the solution was adjusted to 2.7 of the value before the electrolyses. The radionuclidic purity of the 90Y solution was analysed by ITLC and extraction paper chromatography. The labelling of peptide (100 mg DOTATATE with 90YCl3 was performed at 95°C for 30 minutes. Radiochemical purity was determined by HPLC and chromatographic separation, using a solid SepPak C-18 column. Results obtained confirmed the efficiency of our electrochemical separation technique and quality control methods for 90Y. The achieved efficiency of the 90Sr/90Y generator above 96% of the theoretical value represents a good basis for the further development of this generator. The labelling of the DOTATATE with 90Y exhibited a high efficiency, too: there was less than 1% of 90Y3+in the 90Y-DOTATATE.

  5. Nuclear bremsstrahlung in proton induced reactions at 190 MeV (first experiments at AGOR)

    NARCIS (Netherlands)

    Wilschut, HW

    1998-01-01

    An overview is given of the first experiments with the new KVI cyclotron AGOR. First experiments have focused on nuclear bremsstrahlung in few-and many-body reactions. A classical introduction to nuclear bremsstrahlung is given. First results on coherent bremsstrahlung are discussed.

  6. Procedure to carry out leakage test in beta radiation sealed sources emitters of 90Sr/90Y

    International Nuclear Information System (INIS)

    Alvarez R, J. T.

    2010-09-01

    In the alpha-beta room of the Secondary Laboratory of Dosimetric Calibration of the Metrology Department of Ionizing Radiations ophthalmic applicators are calibrated in absorbed dose terms in water D w ; these applicators, basically are emitter sealed sources of pure beta radiation of 90 Sr / 90 Y. Concretely, the laboratory quality system indicates to use the established procedure for the calibration of these sources, which establishes the requirement of to carry out a leakage test, before to calibrate the source. However, in the Laboratory leakage test certificates sent by specialized companies in radiological protection services have been received, in which are used gamma spectrometry equipment s for beta radiation leakage tests, since it is not reliable to detect pure beta radiation with a scintillating detector with NaI crystal, (because it could detect the braking radiation produced in the detector). Therefore the Laboratory has had to verify the results of the tests with a correct technique, with the purpose of determining the presence of sources with their altered integrity and radioactive material leakage. The objective of this work is to describe a technique for beta activity measurement - of the standard ISO 7503, part 1 (1988) - and its application with a detector Gm plane (type pankage) in the realization of leakage tests in emitter sources of pure beta radiation, inside the mark of quality assurance indicated by the report ICRU 76. (Author)

  7. Proton-proton bremsstrahlung in a relativistic covariant model

    NARCIS (Netherlands)

    Martinus, Gerard Henk

    1998-01-01

    Proton-proton bremsstrahlung is one of the simplest processes involving the half off-shell NN interaction. Since protons are equally-charged particles with the same mass, electric-dipole radiation is suppressed and higher-order effects play an important role. Thus it is possible to get information

  8. Evaluation of electon and nuclear bremsstrahlung in heavy ion collisions

    International Nuclear Information System (INIS)

    Gippner, P.

    1975-01-01

    The detection of quasimolecular X-ray continua provides the possibility of investigating the electron shells of quasimolecules transiently formed during adiabatic heavy ion-atomic collision. The contribution of the electron and nuclear bremsstrahlung to quasimolecular X-ray continua observed in bombarding various targets with 65 and 96 MeV Nb ions were estimated

  9. Infrared phenomena in quantum electrodynamics : II. Bremsstrahlung and compton scattering

    NARCIS (Netherlands)

    Haeringen, W. van

    The infrared aspects of quantum electrodynamics are discussed by treating two examples of scattering processes, bremsstrahlung and Compton scattering. As in the previous paper one uses a non-covariant diagram technique which gives very clear insight in the cancelling of infrared divergences between

  10. A detector for use in high energy bremsstrahlung shielding studies

    International Nuclear Information System (INIS)

    Wilson, O.J.; Thomson, J.E.M.

    1983-01-01

    The design, development and calibration of a detector based on the principle of the Moxon-Rae detector is discussed. It is ideally suited to the measurement of the energy fluence of photons transmitted through a thick shield which has been irradiated with high energy bremsstrahlung. The detection sensitivity is 10 4 to 10 5 times that of the P2 ion chamber

  11. Proton-proton bremsstrahlung towards the elastic limit

    Science.gov (United States)

    Mahjour-Shafiei, M.; Amir-Ahmadi, H. R.; Bacelar, J. C. S.; Castelijns, R.; Ermisch, K.; van Garderen, E.; Gašparić, I.; Harakeh, M. N.; Kalantar-Nayestanaki, N.; Kiš, M.; Löhner, H.

    2005-05-01

    In oder to study proton-proton bremsstrahlung moving towards the elastic limit, a detection system, consisting of Plastic-ball and SALAD, was set up and an experiment at 190 MeV incident beam energy was performed. Here, the experimental setup and the data analysis procedure along with some results obtained in the measurement are discussed.

  12. Proton-proton bremsstrahlung towards the elastic limit

    International Nuclear Information System (INIS)

    Mahjour-Shafiei, M.; Amir-Ahmadi, H.R.; Bacelar, J.C.S.; Castelijns, R.; Ermisch, K.; Garderen, E. van; Harakeh, M.N.; Kalantar-Nayestanaki, N.; Kis, M.; Loehner, H.; Gasparic, I.

    2005-01-01

    In oder to study proton-proton bremsstrahlung moving towards the elastic limit, a detection system, consisting of Plastic-ball and SALAD, was set up and an experiment at 190 MeV incident beam energy was performed. Here, the experimental setup and the data analysis procedure along with some results obtained in the measurement are discussed

  13. Soft-photon analysis of pion-proton bremsstrahlung

    International Nuclear Information System (INIS)

    Liou, M.K.; Nutt, W.T.

    1977-01-01

    We define the soft-photon approximation consistent in its treatment of both the kinematical and dynamical aspects of bremsstrahlung. Using this consistent soft-photon approximation, we calculate π +- p cross sections and obtain excellent agreement with experiment. Our results suggest that the contributions from off-mass-shell effects and resonances are small

  14. Control of the formation Yield of complex with DTPA and DOTATATE of the Chloride of 90Y taken place in CENTIS for the obtaining of Radiopharmaceutical

    International Nuclear Information System (INIS)

    Soler Iglesias, Joel; Serra Aguila, Rolando; Morín Zorrilla, José; Pino Peraza, Madián; Alberti Ramírez, Alejandro; Turiño Perez, David

    2016-01-01

    Issuing beta pure with period of semidesintegration of 64,1 hours and 2,28 MeV of energy, the 90Y are useful as therapeutic radionuclide. Radiopharmaceuticals 90Y has been effective in the treatment of chronic synovitis, liver cancer, pain for bony metastasis and tumors of origin neuroendocrine. They are of particular interest the results obtained in the treatment of the lymphomas no-Hodgkin that combine the specificity of an antibody monoclonal for the antigen CD20 and the energy pure beta of the 90Y. It could be verified that for their content of 90Sr similar to 0,110 ± 0,004 (k = 2) kBq / g carried out by different methods and their combination capacity with DTPA And DOTATATE, chelate bifunctional in appropriate range of concentrations and in presence of metallic appearances, it is of excellent characteristics for their use as precursor in the obtaining of therapeutic, included radiopharmaceuticals the radioimmunotherapy. The presence of Faith (III) was studied in details by the addition method and it could be determined that it only affects the yield of labeling of 90Y with DTPA if its presence is superior to a concentration of 0,018 µ mol / L. It is demonstrated that the presence of other metals like Pb (II), Zn (II) and Cu (II) also influence significantly in the yield of included complexation in excess presence of the tying bifunctional. (author)

  15. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice.

    NARCIS (Netherlands)

    Verel, I.; Visser, G.W.; Boellaard, R.; Boerman, O.C.; Eerd-Vismale, J.E.M. van; Snow, G.B.; Lammertsma, A.A.; Dongen, G.A.M.S. van

    2003-01-01

    Immuno-PET as a scouting procedure before radioimmunotherapy (RIT) aims at the confirmation of tumor targeting and the accurate estimation of radiation dose delivery to both tumor and normal tissues. Immuno-PET with (89)Zr-labeled monoclonal antibodies (mAbs) and (90)Y-mAb RIT might form such a

  16. Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study.

    Science.gov (United States)

    Marincek, Nicolas; Jörg, Ann-Catherine; Brunner, Philippe; Schindler, Christian; Koller, Michael T; Rochlitz, Christoph; Müller-Brand, Jan; Maecke, Helmut R; Briel, Matthias; Walter, Martin A

    2013-01-15

    We describe the long-term outcome after clinical introduction and dose escalation of somatostatin receptor targeted therapy with [90Y-DOTA]-TOC in patients with metastasized neuroendocrine tumors. In a clinical phase I dose escalation study we treated patients with increasing [90Y-DOTA]-TOC activities. Multivariable Cox regression and competing risk regression were used to compare efficacy and toxicities of the different dosage protocols. Overall, 359 patients were recruited; 60 patients were enrolled for low dose (median: 2.4 GBq/cycle, range 0.9-7.8 GBq/cycle), 77 patients were enrolled for intermediate dose (median: 3.3 GBq/cycle, range: 2.0-7.4 GBq/cycle) and 222 patients were enrolled for high dose (median: 6.7 GBq/cycle, range: 3.7-8.1 GBq/cycle) [90Y-DOTA]-TOC treatment. The incidences of hematotoxicities grade 1-4 were 65.0%, 64.9% and 74.8%; the incidences of grade 4/5 kidney toxicities were 8.4%, 6.5% and 14.0%, and the median survival was 39 (range: 1-158) months, 34 (range: 1-118) months and 29 (range: 1-113) months. The high dose protocol was associated with an increased risk of kidney toxicity (Hazard Ratio: 3.12 (1.13-8.59) vs. intermediate dose, p = 0.03) and a shorter overall survival (Hazard Ratio: 2.50 (1.08-5.79) vs. low dose, p = 0.03). Increasing [90Y-DOTA]-TOC activities may be associated with increasing hematological toxicities. The dose related hematotoxicity profile of [90Y-DOTA]-TOC could facilitate tailoring [90Y-DOTA]-TOC in patients with preexisting hematotoxicities. The results of the long-term outcome suggest that fractionated [90Y-DOTA]-TOC treatment might allow to reduce renal toxicity and to improve overall survival. (ClinicalTrials.gov number NCT00978211).

  17. Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study

    Directory of Open Access Journals (Sweden)

    Marincek Nicolas

    2013-01-01

    Full Text Available Abstract Background We describe the long-term outcome after clinical introduction and dose escalation of somatostatin receptor targeted therapy with [90Y-DOTA]-TOC in patients with metastasized neuroendocrine tumors. Methods In a clinical phase I dose escalation study we treated patients with increasing [90Y-DOTA]-TOC activities. Multivariable Cox regression and competing risk regression were used to compare efficacy and toxicities of the different dosage protocols. Results Overall, 359 patients were recruited; 60 patients were enrolled for low dose (median: 2.4 GBq/cycle, range 0.9-7.8 GBq/cycle, 77 patients were enrolled for intermediate dose (median: 3.3 GBq/cycle, range: 2.0-7.4 GBq/cycle and 222 patients were enrolled for high dose (median: 6.7 GBq/cycle, range: 3.7-8.1 GBq/cycle [90Y-DOTA]-TOC treatment. The incidences of hematotoxicities grade 1–4 were 65.0%, 64.9% and 74.8%; the incidences of grade 4/5 kidney toxicities were 8.4%, 6.5% and 14.0%, and the median survival was 39 (range: 1–158 months, 34 (range: 1–118 months and 29 (range: 1–113 months. The high dose protocol was associated with an increased risk of kidney toxicity (Hazard Ratio: 3.12 (1.13-8.59 vs. intermediate dose, p = 0.03 and a shorter overall survival (Hazard Ratio: 2.50 (1.08-5.79 vs. low dose, p = 0.03. Conclusions Increasing [90Y-DOTA]-TOC activities may be associated with increasing hematological toxicities. The dose related hematotoxicity profile of [90Y-DOTA]-TOC could facilitate tailoring [90Y-DOTA]-TOC in patients with preexisting hematotoxicities. The results of the long-term outcome suggest that fractionated [90Y-DOTA]-TOC treatment might allow to reduce renal toxicity and to improve overall survival. (ClinicalTrials.gov number NCT00978211.

  18. Targeted radionuclide therapy with RAFT-RGD radiolabelled with {sup 90}Y or {sup 177}Lu in a mouse model of αvβ3-expressing tumours

    Energy Technology Data Exchange (ETDEWEB)

    Bozon-Petitprin, A.; Bacot, S.; Ahmadi, M.; Marti-Batlle, D.; Perret, P.; Broisat, A.; Riou, L.M. [INSERM, U1039, Grenoble (France); Universite de Grenoble, UMR-S1039, Grenoble (France); Gauchez, A.S.; Bourre, J.C.; Fagret, D.; Vuillez, J.P. [INSERM, U1039, Grenoble (France); Universite de Grenoble, UMR-S1039, Grenoble (France); CHRU Grenoble, Hopital Michallon, Service de Medecine Nucleaire, Grenoble (France); Claron, M.; Boturyn, D. [CNRS, UMR 5250, Departement de Chimie Moleculaire, Grenoble (France); Ghezzi, Catherine [INSERM, U1039, Grenoble (France); Universite de Grenoble, UMR-S1039, Grenoble (France); INSERM U1039, Radiopharmaceutiques biocliniques, Batiment Jean Roget, Domaine de la Merci, Faculte de Medecine, La Tronche (France)

    2014-08-28

    The αvβ3 integrin plays an important role in tumour-induced angiogenesis, tumour proliferation, survival and metastasis. The tetrameric RGD-based peptide, regioselectively addressable functionalized template-(cyclo-[RGDfK]){sub 4} (RAFT-RGD), specifically targets the αvβ3 integrin in vitro and in vivo. The aim of this study was to evaluate the therapeutic potential of RAFT-RGD radiolabelled with β{sup -} emitters in a nude mouse model of αvβ3 integrin-expressing tumours. Biodistribution and SPECT/CT imaging studies were performed after injection of {sup 90}Y-RAFT-RGD or {sup 177}Lu-RAFT-RGD in nude mice subcutaneously xenografted with αvβ3 integrin-expressing U-87 MG cells. Experimental targeted radionuclide therapy with {sup 90}Y-RAFT-RGD or {sup 177}Lu-RAFT-RGD and {sup 90}Y-RAFT-RAD or {sup 177}Lu-RAFT-RAD (nonspecific controls) was evaluated by intravenous injection of the radionuclides into mice bearing αvβ3 integrin-expressing U-87 MG tumours of different sizes (small or large) or bearing TS/A-pc tumours that do not express αvβ3. Tumour volume doubling time was used to evaluate the efficacy of each treatment. Injection of 37 MBq of {sup 90}Y-RAFT-RGD into mice with large αvβ3-positive tumours or 37 MBq of {sup 177}Lu-RAFT-RGD into mice with small αvβ3-positive tumours caused significant growth delays compared to mice treated with 37 MBq of {sup 90}Y-RAFT-RAD or 37 MBq of {sup 177}Lu-RAFT-RAD or untreated mice. In contrast, injection of 30 MBq of {sup 90}Y-RAFT-RGD had no effect on the growth of αvβ3-negative tumours. {sup 90}Y-RAFT-RGD and {sup 177}Lu-RAFT-RGD are potent agents targeting αvβ3-expressing tumours for internal targeted radiotherapy. (orig.)

  19. Targeted radionuclide therapy with RAFT-RGD radiolabelled with (90)Y or (177)Lu in a mouse model of αvβ3-expressing tumours.

    Science.gov (United States)

    Bozon-Petitprin, A; Bacot, S; Gauchez, A S; Ahmadi, M; Bourre, J C; Marti-Batlle, D; Perret, P; Broisat, A; Riou, L M; Claron, M; Boturyn, D; Fagret, D; Ghezzi, Catherine; Vuillez, J P

    2015-02-01

    The αvβ3 integrin plays an important role in tumour-induced angiogenesis, tumour proliferation, survival and metastasis. The tetrameric RGD-based peptide, regioselectively addressable functionalized template-(cyclo-[RGDfK])4 (RAFT-RGD), specifically targets the αvβ3 integrin in vitro and in vivo. The aim of this study was to evaluate the therapeutic potential of RAFT-RGD radiolabelled with β(-) emitters in a nude mouse model of αvβ3 integrin-expressing tumours. Biodistribution and SPECT/CT imaging studies were performed after injection of (90)Y-RAFT-RGD or (177)Lu-RAFT-RGD in nude mice subcutaneously xenografted with αvβ3 integrin-expressing U-87 MG cells. Experimental targeted radionuclide therapy with (90)Y-RAFT-RGD or (177)Lu-RAFT-RGD and (90)Y-RAFT-RAD or (177)Lu-RAFT-RAD (nonspecific controls) was evaluated by intravenous injection of the radionuclides into mice bearing αvβ3 integrin-expressing U-87 MG tumours of different sizes (small or large) or bearing TS/A-pc tumours that do not express αvβ3. Tumour volume doubling time was used to evaluate the efficacy of each treatment. Injection of 37 MBq of (90)Y-RAFT-RGD into mice with large αvβ3-positive tumours or 37 MBq of (177)Lu-RAFT-RGD into mice with small αvβ3-positive tumours caused significant growth delays compared to mice treated with 37 MBq of (90)Y-RAFT-RAD or 37 MBq of (177)Lu-RAFT-RAD or untreated mice. In contrast, injection of 30 MBq of (90)Y-RAFT-RGD had no effect on the growth of αvβ3-negative tumours. (90)Y-RAFT-RGD and (177)Lu-RAFT-RGD are potent agents targeting αvβ3-expressing tumours for internal targeted radiotherapy.

  20. Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study

    Science.gov (United States)

    2013-01-01

    Background We describe the long-term outcome after clinical introduction and dose escalation of somatostatin receptor targeted therapy with [90Y-DOTA]-TOC in patients with metastasized neuroendocrine tumors. Methods In a clinical phase I dose escalation study we treated patients with increasing [90Y-DOTA]-TOC activities. Multivariable Cox regression and competing risk regression were used to compare efficacy and toxicities of the different dosage protocols. Results Overall, 359 patients were recruited; 60 patients were enrolled for low dose (median: 2.4 GBq/cycle, range 0.9-7.8 GBq/cycle), 77 patients were enrolled for intermediate dose (median: 3.3 GBq/cycle, range: 2.0-7.4 GBq/cycle) and 222 patients were enrolled for high dose (median: 6.7 GBq/cycle, range: 3.7-8.1 GBq/cycle) [90Y-DOTA]-TOC treatment. The incidences of hematotoxicities grade 1–4 were 65.0%, 64.9% and 74.8%; the incidences of grade 4/5 kidney toxicities were 8.4%, 6.5% and 14.0%, and the median survival was 39 (range: 1–158) months, 34 (range: 1–118) months and 29 (range: 1–113) months. The high dose protocol was associated with an increased risk of kidney toxicity (Hazard Ratio: 3.12 (1.13-8.59) vs. intermediate dose, p = 0.03) and a shorter overall survival (Hazard Ratio: 2.50 (1.08-5.79) vs. low dose, p = 0.03). Conclusions Increasing [90Y-DOTA]-TOC activities may be associated with increasing hematological toxicities. The dose related hematotoxicity profile of [90Y-DOTA]-TOC could facilitate tailoring [90Y-DOTA]-TOC in patients with preexisting hematotoxicities. The results of the long-term outcome suggest that fractionated [90Y-DOTA]-TOC treatment might allow to reduce renal toxicity and to improve overall survival. Trial registration ClinicalTrials.gov number:NCT00978211 PMID:23320604

  1. Treatment with tandem [{sup 90}Y]DOTA-TATE and [{sup 177}Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy

    Energy Technology Data Exchange (ETDEWEB)

    Seregni, E.; Maccauro, M.; Chiesa, C.; Pascali, C.; Lorenzoni, A.; Bogni, A.; Coliva, A.; Bombardieri, E. [Fondazione IRCCS Istituto Nazionale Tumori, Nuclear Medicine, Milan (Italy); Mariani, L.; Vullo, S.Lo [Fondazione IRCCS Istituto Nazionale Tumori, Statistics and Biometry Unit, Milan (Italy); Mazzaferro, V. [Fondazione IRCCS Istituto Nazionale Tumori, Surgery and Liver Transplantation, Milan (Italy); De Braud, F.; Buzzoni, R. [Fondazione IRCCS Istituto Nazionale Tumori, Medical Oncology, Milan (Italy); Milione, M. [Fondazione IRCCS Istituto Nazionale Tumori, Pathology Department, Milan (Italy)

    2014-02-15

    Peptide receptor radionuclide therapy (PRRT) with radiolabelled somatostatin analogues has been demonstrated to be an effective therapeutic option in patients with disseminated neuroendocrine tumours (NET). Treatment with tandem [{sup 90}Y]DOTA-TATE and [{sup 177}Lu]DOTA-TATE may improve the efficacy of PRRT without increasing the toxicity. In a phase II study we evaluated the feasibility of combined PPRT with a high-energy beta emitter ({sup 90}Y) and a medium-energy beta/gamma emitter ({sup 177}Lu) in patients with metastatic NET refractory to conventional therapy. A group of 26 patients with metastatic NET were treated with four therapeutic cycles of alternating [{sup 177}Lu]DOTA-TATE (5.55 GBq) and [{sup 90}Y]DOTA-TATE (2.6 GBq). A dosimetric evaluation was carried out after administration of [{sup 177}Lu]DOTA-TATE to calculate the absorbed doses in healthy organs. The acute and long-term toxicities of repeated treatment were analysed. PRRT efficacy was evaluated according to RECIST. Administration of tandem [{sup 90}Y]DOTA-TATE and [{sup 177}Lu]DOTA-TATE induced objective responses in 42.3 % of patients with metastatic NET with a median progression-free survival longer than 24 months. Of patients with pretreatment carcinoid syndrome, 90 % showed a symptomatic response or a reduction in tumour-associated pain. The cumulative biologically effective doses (BED) were below the toxicity limit in the majority of patients, in the absence of renal function impairment The results of our study indicates that combined [{sup 90}Y]DOTA-TATE and [{sup 177}Lu]DOTA-TATE therapy is a feasible and effective therapeutic option in NET refractory to conventional therapy. Furthermore, the absence of kidney damage and the evaluated cumulative BEDs suggest that increasing the number of tandem administrations is an interesting approach. (orig.)

  2. Standardization of Procedures for the Preparation of (177)Lu- and (90)Y-labeled DOTA-Rituximab Based on the Freeze-dried Kit Formulation.

    Science.gov (United States)

    Wojdowska, Wioletta; Karczmarczyk, Urszula; Maurin, Michal; Garnuszek, Piotr; Mikołajczak, Renata

    2015-01-01

    Rituximab when radiolabelled with (177)Lu or (90)Y has been investigated for the treatment of patients with Non-Hodgkin's Lymphoma. In this study, we optimized the preparation of antibody conjugates with chelating agent in the freeze-dried kit. It shortens procedures needed for the successful radiolabeling with lutetium-177 and yttrium-90 and assures reproducible labelling yields. Various molar ratios of Rituximab:DOTA (from 1:5 to 1:100) were used at the conjugation step and different purification method to remove unbound DOTA were investigated (size-exclusion chromatography, dialysis, ultrafiltration). The final monoclonal antibody concentration was quantified by Bradford method, and the number of DOTA molecules was determined by radiolabeling assay using (64)Cu. The specific activity of (177)Lu-DOTA-Rituximab and (90)Y-DOTA-Rituximab were optimized using various amounts of radiometal. Quality control (SE-HPLC, ITLC) and stability study were performed. An average of 4.2 ± 0.8 p-SCN-Bz-DOTA molecules could be randomly conjugated to a single molecule of Rituximab. The ultrafiltration system was the most efficient for purification and resulted in the highest recovery efficiency (77.2%). At optimized conditions the (177)Lu-DOTARituximab and (90)Y-DOTA-Rituximab were obtained with radiochemical purity >99% and specific activity ca. 600 MBq/mg. The radioimmunoconjugates were stable in human serum and 0.9% NaCl. After 72 h of incubation the radiochemical purity of (177)Lu-DOTA-Rituximab decreased to 94% but it was still more than 88% for (90)Y-DOTA-Rituximab. The radioimmunoconjugate showed stability after six months storage at 2 - 8(0)C, as a lyophilized formulation. Our study shows that Rituximab-DOTA can be efficiently radiolabeled with (177)Lu and (90)Y via p-SCN-Bn-DOTA using a freezedried kit.

  3. Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy.

    Science.gov (United States)

    Seregni, E; Maccauro, M; Chiesa, C; Mariani, L; Pascali, C; Mazzaferro, V; De Braud, F; Buzzoni, R; Milione, M; Lorenzoni, A; Bogni, A; Coliva, A; Lo Vullo, S; Bombardieri, E

    2014-02-01

    Peptide receptor radionuclide therapy (PRRT) with radiolabelled somatostatin analogues has been demonstrated to be an effective therapeutic option in patients with disseminated neuroendocrine tumours (NET). Treatment with tandem [(90)Y]DOTA-TATE and [(177)Lu]DOTA-TATE may improve the efficacy of PRRT without increasing the toxicity. In a phase II study we evaluated the feasibility of combined PPRT with a high-energy beta emitter ((90)Y) and a medium-energy beta/gamma emitter ([(177)Lu) in patients with metastatic NET refractory to conventional therapy. A group of 26 patients with metastatic NET were treated with four therapeutic cycles of alternating [[(177)Lu]DOTA-TATE (5.55 GBq) and [(90)Y]DOTA-TATE (2.6 GBq). A dosimetric evaluation was carried out after administration of [[(177)Lu]DOTA-TATE to calculate the absorbed doses in healthy organs. The acute and long-term toxicities of repeated treatment were analysed. PRRT efficacy was evaluated according to RECIST. Administration of tandem [(90)Y]DOTA-TATE and [[(177)Lu]DOTA-TATE induced objective responses in 42.3 % of patients with metastatic NET with a median progression-free survival longer than 24 months. Of patients with pretreatment carcinoid syndrome, 90 % showed a symptomatic response or a reduction in tumour-associated pain. The cumulative biologically effective doses (BED) were below the toxicity limit in the majority of patients, in the absence of renal function impairment. The results of our study indicates that combined [(90)Y]DOTA-TATE and [(177)Lu]DOTA-TATE therapy is a feasible and effective therapeutic option in NET refractory to conventional therapy. Furthermore, the absence of kidney damage and the evaluated cumulative BEDs suggest that increasing the number of tandem administrations is an interesting approach.

  4. The resonance Bremsstrahlung of a fast charged particle in a medium

    International Nuclear Information System (INIS)

    Beshtoev, Kh.M.

    1998-01-01

    The Bremsstrahlung of the fast charged particle in the medium with dielectric permittivity ε at velocities υ ≥ c/n (n 2 =Reε) is considered. The Bremsstrahlung has singularity at β = 1/ncosθ (β = υ/c, θ is an angle of the Bremsstrahlung). This Bremsstrahlung is interpreted as resonance Bremsstrahlung with the width characterized by Imε=ε 2 , and the less ε 2 is, the higher the peak of this resonance rises. The angular distribution of the Bremsstrahlung is determined by cos θ=1/nβ and this angle coincides with the angle of the Cherenkov radiation. At β=1/n this resonance Bremsstrahlung goes in the forward direction and depends on frequency ω (ε=ε (ω))

  5. Country report: Pakistan. Second Research Co-ordination Meeting on Development of Radiopharmaceuticals Based on {sup 188}Re and {sup 90}Y for Radionuclide Therapy, 22-26 March 2010, Vienna

    Energy Technology Data Exchange (ETDEWEB)

    Mansur, M. S.; Mushtaq, A. [Isotope Production Division, Pakistan Institute of Nuclear Science and Technology, P.O. Nilore, Islamabad (Pakistan)

    2010-07-01

    Various experiments were carried out for the separation of {sup 90}Y from {sup 90}Sr using colloid formation behavior of {sup 90}Y in basic pH range. When the acidic solution of {sup 90}Sr/{sup 90}Y was treated with NaOH and passed through a small glass wool column, more than 95% {sup 90}Y was retained on glass wool, which was further washed with 0.1 M NaOH. The {sup 90}Y was extracted in 1 M HCl. Radionuclidic purity was determined by half life measurement. The contamination of parent was less than 0.0001%. Similarly when the colloid was passed through membrane filter more than 95% {sup 90}Y was retained which was recovered by 1 M HCl. The contamination of {sup 90}Sr was less than 0.0001%. The stock solution of {sup 90}Sr/{sup 90}Y in NH{sub 4}OH/NaOH was again passed through Millipore filter paper or glass wool after one week. The retention of 90Y was insignificant. The equilibrium mixture of {sup 90}Sr/{sup 90}Y was acidified with HCl and again precipitated with addition of NH{sub 4}OH or NaOH. The basic solution was passed through the Millipore filter or glass wool. More than 90% activity of {sup 90}Y was retained, which was finally extracted in 1 M HCl It was concluded that for recovery of {sup 90}Y from {sup 90}Sr by colloid formation, the acidic solution of {sup 90}Sr/{sup 90}Y shall be freshly precipitated by NH{sub 4}OH or NaOH. It was also observed that the adsorption of {sup 90}Y was quite high when the {sup 90}Sr solution was left in a glass vial for the growth of {sup 90}Y. However it can be easily extracted after keeping it in boiling water bath for few minutes. The separated {sup 90}Y via colloid formation was used for the labeling of EDTMP. Labeling efficiency of {sup 90}Y-EDTMP was more than 98%.

  6. Comparative study on DOTA-derivatized bombesin analog labeled with {sup 90}Y and {sup 177}Lu: in vitro and in vivo evaluation

    Energy Technology Data Exchange (ETDEWEB)

    Koumarianou, Eftychia [Institute R-RP, NCSR ' Demokritos' , Athens (Greece); IAE, Radioisotope Centre POLATOM, 05-400 Swierk-Otwock (Poland)], E-mail: eytyxiak@yahoo.com; Mikolajczak, Renata; Pawlak, Dariusz [IAE, Radioisotope Centre POLATOM, 05-400 Swierk-Otwock (Poland); Zikos, Xhristos; Bouziotis, Pinelopi [Institute R-RP, NCSR ' Demokritos' , Athens (Greece); Garnuszek, Piotr; Karczmarczyk, Urszula; Maurin, Michal [Department of Radiopharmaceuticals, National Medicines Institute, Chelmska 30/34, 00-725 Warsaw (Poland); Archimandritis, Spyridon C. [Institute R-RP, NCSR ' Demokritos' , Athens (Greece)

    2009-08-15

    Introduction: The aim of the study was to compare in vitro and in vivo a novel DOTA-chelated bombesin (BN) analog of the amino acid sequence, QRLGNQWAVGHLM-CONH{sub 2} (BN[2-14]NH{sub 2}), labeled with {sup 90}Y and {sup 177}Lu, for its potential use in targeted radiotherapy of tumors expressing gastrin releasing peptide (GRP) receptors. The same amino acid sequence, but with different chelator, referred as BN1.1 (Gly-Gly-Cys-Aca-QRLGNQWAVGHLM-CONH{sub 2}), has already been studied and reported; however, the DOTA-chelated one, suitable for labeling with M{sup +3} type radiometals, was not yet described. Methods: The conditions for labeling of DOTA-BN[2-14]NH{sub 2} with noncarrier added {sup 90}Y and with {sup 177}Lu [specific activity (SA), 15 Ci/mg Lu] were investigated and optimized to provide {sup 90}Y-DOTA-BN[2-14]NH{sub 2} and {sup 177}Lu-DOTA-BN[2-14]NH{sub 2} of high SA. The stability of the radiolabeled compounds in human serum was evaluated over a period of 24 h. The human prostate cancer cell line PC-3, known to express GRP receptors, was used for in vitro evaluation of radiolabeled peptide affinity to GRP receptors and for assessment of cytotoxicity of both nonlabeled and radiolabeled peptide. Biodistribution accompanied by receptor blocking was studied in normal Swiss mice. Results: {sup 90}Y-DOTA-BN[2-14]NH{sub 2} and {sup 177}Lu-DOTA-BN[2-14]NH{sub 2} were obtained with radiochemical yield >98% and high SA (67.3 GBq {sup 90}Y/{mu}mol and 33.6 GBq {sup 177}Lu/{mu}mol, respectively). They were stable when incubated in human serum for up to 24 h. The binding affinities of DOTA-BN[2-14]NH{sub 2} and both {sup nat}Y- and {sup nat}Lu-labeled analogs to GRP receptors were high (IC{sub 50}=1.78, 1.99, and 1.34 nM, respectively), especially for the {sup nat}Lu-DOTA-BN[2-14]NH{sub 2} complex. The cytotoxicity study of DOTA-BN[2-14]NH{sub 2} to PC-3 cells revealed an IC{sub 50}=6300 nM after 72 h of exposition, while the labeled derivatives showed no

  7. Comparative study on DOTA-derivatized bombesin analog labeled with 90Y and 177Lu: in vitro and in vivo evaluation

    International Nuclear Information System (INIS)

    Koumarianou, Eftychia; Mikolajczak, Renata; Pawlak, Dariusz; Zikos, Xhristos; Bouziotis, Pinelopi; Garnuszek, Piotr; Karczmarczyk, Urszula; Maurin, Michal; Archimandritis, Spyridon C.

    2009-01-01

    Introduction: The aim of the study was to compare in vitro and in vivo a novel DOTA-chelated bombesin (BN) analog of the amino acid sequence, QRLGNQWAVGHLM-CONH 2 (BN[2-14]NH 2 ), labeled with 90 Y and 177 Lu, for its potential use in targeted radiotherapy of tumors expressing gastrin releasing peptide (GRP) receptors. The same amino acid sequence, but with different chelator, referred as BN1.1 (Gly-Gly-Cys-Aca-QRLGNQWAVGHLM-CONH 2 ), has already been studied and reported; however, the DOTA-chelated one, suitable for labeling with M +3 type radiometals, was not yet described. Methods: The conditions for labeling of DOTA-BN[2-14]NH 2 with noncarrier added 90 Y and with 177 Lu [specific activity (SA), 15 Ci/mg Lu] were investigated and optimized to provide 90 Y-DOTA-BN[2-14]NH 2 and 177 Lu-DOTA-BN[2-14]NH 2 of high SA. The stability of the radiolabeled compounds in human serum was evaluated over a period of 24 h. The human prostate cancer cell line PC-3, known to express GRP receptors, was used for in vitro evaluation of radiolabeled peptide affinity to GRP receptors and for assessment of cytotoxicity of both nonlabeled and radiolabeled peptide. Biodistribution accompanied by receptor blocking was studied in normal Swiss mice. Results: 90 Y-DOTA-BN[2-14]NH 2 and 177 Lu-DOTA-BN[2-14]NH 2 were obtained with radiochemical yield >98% and high SA (67.3 GBq 90 Y/μmol and 33.6 GBq 177 Lu/μmol, respectively). They were stable when incubated in human serum for up to 24 h. The binding affinities of DOTA-BN[2-14]NH 2 and both nat Y- and nat Lu-labeled analogs to GRP receptors were high (IC 50 =1.78, 1.99, and 1.34 nM, respectively), especially for the nat Lu-DOTA-BN[2-14]NH 2 complex. The cytotoxicity study of DOTA-BN[2-14]NH 2 to PC-3 cells revealed an IC 50 =6300 nM after 72 h of exposition, while the labeled derivatives showed no significant cytotoxic effect. The internalization rate to PC-3 cells was more rapid for 177 Lu-labeled peptide (84.87%) than for the 90 Y

  8. Cellular and molecular properties of {sup 90}Y-labeled cetuximab in combination with radiotherapy on human tumor cells in vitro

    Energy Technology Data Exchange (ETDEWEB)

    Saki, M.; Toulany, M.; Rodemann, H.P. [Tuebingen Univ. (Germany). Div. of Radiobiology and Molecular Environmental Research; Sihver, W.; Zenker, M.; Heldt, J.M.; Mosch, B.; Pietzsch, H.J.; Steinbach, J. [Helmholtz-Zentrum Dresden-Rossendorf (HZDR) e.V., Dresden (Germany). Inst. of Radiopharmacy; Baumann, M. [Technische Univ. Dresden (Germany). Dept. of Radiation Oncology

    2012-09-15

    Purpose: Anti-EGFR antibody cetuximab (C225) is used in combination with radiotherapy of head and neck squamous cell carcinoma (HNSCC) patients. We investigated whether conjugation of cetuximab with trans-cyclohexyl-diethylene-triamine-pentaacetic acid (CHX-A''-DTPA) and radiolabeling with {sup 90}Yttrium affect the molecular and cellular function of cetuximab and improve its combined effect with external-beam irradiation (EBI). Methods: The following cell lines were used: HNSCC UT5, SAS, FaDu, as well as A43, Chinese hamster ovary cells (CHO), and human skin fibroblast HSF7. Binding affinity and kinetics, specificity, retention, and the combination of {sup 90}Y-cetuximab with EBI were evaluated. Results: Control cetuximab and CHX-A''-DTPA-cetuximab blocked the proliferation activity of UT5 cells. In combination with EBI, CHX-A''-DTPA-cetuximab increased the radiosensitivity of UT5 to a similar degree as control cetuximab did. In contrast, in SAS and HSF7 cells neither proliferation nor radiosensitivity was affected by either of the antibodies. Binding [{sup 90}Y]Y-CHX-A''-DTPA-cetuximab ({sup 90}Y-cetuximab) to EGFR in HNSCC cells occurred time dependently with a maximum binding at 24 h. Retention of {sup 90}Y-cetuximab was similar in both HNSCC cell lines; 24 h after treatment, approximately 90% of bound activity remained in the cell layer. Competition assays, using cell membranes in the absence of an internalized fraction of cetuximab, showed that the cetuximab affinity is not lost as a result of conjugation with CHX-A''-DTPA. Cetuximab and CHX-A''-DTPA-cetuximab blocked EGF-induced Y1068 phosphorylation of EGFR. The lack of an effect of cetuximab on EGF-induced Akt and ERK1/2 phosphorylation and the inhibition of irradiation (IR)-induced Akt and ERK1/2 phosphorylation by cetuximab were not affected by DTPA conjugation. {sup 90}Y-cetuximab in combination with EBI resulted in a pronounced inhibition of

  9. Monte Carlo dose characterization of a new 90Sr/90Y source with balloon for intravascular brachytherapy

    International Nuclear Information System (INIS)

    Wang Ruqing; Li, X. Allen; Lobdell, John

    2003-01-01

    Beta emitting source wires or seeds have been adopted in clinical practice of intravascular brachytherapy for coronary vessels. Due to the limitation of penetration depth, this type of source is normally not applicable to treat vessels with large diameter, e.g., peripheral vessel. In the effort to extend application of its beta source for peripheral vessels, Novoste has recently developed a new catheter-based system, the Corona trade mark sign 90 Sr/ 90 Y system. It is a source train of 6 cm length and is jacketed by a balloon. The existence of the balloon increases the penetration of the beta particles and maintains the source within a location away from the vessel wall. Using the EGSnrc Monte Carlo system, we have calculated the two-dimensional (2-D) dose rate distribution of the Corona trade mark sign system in water for a balloon diameter of 5 mm. The dose rates on the transverse axis obtained in this study are in good agreement with calibration results of the National Institute of Standards and Technology for the same system for balloon diameters of 5 and 8 mm. Features of the 2-D dose field were studied in detail. The dose parameters based on AAPM TG-60 protocol were derived. For a balloon diameter of 5 mm, the dose rate at the reference point (defined as r 0 =4.5 mm, 2 mm from the balloon surface) is found to be 0.010 28 Gy min -1 mCi -1 . A new formalism for a better characterization of this long source is presented. Calculations were also performed for other balloon diameters. The dosimetry for this source is compared with a 192 Ir source, commonly used for peripheral arteries. In conclusion, we have performed a detailed dosimetric characterization for a new beta source for peripheral vessels. Our study shows that, from dosimetric point of view, the Corona trade mark sign system can be used for the treatment of an artery with a large diameter, e.g., peripheral vessel

  10. Peptide receptor radionuclide therapy with 90Y/177Lu-labelled peptides for inoperable head and neck paragangliomas (glomus tumours)

    International Nuclear Information System (INIS)

    Puranik, Ameya D.; Kulkarni, Harshad R.; Singh, Aviral; Baum, Richard P.

    2015-01-01

    Head and neck paragangliomas (HNPGLs) are rare tumours arising from autonomic nervous system ganglia. Although surgery offers the best chance of complete cure, there is associated morbidity due to the crucial location of these tumours. Radiotherapy arrests tumour growth and provides symptomatic improvement, but has long-term consequences. These tumours express somatostatin receptors (SSTR) and hence peptide receptor radionuclide therapy (PRRT) is now a treatment option. We assessed the molecular, morphological and clinical responses of inoperable HNPGLs to PRRT. Nine patients with inoperable HNPGL assessed between June 2006 and June 2014 were included. Four patients had a solitary lesion, four had multifocal involvement and one had distant metastases (bone and lungs). The patients were treated with PRRT using 90 Y/ 177 Lu-labelled peptides after positive confirmation of SSTR expression on 68 Ga-DOTATOC PET/CT. All patients received two to four courses of PRRT. Subsequent serial imaging with 68 Ga-DOTATOC PET/CT was carried out every 6 months to assess response to treatment. Clinical (symptomatic) response was also assessed. Based on molecular response (EORTC) criteria, four of the nine patients showed a partial molecular response to treatment seen as significant decreases in SUV max , accompanied by a reduction in tumour size. Five patients showed stable disease on both molecular and morphological criteria. Six out of nine patients were symptomatic at presentation with manifestations of cranial nerve involvement, bone destruction at the primary site and metastatic bone pain. Molecular responses were correlated with symptomatic improvement in four out of these six patients; while two patients showed small reductions in tumour size and SUV max . The three asymptomatic patients showed no new lesions or symptomatic worsening. PRRT was effective in all patients, with no disease worsening seen, either in the form of neurological symptoms or distant spread. Though these

  11. {sup 18}F-FDG PET independently predicts survival in patients with cholangiocellular carcinoma treated with {sup 90}Y microspheres

    Energy Technology Data Exchange (ETDEWEB)

    Haug, Alexander R. [Ludwig-Maximilians-University, Department of Nuclear Medicine, Munich (Germany); Klinikum Grosshadern, Department of Nuclear Medicine, Munich (Germany); Heinemann, Volker [Ludwig-Maximilians-University, Department of Internal Medicine III, Munich (Germany); Bruns, Christiane J. [Ludwig-Maximilians-University, Department of Surgery, Munich (Germany); Hoffmann, Ralf; Jakobs, Tobias [Ludwig-Maximilians-University, Institute of Clinical Radiology, Munich (Germany); Bartenstein, Peter; Hacker, Marcus [Ludwig-Maximilians-University, Department of Nuclear Medicine, Munich (Germany)

    2011-06-15

    {sup 90}Y radioembolization has emerged as a valuable therapy for intrahepatic cholangiocellular carcinomas (ICC). We aimed to evaluate the prognostic power of FDG PET/CT and that of pretherapeutic scintigraphy with {sup 99m}Tc-labelled macroagglutinated albumin (MAA), an index of tumour vascularization. The study group comprised 26 consecutive patients suffering from nonresectable ICC. Before treatment with radioembolization, all patients underwent MRI of the liver, as well as MAA scintigraphy, which was followed immediately by SPECT(/CT) to quantify the liver-lung shunt fraction. Using image fusion, regions of interest were drawn around the tumours and the entire liver, and the tumour-to-liver quotient was calculated. In addition, FDG PET/CT was performed at baseline and 3 months after radioembolization, and the percentage changes in peak ({delta}SUV{sub max}) and mean ({delta}SUV{sub mean}) FDG uptake and in metabolic tumour volume ({delta}Vol{sub 2SD}) relative to baseline were calculated. Treatment response at 3 months was also assessed using contrast-enhanced MRI and CT on the basis of standard criteria. Of 23 patients in whom follow-up MRI was available, 5 (22%) showed a partial response, 15 (65%) stable disease and 3 (13%) progressive disease. The change in all FDG values significantly predicted survival by Kaplan-Meier analysis after radioembolization; {delta}Vol{sub 2SD} responders had a median survival of 97 weeks versus 30 weeks in nonresponders (P = 0.02), whereas {delta}SUV{sub max} and {delta}SUV{sub mean} responders had a median survival of 114 weeks (responder) versus 19 weeks (nonresponder) and 69 weeks in patients with stable disease (P < 0.05). Pretherapeutic MAA scintigraphy or MRI did not predict survival, nor did the presence of extrahepatic metastases, or prior therapies. Only {delta}Vol{sub 2SD} was significantly associated with survival by univariate analysis (hazard ratio 0.25; P = 0.04) and multivariate analysis (hazard ratio 0.20, P = 0

  12. Bremsstrahlung Based Positron Annihilation Spectroscopy for Material Defect Analysis

    International Nuclear Information System (INIS)

    Selim, F.A.; Wells, D.P.; Harmon, F.; Kwofie, J.; Lancaster, G.; Jones, J.L.

    2003-01-01

    The Idaho Accelerator Center (IAC) has developed new techniques for Positron Annihilation Spectroscopy (PAS) using highly penetrating γ-rays to create positrons inside the material via pair production. γ-Ray induced positron annihilation spectroscopy can provide highly penetrating probes for material characterization and defect analysis. Bremsstrahlung beams from small, pulsed electron Linacs (6 MeV) have been used to bombard the materials to generate positrons, which annihilate with the material electrons emitting 511 keV radiation. We have also synchronized bremsstrahlung pulses with laser irradiation pulses to study dynamic structural changes in material. In addition, we have developed another method using (p,γ) reactions from a 2 MeV proton beam, which induce coincident γ-rays to perform positron life-time spectroscopy. We have showed the feasibility of extending PAS into thick samples and a wide variety of materials and industrial applications

  13. The LPM effect in sequential bremsstrahlung: 4-gluon vertices

    Energy Technology Data Exchange (ETDEWEB)

    Arnold, Peter; Chang, Han-Chih [Department of Physics, University of Virginia,382 McCormick Road, Charlottesville, Virginia 22904-4714 (United States); Iqbal, Shahin [National Centre for Physics, Quaid-i-Azam University Campus, Islamabad, 45320 (Pakistan)

    2016-10-24

    The splitting processes of bremsstrahlung and pair production in a medium are coherent over large distances in the very high energy limit, which leads to a suppression known as the Landau-Pomeranchuk-Migdal (LPM) effect. In this paper, we continue study of the case when the coherence lengths of two consecutive splitting processes overlap (which is important for understanding corrections to standard treatments of the LPM effect in QCD), avoiding soft-gluon approximations. In particular, this paper completes the calculation of the rate for real double gluon bremsstrahlung from an initial gluon with various simplifying assumptions (thick media; q̂ approximation; and large N{sub c}) by now including processes involving 4-gluon vertices.

  14. Neutral bremsstrahlung radiation of Ne, Ar and O

    International Nuclear Information System (INIS)

    Kung, R.T.V.; Chang, C.H.

    1976-01-01

    The neutral Bremsstrahlung cross-sections of Ne, Ar and atomic oxygen around the 3 and 10μ wavelength regions were measured in a high temperature plasma generated in a shock tube. The results were generally a factor of three higher than the theoretical values calculated by Geltman (Geltman, S., JQSRT vol.13, 601 (1973)). Agreement with the experimental results of Taylor and Caledonia (Taylor, R.L. and Caledonia, G., JQSRT vol.9, 657; 681, 1969) around 3μ was good except for the case of Ne. The cross-sections around 10μ are the first measurements in this wavelength region. Enhanced radiation due to atomic line emission on top of the Bremsstrahlung continuum, as predicted by Hyman (Hyman, H.A. and Von Rosenberg, C.W. Jr., JQSRT, vol.15, 919, 1975) was observed around 7.44μ. (author)

  15. Nuclear effects on bremsstrahlung neutrino rates of astrophysical interest

    International Nuclear Information System (INIS)

    Stoica, Sabin; Horvath, J.E.

    2002-01-01

    We calculate in this work the rates for the neutrino pair production by nucleon-nucleon bremsstrahlung taking into account the full contribution from a nuclear one-pion-exchange potential. It is shown that if the temperatures are low enough (T≤20 MeV), the integration over the nuclear part can be done for the general case, ranging from the completely degenerate (D) to the nondegenerate (ND) regime. We find that the inclusion of the full nuclear contribution enhances the neutrino pair production by nn and pp bremsstrahlung by a factor of about 2 in both the D and ND limits when compared with previous calculations. This result may be relevant for the physical conditions of interest in the semitransparent regions near the neutrinosphere in type II supernovae, cooling of neutron stars, and other astrophysical situations

  16. Simulation of the Focal Spot of the Accelerator Bremsstrahlung Radiation

    Science.gov (United States)

    Sorokin, V.; Bespalov, V.

    2016-06-01

    Testing of thick-walled objects by bremsstrahlung radiation (BR) is primarily performed via high-energy quanta. The testing parameters are specified by the focal spot size of the high-energy bremsstrahlung radiation. In determining the focal spot size, the high- energy BR portion cannot be experimentally separated from the low-energy BR to use high- energy quanta only. The patterns of BR focal spot formation have been investigated via statistical modeling of the radiation transfer in the target material. The distributions of BR quanta emitted by the target for different energies and emission angles under normal distribution of the accelerated electrons bombarding the target have been obtained, and the ratio of the distribution parameters has been determined.

  17. Bremsstrahlung radiation of a plasma expanding into vacuum

    International Nuclear Information System (INIS)

    Grigor'ev, V.G.; Silakov, V.P.; Fetisov, V.S.

    1978-01-01

    Bremsstrahlung of a flat layer of a dense hot homogeneous plasma expanding to vacuum is considered. The spread of plasma is assumed to be adiabatic, and the plasma density and temperature are considered as known functions of coordinates and time in the radiation transport equation. Formulae for radiation intensity have been obtained in cases when the plasma layer covered by the rarefaction wave are optically thin and optically thick. The dependences of radiation intensity on the parameter α characterizing the optical thickness of the plasma layer and the spectrum of radiation of the spreading layer are presented graphically. It is shown that spread has an essential effect on the heat transfer and the spectral composition of the bremsstrahlung of a dense high-temperature plasma

  18. Density oscillations of nuclear matter probed via Bremsstrahlung photons

    International Nuclear Information System (INIS)

    Marques, F.M.; Ostendorf, R.W.

    1996-01-01

    From the extended experimental data on hard-photon production at intermediate energies the dominant source of hard-photons has been attributed to the Bremsstrahlung radiation emitted in first-chance proton-neutron (pn) collisions. Aside of the dominant source which produces direct hard-photons, at intermediate energies BUU calculations predict the existence of a second source of pn Bremsstrahlung photons occurring at a later stage of the heavy-ion collision when the system is almost fully thermalized, thermal hard-photons. The existence of this second photon source is searched for by analysing the energy spectra of inclusive and exclusive hard-photons and the photon-photon correlation function for three different systems. (K.A.)

  19. Diffractive bremsstrahlung at high-β{sup *} LHC. Case study

    Energy Technology Data Exchange (ETDEWEB)

    Chwastowski, Janusz J.; Czekierda, Sabina; Staszewski, Rafal; Trzebinski, Maciej [The Henryk Niewodniczanski Institute of Nuclear Physics Polish Academy of Sciences, Krakow (Poland)

    2017-04-15

    Feasibility studies of the measurement of the exclusive diffractive bremsstrahlung cross-section in proton-proton scattering at the centre of mass energy of 13 TeV at the LHC are reported. Present studies were performed for the low luminosity LHC running with the betatron function value of 90 m using the ATLAS associated forward detectors ALFA and ZDC. A simplified approach to the event simulation and reconstruction is used. The background influence is also discussed. (orig.)

  20. Possibility of some radionuclides production using high energy electron Bremsstrahlung

    International Nuclear Information System (INIS)

    Balzhinnyam, N.; Belov, A.G.; Gehrbish, Sh; Maslov, O.D.; Shvetsov, V.N.; Ganbold, G.

    2008-01-01

    The method of some radionuclides production using high energy Bremsstrahlung of electron accelerators and determination of photonuclear reaction yield and specific activities for some radionuclides is described. Photonuclear reaction yield and specific activities for some radionuclides are determined for 117m Sn, 111 In and 195m Pt. Based on the experimental data obtained at low energy (E e- e- = 75 MeV) of the IREN facility (FLNR, JINR) at irradiation of high purity platinum and tin metals

  1. Excitation of spin-1 states in 166168170Er using bremsstrahlung

    International Nuclear Information System (INIS)

    Metzger, F.R.

    1976-01-01

    Some 40 states in 166 , 168 , 170 Er, most of them previously unknown, have been excited using bremsstrahlung with < or =4.2 MeV endpoint energy. For all but three of these levels, the angular distribution of the resonantly scattered radiation favors the assignment of spin 1. For some of the strongly excited levels, linear polarization measurements have been performed. They indicate that these levels have positive parity. The branching ratios further characterize them as K=1 excitations

  2. Diffractive production off nuclei-shadow of hadronic bremsstrahlung

    International Nuclear Information System (INIS)

    Bialas, A.; Czyz, W.

    1974-01-01

    Diffractive production on nuclei is calculated using as an input a specific model for diffractive production on nucleons. In this model diffractive production is described as a shadow of non-diffractive multiple production of particles. The mechanism for non-diffractive production is taken to be hadronic bremsstrahlung of independently produced clusters. It is shown that such a model naturally explains the strikingly simple pattern of absorption observed in coherent production on nuclei. Possible generalizations of these results are indicated. (author)

  3. Electron bremsstrahlung spectrum, 1--500 keV

    International Nuclear Information System (INIS)

    Lee, C.M.; Kissel, L.; Pratt, R.H.; Tseng, H.K.

    1976-01-01

    Numerical data are obtained for the electron bremsstrahlung energy spectrum resulting from incident electrons of kinetic energy 1--500 keV, under the assumption that the process is described as a single-electron transition in a relativistic self-consistent screened potential, using partial-wave expansions. Comparisons with simpler analytical approximations show that these are at best of qualitative validity in this energy range. Our data are used to construct more complete tables of the spectrum by interpolation

  4. Assembler absolute forward thick-target bremsstrahlung spectra program

    International Nuclear Information System (INIS)

    Niculescu, V.I.R.; Baciu, G.; Ionescu-Bujor, M.

    1981-12-01

    The program is intended to compute the absolute forward thick-target bremsstrahlung spectrum for electrons in the energy range 1-24 MeV. The program takes into account the following phenomena: multiple scattering, energy loss and the attenuation of the emitted gamma rays. The computer program is written in Assembler having a higher degree of generality and is more performant than the FORTRAN version. (authors)

  5. Bremsstrahlung of La and its dependence on electron energy

    International Nuclear Information System (INIS)

    Riehle, F.

    1977-01-01

    Measurements of La-bremsstrahlung isocromates with high resolution for quantum energies between 135 eV and 1867 eV are presented and discussed. In the whole energy range investigated, the isocromate structure, identified with the 4f band of La, is placed 5,45 +- 10,1 eV above the Fermi level. This is in contradiction with a calculation of Gloetzel, which predicts the 4f band maximum about 3eV above the Fermi level. This discrepancy is explained in the present work by the fact that the La electronic density of states depends on the occupation number of the states. The bremsstrahlung isocromate has to be considered as a direct copy of the La ion density of states, consisting of the La-atom and the additional primary electron. Resonance like intensity modulations of the x-ray radiation, resulting from transitions of the primary electron in f-like final states, are observed in an analysis of the La-bremsstrahlung isochromate energy dependence. For transitions of the primary electron in d-like final states, no resonances have been found. The energy dependence of the scattering probability in f-like final states can be explained by a model which assumes the final state as composed by a continuum state and a discrete state. (orig.) [de

  6. Scintillating fiber array for tagging post-bremsstrahlung electrons

    Science.gov (United States)

    Cole, Philip; Alef, Stefan; Reitz, Björn-Eric; Schmieden, Hartmut; Hannappel, Jürgen; Jude, Thomas; Sandri, Paolo Levi; BGO-OD Collaboration

    2016-03-01

    We seek to extract the kinematic fingerprints of baryon resonances by making use of a high-quality beam of linearly polarized photons at the BGO-OD experiment at ELSA (Bonn, German). We constructed a unique device for precisely determining the degree of polarization in the coherent bremsstrahlung peak. Deflection of post-bremsstrahlung electrons in the magnetic field of the photon tagger provides precise information on the energy and polarization of the bremsstrahlung photons. And thereby will constrain the overall kinematics of the final-state particles in all decay channels of the photoproduced baryon resonances. We designed, prototyped, built, calibrated, and have been operating a three-layered, multi-stranded, scintillating-fiber detector for ensuring the quality of the linearly polarization of the photon beam. The overlapping 2.00-mm scintillating fibers form an array giving ARGUS over 500 channels. The very befitting name harkens to the mythological all-seeing creature Argus Panoptes, the multi-eyed giant. Our work was supported through a Fulbright Scholarship Award and by the Deutsche Forschungsgemeinschaft through the Collaborative Research Center (Sonderforschungsbereich SFB/TR-16) of the universities in Bonn, Giessen and Bochum, Germany. NSF-PHY-1307340.

  7. Two-stage supported liquid membrane method for the separation of carrier-free {sup 90}Y from {sup 90}Sr using KSM-17 and CMPO as carriers

    Energy Technology Data Exchange (ETDEWEB)

    Dhami, P S; Naik, P W; Dudwadkar, N L; Kannan, R; Achuthan, P V; Dakshinamoorthy, A; Jambunathan, U; Munshi, S K; Dey, P K [Fuel Reprocessing Division, Bhabha Atomic Research Centre, Mumbai (India); Pandey, Usha; Venkatesh, Meera [Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai (India)

    2007-07-01

    A two stage supported liquid membrane system is developed for the separation of carrier free {sup 90}Y from {sup 90}Sr for therapeutic applications. The feed containing {sup 90}Sr-{sup 90}Y in nitric acid solution at pH 2 is placed in the feed compartment and transported across a polytetrafluoroethylene membrane containing 2-ethyhexyl2ethylhexyl phosphonic acid to a 4M HNO{sub 3} receiver phase. This is then transported across another polytetrafluoroethylene membrane containing octyl phenyl N,N-diisobutylcarbamoyl methylphosphene oxide to another receiving phase, 1 M acetic acid. This has been implemented on simultaneous and sequential modes with very good yield. The second stage will act as a barrier for {sup 90}Sr, and will improve the product purity. (author)

  8. Radioimmunotherapy of small cell lung cancer xenograft mice with a 90Y anti-ROBO1 monoclonal antibody: Pathological study of effects on tumor and normal organs

    International Nuclear Information System (INIS)

    Fujiwara, K.; Koyama, K.; Kitada, T.; Takahashi, M.; Momose, T.; Suga, K.

    2015-01-01

    Full text of publication follows. ROBO1 is a membrane protein that is concerned about axon guidance. It is reported that ROBO1 contributes to tumor metastasis and angio genesis. ROBO1 is specifically expressed at high levels in small cell lung cancer (SCLC). In this study, we performed radioimmunotherapy (RIT) to SCLC models, and analyzed pathological alteration of tumor and organs. Methods: For the biodistribution study, 111 In-DOTA anti-ROBO1 IgG (about 370 kBq, 111 In anti-ROBO1) was injected into NCI-H69 xenograft mice via tail vein. To evaluate antitumor effect, RIT study was performed. 90 Y-DOTA anti-ROBO1 IgG (about 7.4 MBq, 90 Y anti-ROBO1) was injected. The experiments measured tumor volume, mouse weights and blood cell counts periodically. The tumors and organs (liver, kidney, intestine, spleen, femoral and sternum) of mice were obtained, and histopathologic analysis were carried out. Results: as a result of biodistribution study, the specific accumulation in the tumor of 111 In anti-ROBO1 was observed. Liver, kidney, spleen and lung showed comparatively high accumulation of 111 In anti-ROBO1. In the RIT study, 90 Y anti-ROBO1 significantly reduced tumor volume compared with original volume and increased median survival time to 58 days (p<0.01, versus saline, 28 days), while 90 Y anti-ROBO1 induced transient pancytopenia. Histopathologic analysis of tumors and organs further validated the therapeutic efficacy and the systemic toxicity of 90 Y anti-ROBO1. In day 7 when tumor volume reduced to 60% compared with original volume, irreversible nuclear denaturation and fibrosis were observed. The percentage of TUNEL-positive cells increased to 11.4%±5.1 in the day 7 (p<0.01, versus control, 4.14%±1.4), which showed increase of DNA fragmentation and apoptosis in the tumor tissues. Normal organs excluding spleen and sternum showed no significant injury. In day 7 post injection, spleen showed transient reduction of hematopoietic cells. Hematopoietic cells in

  9. Labelling of 90Y- and 177Lu-DOTA-Bioconjugates for Targeted Radionuclide Therapy: A Comparison among Manual, Semiautomated, and Fully Automated Synthesis

    Directory of Open Access Journals (Sweden)

    Michele Iori

    2017-01-01

    Full Text Available In spite of the hazard due to the radiation exposure, preparation of 90Y- and 177Lu-labelled radiopharmaceuticals is still mainly performed using manual procedures. In the present study the performance of a commercial automatic synthesizer based on disposable cassettes for the labelling of 177Lu- and 90Y-DOTA-conjugated biomolecules (namely, DOTATOC and PSMA-617 was evaluated and compared to a manual and a semiautomated approach. The dose exposure of the operators was evaluated as well. More than 300 clinical preparations of both 90Y- and 177Lu-labelled radiopharmaceuticals have been performed using the three different methods. The mean radiochemical yields for 90Y-DOTATOC were 96.2±4.9%, 90.3±5.6%, and 82.0±8.4%, while for 177Lu-DOTATOC they were 98.3%  ± 0.6, 90.8%  ± 8.3, and 83.1±5.7% when manual, semiautomated, and automated approaches were used, respectively. The mean doses on the whole hands for yttrium-90 preparations were 0.15±0.4 mSv/GBq, 0.04±0.1 mSv/GBq, and 0.11±0.3 mSv/GBq for manual, semiautomated, and automated synthesis, respectively, and for lutetium-177 preparations, they were 0.02±0.008 mSv/GBq, 0.01±0.03 mSv/GBq, and 0.01±0.02 mSv/GBq, respectively. In conclusion, the automated approach guaranteed reliable and reproducible preparations of pharmaceutical grade therapeutic radiopharmaceuticals in a decent RCY. The radiation exposure of the operators remained comparable to the manual approach mainly due to the fact that a dedicated shielding was still not available for the system.

  10. Sustained safety and efficacy of extended-shelf-life {sup 90}Y glass microspheres: long-term follow-up in a 134-patient cohort

    Energy Technology Data Exchange (ETDEWEB)

    Lewandowski, Robert J.; Minocha, Jeet; Memon, Khairuddin; Riaz, Ahsun; Gates, Vanessa L.; Ryu, Robert K.; Sato, Kent T.; Omary, Reed; Salem, Riad [Northwestern University, Department of Radiology, Chicago, IL (United States)

    2014-03-15

    To validate our initial pilot study and confirm sustained safety and tumor response of extended-shelf-life {sup 90}Y glass microspheres. We hypothesized that for the same planned tissue dose, the increase in number of glass microspheres (decayed to the second week of their allowable shelf-life) administered for the same absorbed dose would result in better tumor distribution of the microspheres without causing additional adverse events. Between June 2007 and January 2010, 134 patients underwent radioembolization with extended-shelf-life {sup 90}Y glass microspheres; data from 84 new patients were combined with data from our 50-patient pilot study cohort. Baseline and follow-up imaging and laboratory data were obtained 1 and 3 months after therapy and every 3 months thereafter. Clinical and biochemical toxicities were prospectively captured and categorized according to the Common Terminology Criteria. Response in the index lesion was assessed using WHO and EASL guidelines. The mean delivered radiation dose was 123 Gy to the target liver tissue. The mean increase in number of microspheres with this approach compared to standard {sup 90}Y glass microsphere dosimetry was 103 %, corresponding to an increase from 3.84 to 7.78 million microspheres. Clinical toxicities included fatigue (89 patients, 66 %), abdominal pain (49 patients, 36.6 %), and nausea/vomiting (25 patients, 18.7 %). Grade 3/4 bilirubin toxicity was seen in three patients (2 %). Two (1 %) of the initial 50-patient cohort showed gastroduodenal ulcers; gastroduodenal ulcers were not seen in any of the subsequent 84 patients. According to WHO and EASL guidelines, response rates were 48 % and 57 %, respectively, and 21 % demonstrated a complete EASL response. This study showed sustained safety and efficacy of extended-shelf-life {sup 90}Y glass microspheres in a larger, 134-patient cohort. The increase in number of microspheres administered theoretically resulted in better tumor distribution of the

  11. Carcinoid crisis induced by receptor radionuclide therapy with 90Y-DOTATOC in a case of liver metastases from bronchial neuroendocrine tumor (atypical carcinoid).

    Science.gov (United States)

    Davì, M V; Bodei, L; Francia, G; Bartolomei, M; Oliani, C; Scilanga, L; Reghellin, D; Falconi, M; Paganelli, G; Lo Cascio, V; Ferdeghini, M

    2006-06-01

    SS receptors are overexpressed in many tumors, mainly of neuroendocrine origin, thus enabling the treatment with SS analogs. The clinical experience of receptor radionuclide therapy with the new analog [90Y-DOTA0-Tyr3 ]-octreotide [90Y-DOTATOC] has been developed over the last decade and is gaining a pivotal role in the therapeutic workout of these tumors. It is well known that some procedures performed in diagnostic and therapeutic management of endocrine tumors, such as agobiopsy and hepatic chemoembolization, can be associated with the occurrence of symptoms related to the release of vasoactive amines and/or hormonal peptides from tumor cell lysis. This is the first report of a severe carcinoid crisis developed after receptor radionuclide therapy with 90Y-DOTATOC administered in a patient affected by liver metastases from bronchial neuroendocrine tumor (atypical carcinoid). Despite protection with H1 receptor antagonists, octreotide and corticosteroids, few days after the therapy the patient complained of persistent flushing of the face and upper trunk, severe labial and periocular oedema, diarrhoea and loss of appetite. These symptoms increased and required new hospitalisation. The patient received iv infusion of octreotide associated with H1 and H2 receptor antagonists and corticosteroid therapy, which induced symptom remission within few days. The case here reported confirms that radionuclide therapy is highly effective in determining early rupture of metastatic tissue and also suggests that pre-medication should be implemented before the radiopeptide administration associated with a close monitoring of the patient in the following days.

  12. Preclinical evaluation of intravenously administered 111In-and 90Y-labeled B72.3 immunoconjugate (GYK-DTPA) in beagle dogs

    International Nuclear Information System (INIS)

    Quadri, S.M.; Vriesendorp, H.M.; Yi Shao; Blum, J.E.; Leichner, P.K.; Williams, J.R.

    1993-01-01

    B72.3, a monoclonal antibody with reactivity against human adenocarcinomas was obtained from the Cytogen Corporation in the form of an immunoconjugate coupled with linker-chelator GYK-DTPA by using proprietary carbohydrate directed site specific chemistry. The immunoconjugate was radiolabeled with indium-111 or yttrium-90. A preclinical analysis was performed in 10 normal beagle dogs. The pharmacokinetics of intravenously administered indium- and yttrium-labeled immunoconjugates were compared serially in blood, bone marrow and urine samples. Compared to 90 Y less of the 111 In label ended up in urine and more was found in blood and bone marrow. Indium-labeled B72.3 GYK-DTPA had relatively higher uptake in most glandular tissues than 111 In-labeled antiferritin immunoconjugate. Bone marrow toxicity was the dose limiting side effect after intravenous infusion of 90 Y-labeled B72.3 GYK-DTPA. Toxicity was also observed in the liver but not in other organ systems. Recently other investigators obtained similar results with these immunoconjugates in human patients. A preclinical pharmacokinetic analysis of radioimmunoconjugates in beagle dogs provided useful information regarding bone marrow toxicity, liver toxicity and in vivo instability of the immunoconjugate. Data suggest that for future trials in human patients, a more stable chelated immunoconjugate for yttrium is needed to achieve less liver uptake and a better correlation with the 111 In-labeled product than the 90 Y-labeled B72.3 GYK-DTPA used in this investigation. (Author)

  13. 166Ho and 90Y labeled 6D2 monoclonal antibody for targeted radiotherapy of melanoma: Comparison with 188Re radiolabel

    International Nuclear Information System (INIS)

    Thompson, S.; Ballard, B.; Jiang, Z.; Revskaya, E.; Sisay, N.; Miller, W.H.; Cutler, C.S.; Dadachova, E.; Francesconi, L.C.

    2014-01-01

    Introduction: An approach to radioimmunotherapy (RIT) of metastatic melanoma is the targeting of melanin pigment with monoclonal antibodies (mAbs) to melanin radiolabeled with therapeutic radionuclides. The proof of principle experiments were performed using a melanin-binding antibody 6D2 of IgM isotype radiolabeled with a β emitter 188 Re and demonstrated the inhibition of tumor growth. In this study we investigated the efficacy of 6D2 antibody radiolabeled with two other longer lived β emitters 90 Y and 166 Ho in treatment of experimental melanoma, with the objective to find a possible correlation between the efficacy and half-life of the radioisotopes which possess high energy β (E max > 1.5 MeV) emission properties. Methods: 6D2 was radiolabeled with longer lived β emitters 90 Y and 166 Ho in treatment of experimental melanoma in A2058 melanoma tumor-bearing nude mice. The immunoreactivity of the radiolabeled 6D2 mAb, its in vitro binding to the MNT1 human melanoma cells, the biodistribution and therapy in A2058 human melanoma bearing nude mice as well as dosimetry calculations were performed. Results: When labeled with the longer lived 90 Y radionuclide, the 6D2 mAb did not produce any therapeutic effect in tumor bearing mice while the reduction of the tumor growth by 166 Ho-6D2 was very similar to the previously reported therapy results for 188 Re-6D2. In addition, 166 Ho-labeled mAb produced the therapeutic effect on the tumor without any toxic effects while the administration of the 90 Y-labeled radioconjugate was toxic to mice with no appreciable anti-tumor effect. Conclusions: 166 Ho-labeled mAb to melanin produced some therapeutic effect on the tumor without any toxic effects while the administration of the 90 Y-labeled radioconjugate was toxic to mice with no appreciable anti-tumor effect. We concluded that the serum half-life of the 6D2 carrier antibody matched well the physical half-life of 166 Ho to deliver the tumoricidal absorbed dose to the

  14. High clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours.

    Science.gov (United States)

    Kong, Grace; Callahan, Jason; Hofman, Michael S; Pattison, David A; Akhurst, Tim; Michael, Michael; Eu, Peter; Hicks, Rodney J

    2017-03-01

    Bulky disease is an adverse prognostic factor for 177 Lu-DOTA-octreotate ( 177 Lu-DOTATATE) peptide receptor radionuclide therapy (PRRT). 90 Y-DOTA-octreotate ( 90 Y-DOTATATE) has theoretical advantages in this setting but may less effectively treat co-existent smaller deposits and have higher toxicity than 177 Lu-DOTATATE. The aim of this study was to assess the efficacy and safety of using these agents sequentially. We reviewed patients (pts) with at least one lesion of a transaxial diameter >4 cm who completed 1-2 cycles of 90 Y-DOTATATE followed by 2-3 cycles of 177 Lu-DOTATATE, with treatment empirically adapted to disease size and burden in individual patients. Data collected included morphological and molecular imaging response, toxicity, and progression-free and overall survival. Twenty-six pts (17 men; aged 27-74 years) received a median cumulative activity of 6.5 GBq 90 Y-DOTATATE, and 21 GBq 177 Lu-DOTATATE. All but one received radiosensitising chemotherapy. Adverse prognostic factors included ENETS grade 2 or 3 in 58 %, and FDG-avid disease in 73 %. Nineteen pts treated for progressive disease had stabilisation (37 %) or regression on CT (42 % partial response, 21 % minor response), with a mean 59 % (8-99 %) reduction in disease burden. All seven pts treated for uncontrolled symptoms reported improvement during PRRT with 4/7 having complete symptom resolution at 3 months. Eight patients had grade 3/4 lymphopaenia, and two patients grade 3/4 thrombocytopaenia without significant hepatic or renal toxicity. Median survival was not reached after a median follow-up of 35 months. Median progression-free survival was 33 months. PRCRT with 90 Y -DOTATATE followed by 177 Lu-DOTATATE in individualised regimens achieved high clinical and morphological response in patients with bulky tumours. Despite lack of a control arm, the efficacy of this treatment approach appears higher than reported results with either agent used alone or other approved

  15. Evaluation of Efficacy of Radioimmunotherapy with 90Y-Labeled Fully Human Anti-Transferrin Receptor Monoclonal Antibody in Pancreatic Cancer Mouse Models.

    Directory of Open Access Journals (Sweden)

    Aya Sugyo

    Full Text Available Pancreatic cancer is an aggressive tumor and the prognosis remains poor. Therefore, development of more effective therapy is needed. We previously reported that 89Zr-labeled TSP-A01, an antibody against transferrin receptor (TfR, is highly accumulated in a pancreatic cancer xenograft, but not in major normal organs. In the present study, we evaluated the efficacy of radioimmunotherapy (RIT with 90Y-TSP-A01 in pancreatic cancer mouse models.TfR expression in pancreatic cancer cell lines (AsPC-1, BxPC-3, MIAPaCa-2 was evaluated by immunofluorescence staining. 111In-labeled anti-TfR antibodies (TSP-A01, TSP-A02 were evaluated in vitro by cell binding assay with the three cell lines and by competitive inhibition assay with MIAPaCa-2. In vivo biodistribution was evaluated in mice bearing BxPC-3 and MIAPaCa-2 xenografts. Tumor volumes of BxPC-3 and MIAPaCa-2 were sequentially measured after 90Y-TSP-A01 injection and histological analysis of tumors was conducted.MIAPaCa-2 cells showed the highest TfR expression, followed by AsPC-1 and BxPC-3 cells. 111In-TSP-A01 and 111In-TSP-A02 bound specifically to the three cell lines according to TfR expression. The dissociation constants for TSP-A01, DOTA-TSP-A01, TSP-A02, and DOTA-TSP-A02 were 0.22, 0.28, 0.17, and 0.22 nM, respectively. 111In-TSP-A01 was highly accumulated in tumors, especially in MIAPaCa-2, but this was not true of 111In-TSP-A02. The absorbed dose for 90Y-TSP-A01 was estimated to be 8.3 Gy/MBq to BxPC-3 and 12.4 Gy/MBq to MIAPaCa-2. MIAPaCa-2 tumors treated with 3.7 MBq of 90Y-TSP-A01 had almost completely disappeared around 3 weeks after injection and regrowth was not observed. Growth of BxPC-3 tumors was inhibited by 3.7 MBq of 90Y-TSP-A01, but the tumor size was not reduced.90Y-TSP-A01 treatment achieved an almost complete response in MIAPaCa-2 tumors, whereas it merely inhibited the growth of BxPC-3 tumors. 90Y-TSP-A01 is a promising RIT agent for pancreatic cancer, although further

  16. Internal bremsstrahlung signatures in light of direct dark matter searches

    Energy Technology Data Exchange (ETDEWEB)

    Garny, Mathias [Deutsches Elektronen-Synchrotron (DESY), Hamburg (Germany); Ibarra, Alejandro; Pato, Miguel; Vogl, Stefan [Technische Univ. Muenchen, Garching (Germany). Physik Dept. T30d

    2013-06-15

    Although proposed long ago, the search for internal bremsstrahlung signatures has only recently been made possible by the excellent energy resolution of ground-based and satellite-borne gamma-ray instruments. Here, we investigate thoroughly the current status of internal bremsstrahlung searches in light of the results of direct dark matter searches and in the framework of minimal mass-degenerate scenarios. The constraints set by Fermi-LAT and H.E.S.S. extend uninterrupted from tens of GeV up to tens of TeV and are rather insensitive to the mass degeneracy in the particle physics model. In contrast, direct searches are best in the moderate to low mass splitting regime, where XENON100 limits overshadow Fermi-LAT and H.E.S.S. up to TeV masses if dark matter couples to (light) quarks. We examine carefully the prospects for GAMMA-400, CTA and XENON1T, all planned to come online in the near future, and find that: (a) CTA and XENON1T are fully complementary, with CTA most sensitive to multi-TeV masses and mass splittings around 10%, and XENON1T probing best small mass splittings up to TeV masses; and (b) current constraints from XENON100 already preclude the observation of any spectral feature with GAMMA-400 in spite of its impressive energy resolution, unless dark matter does not couple to light quarks. Finally, we point out that, unlike for direct searches, the possibility of detecting thermal relics in upcoming internal bremsstrahlung searches requires boost factors larger than {proportional_to}10.

  17. Internal bremsstrahlung signatures in light of direct dark matter searches

    International Nuclear Information System (INIS)

    Garny, Mathias; Ibarra, Alejandro; Pato, Miguel; Vogl, Stefan

    2013-07-01

    Although proposed long ago, the search for internal bremsstrahlung signatures has only recently been made possible by the excellent energy resolution of ground-based and satellite-borne gamma-ray instruments. Here, we investigate thoroughly the current status of internal bremsstrahlung searches in light of the results of direct dark matter searches and in the framework of minimal mass-degenerate scenarios. The constraints set by Fermi-LAT and H.E.S.S. extend uninterrupted from tens of GeV up to tens of TeV and are rather insensitive to the mass degeneracy in the particle physics model. In contrast, direct searches are best in the moderate to low mass splitting regime, where XENON100 limits overshadow Fermi-LAT and H.E.S.S. up to TeV masses if dark matter couples to (light) quarks. We examine carefully the prospects for GAMMA-400, CTA and XENON1T, all planned to come online in the near future, and find that: (a) CTA and XENON1T are fully complementary, with CTA most sensitive to multi-TeV masses and mass splittings around 10%, and XENON1T probing best small mass splittings up to TeV masses; and (b) current constraints from XENON100 already preclude the observation of any spectral feature with GAMMA-400 in spite of its impressive energy resolution, unless dark matter does not couple to light quarks. Finally, we point out that, unlike for direct searches, the possibility of detecting thermal relics in upcoming internal bremsstrahlung searches requires boost factors larger than ∝10.

  18. Polarization of Bremsstrahlung; Polarisation du rayonnement de freinage

    Energy Technology Data Exchange (ETDEWEB)

    Miller, J [Commissariat a l' Energie Atomique, Saclay (France). Centre d' Etudes Nucleaires

    1957-07-01

    The numerical results for the polarization of Bremsstrahlung are presented. The multiple scattering of electrons in the target is taken into account. The angular-and photon energy dependences are seen on the curves for an incident 25 MeV electron energy. (Author) [French] Le taux de polarisation d'un spectre de rayonnement de freinage est calcule pour une cible d'epaisseur finie en tenant compte de la diffusion multiple des electrons dans la cible. Les courbes sont tracees pour les electrons incidents d'energie 25 MeV, pour differentes energies de photons, et a differents angles. (auteur)

  19. Secondary-electron-bremsstrahlung imaging for proton therapy

    Energy Technology Data Exchange (ETDEWEB)

    Yamaguchi, Mitsutaka; Nagao, Yuto [Takasaki Advanced Radiation Research Institute, Quantum Beam Science Research Directorate, National Institutes for Quantum and Radiological Science and Technology, 1233 Watanuki-Machi, Takasaki, Gunma (Japan); Ando, Koki; Yamamoto, Seiichi [Department of Radiological and Medical Laboratory Sciences, Nagoya University Graduate School of Medicine, 1-1-20 Daiko-Minami, Higashi-Ku, Nagoya, Aichi (Japan); Toshito, Toshiyuki [Department of Proton Therapy Physics, Nagoya Proton Therapy Center, Nagoya City West Medical Center, 1-1-1 Hirate-cho, Kita-Ku, Nagoya, Aichi (Japan); Kataoka, Jun [Research Institute for Science and Engineering, Waseda University, 3-4-1 Okubo, Shinjuku, Tokyo (Japan); Kawachi, Naoki [Takasaki Advanced Radiation Research Institute, Quantum Beam Science Research Directorate, National Institutes for Quantum and Radiological Science and Technology, 1233 Watanuki-Machi, Takasaki, Gunma (Japan)

    2016-10-11

    A feasibility study on an imaging technique of a therapeutic proton-beam trajectory using a gamma camera by measuring secondary electron bremsstrahlung (SEB) was performed by means of Monte Carlo simulations and a beam-irradiation experiment. From the simulation and experimental results, it was found that a significant amount of SEB yield exists between the beam-injection surface and the range position along the beam axis and the beam trajectory is clearly imaged by the SEB yield. It is concluded that the SEB imaging is a promising technique for monitoring of therapeutic proton-beam trajectories.

  20. Electron-electron Bremsstrahlung for bound target electrons

    International Nuclear Information System (INIS)

    Haug, E.

    2008-01-01

    For the process of electron-electron (e-e) Bremsstrahlung the momentum and energy distributions of the recoiling electrons are calculated in the laboratory frame. In order to get the differential cross section and the photon spectrum for target electrons which are bound to an atom, these formulae are multiplied by the incoherent scattering function and numerically integrated over the recoil energy. The effect of atomic binding is most pronounced at low energies of the incident electrons and for target atoms of high atomic numbers. The results are compared to those of previous calculations. (authors)

  1. Decay energy of 55Fe from its inner Bremsstrahlung spectrum

    Science.gov (United States)

    Keshava, S. L.; Gopala, K.; Venkataramaiah, P.

    2001-06-01

    Several measurements of decay energy using the inner Bremsstrahlung spectrum (IB) due to radiative electron capture in 55Fe has been made. But the results are not uniform. Hence another attempt has been made at the same. Experimental data was obtained with a 4.445 cm. dia ' 5.08 cm thick NaI (Tl) detector. It was subjected to suitable statistical treatment and various corrections using Liden and Starfelt procedure. The corrected spectrum agrees well with the Glauber and Martin theory for 1s electron capture beyond 100 keV. From the Jauch plot, the decay energy of 232.36 +/-0.64 keV was obtained.

  2. Study of 1s internal bremsstrahlung spectrum from 57Co

    Science.gov (United States)

    Raghavendra, M. K.; Azeez, Syed; Ramaswamy, C. R.; Umesh, T. K.; Gowda, Ramakrishna

    2002-07-01

    The internal bremsstrahlung contribution from the electron capture of 57Co has been measured in coincidence with K-X-ray of the residual atom. The end-point energy (EPE) is extracted from the data using the linearised Jauch plot. The transition energy obtained using the (EPE) is 842.7 keV, which is close to the value given by Audi and Wapstra. The measured intensity and shape factor from 300 to 600 keV are found to be in good agreement with the Glauber and Martin theory.

  3. Study of 1s internal bremsstrahlung spectrum from 57Co

    International Nuclear Information System (INIS)

    Raghavendra, M.K.; Azeez, Syed; Ramaswamy, C.R.; Umesh, T.K.; Gowda, Ramakrishna

    2002-01-01

    The internal bremsstrahlung contribution from the electron capture of 57 Co has been measured in coincidence with K-X-ray of the residual atom. The end-point energy (EPE) is extracted from the data using the linearised Jauch plot. The transition energy obtained using the (EPE) is 842.7 keV, which is close to the value given by Audi and Wapstra. The measured intensity and shape factor from 300 to 600 keV are found to be in good agreement with the Glauber and Martin theory

  4. Suppression of soft nuclear bremsstrahlung in proton-nucleus collisions

    International Nuclear Information System (INIS)

    Goethem, M.J. van; Bacelar, J.C.S.; Hoefman, M.; Huisman, H.; Kalantar-Nayestanaki, N.; Loehner, H.; Messchendorp, J.G.; Ostendorf, R.W.; Schadmand, S.; Siemssen, R.H.; Turrisi, R.; Volkerts, M.; Wilschut, H.W.; Aphecetche, L.; Delagrange, H.; D'Enterria, D.; Martinez, G.; Schutz, Y.; Diaz, J.; Holzmann, R.

    2002-01-01

    Photon energy spectra up to the kinematic limit have been measured in 190 MeV proton reactions with light and heavy nuclei to investigate the influence of the multiple-scattering process on the photon production. Relative to the predictions of models based on a quasifree production mechanism, a strong suppression of bremsstrahlung is observed in the low-energy region of the photon spectrum. We attribute this effect to the interference of photon amplitudes due to multiple scattering of nucleons in the nuclear medium

  5. Study of Diffractive Bremsstrahlung at 13 TeV LHC

    CERN Document Server

    Czekierda, Sabina

    2016-01-01

    Feasibility studies of the diffractive bremsstrahlung measurement at the LHC at $\\sqrt s$ = 13 TeV are presented. The method considered for this measurement uses the ATLAS detector and, in particular, the Zero Degree Calorimeter and the ATLAS Forward Proton detectors. The signal and background processes were generated with GenEx and PYTHIA 8.2 generators, respectively. The obtained fiducial cross sections are 1.2 ub for the signal and 6 ub for the background. Further reduction of the background is possible by the optimisation of event selection cuts.

  6. Application of electron and Bremsstrahlung beams for composite materials processing

    International Nuclear Information System (INIS)

    Zalyubovsky, I.I.; Avilov, A.M.; Popov, G.F.; Rudychev, V.G.

    1998-01-01

    In Kharkiv University the radiation process of obtaining composite polymer materials, CPM, with high strength properties and corrosion resistance was studied. CPM are manufactured by vacuum impregnating capillary-porous materials with synthetic monomers and oligomers or by molding granular waste and resins which are further treated by relativistic electron or Bremsstrahlung beam. Such radiation treatment yields new CPM in which capillary-porous structure acting as reinforcement is filled with polymer. The results of the applied research with industrial electron accelerator in the field of thick CPM formation are presented

  7. Inner bremsstrahlung accompanying β-decay of 170Tm

    International Nuclear Information System (INIS)

    Gundu Rao, K.S.; Venkataramaiah, P.; Gopala, K.; Sanjeeviah, H.

    1981-01-01

    Inner bremsstrahlung accompanying non-unique first-forbidden β-decay of 170 Tm has been measured employing a magnetic deflection technique with a (4.5 x 5.1 cm) NaI(Tl) scintillation spectrometer in the energy region 200 keV to 900 keV. The raw spectrum is unfolded using the Liden and Starfelt procedure, and compared with the theories of KUB, Lewis and Ford, and Ford and Martin. The results are close to the Lewis and Ford theory over the major portion of the measured spectrum. (orig.)

  8. SU-G-201-12: Investigation of Beta-Emitter 90Sr-90Y Dose Distribution Using Gafchromic EBT3 Film for Application On Conformal Skin Brachytherapy Device

    International Nuclear Information System (INIS)

    Ferreira, C; Johnson, D; Ahmad, S; Rasmussen, K; Jung, J

    2016-01-01

    Purpose: To investigate 90 Sr- 90 Y as a high dose rate (HDR) source for application in a conformal skin brachytherapy (CSBT) device. The CSBT device has been previously developed to provide patient specific treatment for small inoperable lesions and irregular surfaces. Methods: A popular beta emitter, 90 Sr- 90 Y was tested for feasibility in a CSBT device. A 1 cm diameter plaque was used to deliver dose to a solid water phantom containing EBT3 Gafchromic films arranged at the surface and perpendicular to it. Additionally, a 1 cm diameter 6 MeV electron beam was used to irradiate EBT3 film at 100 cm SSD with a 0.5 cm bolus. Films were digitized with an Epson Expression 10000 XL scanner and calibrated with a 6 MeV electron specific dose curve. Normalized percent depth doses (PDD) and dose profiles for both techniques were analyzed using ImageJ. Results: Dose distributions achieved with the 90 Sr- 90 Y sources were compared with those of external electron beam radiation therapy (EBRT). Penumbra (20%- 80%) for EBRT and 90Sr-90Y were 4.3 mm and 1.6 mm, respectively. PDD values of 50% (normalized to 2 mm) were 10.1 mm and 2.8 mm for electron and 90 Sr- 90 Y, respectively. Flatness (80% of the central beam profile) was 14.1% at a 5 mm depth for EBRT and 4.0% at surface for the 90 Sr- 90 Y. Conclusion: As expected, the PDDs of 90 Sr- 90 Y in water are shallower than that of external electron beams for the same field size. 90 Sr- 90 Y can be used in CSBT to provide patient specific treatment where shallower depth doses than that provided by electron external beams may be required: e.g. eyelids, nose, lips, ears, etc. The customizability of EBRT could be replicated by using multiple adjacent 90 Sr- 90 Y plaque placements.

  9. Role of diluent on the separation of {sup 90}Y from {sup 90}Sr by solvent extraction and supported liquid membrane using T2EHDGA as the extractant

    Energy Technology Data Exchange (ETDEWEB)

    Dutta, S. [Planning and Coordination Division, Bhabha Atomic Research Centre, Trombay, Mumbai - 400 085 (India); Raut, D.R. [Radiochemistry Division, Bhabha Atomic Research Centre, Trombay, Mumbai - 400 085 (India); Mohapatra, P.K., E-mail: mpatra@barc.gov.in [Radiochemistry Division, Bhabha Atomic Research Centre, Trombay, Mumbai - 400 085 (India)

    2012-04-15

    The separation behaviour of {sup 90}Y from {sup 90}Sr was investigated by diluent variation using solvent extraction and supported liquid membrane techniques employing N,N,N Prime ,N Prime -tetra-2-ethylhexyldiglycolamide (T2EHDGA) as the extractant. Both D{sub Y} (distribution ratio of Y(III)) and S.F. (separation factor) were found to be high in the solvent extraction studies when chloroform was used as the diluent. Subsequent supported liquid membrane (SLM) studies using PTFE flat sheet membranes containing 0.2 M T2EHDGA in various diluents indicated the trend of Y transport as xylene>hexone>chloroform>carbon tetrachloride>n-dodecane+30% iso-decanol mixture. However, the Sr(II) transport rates were also high with xylene, hexone, and carbon tetrachloride as the diluents which led us to carry out subsequent studies using chloroform and n-dodecane+30% iso-decanol mixture. Acid variation studies in chloroform system indicated an interesting phenomena of increasing Y(III) transport and decreasing Sr(II) transport with increasing acid concentration. Separation of {sup 90}Y from a mixture of {sup 90}Sr and {sup 90}Y was also attempted. - Highlights: Black-Right-Pointing-Pointer SLM studies using PTFE flat sheet membranes containing T2EHDGA as carrier was carried out for Y-90 separation from Sr-90. Black-Right-Pointing-Pointer The trend of Y transport as xylene>hexone>chloroform>carbon tetrachloride>n-dodecane+30% iso-decanol mixture. Black-Right-Pointing-Pointer Acid variation studies in chloroform system indicated an interesting phenomena of increasing Y(III) transport and decreasing Sr(II) transport with increasing acid concentration. Black-Right-Pointing-Pointer The present studies suggested that T2EHDGA-SLM show limited promise if coupled to another separation method such as extraction chromatography.

  10. Intraoperative avidination for radionuclide treatment as a radiotherapy boost in breast cancer: results of a phase II study with 90Y-labeled biotin

    International Nuclear Information System (INIS)

    Paganelli, Giovanni; De Cicco, Concetta; Carbone, Giuseppe; Pacifici, Monica; Ferrari, Mahila E.; Cremonesi, Marta; Di Dia, Amalia; Pagani, Gianmatteo; Galimberti, Viviana; Luini, Alberto; Leonardi, Maria Cristina; Ferrari, Annamaria; Orecchia, Roberto; De Santis, Rita; Zurrida, Stefano; Veronesi, Umberto

    2010-01-01

    External beam radiotherapy (EBRT) after conservative surgery for early breast cancer requires 5-7 weeks. For elderly patients and those distant from an RT center, attending for EBRT may be difficult or impossible. We investigated local toxicity, cosmetic outcomes, and quality of life in a new breast irradiation technique - intraoperative avidination for radionuclide therapy (IART) - in which avidin is administered to the tumor bed and 90 Y-labelled biotin later administered intravenously to bind the avidin and provide irradiation. Reduced duration EBRT (40 Gy) is given subsequently. After surgery, 50 (ten patients), 100 (15 patients) or 150 mg (ten patients) of avidin was injected into the tumor bed. After 12-24 h, 3.7 GBq 90 Y-biotin (beta source for therapeutic effect) plus 185 MBq 111 In-biotin (gamma source for imaging and dosimetry) was infused slowly. Whole-body scintigraphy and SPECT/CT images were taken for up to 30 h. Shortened EBRT started 4 weeks later. Local toxicity was assessed by RTOG scale; quality of life was assessed by EORTC QOL-30. Of 35 patients recruited (mean age 63 years; range 42-74) 32 received IART plus EBRT. 100 mg avidin provided 19.5 ± 4.0 Gy to the tumor bed and was considered the optimum dose. No side-effects of avidin or 90 Y-biotin occurred, with no hematological or local toxicity. Local G3 toxicity occurred in 3/32 patients during EBRT. IART plus EBRT was well accepted, with good cosmetic outcomes and maintained quality of life. IART plus reduced EBRT can accelerate irradiation after conservative breast surgery. (orig.)

  11. Ultrarelativistic electron and positron radiation in planar channeling

    International Nuclear Information System (INIS)

    Kalashnikov, N.P.; Olchack, A.S.

    1980-01-01

    The coherent electromagnetic radiation from channeling electrons and positrons is given by similar expression. However for the channeling positrons the close collisions are suppressed due to the fact that the positron wave function is exponentially small near the atoms of the crystal lattice. It follows that the coherent bremsstrahlung decreases for the channeling positrons. We have investigated the ultrarelativistic channeling electron and positron radiations, connected with the electromagnetic transitions from the continuum spectrum states to the quasi-bound spectrum states and between the different quasi-bound spectrum states. The radiation probabilities are calculated by using the model continuum planar potential. It is shown that the radiation from the channeling electrons is several orders of magnitude larger than the positron radiation, while the electron and positron radiation have similar characteristics such as frequency limitation and angular distribution of the radiation. (orig.)

  12. Pyclen Tri-n-butylphosphonate Ester as Potential Chelator for Targeted Radiotherapy: From Yttrium(III) Complexation to (90)Y Radiolabeling.

    Science.gov (United States)

    Le Fur, Mariane; Beyler, Maryline; Lepareur, Nicolas; Fougère, Olivier; Platas-Iglesias, Carlos; Rousseaux, Olivier; Tripier, Raphaël

    2016-08-15

    The Y(3+) complex of PCTMB, the tri-n-butyl phosphonate ester of pyclen (3,6,9,15-tetraazabicyclo[9.3.1]pentadeca-1(15),11,13-triene), was synthesized as well as its Ho(3+) and Lu(3+) analogues. X-ray diffraction analyses revealed isomorphous dimeric M2(PCTMB)2·9H2O (M = Y, Ho, Lu) structures that crystallize in the centrosymmetric P1̅ triclinic space group. (1)H NMR and UV studies in aqueous solutions indicated that Y(3+) complexation is fast, being quantitative in 167 min at pH 3.8 and in 13 min at pH 5.5 (25 °C, acetate buffer, I = 0.150 M, [Y(3+)] = [PCTMB] = 0.2 mM). (1)H NMR DOSY and photon correlation spectroscopy experiments evidenced the formation of aggregates in chloroform with a bimodal distribution that changes slightly with concentration (11-24 and 240-258 nm). The behavior of the acid-assisted dissociation of the complex of Y(3+) with PCTMB was studied under pseudo-first-order conditions, and the half-life of the [Y(PCTMB)] complex in 0.5 M HCl at 25 °C was found to be 37 min, a value that decreases to 2.6 min in 5 M HCl. The Y(3+) complex of PCTMB is thermodynamically very stable, with a stability constant of log KY-PCTMB = 19.49 and pY = 16.7 measured by potentiometry. (90)Y complexation studies revealed fast radiolabeling kinetics; optimal radiolabeling conditions were obtained for (90)Y in acetate medium, PCTMB at 10(-4) to 10(-2) M in acetate buffer pH = 4.75, 15 min at 45-60 °C. In vitro stability studies in human serum showed that [(90)Y(PCTMB)] is quite stable, with about 90% of the activity still in the form of the radiotracer at 24 h and 80% from 48 h to 72 h. A comparison with other ligands such as PCTA, DOTA, and DTPA already used for in vivo application shows that [(90)Y(PCTMB)] is an interesting lipophilic and neutral analogue of these reference chelates for therapeutic applications in aqueous and nonaqueous media.

  13. The Schiff angular bremsstrahlung distribution from composite media

    International Nuclear Information System (INIS)

    Taylor, M.L.; Dalton, B.; Franich, R.D.

    2012-01-01

    The Schiff differential for the angular distribution of bremsstrahlung is widely employed, but calculations involving composite materials (i.e. compounds and mixtures) are often undertaken in a somewhat ad hoc fashion. In this work, we suggest an alternative approach to power-law estimates of the effective atomic number utilising Seltzer and Berger’s combined approach in order to generate single-valued effective atomic numbers applicable over a large energy range (in the worst case deviation from constancy of about 2% between 10 keV and 1 GeV). Differences with power-law estimates of Z for composites are potentially significant, particularly for low-Z media such as biological or surrogate materials as relevant within the context of medical physics. As an example, soft tissue differs by >70% and cortical bone differs by >85%, while for high-Z composites such as a tungsten–rhenium alloy the difference is of the order of 1%. Use of the normalised Schiff formula for shape only does not exhibit strong Z dependence. Consequently, in such contexts the differences are negligible – the power-law approach overestimates the magnitude by 1.05% in the case of water and underestimates it by <0.1% for the high-Z alloys. The differences in the distribution are most pronounced for small angles and where the bremsstrahlung quanta are low energy.

  14. Bremsstrahlung of fast electrons in long air gaps

    Energy Technology Data Exchange (ETDEWEB)

    Oreshkin, E. V.; Barengolts, S. A. [P. N. Lebedev Physical Institute, RAS, 119991 Moscow (Russian Federation); General Physics Institute, RAS, 119991 Moscow (Russian Federation); Chaikovsky, S. A. [P. N. Lebedev Physical Institute, RAS, 119991 Moscow (Russian Federation); Institute of High Current Electronics, SB RAS, 634055 Tomsk (Russian Federation); Oginov, A. V.; Shpakov, K. V.; Bogachenkov, V. A. [P. N. Lebedev Physical Institute, RAS, 119991 Moscow (Russian Federation)

    2012-01-15

    The results of an experiment on discharges in long atmospheric pressure air gaps at a pulsed voltage of amplitude up to 800 kV and risetime 150-200 ns have been analyzed. In the experiment, a radiation pulse of photon energy >5 keV and duration 10-20 ns was observed. In analyzing the experimental data it was supposed that a streamer is a plasma protrusion whose surface is equipotential to the cathode surface. It has been shown that the x-ray pulse results from the switch of electrons into the mode of ''runaway'' from the head of anode-directed streamers. For the electrons injected in the electrode gap from the streamer head, conditions for their switching into the mode of continuous acceleration are realized due to the enhanced electric field at the head. The predicted maximum of the spectrum of the bremsstrahlung generated by the runaway electron beam is around 15 keV. The presence of a maximum in the bremsstrahlung spectrum is due to that the photons emitted by electrons are absorbed by atoms of the gas in which the discharge operate.

  15. Revisiting Bremsstrahlung emission associated with Light Dark Matter annihilations

    CERN Document Server

    Böhm, C

    2006-01-01

    We compute the single bremsstrahlung emission associated with the pair annihilation of spin-0 particles into electrons and positrons, via the t-channel exchange of a heavy fermion. We compare our result with the work of Beacom et al. . Unlike what is stated in the literature, we show that the Bremsstrahlung cross section is not necessarily given by the tree-level annihilation cross section (for a generalized kinematics) times a factor related to the emission of a soft photon. Such a factorization appears only in the soft photon limit or in the approximation where the masses of the particles in the initial and final states are negligible with respect to the mass of the internal particle. However, in the latter case, we do not recover the same factor as for e^+ e- --> mu^+ mu^- gamma. Numerically the difference, in the hard photon limit, is as large as a factor 3.6. However the effect on the upper limit of the dark matter mass is not significant. Using gamma ray observations, we obtain an upper limit on the dar...

  16. Internal bremsstrahlung spectra from 185W and 32P

    International Nuclear Information System (INIS)

    Babu, R.P.; Murty, K.N.; Murty, V.A.N.

    1976-01-01

    The internal bremsstrahlung spectra from the β decay of 185 W and 32 P were measured using a NaI(Tl) scintillation spectrometer with a standard geometrical arrangement. After making all the necessary corrections the experimental results are compared with the allowed theory of the Knipp, Uhlenbeck, and Bloch (KUB theory) and also with the Coulomb corrected theories of Lewis, Ford, and Nilsson. In the case of 185 W it is found that from 78 to 200 keV the experimental distribution is in good agreement with the KUB theory whereas beyond 200 keV and below 78 keV the experimental points are far above even the highest Coulomb corrected theoretical distribution of Nilsson. The internal bremsstrahlung from this isotope has not been previously investigated. In the case of 32 P the experimental relative intensity spectrum is compared with the KUB theory and also with the Coulomb corrected theory of Lewis and Ford. Fairly good agreement is obtained from 30 to 200 keV with the KUB theory but in the energy region from 200 to 900 keV, the experimental results deviate positively from both the KUB and Lewis and Ford theories. The experimental excess over the Lewis and Ford theory is 15% on the average

  17. Beyond level planarity

    NARCIS (Netherlands)

    Angelini, P.; Da Lozzo, G.; Di Battista, G.; Frati, F.; Patrignani, M.; Rutter, I.; Hu, Y.; Nöllenburg, M.

    2016-01-01

    In this paper we settle the computational complexity of two open problems related to the extension of the notion of level planarity to surfaces different from the plane. Namely, we show that the problems of testing the existence of a level embedding of a level graph on the surface of the rolling

  18. HP Ge planar detectors

    International Nuclear Information System (INIS)

    Gornov, M.G.; Gurov, Yu.B.; Soldatov, A.M.; Osipenko, B.P.; Yurkowski, J.; Podkopaev, O.I.

    1989-01-01

    Parameters of planar detectors manufactured of HP Ge are presented. The possibilities to use multilayer spectrometers on the base of such semiconductor detectors for nuclear physics experiments are discussed. It is shown that the obtained detectors including high square ones have spectrometrical characteristics close to limiting possible values. 9 refs.; 3 figs.; 1 tab

  19. Electron-electron collision effects on the bremsstrahlung emission in Lorentzian plasmas

    International Nuclear Information System (INIS)

    Jung, Young-Dae; Kato, Daiji

    2009-01-01

    Electron-electron collision effects on the electron-ion bremsstrahlung process are investigated in Lorentzian plasmas. The effective electron-ion interaction potential is obtained by including the far-field terms caused by electron-electron collisions with an effective Debye length in Lorentzian plasmas. The bremsstrahlung radiation cross section is obtained as a function of the electron energy, photon energy, collision frequency, spectral index and Debye length using the Born approximation for the initial and final states of the projectile electron. It is shown that the non-Maxwellian character suppresses the bremsstrahlung radiation cross section. It is also shown that the electron-electron collision effect enhances the bremsstrahlung emission spectrum. In addition, the bremsstrahlung radiation cross section decreases with an increase in the plasma temperature.

  20. 90Y and 90Sr separation from hydrochloric acid solutions using TODGA as the extractant by solvent extraction and SLM methods

    International Nuclear Information System (INIS)

    Dutta, S.; Raut, D.R.; Mohapatra, P.K.; Manchanda, V.K.

    2010-01-01

    Yttrium-90 is an important radionuclide known for its therapeutic application in nuclear medicine. It is a pure β-emitter with no associated gamma rays and decays to stable daughter 90 Zr. Suitability of this isotope is because of its short half-life (t 1/2 = 64.2 hrs) and high β emissions (E max = 2.28 MeV. An important source of 90 Y is through the decay of 90 Sr, which produces carrier free isotope. 90 Sr (t 1/2 28 yrs) attains secular equilibrium with 90 Y in a short period and can serve as a long term source for the latter isotope because of relatively long half-life of the parent isotope. Solvent extraction studies with N,N,N',N'-tetra-octyldiglycolamide (TODGA) has shown that Y(III) is well extracted in 6 M HCI while at the same time, extraction of Sr(II) is very low leading to a separation factor (D Y /D Sr = 60,000). This property of TODGA can be exploited for the separation of Y from Sr. In the present work, Supported Liquid Membrane (SLM) based separation of Y and Sr has been explored using TODGA as the carrier

  1. Mechanism and energetics for complexation of 90Y with 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), a model for cancer radioimmunotherapy

    International Nuclear Information System (INIS)

    Jang, Y.H.; Blanco, M.; Dasgupta, S.; Keire, D.A.; Shively, J.E.; Goddard, W.A. III

    1999-01-01

    A promising cancer therapy involves the use of the macrocyclic polyaminoacetate DOTA (1,4,6,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) attached to a tumor-targeting antibody complexed with the β emitter 90 Y 3+ . However, incorporation of the 90 Y into the DOTA conjugate is too slow. To identify the origins of this problem, ab initio quantum chemistry methods (B3LYP/:ACVP* and HF/LACVP*) were used to predict structures and energetics. The authors find that the initial complex YH 2 (DOTA) + is 4-coordinate (the four equivalent carboxylate oxygens), which transforms to YH(DOTA) (5-coordinate with one ring N and four carboxylate oxygens), and finally to Y(DOTA) - , which is 8-coordinate (four oxygens and four nitrogens). The rate-determining step is the conversion of YH(DOTA) to Y(DOTA) - , which was calculated to have an activation free energy (aqueous phase) of 8.4 kcal/mol, in agreement with experimental results (8.1--9.3 kcal/mol) for various metals to DOTA [Kumar, K.; Tweedle, M.F. Inorg. Chem. 1993, 32, 4193--4199; Wu, S.L.; Horrocks, W.D., Jr., Inorg. Chem. 1995, 34, 3724--2732]. On the basis of this mechanism the authors propose a modified chelate, DO3AlPr, which has calculated at a much faster rate of incorporation

  2. How to draw a planarization

    NARCIS (Netherlands)

    Bläsius, T.; Radermacher, M.; Rutter, I.; Steffen, B.; Baier, C.; van den Brand, M.; Eder, J.; Hinchey, M.; Margaria, T.

    2017-01-01

    We study the problem of computing straight-line drawings of non-planar graphs with few crossings. We assume that a crossing-minimization algorithm is applied first, yielding a planarization, i.e., a planar graph with a dummy vertex for each crossing, that fixes the topology of the resulting drawing.

  3. Dosimetry analysis of distributions radials dose profiles of {sup 90}Sr + {sup 90}Y beta therapy applicators using the MCNP-4C code and radio chromium films; Analise dosimetrica de perfis de distribuicoes radias de doses relativas de um aplicador de betaterapia de {sup 90}Sr + {sup 90}Y utilizando o codigo MCNP-4C e filmes radiocromicos

    Energy Technology Data Exchange (ETDEWEB)

    Coelho, Talita S.; Yoriyaz, Helio [Instituto de Pesquisas Energeticas e Nucleares (IPEN/CNEN-SP), Sao Paulo, SP (Brazil); Fernandes, Marco A.R., E-mail: tasallesc@gmail.co [UNESP, Botucatu, SP (Brazil). Faculdade de Medicina. Servico de Radioterapia; Louzada, Mario J.Q. [UNESP, Aracatuba, SP (Brazil). Curso de Medicina Veterinaria

    2011-07-01

    Although they are no longer manufactured, the applicators of {sup 90}Sr + {sup 90}Y acquired in the decades of 1990 are still in use, by having half-life of 28.5 years. These applicators have calibration certificate given by their manufacturers, where few have been re calibrated. Thus it becomes necessary to accomplish thorough dosimetry of these applicators. This paper presents a dosimetric analysis distribution radial dose profiles for emitted by an {sup 90}Sr + {sup 90}Y beta therapy applicator, using the MCNP-4C code to simulate the distribution radial dose profiles and radio chromium films to get them experimentally . The results with the simulated values were compared with the results of experimental measurements, where both curves show similar behavior, which may validate the use of MCNP-4C and radio chromium films for this type of dosimetry. (author)

  4. Dosimetry analysis of distribution radial dose profiles of {sup 90}Sr + {sup 90}Y beta therapy applicators using the MCNP-4C code and radio chromium films; Analise dosimetrica de perfis de distribuicoes radiais de doses relativas de um aplicador de betaterapia de {sup 90}Sr + {sup 90}Y utilizando o codigo MCNP-4C e filmes radiocromicos

    Energy Technology Data Exchange (ETDEWEB)

    Coelho, T.S.; Yoriyaz, H. [Instituto de Pesquisas Energeticas e Nucleares (IPEN/CNEN-SP), Sao Paulo, SP (Brazil); Fernandes, M.A.R. [Universidade Estadual Paulista Julio de Mesquita Filho (UNESP), Botucatu, SP (Brazil). Fac. de Medicina. Servico de Radioterapia; Louzada, M.J.Q. [Universidade Estadual Paulista Julio de Mesquita Filho (UNESP), Aracatuba, SP (Brazil). Curso de Medicina Veterinaria

    2010-07-01

    Although they are no longer manufactured, the applicators of {sup 90}Sr +{sup 90}Y acquired in the decades of 1990 are still in use, by having half-life of 28.5 years. These applicators have calibration certificate given by their manufacturers, where few have been recalibrated. Thus it becomes necessary to accomplish thorough dosimetry of these applicators. This paper presents a dosimetric analysis distribution radial dose profiles for emitted by an {sup 90}Sr+{sup 90}Y beta therapy applicator, using the MCNP-4C code to simulate the distribution radial dose profiles and radiochromium films to get them experimentally . The results with the simulated values were compared with the results of experimental measurements, where both curves show similar behavior, which may validate the use of MCNP-4C and radiochromium films for this type of dosimetry. (author)

  5. Hematological toxicity of Zevalin1-{sup 90}Y used in mono-therapy or in consolidation among 39 patients suffering of B non Hodgkin lymphomas (B-N.H.L.); Toxicite hematologique du Zevalin1-90Y utilise en monotherapie ou en consolidation chez 39 patients atteints de LNH B

    Energy Technology Data Exchange (ETDEWEB)

    Boin, C.; Barre, E.; Gaillard, I.; Faure, P.; Moretti, J.L. [Hopital Saint-Louis, Service de pharmacie/medecine nucleaire, 75 - Paris (France); Sibon, D.; Brice, P.; Thieblemont, C. [Hopital Saint-Louis, Service d' hemato-oncologie, 75 - Paris (France); Bonnot-Lours, S.; Meignan, M. [Hopital Henri-Mondor, service de pharmacie/medecine nucleaire, 94 - Creteil (France)

    2010-07-01

    Purpose: an important heterogeneity of hematological toxicity of Zevalin -{sup 90}Y was observed in patients treated in mono-therapy or consolidation. In a context of ambulatory follow-up, it seems interesting to look for predicting this toxicity according to the clinico biological characteristics of patients. This would allow to select and follow in an optimum way the candidates to this treatment. A bi-centric retrospective study was lead for which objective was to enlighten the factors associated to this toxicity. Conclusions: a comprehensive study of clinico biological history and compliance with warnings of product characteristics summary will allow to select at the best the candidates to radioimmunotherapy by Zevalin-{sup 90}Y. this treatment represents an interesting option in some patients (particularly aged patients), stays efficient and well tolerated. (N.C.)

  6. Report on the 2nd Research Coordination Meeting on The Development of Therapeutic Radiopharmaceuticals Based on 188Re and 90Y for Radionuclide. Working Document

    International Nuclear Information System (INIS)

    2010-01-01

    Radionuclide therapy is practiced for the treatment of malignant disorders of various organs and tissues as well as for treating certain other diseases such as rheumatoid arthritis. Advances in understanding tumor biology as well as developments in peptide chemistry and monoclonal antibody technology are opening new opportunities for the development of therapeutic radiopharmaceuticals, thereby widening the scope of radionuclide therapy. In addition, particulate based radiopharmaceuticals are useful for treating hepatocarcinoma as well as in radiation synovectomy. With the establishment of new products the demand and application of therapeutic nuclear medicine is expected to grow rapidly. While there are a large number of radioisotopes proposed for targeted therapy, practical considerations had been limiting the number of usable isotopes. Generator-produced radionuclides are an attractive option for the large scale on-site availability of therapeutic isotopes. The IAEA’s CRP on the ‘Development of generator technologies for therapeutic radionuclides’ (2004-2007) was successful in developing technologies for the preparation of 188 W/ 188 Re and 90 Sr/ 90 Y generators for eluting 188 Re and 90 Y of high radionuclidic and chemical purity usable for research applications in the development of therapeutic radiopharmaceuticals. The IAEA’s CRP on ‘The development of therapeutic radiopharmaceuticals based on 188 Re and 90 Y for radionuclide therapy’ was formulated to focus on enhancing the capacity of the 90 Sr/ 90 Y generator; to develop and validate quality control methods for the generator eluate; and to develop therapeutic radiopharmaceuticals based on 188 Re and 90 Y. The first RCM of the CRP was held in Polatom, Warsaw, Poland from 30 June to 4 July 2008. The meeting reviewed the work going on in the different participating laboratories, and the facilities, expertise and capabilities of the different participating groups, and formulated the work plan of

  7. Report on the 2{sup nd} Research Coordination Meeting on The Development of Therapeutic Radiopharmaceuticals Based on {sup 188}Re and {sup 90}Y for Radionuclide. Working Document

    Energy Technology Data Exchange (ETDEWEB)

    NONE

    2010-07-01

    Radionuclide therapy is practiced for the treatment of malignant disorders of various organs and tissues as well as for treating certain other diseases such as rheumatoid arthritis. Advances in understanding tumor biology as well as developments in peptide chemistry and monoclonal antibody technology are opening new opportunities for the development of therapeutic radiopharmaceuticals, thereby widening the scope of radionuclide therapy. In addition, particulate based radiopharmaceuticals are useful for treating hepatocarcinoma as well as in radiation synovectomy. With the establishment of new products the demand and application of therapeutic nuclear medicine is expected to grow rapidly. While there are a large number of radioisotopes proposed for targeted therapy, practical considerations had been limiting the number of usable isotopes. Generator-produced radionuclides are an attractive option for the large scale on-site availability of therapeutic isotopes. The IAEA’s CRP on the ‘Development of generator technologies for therapeutic radionuclides’ (2004-2007) was successful in developing technologies for the preparation of {sup 188}W/{sup 188}Re and {sup 90}Sr/{sup 90}Y generators for eluting {sup 188}Re and {sup 90}Y of high radionuclidic and chemical purity usable for research applications in the development of therapeutic radiopharmaceuticals. The IAEA’s CRP on ‘The development of therapeutic radiopharmaceuticals based on {sup 188}Re and {sup 90}Y for radionuclide therapy’ was formulated to focus on enhancing the capacity of the {sup 90}Sr/{sup 90}Y generator; to develop and validate quality control methods for the generator eluate; and to develop therapeutic radiopharmaceuticals based on {sup 188}Re and {sup 90}Y. The first RCM of the CRP was held in Polatom, Warsaw, Poland from 30 June to 4 July 2008. The meeting reviewed the work going on in the different participating laboratories, and the facilities, expertise and capabilities of the different

  8. Determination of the photoeffect cross section and the K- absorption edge energy of Dy, Ta, Pt and Au atoms using Bremsstrahlung

    International Nuclear Information System (INIS)

    Garcia-Alvarez, J. A.; Lopez-Pino, N.; Diaz Rizo, O.; Corrales, Y.; Padilla-Cabal, F.; Perez-Liva, M.; D' Alessandro, K.; Maidana, N. L.

    2011-01-01

    An experiment to determine the K-shell photoelectric cross-section (CS) of Dy, Ta, Pt and Au atoms was implemented at the Nuclear Analytical Laboratory (LAN) of the InSTEC. Bremsstrahlung photons, produced by 90 Sr- 90 Y beta particles hitting a thin Ni converter, were used to irradiate the foils target of the elements under study. A HPGe detector, coupled to standard nuclear instrumentation, collected the incident and transmitted spectra. A sharp decrease in intensity at the K-shell binding energy was observed in the transmitted spectra. The photon beam divergence effects were corrected with a calibration curve calculated by means of Monte Carlo simulations (MCNPX 2.6). In order to establish accurately the CS at the K-edge energy, the obtained data was processed by two methods: fitting the total CS to a sigmoidal function, as well as the CS branches around the K edge to the empirical law σ=(A/E) n . The results were compared with experimental and theoretical values showing the best agreement when the thinner foils were used. (Author)

  9. Study of nuclear bremsstrahlung in the model independent approach

    International Nuclear Information System (INIS)

    Liu, C.K.

    1980-01-01

    The bremsstrahlung cross section for the scattering of protons by 12 C near the 1.7-MeV resonance has been measured by the Bologna group and the Brooklyn group. In this study, we have included in our calculations the correction terms in the Feshbach-Yennie approximation and have extracted the time delay in the P- 12 C reaction from the data of the Brooklyn group. The + p process near the (1236) has been systematically studied by an experimental group at UCLA. Recently, Liou and Nutt reported a calculation using the soft-photon approximation and their results agree very well with experiment for coplanar events. We have extended their calculation to noncoplanar cases and have found that the soft-photon approximation of Liou and Nutt can describe the experimental data very well not only for coplanar cases but also for noncoplanar cases for most photon angles. In addition, we have also used the Feshbach-Yennie approximation to calculate the + p cross sections. This approximation always predicts a bump in the bremsstrahlung spectrum, although the bump may be small for some photon angles. In most cases, the predicted cross sections are in good agreement with the UCLA data. However, the data for some angles can only be described by the Feshbach-Yennie approximation, and the peak cross section is too large at some angles. We have applied the soft-photon approximation of Liou and Nutt to calculate the proton-proton bremsstrahlung (pp) cross section and have compared our results with the experimental data at 730, 157, 48 and 42 MeV. We have found that we can use the soft-photon approximation to calculate the R-type cross section without any difficulty, but we cannot use the same approximation to predict the H-type cross section without some ambiguity. We have also applied the Feshbach-Yennie approximation to the pp process at 730-MeV taking into account the principal and correction terms

  10. Planar metasurface retroreflector

    Science.gov (United States)

    Arbabi, Amir; Arbabi, Ehsan; Horie, Yu; Kamali, Seyedeh Mahsa; Faraon, Andrei

    2017-07-01

    Metasurfaces are two-dimensional arrangements of subwavelength scatterers that control the propagation of optical waves. Here, we show that cascaded metasurfaces, each performing a predefined mathematical transformation, provide a new optical design framework that enables new functionalities not yet demonstrated with single metasurfaces. Specifically, we demonstrate that retroreflection can be achieved with two vertically stacked planar metasurfaces, the first performing a spatial Fourier transform and its inverse, and the second imparting a spatially varying momentum to the Fourier transform of the incident light. Using this concept, we fabricate and test a planar monolithic near-infrared retroreflector composed of two layers of silicon nanoposts, which reflects light along its incident direction with a normal incidence efficiency of 78% and a large half-power field of view of 60°. The metasurface retroreflector demonstrates the potential of cascaded metasurfaces for implementing novel high-performance components, and enables low-power and low-weight passive optical transmitters.

  11. Routed planar networks

    Directory of Open Access Journals (Sweden)

    David J. Aldous

    2016-04-01

    Full Text Available Modeling a road network as a planar graph seems very natural. However, in studying continuum limits of such networks it is useful to take {\\em routes} rather than {\\em edges} as primitives. This article is intended to introduce the relevant (discrete setting notion of {\\em routed network} to graph theorists. We give a naive classification of all 71 topologically different such networks on 4 leaves, and pose a variety of challenging research questions.

  12. Bremsstrahlung and pair production in crystals at very high energies

    International Nuclear Information System (INIS)

    Nikishov, A.I.

    1981-01-01

    The probabilities for bremsstrahlung and pair production in crystals are discussed under stringent condition when the trajectory of the high-energy electron crosses very many atoms of a crystal row (or plane). It is shown that for sufficiently long path in such conditions the probabilities are described by the formulas for these processes in a strong constant magnetic field exerting on electron the same deflection as the atom row. It turns out that for lead at energy approximately 10 12 eV the radiation length is shortened many hundred times. For greater energies the decrease of probabilities per unit length with increase of energy goes as W varies as Esup(-1/3)

  13. The LPM effect in sequential bremsstrahlung: dimensional regularization

    Energy Technology Data Exchange (ETDEWEB)

    Arnold, Peter; Chang, Han-Chih [Department of Physics, University of Virginia,382 McCormick Road, Charlottesville, VA 22894-4714 (United States); Iqbal, Shahin [National Centre for Physics,Quaid-i-Azam University Campus, Islamabad, 45320 (Pakistan)

    2016-10-19

    The splitting processes of bremsstrahlung and pair production in a medium are coherent over large distances in the very high energy limit, which leads to a suppression known as the Landau-Pomeranchuk-Migdal (LPM) effect. Of recent interest is the case when the coherence lengths of two consecutive splitting processes overlap (which is important for understanding corrections to standard treatments of the LPM effect in QCD). In previous papers, we have developed methods for computing such corrections without making soft-gluon approximations. However, our methods require consistent treatment of canceling ultraviolet (UV) divergences associated with coincident emission times, even for processes with tree-level amplitudes. In this paper, we show how to use dimensional regularization to properly handle the UV contributions. We also present a simple diagnostic test that any consistent UV regularization method for this problem needs to pass.

  14. The double copy: Bremsstrahlung and accelerating black holes

    CERN Document Server

    Luna, Andres; Nicholson, Isobel; O'Connell, Donal; White, Chris D

    2016-01-01

    Advances in our understanding of perturbation theory suggest the existence of a correspondence between classical general relativity and Yang-Mills theory. A concrete example of this correspondence, which is known as the double copy, was recently introduced for the case of stationary Kerr-Schild spacetimes. Building on this foundation, we examine the simple time-dependent case of an accelerating, radiating point source. The gravitational solution, which generalises the Schwarzschild solution, includes a non-trivial stress-energy tensor. This stress-energy tensor corresponds to a gauge theoretic current in the double copy. We interpret both of these sources as representing the radiative part of the field. Furthermore, in the simple example of Bremsstrahlung, we determine a scattering amplitude describing the radiation, maintaining the double copy throughout. Our results provide the strongest evidence yet that the classical double copy is directly related to the BCJ double copy for scattering amplitudes.

  15. Channeling and coherent bremsstrahlung effects for relativistic positrons and electrons

    International Nuclear Information System (INIS)

    Walker, R.L.

    1976-01-01

    Channeling of positrons in single crystals of silicon was observed in transmission and scattering measurements for incident energies from 16 to 28 MeV. In addition, the spectral dependence upon crystal orientation of the forward coherent bremsstrahlung produced by beams of 28-MeV positrons and electrons incident upon a 5 μm thick single crystal of silicon was measured with a NaI photon spectrometer. Effects of channeling and perhaps of the nonvalidity of the first Born approximation were observed for beam directions near the [111] axis of the crystal, and coherent peaks near 0.5 MeV were observed for a compound interference direction, in agreement with first-order theoretical calculations. 32 fig

  16. Decay energy of 55Fe from its inner Bremsstrahlung spectrum

    International Nuclear Information System (INIS)

    Keshava, S.L.; Gopala, K.; Venkataramaiah, P.

    2001-01-01

    Several measurements of decay energy using the inner Bremsstrahlung spectrum (IB) due to radiative electron capture in 55 Fe has been made. But the results are not uniform. Hence another attempt has been made at the same. Experimental data was obtained with a 4.445 cm dia x 5.08 cm thick NaI (Tl) detector. It was subjected to suitable statistical treatment and various corrections using Liden and Starfelt procedure. The corrected spectrum agrees well with the Glauber and Martin theory for l s electron capture beyond 100 keV. From the Jauch plot, the decay energy of 232.36±0.64 keV was obtained. (author)

  17. Nonlinear Breit–Wheeler pair creation with bremsstrahlung γ rays

    Science.gov (United States)

    Blackburn, T. G.; Marklund, M.

    2018-05-01

    Electron–positron pairs are produced through the Breit–Wheeler process when energetic photons traverse electromagnetic fields of sufficient strength. Here we consider a possible experimental geometry for observation of pair creation in the highly nonlinear regime, in which bremsstrahlung of an ultrarelativistic electron beam in a high-Z target is used to produce γ rays that collide with a counter-propagating laser pulse. We show how the target thickness may be chosen to optimize the yield of Breit–Wheeler positrons, and verify our analytical predictions with simulations of the cascade in the material and in the laser pulse. The electron beam energy and laser intensity required are well within the capability of today’s high-intensity laser facilities.

  18. 200-MeV bremsstrahlung tagged photon beams at Sendai

    International Nuclear Information System (INIS)

    Hirose, K.; Chiba, M.; Inoue, M.; Kanda, H.; Kimura, R.; Kino, K.; Kobayashi, Y.; Konno, O.; Maeda, K.; Miyase, H.; Miyamoto, A.; Ohtsuki, T.; Saito, A.; Suda, T.; Takahashi, K.; Tamae, T.; Terasaki, Y.; Terasawa, T.; Tsubota, H.; Tsuruta, T.; Utoyama, M.; Yuuki, H.; Yamaguchi, Y.; Yamazaki, H.

    2006-01-01

    A new beam line for photonuclear reaction experiments using tagged photons has been constructed to take advantage of the completion of the 1.2-GeV STretcher Booster (STB) ring at the Laboratory of Nuclear Science (LNS), Tohoku University. A photon tagging system was installed at the end of the new beam line. It provides bremsstrahlung tagged photon beams in an energy range from 0.2E 0 to 0.8E 0 MeV at the incident electron energy E 0 with an energy resolution of ΔE/E∼10 -2 . The tagged photon intensity I= 6 photons/s is available for typical photonuclear reaction experiments. We introduce the basic parameters of the tagged photons by showing the commissioning data

  19. Laser radiography forming bremsstrahlung radiation to image an object

    Science.gov (United States)

    Perry, Michael D.; Sefcik, Joseph A.

    2004-01-13

    A method of imaging an object by generating laser pulses with a short-pulse, high-power laser. When the laser pulse strikes a conductive target, bremsstrahlung radiation is generated such that hard ballistic high-energy electrons are formed to penetrate an object. A detector on the opposite side of the object detects these electrons. Since laser pulses are used to form the hard x-rays, multiple pulses can be used to image an object in motion, such as an exploding or compressing object, by using time gated detectors. Furthermore, the laser pulses can be directed down different tubes using mirrors and filters so that each laser pulse will image a different portion of the object.

  20. A high resolution beam profile monitor using Bremsstrahlung

    International Nuclear Information System (INIS)

    Norem, J.

    1988-01-01

    The development of efficient high energy linear colliders in the 1 TeV range requires final focus systems capable of producing beam spot sizes on the order of 1--20 nm, about three orders of magnitude smaller than those produced at the SLC. Although beam line designs exist which can, in principle, produce the required optics, the construction of quadrupoles with the size and precision required will be challenging. Field errors in these quads must be small and should be verified experimentally, which is difficult with existing technology. This paper describes a proposal to use bremsstrahlung from heavy targets to measure high energy beam profiles and positions with a resolution approaching a few nm. The method is also applicable to tests of other final focus systems (flat beams, plasma lenses) at lower energies. 6 refs., 3 figs., 1 tab

  1. Neutrino-antineutrino pair production by hadronic bremsstrahlung

    Science.gov (United States)

    Bacca, Sonia

    2016-09-01

    I will report on recent calculations of neutrino-antineutrino pair production from bremsstrahlung processes in hadronic collisions and consider temperature conditions relevant for core collapse supernovae. Earlier studies on bremsstrahlung from neutron-neutron collisions showed that the approximation used in typical supernova simulation to model this process differs by about a factor of 2 from predictions based on chiral effective field theory, where the chiral expansion of two-body forces is considered up to the next-to-next-to-next-to-leading order. When the density of neutrons is large enough this process may compete with other non-hadronic reactions in the production of neutrinos, in particular in the case of μ and τ neutrinos, which are not generated by charged-current reactions. A natural question to ask is then: what is the effect of neutrino pair production from collisions of neutrons with finite nuclei? To tackle this question, we recently have addressed the case of neutron- α collisions, given that in the P-wave channels the neutron- α scattering features a resonance near 1 MeV. We find that the resonance leads to an enhanced contribution in the neutron spin structure function at temperatures in the range of 0 . 1 - 4 MeV. For significant density fractions of α in this temperature range, this process is competitive with contributions from neutron-neutron scattering. TRIUMF receives federal funding via a contribution agreement with the National Research Council of Canada. This work was supported in parts by the Natural Sciences and Engineering Research Council (Grant Number SAPIN-2015-0003).

  2. Effects of a neutral current on the neutrino bremsstrahlung

    International Nuclear Information System (INIS)

    Ju, I.

    1977-01-01

    The energy-loss rate due to the neutrino bremsstrahlung from relativistic electrons in a dense matter such as a star is calculated in the framework of Weinberg's unified theory of weak and electromagnetic interactions by using the method of neutrino-energy expansion. The momentum-transfer integration, though complicated, can be carried out analytically, but the subsequent two electron integrals, called the distribution integrals, are helpless and do not allow any further analytic calculation. In order to avoid this difficulty, we set up a set of variables whose integration is simple enough to be expanded in series. It turns out that this series becomes a power series in the Fermi energy inverse after the distribution integrals. This enables us to keep only the leading terms, greatly simplifying the final result. Thus in principle we will be able to calculate arbitrary higher-order terms, even though most of them require prohibitively tedious labor. We carry out the next-higher-order calculations to find that the correction to the lowest-order contribution is within 5%. This confirms the earlier calculations of Festa and Ruderman, even though the two approaches are quite different: the neutrino-bremsstrahlung energy-loss rate is proportional to T 6 and independent of the density at extremely relativistic degenerate regions. We find that the asymptotic expression for the energy-loss rate is of the form A (β) + (rho/μ/sub e/) -1 / 3 kTB (β). The most striking effect of the neutral current is the muon-neutrino emission. The ratio of the energy-loss rate in Weinberg's theory to that in the conventional theory is 1/2 + 4 sin 4 theta/sub W/ at the extreme relativistic-degenerate and nondegenerate-nonrelativistic regions

  3. Measurements of Bremsstrahlung radiation and X-ray heat load to cryostat on SECRAL

    International Nuclear Information System (INIS)

    Zhao, H.Y.; Cao, Y.; Lu, W.; Zhang, W.H.; Zhao, H.W.; Zhang, X.Z.; Zhu, Y.H.; Li, X.X.; Xie, D.Z.

    2012-01-01

    The measurement of Bremsstrahlung radiation from ECR (Electron Cyclotron Resonance) plasma can yield certain information about the ECR heating process and the plasma confinement, and more important it can give a plausible estimate of the X-ray heat load to the cryostat of a superconducting ECR source. To better understand the additional heat load to the cryostat due to Bremsstrahlung radiation, the axial Bremsstrahlung measurements have been conducted on SECRAL (Superconducting Electron Cyclotron Resonance ion source with Advanced design in Lanzhou) with different source parameters. In addition, the heat load induced by intense X-ray or even γ-ray was estimated in terms of liquid helium consumption. The relationship between these two parameters is presented here. Thick-target Bremsstrahlung, induced by the collision of hot electrons with the wall or the source electrode, is much more intensive compared with the radiation produced in the plasma and, consequently, much more difficult to shield off. In this paper the presence of the thick-target Bremsstrahlung is correlated with the magnetic confinement configuration, specifically, the ratio of B(last) to B(ext). And possible solutions to reduce the X-ray heat load induced by Bremsstrahlung radiation are proposed and discussed. It appears that by choosing an appropriate ratio of B(last) to B(ext) the thick-target Bremsstrahlung radiation can be avoided effectively. The paper is followed by the associated poster

  4. Country report: Italy (Chinol). Pre-clinical evaluation of a new biotin-DOTA conjugate labeled with 90Y for application in pretargeting clinical protocols

    International Nuclear Information System (INIS)

    Chinol, Marco

    2010-01-01

    In the attempt to improve the therapeutic efficacy of radiolabeled mAbs in cancer radioimmunotherapy, various studies have examined the concept of tumor pretargeting. The so called three-step pretargeting technique, employing the avidin–biotin system, was applied in phase I-II clinical trials showing low toxicity and therapeutic efficacy. The final step of the pretargeting protocols consists in the systemic injection of radiolabeled biotin. The worldwide recognized “successful association” is between 90 Y and the tetraazamacrocycle DOTA chelator chemically bound to biotin. Improvements in the structure of the biotin-DOTA conjugate have been reported by our group following a novel approach which simplified the synthetic pattern by reducing the amide group to a methylene group, thus transforming the amide into a secondary amine without affecting the length of the biotin side arm. Preliminary in-vitro experiments, previously published by our group, indicated the potential of the new conjugate. Based on our previous experience with avidin-based pre-targeting followed 90 Y-DOTA-biotin in the locoregional treatment of peritoneal carcinomatosis and malignant glioma suggested that similar radionuclide therapy might be worth investigating as a partial replacement of external beam radiotherapy in breast cancer. We have developed IART® the Intra-operative Avidination for Radionuclide Therapy that relies on the avidin-biotin binding system. In fact, the “avidination” of the anatomical area of the tumor with native avidin, directly injected by the surgeon into and around the tumor bed, provides a target for the radiolabeled biotin intravenously (iv) injected one day later. In order to optimize the overall strategy, further efforts were needed to optimize the use of the labeled new biotin conjugate and to elucidate its chemical and biological properties. In the first 18 months of this CRP, the pre-clinical evaluation of this new reduced biotinamidohexylamine

  5. Country report: Italy (Chinol). Pre-clinical evaluation of a new biotin-DOTA conjugate labeled with {sup 90}Y for application in pretargeting clinical protocols

    Energy Technology Data Exchange (ETDEWEB)

    Chinol, Marco

    2010-07-01

    In the attempt to improve the therapeutic efficacy of radiolabeled mAbs in cancer radioimmunotherapy, various studies have examined the concept of tumor pretargeting. The so called three-step pretargeting technique, employing the avidin–biotin system, was applied in phase I-II clinical trials showing low toxicity and therapeutic efficacy. The final step of the pretargeting protocols consists in the systemic injection of radiolabeled biotin. The worldwide recognized “successful association” is between {sup 90}Y and the tetraazamacrocycle DOTA chelator chemically bound to biotin. Improvements in the structure of the biotin-DOTA conjugate have been reported by our group following a novel approach which simplified the synthetic pattern by reducing the amide group to a methylene group, thus transforming the amide into a secondary amine without affecting the length of the biotin side arm. Preliminary in-vitro experiments, previously published by our group, indicated the potential of the new conjugate. Based on our previous experience with avidin-based pre-targeting followed {sup 90}Y-DOTA-biotin in the locoregional treatment of peritoneal carcinomatosis and malignant glioma suggested that similar radionuclide therapy might be worth investigating as a partial replacement of external beam radiotherapy in breast cancer. We have developed IART® the Intra-operative Avidination for Radionuclide Therapy that relies on the avidin-biotin binding system. In fact, the “avidination” of the anatomical area of the tumor with native avidin, directly injected by the surgeon into and around the tumor bed, provides a target for the radiolabeled biotin intravenously (iv) injected one day later. In order to optimize the overall strategy, further efforts were needed to optimize the use of the labeled new biotin conjugate and to elucidate its chemical and biological properties. In the first 18 months of this CRP, the pre-clinical evaluation of this new reduced biotinamidohexylamine

  6. The role of phantom and treatment head generated bremsstrahlung in high-energy electron beam dosimetry

    International Nuclear Information System (INIS)

    Sorcini, B.B.; Hyoedynmaa, S.; Brahme, A.

    1996-01-01

    An analytical expression has been derived for the phantom generated bremsstrahlung photons in plane-parallel monoenergetic electron beams normally incident on material of any atomic number (Be, H 2 O, Al, Cu and U). The expression is suitable for the energy range from 1 to 50 MeV and it is solely based on known scattering power and radiative and collision stopping power data for the material at the incident electron energy. The depth dose distribution due to the bremsstrahlung generated by the electrons in the phantom is derived by convolving the bremsstrahlung energy fluence produced in the phantom with a simple analytical energy deposition kernel. The kernel accounts for both electrons and photons set in motion by the bremsstrahlung photons. The energy loss by the primary electrons, the build-up of the electron fluence and the generation, attenuation and absorption of bremsstrahlung photons are all taken into account in the analytical formula. The longitudinal energy deposition kernel is derived analytically and it is consistent with both the classical biexponential relation describing the photon depth dose distribution and the exponential attenuation of the primary photons. For comparison Monte Carlo calculated energy deposition distributions using ITS3 code were used. Good agreement was found between the results with the analytical expression and the Monte Carlo calculation. For tissue equivalent materials, the maximum total energy deposition differs by less than 0.2% from Monte Carlo calculated dose distributions. The result can be used to estimate the depth dependence of phantom generated bremsstrahlung in different materials in therapeutic electron beams and the bremsstrahlung production in different electron absorbers such as scattering foils, transmission monitors and photon and electron collimators. By subtracting the phantom generated bremsstrahlung from the total bremsstrahlung background the photon contamination generated in the treatment head can be

  7. Ab initio simulation of stimulated bremsstrahlung in an intense laser field

    International Nuclear Information System (INIS)

    Volkova, E.A.; Popov, A.M.; Popovicheva, O.B.

    1992-01-01

    Numerical solution of the time-dependent Schroedinger equation for a quantum system in the field of an electromagnetic wave is used to study a one-dimensional model of stimulated bremsstrahlung (absorption or emission of photons by a field in connection with Coulomb scattering of an electron). The time dependence of the stimulated bremsstrahlung effect is analyzed for various laser radiation intensities. The process of stimulated photorecombination is examined. The results of the calculation are compared with the analytical theory of the stimulated bremsstrahlung effect. 14 refs., 6 figs

  8. Study on the Preparation and Quality Control of 131I-Rituximab and 90Y-Rituximab for Non-Hodgkin-Lymphoma Therapy

    International Nuclear Information System (INIS)

    NguyenThi Thu; Duong Van Dong; Vo Thi Cam Hoa; Chu Van Khoa; Bui Van Cuong; Pham Ngoc Dien; Mai Phuoc Tho; Nguyen Thanh Binh; Dang Ho Hong Quang; Phan Quoc Thong; Mai Trong Khoa

    2009-01-01

    ratios of 1, 3, 5, 10, 20 at concentration of 5mg/ml and 10mg/ml Rituximab was around 85,0 - 53,5% and 82,2 - 44,2%, respectively. A 70% coupling efficiency at a 3:1 molar ratio results in an average of 2 groups per molecular. The conjugation mixture was diluted to about 0.2 ml with the bicarbonate buffer and loaded onto a PD-10 column (Sephadex G-25, Pharmacia, Biotech). After purification, the conjugation DTPA-Rituximab was collected and labeled with Y- 90 in 0.5M acetate buffer, pH 5, at room temperature ( 90 Y obtained from 90 Sr/ 90 Y generator based on Supported Liquid Membrane). The labeling yield was about 99%. The radiochemical purity of 90 Y-DTPA-Rituximab was determined by ITLC and developed in 0.1M acetate at pH6 as mobile phase. Radiochemical purity of 90 Y-DTPA-Rituximab was more than 99%. The radiopharmaceutical has been tested for sterility, apyrogenicity and biodistribution. These are potential products for the uses in diagnosis and therapy of non-Hodgkin-lymphoma. (author)

  9. Large-scale purification of {sup 90}Sr from nuclear waste materials for production of {sup 90}Y, a therapeutic medical radioisotope

    Energy Technology Data Exchange (ETDEWEB)

    Wester, D.W.; Steele, R.T.; Rinehart, D.E.; DesChane, J.R.; Carson, K.J.; Rapko, B.M.; Tenforde, T.S. E-mail: tenforde@ncrp.com

    2003-07-01

    A major limitation on the supply of the short-lived medical isotope {sup 90}Y (t{sub 1/2}=64 h) is the available quantity of highly purified {sup 90}Sr generator material. A radiochemical production campaign was therefore undertaken to purify 1500 Ci of {sup 90}Sr that had been isolated from fission waste materials. A series of alkaline precipitation steps removed all detectable traces of {sup 137}Cs, alpha emitters, and uranium and transuranic elements. Technical obstacles such as the buildup of gas pressure generated upon mixing large quantities of acid with solid {sup 90}Sr carbonate were overcome through safety features incorporated into the custom-built equipment used for {sup 90}Sr purification. Methods are described for analyzing the chemical and radiochemical purity of the final product and for accurately determining by gravimetry the quantities of {sup 90}Sr immobilized on stainless steel filters for future use.

  10. Spin-flip isovector giant resonances from the 90Zr (n,p) 90Y reaction at 200 MeV

    International Nuclear Information System (INIS)

    Raywood, K.J.; Spicer, B.M.

    1989-01-01

    Doubly differential cross sections of the reaction 90 Zr(n,p) 90 Y have been measured at 200 MeV for excitations up to 38 MeV in the residual nucleus. An overall resolution of 1.3 MeV was achieved. The spectra show qualitative agreement in shape and magnitude with recent RPA calculations; however all of the calculations underestimate the high excitation region of the spectra. A multipole decomposition of the data has been performed using differential cross sections calculated in the DWIA. An estimate of the Gamow-Teller strength in the reaction is given. The isovector spin-flip dipole giant resonance has been identified and there is also an indication of isovector monopole strength. 39 refs., 16 figs., 1 tab

  11. Local injection of the 90Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: an extended pilot study

    International Nuclear Information System (INIS)

    Schumacher, T.; Mueller-Brand, J.; Hofer, S.; Wasner, M.; Zimmerer, S.; Gratzl, O.; Merlo, A.; Eichhorn, K.; Freitag, P.; Probst, A.; Reubi, J.-C.; Maecke, H.R.

    2002-01-01

    We have previously presented preliminary observations on targeting somatostatin receptor-positive malignant gliomas of all grades by local injection of the radiolabelled peptidic vector 90 Y-DOTATOC. We now report on our more thorough clinical experience with this novel compound, focussing on low-grade and anaplastic gliomas. Small peptidic vectors have the potential to target invisible infiltrative disease within normal surrounding brain tissue, thereby opening a window of opportunity for early intervention. Five progressive gliomas of WHO grades II and III and five extensively debulked low-grade gliomas were treated with varying fractions of 90 Y-DOTATOC. The vectors were locally injected into the resection cavity or into solid tumour. The activity per single injection ranged from 555 to 1,875 MBq, and the cumulative activity from 555 to 7,030 MBq, according to tumour volumes and eloquence of the affected brain area, yielding dose estimates from 76±15 to 312±62 Gy. Response was assessed by the clinical status, by steroid dependence and, every 4-6 months, by magnetic resonance imaging and fluorine-18 fluorodeoxyglucose positron emission tomography. In the five progressive gliomas, lasting responses were obtained for at least 13-45 months without the need for steroids. Radiopeptide brachytherapy had been the only modality applied to counter tumour progression. Interestingly, we observed the slow transformation of a solid, primarily inoperable anaplastic astrocytoma into a resectable multi-cystic lesion 2 years after radiopeptide brachytherapy. Based on these observations, we also assessed the feasibility of local radiotherapy following extensive debulking, which was well tolerated. Targeted beta-particle irradiation based on diffusible small peptidic vectors appears to be a promising modality for the treatment of malignant gliomas. (orig.)

  12. Radioimmunotherapy for non-Hodgkin's lymphoma; positioning, safety, and efficacy of 90Y-Ibritumomab. 10 years of experience and follow-up.

    Science.gov (United States)

    Martínez, A; Martínez-Ramirez, M; Martínez-Caballero, D; Beneit, P; Clavel, J; Figueroa, G; Verdú, J

    Radioimmunotherapy (RIT) is one of the therapies directed against molecular targets in non-Hodgkin's lymphoma (NHL). To evaluate the positioning, safety, and effectiveness of RIT with 90Y-Ibritumomab in NHL patients. A retrospective study was conducted on patients with NHL who received RIT with 90Y-Ibritumomab. An evaluation was made of the concordance with clinical guidelines, toxicity as rated by the Common Terminology Criteria for Adverse Events (CTCAE), and effectiveness was assessed based on response to treatment, overall survival (OS), and progression-free survival (PFS). RIT was requested in 26 patients, of whom 21 (11 women, mean age 56±10 years) were included in the study, with the following distribution: Follicular NHL, 67%, Mantle NHL, 14%, Diffuse large B-cell NHL, 9.5%, and Transformed NHL 9.5%. Twelve patients with refractory NHL, 7 for consolidation response, and 2 transplant conditioning, were treated. Adverse effects were observed in 71% of patients, which were usually manageable and transient, and with the most common being thrombocytopenia. At 3-4 months, overall response rate was 76.2% (71.4% complete and 4.8% partial response), and 19% had progression of disease. With a median follow up of 70 months, the OS was 96±8 months, and the PFS was 54±11 months. RIT showed a moderate correlation with clinical guidelines, and is probably underused. Adverse effects were common, mild, and manageable. The data show a high complete response rate and an increase in the OS and PFS. Copyright © 2016 Elsevier España, S.L.U. y SEMNIM. All rights reserved.

  13. Planar Dirac diffusion

    International Nuclear Information System (INIS)

    Leo, Stefano de; Rotelli, Pietro

    2009-01-01

    We present the results of the planar diffusion of a Dirac particle by step and barrier potentials, when the incoming wave impinges at an arbitrary angle with the potential. Except for right-angle incidence this process is characterized by the appearance of spin flip terms. For the step potential, spin flip occurs for both transmitted and reflected waves. However, we find no spin flip in the transmitted barrier result. This is surprising because the barrier result may be derived directly from a two-step calculation. We demonstrate that the spin flip cancellation indeed occurs for each ''particle'' (wave packet) contribution. (orig.)

  14. Simplifying massive planar subdivisions

    DEFF Research Database (Denmark)

    Arge, Lars; Truelsen, Jakob; Yang, Jungwoo

    2014-01-01

    We present the first I/O- and practically-efficient algorithm for simplifying a planar subdivision, such that no point is moved more than a given distance εxy and such that neighbor relations between faces (homotopy) are preserved. Under some practically realistic assumptions, our algorithm uses ....... For example, for the contour map simplification problem it is significantly faster than the previous algorithm, while obtaining approximately the same simplification factor. Read More: http://epubs.siam.org/doi/abs/10.1137/1.9781611973198.3...

  15. Comparisons of angularly and spectrally resolved Bremsstrahlung measurements to two-dimensional multi-stage simulations of short-pulse laser-plasma interactions

    Energy Technology Data Exchange (ETDEWEB)

    Chen, C. D.; Kemp, A. J.; Pérez, F.; Link, A.; Key, M. H.; McLean, H.; Ping, Y.; Patel, P. K. [Lawrence Livermore National Laboratory (United States); Beg, F. N.; Chawla, S.; Sorokovikova, A.; Westover, B. [University of California, San Diego (United States); Morace, A. [University of Milan (Italy); Stephens, R. B. [General Atomics (United States); Streeter, M. [Imperial College London (United Kingdom)

    2013-05-15

    A 2-D multi-stage simulation model incorporating realistic laser conditions and a fully resolved electron distribution handoff has been developed and compared to angularly and spectrally resolved Bremsstrahlung measurements from high-Z planar targets. For near-normal incidence and 0.5-1 × 10{sup 20} W/cm{sup 2} intensity, particle-in-cell (PIC) simulations predict the existence of a high energy electron component consistently directed away from the laser axis, in contrast with previous expectations for oblique irradiation. Measurements of the angular distribution are consistent with a high energy component when directed along the PIC predicted direction, as opposed to between the target normal and laser axis as previously measured.

  16. Precision gamma-ray polarimetry applied to studies of bremsstrahlung produced by polarized electrons

    Energy Technology Data Exchange (ETDEWEB)

    Kovtun, Oleksiy

    2015-12-16

    The thesis reports on the measurement of bremsstrahlung linear polarization produced in collisions of longitudinally and transversely polarized electrons with gold atoms. The experiment was performed at the Mainzer Microtron MAMI in the Institut fuer Kernphysik of Johannes Gutenberg-Universitaet Mainz, Germany. Spin-oriented electrons with 2.15 MeV kinetic energy collided with a thin golden target and produced bremsstrahlung. Linear polarization of the emitted photons was measured by means of Compton polarimetry applied to a segmented high-purity germanium detector. Experimental results reveal a strong correlation between the electron spin orientation and bremsstrahlung linear polarization. This indicates a dominant role of the electron spin in atomic-field bremsstrahlung and Coulomb scattering.

  17. SU-G-201-12: Investigation of Beta-Emitter 90Sr-90Y Dose Distribution Using Gafchromic EBT3 Film for Application On Conformal Skin Brachytherapy Device

    Energy Technology Data Exchange (ETDEWEB)

    Ferreira, C; Johnson, D; Ahmad, S [University of Oklahoma Health Sciences Center, Oklahoma City, OK (United States); Rasmussen, K [University of Texas HSC SA, San Antonio, TX (United States); Jung, J [East Carolina University Greenville, NC (United States)

    2016-06-15

    Purpose: To investigate {sup 90}Sr-{sup 90}Y as a high dose rate (HDR) source for application in a conformal skin brachytherapy (CSBT) device. The CSBT device has been previously developed to provide patient specific treatment for small inoperable lesions and irregular surfaces. Methods: A popular beta emitter, {sup 90}Sr-{sup 90}Y was tested for feasibility in a CSBT device. A 1 cm diameter plaque was used to deliver dose to a solid water phantom containing EBT3 Gafchromic films arranged at the surface and perpendicular to it. Additionally, a 1 cm diameter 6 MeV electron beam was used to irradiate EBT3 film at 100 cm SSD with a 0.5 cm bolus. Films were digitized with an Epson Expression 10000 XL scanner and calibrated with a 6 MeV electron specific dose curve. Normalized percent depth doses (PDD) and dose profiles for both techniques were analyzed using ImageJ. Results: Dose distributions achieved with the {sup 90}Sr-{sup 90}Y sources were compared with those of external electron beam radiation therapy (EBRT). Penumbra (20%- 80%) for EBRT and 90Sr-90Y were 4.3 mm and 1.6 mm, respectively. PDD values of 50% (normalized to 2 mm) were 10.1 mm and 2.8 mm for electron and {sup 90}Sr-{sup 90}Y, respectively. Flatness (80% of the central beam profile) was 14.1% at a 5 mm depth for EBRT and 4.0% at surface for the {sup 90}Sr-{sup 90}Y. Conclusion: As expected, the PDDs of {sup 90}Sr-{sup 90}Y in water are shallower than that of external electron beams for the same field size. {sup 90}Sr-{sup 90}Y can be used in CSBT to provide patient specific treatment where shallower depth doses than that provided by electron external beams may be required: e.g. eyelids, nose, lips, ears, etc. The customizability of EBRT could be replicated by using multiple adjacent {sup 90}Sr-{sup 90}Y plaque placements.

  18. Dynamic Planar Convex Hull

    DEFF Research Database (Denmark)

    Brodal, Gerth Stølfting; Jacob, Rico

    2002-01-01

    In this paper we determine the computational complexity of the dynamic convex hull problem in the planar case. We present a data structure that maintains a finite set of n points in the plane under insertion and deletion of points in amortized O(log n) time per operation. The space usage of the d......In this paper we determine the computational complexity of the dynamic convex hull problem in the planar case. We present a data structure that maintains a finite set of n points in the plane under insertion and deletion of points in amortized O(log n) time per operation. The space usage...... of the data structure is O(n). The data structure supports extreme point queries in a given direction, tangent queries through a given point, and queries for the neighboring points on the convex hull in O(log n) time. The extreme point queries can be used to decide whether or not a given line intersects...... the convex hull, and the tangent queries to determine whether a given point is inside the convex hull. We give a lower bound on the amortized asymptotic time complexity that matches the performance of this data structure....

  19. Spectroelectrochemical sensing: planar waveguides

    Energy Technology Data Exchange (ETDEWEB)

    Ross, Susan E.; Shi Yining; Seliskar, Carl J.; Heineman, William R

    2003-09-30

    The spectroelectrochemical sensor combines in a single device electrochemistry, spectroscopy, and selective partitioning into a film, giving improved selectivity for applications that involve complex samples. Sensing is based on the change in optical signal that accompanies electrochemical modulation of analyte that has partitioned into the film. Two classes of optical quality chemically-selective films based on two different host materials, namely, sol-gel processed silica and cross-linked poly(vinyl alcohol) have been developed. Films are typically 400-700 nm thick. Three types of sensor platforms are discussed: a multiple internal reflection (MIR) optic consisting of a bilayer of an indium tin oxide (ITO) optically transparent electrode deposited on a 1-mm thick glass substrate, a planar waveguide in which a potassium ion-exchanged BK7 glass waveguide (5-9 {mu}m thick) was over-coated with a thin film of ITO, and a planar waveguide in which a potassium ion-exchanged BK7 glass waveguide channel was formed and a pair of electrodes deposited along side the channel. These sensors were evaluated with ferrocyanide and a selective film of PDMDAAC-SiO{sub 2}, where PDMDAAC=poly(dimethyl diallylammonium chloride)

  20. Spectroelectrochemical sensing: planar waveguides

    International Nuclear Information System (INIS)

    Ross, Susan E.; Shi Yining; Seliskar, Carl J.; Heineman, William R.

    2003-01-01

    The spectroelectrochemical sensor combines in a single device electrochemistry, spectroscopy, and selective partitioning into a film, giving improved selectivity for applications that involve complex samples. Sensing is based on the change in optical signal that accompanies electrochemical modulation of analyte that has partitioned into the film. Two classes of optical quality chemically-selective films based on two different host materials, namely, sol-gel processed silica and cross-linked poly(vinyl alcohol) have been developed. Films are typically 400-700 nm thick. Three types of sensor platforms are discussed: a multiple internal reflection (MIR) optic consisting of a bilayer of an indium tin oxide (ITO) optically transparent electrode deposited on a 1-mm thick glass substrate, a planar waveguide in which a potassium ion-exchanged BK7 glass waveguide (5-9 μm thick) was over-coated with a thin film of ITO, and a planar waveguide in which a potassium ion-exchanged BK7 glass waveguide channel was formed and a pair of electrodes deposited along side the channel. These sensors were evaluated with ferrocyanide and a selective film of PDMDAAC-SiO 2 , where PDMDAAC=poly(dimethyl diallylammonium chloride)

  1. Design of special planar linkages

    CERN Document Server

    Zhao, Jing-Shan; Ma, Ning; Chu, Fulei

    2013-01-01

    Planar linkages play a very important role in mechanical engineering. As the simplest closed chain mechanisms, planar four-bar linkages are widely used in mechanical engineering, civil engineering and aerospace engineering.Design of Special Planar Linkages proposes a uniform design theory for planar four-bar linkages. The merit of the method proposed in this book is that it allows engineers to directly obtain accurate results when there are such solutions for the specified n precise positions; otherwise, the best approximate solutions will be found. This book discusses the kinematics and reach

  2. Analytical expression for the phantom generated bremsstrahlung background in high energy electron beams

    International Nuclear Information System (INIS)

    Sorcini, B.B.; Hyoedynmaa, S; Brahme, A.

    1995-01-01

    Qualification of the bremsstrahlung photon background generated by an electron beam in a phantom is important for accurate high energy electron beam dosimetry in radiation therapy. An analytical expression has been derived for the background of phantom generated bremsstrahlung photons in plane parallel electron beams normally incident on phantoms of any atomic number between 4 and 92 (Be, C, H 2 O, Al, Cu, Ag, Pb and U). The expression can be used with fairly good accuracy in the energy range between 1 and 50 MeV. The expression is globally based on known scattering power and radiation and collision stopping power data for the phantom material at the mean energy of the incident electrons. The depth dose distribution due to the bremsstrahlung generated in the phantom is derived by folding the bremsstrahlung energy fluence with a simple analytical one-dimensional photon energy deposition kernel. The energy loss of the primary electrons and the generation, attenuation and absorption of bremsstrahlung photons are taken into account in the analytical formula. The photon energy deposition kernel is used to account for the bremsstrahlung produced at one depth that will contribute to the down stream dose. A simple analytical expression for photon energy deposition kernel is consistent with the classical analytical relation describing the photon depth dose distribution. From the surface to the practical range the photon dose increases almost linearly due to accumulation and buildup of the photon produced at different phantom layers. At depths beyond the practical range a simple exponential function can be use to describe the bremsstrahlung attenuation in the phantom. For comparison Monte Carlo calculated distributions using ITS3 Monte Carlo Code were used. Good agreement is found between the analytical expression and Monte Carlo calculation. Deviations of 5% from Monte Carlo calculated bremmstrahlung background are observed for high atomic number materials. The method can

  3. Dose Measurements of Bremsstrahlung-Produced Neutrons at the Advanced Photon Source

    International Nuclear Information System (INIS)

    Job, P.K.; Pisharody, M.; Semones, E.

    1998-01-01

    Bremsstrahlung is generated in the storage rings of the synchrotron radiation facilities by the radiative interaction of the circulating particle beam with both the residual gas molecules and storage ring components. These bremsstrahlung photons, having an energy range of zero to the maximum energy of the particle beam, interact with beamline components like beam stops and collimators generating photoneutrons of varying energies. There are three main processes by which photoneutrons may be produced by the high energy bremsstrahlung photons: giant nuclear dipole resonance and decay (10 MeV γ γ γ > 140 MeV). The giant resonance neutrons are emitted almost isotropically and have an average energy of about 2 MeV. High energy neutrons (E > 10 MeV) emitted from the quasi-deuteron decay and intranuclear cascade are peaked in the forward direction. At the Advanced Photon Source (APS), where bremsstrahlung energy can be as high as 7 GeV, production of photoneutrons in varying yields is possible from all of the above three processes. The bremsstrahlung produced along a typical 15.38-m straight path of the insertion device (ID) beamline of the APS has been measured and analyzed in previous studies. High-Z materials constituting the beamline components, such as collimators and beam stops, can produce photoneutrons upon interaction with these bremsstrahlung photons. The 1/E nature of the bremsstrahlung spectrum and the fact that the photoneutron production cross section is comparatively larger in the energy region 10 MeV γ 3 detector, as well as a very sensitive pressurized 3 He detector, is used for neutron dose measurements. The dose equivalent rates, normalized to bremsstrahlung power, beam current, and storage ring vacuum, are measured for various targets. This report details the experimental setup,

  4. Monitoring of energetic characteristics of electron beams during formation of high-power pulsed bremsstrahlung

    International Nuclear Information System (INIS)

    Ivaschenko, D.M.; Mordasov, N.G.; Chlenov, A.M.

    2005-01-01

    A method and a device for monitoring the dynamic and integrated characteristics of high-power electron and bremsstrahlung beams of the pulse accelerators are proposed. The transfer functions for various types of a target in operating conditions of the pulse accelerator UIN-10 are presented. Possibilities if the integrated diagnostics of acceleration rate of the electron beams with simultaneous testing of the bremsstrahlung parameters as a local field point beyond the converting target are shown [ru

  5. Measuring the electron-ion ring parameters by bremsstrahlung

    International Nuclear Information System (INIS)

    Inkin, V.D.; Mozelev, A.A.; Sarantsev, V.P.

    1982-01-01

    A system is described for measuring the number of electrons and ions in the electron-ion rings of a collective heavy ion accelerator. The system operation is based on detecting gamma quanta of bremsstrahlung following the ring electron interaction with the nuclei of neutral atoms and ions at different stages of filling the ring with ions. The radiation detector is a scintillation block - a photomultiplier operating for counting with NaI(Tl) crystal sized 30x30 mm and ensuring the detection efficiency close to unity. The system apparatus is made in the CAMAC standard and rems on-line with the TRA/i miniature computer. The block-diagrams of the system and algorithm of data processing are presented. A conclusion is drawn that the results of measuring the ring parameters with the use of the diagnostics system described are in good agreement within the range of measuring errors with those obtained by means of the diagnostics system employing synchrotron radiation and induction sensors

  6. Bremsstrahlung background and quantitation of thin biological samples

    International Nuclear Information System (INIS)

    Khan, K.M.

    1991-02-01

    An inherent feature of all electron-excited X-ray spectra is the presence of a background upon which the characteristic peaks of interest are superimposed. To extract the x-ray intensity of the characteristics lines of interest, it is necessary to subtract this background, which may be due to both specimen generated Bremsstrahlung and extraneous sources, from a measured x-ray spectrum. Some conventional methods of background subtraction will be briefly reviewed. It has been seen that these conventional methods do not give sufficiently accurate results in biological analysis where the peaks of interest are not well-separated and most of the peaks lie in the region where the background is appreciably curved. An alternative approach of background subtraction for such samples is investigated which involves modelling the background using the currently available knowledge of x-ray physics and energy dispersive detectors. This method is particularly suitable for biological samples as well as other samples having an organic matrix. 6 figs. (author)

  7. A Single Bremsstrahlung Monitor to Measure Luminosity at LEP

    CERN Multimedia

    2002-01-01

    The luminosity, the beam divergence and the longitudinal polarization can be measured at an interaction point of LEP by dectecting the energy, the angular distribution and the circular polarization of the single bremsstrahlung photons (SB) emitted at very forward angle. The luminosity can be measured by this met than by the conventional method of detecting small angle Bhabha scattering. The bunch to bunch relative luminosity can be monitored at a few per mil level in few minutes. Absolute values of the luminosity and of the polarization can be measured with a precision of the order of 1\\%. \\\\ \\\\ The apparatus to detect SB photons consists of a low Z absorber and of an EM calorimeter made of lead and scintillating fibres. Both the total energy and the space distribution of the SB photons are measured. This apparatus has been designed and built at the Department of Physics and INFN Section of the University of Rome ``La Sapienza''. Later on, together with suitable monocrystal converters, it may be used also for...

  8. Internal bremsstrahlung spectral shapes of 45Ca and 35S

    International Nuclear Information System (INIS)

    Babu, R.P.; Murty, K.N.; Murty, V.A.N.

    1976-01-01

    The internal bremsstrahlung spectra emitted in the beta decays of 45 Ca and 35 S were measured using a multichannel NaI(Tl) scintillation spectrometer with a standard geometrical arrangement. After making all the necessary corrections, the experimental results were compared with the allowed theory of Knipp and Uhlenbeck (Physica; 3:425 (1936)) and of Bloch (Phys. Rev.; 50:272 (1936)) (KUB theory) and also with the Coulomb-corrected theories of Lewis and Ford (Phys. Rev.; 107:756 (1957)) and of Nilsson (Ark. Fys.; 10:467 (1956)). In the case of 45 Ca, fairly good agreement with KUB theory was obtained from 30 to 155 keV and above 155 keV the experimental results were in agreement with the Lewis and Ford theory up to 210 keV, the maximum limit of the photon energy investigated. For 35 S, the experimental results are in quite good agreement with KUB theory from 25 to 45 keV, but beyond 45 keV the values are greater than the Coulomb-corrected theories due to both Lewis and Ford and to Nilsson, the experimental excess over Nilsson Coulomb-corrected theory being by factors of 1.07, 1.12 and 1.63 at energies 60, 90 and 110 keV respectively. (author)

  9. Internal bremsstrahlung from 89Sr and 90Sr

    International Nuclear Information System (INIS)

    Sayibaba, T.; Narasimha Murity, K.; Rao, C.R.; Satyaprakash; Gubbi, G.K.

    1987-01-01

    The internal bremsstrahlung (IB) spectra emitted in the beta-decays of 89 Sr and 90 Sr were measured with a HPGe detector and a multichannel analyser along with a standard geometrical set-up. Sufficient care has been taken to avoid spurious effects. After making all the necessary corrections, the experimental results were compared with the corresponding theoretical distributions due to Knipp and Uhlenbeck and Bloch (KUB), Lewis and Ford, Nilsson, and also due to Ford and Martin (detour theory). The total IB yields of intensity and energy from each of the isotopes in the investigated energy regions are also determined and compared with the corresponding theoretical values. The present results of IB from 89 Sr are satisfactorily accounted for by the KUB theory. In the case of 90 Sr the experimental results of IB coincide with the Coulomb-corrected theoretical distibution due to Nilsson in the energy range from 60 keV to 110 keV and Beyond 110 keV, they are found to be in excess over Nilsson's theory as well as the detour theory due to Ford and Martin up to the maximum photon energy studied, namely 350 keV

  10. Planar elliptic growth

    Energy Technology Data Exchange (ETDEWEB)

    Mineev, Mark [Los Alamos National Laboratory

    2008-01-01

    The planar elliptic extension of the Laplacian growth is, after a proper parametrization, given in a form of a solution to the equation for areapreserving diffeomorphisms. The infinite set of conservation laws associated with such elliptic growth is interpreted in terms of potential theory, and the relations between two major forms of the elliptic growth are analyzed. The constants of integration for closed form solutions are identified as the singularities of the Schwarz function, which are located both inside and outside the moving contour. Well-posedness of the recovery of the elliptic operator governing the process from the continuum of interfaces parametrized by time is addressed and two examples of exact solutions of elliptic growth are presented.

  11. Dynamic Planar Convex Hull

    DEFF Research Database (Denmark)

    Jacob, Riko

    We determine the computational complexity of the dynamic convex hull problem in the planar case. We present a data structure that maintains a finite set of n points in the plane under insertion and deletion of points in amortized O(log n) time per operation. The space usage of the data structure...... is O(n). The data structure supports extreme point queries in a given direction, tangent queries through a given point, and queries for the neighboring points on the convex hull in O(log n) time. The extreme point queries can be used to decide whether or not a given line intersects the convex hull......, and the tangent queries to determine whether a given point is inside the convex hull. The space usage of the data structure is O(n). We give a lower bound on the amortized asymptotic time complexity that matches the performance of this data structure....

  12. Improved Dynamic Planar Point Location

    DEFF Research Database (Denmark)

    Brodal, Gerth Stølting; Arge, Lars; Georgiadis, Loukas

    2006-01-01

    We develop the first linear-space data structures for dynamic planar point location in general subdivisions that achieve logarithmic query time and poly-logarithmic update time.......We develop the first linear-space data structures for dynamic planar point location in general subdivisions that achieve logarithmic query time and poly-logarithmic update time....

  13. Contracting a planar graph efficiently

    DEFF Research Database (Denmark)

    Holm, Jacob; Italiano, Giuseppe F.; Karczmarz, Adam

    2017-01-01

    the data structure, we can achieve optimal running times for decremental bridge detection, 2-edge connectivity, maximal 3-edge connected components, and the problem of finding a unique perfect matching for a static planar graph. Furthermore, we improve the running times of algorithms for several planar...

  14. Monte Carlo simulation of radiation transport and dose deposition from locally released gold nanoparticles labeled with 111In, 177Lu or 90Y incorporated into tissue implantable depots

    Science.gov (United States)

    Lai, Priscilla; Cai, Zhongli; Pignol, Jean-Philippe; Lechtman, Eli; Mashouf, Shahram; Lu, Yijie; Winnik, Mitchell A.; Jaffray, David A.; Reilly, Raymond M.

    2017-11-01

    Permanent seed implantation (PSI) brachytherapy is a highly conformal form of radiation therapy but is challenged with dose inhomogeneity due to its utilization of low energy radiation sources. Gold nanoparticles (AuNP) conjugated with electron emitting radionuclides have recently been developed as a novel form of brachytherapy and can aid in homogenizing dose through physical distribution of radiolabeled AuNP when injected intratumorally (IT) in suspension. However, the distribution is unpredictable and precise placement of many injections would be difficult. Previously, we reported the design of a nanoparticle depot (NPD) that can be implanted using PSI techniques and which facilitates controlled release of AuNP. We report here the 3D dose distribution resulting from a NPD incorporating AuNP labeled with electron emitters (90Y, 177Lu, 111In) of different energies using Monte Carlo based voxel level dosimetry. The MCNP5 Monte Carlo radiation transport code was used to assess differences in dose distribution from simulated NPD and conventional brachytherapy sources, positioned in breast tissue simulating material. We further compare these dose distributions in mice bearing subcutaneous human breast cancer xenografts implanted with 177Lu-AuNP NPD, or injected IT with 177Lu-AuNP in suspension. The radioactivity distributions were derived from registered SPECT/CT images and time-dependent dose was estimated. Results demonstrated that the dose distribution from NPD reduced the maximum dose 3-fold when compared to conventional seeds. For simulated NPD, as well as NPD implanted in vivo, 90Y delivered the most homogeneous dose distribution. The tumor radioactivity in mice IT injected with 177Lu-AuNP redistributed while radioactivity in the NPD remained confined to the implant site. The dose distribution from radiolabeled AuNP NPD were predictable and concentric in contrast to IT injected radiolabeled AuNP, which provided irregular and temporally variant dose distributions

  15. 3D inpatient dose reconstruction from the PET-CT imaging of {sup 90}Y microspheres for metastatic cancer to the liver: Feasibility study

    Energy Technology Data Exchange (ETDEWEB)

    Fourkal, E.; Veltchev, I.; Lin, M.; Meyer, J. [Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 (United States); Koren, S. [Department of Radiation Oncology, Beth Israel Comprehensive Cancer Center, New York, New York 10011 (United States); Doss, M.; Yu, J. Q. [Department of Diagnostic Imaging, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 (United States)

    2013-08-15

    Purpose: The introduction of radioembolization with microspheres represents a significant step forward in the treatment of patients with metastatic disease to the liver. This technique uses semiempirical formulae based on body surface area or liver and target volumes to calculate the required total activity for a given patient. However, this treatment modality lacks extremely important information, which is the three-dimensional (3D) dose delivered by microspheres to different organs after their administration. The absence of this information dramatically limits the clinical efficacy of this modality, specifically the predictive power of the treatment. Therefore, the aim of this study is to develop a 3D dose calculation technique that is based on the PET imaging of the infused microspheres.Methods: The Fluka Monte Carlo code was used to calculate the voxel dose kernel for {sup 90}Y source with voxel size equal to that of the PET scan. The measured PET activity distribution was converted to total activity distribution for the subsequent convolution with the voxel dose kernel to obtain the 3D dose distribution. In addition, dose-volume histograms were generated to analyze the dose to the tumor and critical structures.Results: The 3D inpatient dose distribution can be reconstructed from the PET data of a patient scanned after the infusion of microspheres. A total of seven patients have been analyzed so far using the proposed reconstruction method. Four patients underwent treatment with SIR-Spheres for liver metastases from colorectal cancer and three patients were treated with Therasphere for hepatocellular cancer. A total of 14 target tumors were contoured on post-treatment PET-CT scans for dosimetric evaluation. Mean prescription activity was 1.7 GBq (range: 0.58–3.8 GBq). The resulting mean maximum measured dose to targets was 167 Gy (range: 71–311 Gy). Mean minimum dose to 70% of target (D70) was 68 Gy (range: 25–155 Gy). Mean minimum dose to 90% of target

  16. Booted selective internal radiation therapy (B-SIRT) using 90Y-loaded glass microspheres induces prolonged overall survival for PVT patients

    International Nuclear Information System (INIS)

    Garin, E.; Lenoir, L.; Edeline, J.; Laffont, S.; Mesbah, H.; Poree, P.; Boucher, E.; Rolland, Y.

    2015-01-01

    Full text of publication follows. Goal: evaluation of the response rate and survival of hepatocellular carcinoma PVT patients treated with Therasphere using the boost concept. Material and methods: Therasphere was administered in 40 PVT hepatocellular carcinoma patients (main = 11, lobar = 23, segmental = 6). MAA SPECT/CT quantitative analysis was used for the calculation of the tumour dose (TD), the healthy injected liver dose (HLD) and the injected liver dose (LD). Response was evaluated at 3 months using EASL criterion. OS was evaluated using Kaplan and Meyer tests. Results: Mean 90 Y-loaded microspheres injected activity was 3.1 ± 1.5 GBq. Mean LD was 143 ± 49 Gy. Median TD was 316 Gy for responding lesions versus 133 Gy for non responding lesion (p<0.0001). With a threshold TD of 205 Gy, MAA-SPECT/CT was predictive of response with a sensibility of 100%, and an overall accuracy of 90% (0FN, 4FP). Knowing the TD and the HLD, 40% of the patients received an intensification of the treatment (increase of the injected activity with the goal to achieve a TD> 205 Gy with a LD > 150 Gy and a HLD<120 Gy) with a good response rate (81%) and without increased liver grade III toxicity (6.2% as against 12.5% in the non boosted patients, ns). 6 patients were put aside, 5 received a lobar hepatectomy. Median OS was 18.2 months [12-27]. It was 4 m [12-27] for patients with a TD < 205 Gy versus 21.5 m [12-28.5] for patients with a TD > 205 Gy. OS was 12 m [3-∞] for patients with main PVT versus 21.5 m [12-28.7] for patients segmental or lobar PVT (ns). Finally Os was 23.2 m for patients with a TD > 205 Gy and a good PVT targeting (n = 34). Conclusion: boosted selective internal radiation therapy using 90 Y-loaded glass microspheres induces prolonged overall survival for PVT patients without increasing liver toxicity. (authors)

  17. 3D inpatient dose reconstruction from the PET-CT imaging of 90Y microspheres for metastatic cancer to the liver: feasibility study.

    Science.gov (United States)

    Fourkal, E; Veltchev, I; Lin, M; Koren, S; Meyer, J; Doss, M; Yu, J Q

    2013-08-01

    The introduction of radioembolization with microspheres represents a significant step forward in the treatment of patients with metastatic disease to the liver. This technique uses semiempirical formulae based on body surface area or liver and target volumes to calculate the required total activity for a given patient. However, this treatment modality lacks extremely important information, which is the three-dimensional (3D) dose delivered by microspheres to different organs after their administration. The absence of this information dramatically limits the clinical efficacy of this modality, specifically the predictive power of the treatment. Therefore, the aim of this study is to develop a 3D dose calculation technique that is based on the PET imaging of the infused microspheres. The Fluka Monte Carlo code was used to calculate the voxel dose kernel for 90Y source with voxel size equal to that of the PET scan. The measured PET activity distribution was converted to total activity distribution for the subsequent convolution with the voxel dose kernel to obtain the 3D dose distribution. In addition, dose-volume histograms were generated to analyze the dose to the tumor and critical structures. The 3D inpatient dose distribution can be reconstructed from the PET data of a patient scanned after the infusion of microspheres. A total of seven patients have been analyzed so far using the proposed reconstruction method. Four patients underwent treatment with SIR-Spheres for liver metastases from colorectal cancer and three patients were treated with Therasphere for hepatocellular cancer. A total of 14 target tumors were contoured on post-treatment PET-CT scans for dosimetric evaluation. Mean prescription activity was 1.7 GBq (range: 0.58-3.8 GBq). The resulting mean maximum measured dose to targets was 167 Gy (range: 71-311 Gy). Mean minimum dose to 70% of target (D70) was 68 Gy (range: 25-155 Gy). Mean minimum dose to 90% of target (D90) was 53 Gy (range: 13-125 Gy). A

  18. 3D inpatient dose reconstruction from the PET-CT imaging of 90Y microspheres for metastatic cancer to the liver: Feasibility study

    International Nuclear Information System (INIS)

    Fourkal, E.; Veltchev, I.; Lin, M.; Meyer, J.; Koren, S.; Doss, M.; Yu, J. Q.

    2013-01-01

    Purpose: The introduction of radioembolization with microspheres represents a significant step forward in the treatment of patients with metastatic disease to the liver. This technique uses semiempirical formulae based on body surface area or liver and target volumes to calculate the required total activity for a given patient. However, this treatment modality lacks extremely important information, which is the three-dimensional (3D) dose delivered by microspheres to different organs after their administration. The absence of this information dramatically limits the clinical efficacy of this modality, specifically the predictive power of the treatment. Therefore, the aim of this study is to develop a 3D dose calculation technique that is based on the PET imaging of the infused microspheres.Methods: The Fluka Monte Carlo code was used to calculate the voxel dose kernel for 90 Y source with voxel size equal to that of the PET scan. The measured PET activity distribution was converted to total activity distribution for the subsequent convolution with the voxel dose kernel to obtain the 3D dose distribution. In addition, dose-volume histograms were generated to analyze the dose to the tumor and critical structures.Results: The 3D inpatient dose distribution can be reconstructed from the PET data of a patient scanned after the infusion of microspheres. A total of seven patients have been analyzed so far using the proposed reconstruction method. Four patients underwent treatment with SIR-Spheres for liver metastases from colorectal cancer and three patients were treated with Therasphere for hepatocellular cancer. A total of 14 target tumors were contoured on post-treatment PET-CT scans for dosimetric evaluation. Mean prescription activity was 1.7 GBq (range: 0.58–3.8 GBq). The resulting mean maximum measured dose to targets was 167 Gy (range: 71–311 Gy). Mean minimum dose to 70% of target (D70) was 68 Gy (range: 25–155 Gy). Mean minimum dose to 90% of target (D90

  19. ANÁLISIS COMPARATIVO DE LOS EFECTOS AGUDOS DE SESIONES DE ENTRENAMIENTO DE FUERZA CON CARGAS DEL 90 Y 30% 1 RM.

    Directory of Open Access Journals (Sweden)

    Jorge Dopico Calvo

    2010-10-01

    Full Text Available En una medición inicial (Pretest se obtuvo la 1RM de 23 sujetos masculinos en el ejercicio press banca, así como la potencia y fuerza media aplicada al 90 y 30% de 1RM (PMED90, FMED90, PMED30, FMED 30. Posteriormente 11 sujetos (Gr90 llevaron a cabo 2 sesiones de entrenamiento con cargas del 90%, mientras los 12 sujetos restantes (Gr30 lo hacían con cargas del 30%. Inmediatamente finalizada cada una de las sesiones se valoraba nuevamente PMED90, FMED90, PMED30, FMED30. Una semana después de la finalización de los entrenamientos se efectuó un Postest. Los resultados mostraron una mejora estadísticamente significativa del rendimiento de Gr30 al final de cada una de las sesiones de entrenamiento, respecto a Pretest y Postest, con el 90% de 1RM, mientras que Gr90 obtuvo mejoras significativas con el 30% respecto a Pretest, pero no respecto a Postest.
    PALABRAS CLAVE: fuerza, potencia, medición, efecto agudo.

  20. A comparative study of preliminary dosimetry for human based on distribution data in rats with 111In, 90Y, 153Sm, and 177Lu labeled rituximab

    Directory of Open Access Journals (Sweden)

    Radfar Edalat

    2012-01-01

    Full Text Available Radio immunotherapy is one of the most important and effective therapies for B-cell non Hoddgkin’s lymphoma treatment. Today, anti CD-20 antibodies labeled with beta emitter radionuclides are used in radio immunotherapy. Various radionuclides for labeling anti CD-20 antibodies have been studied and developed for the treatment and diagnosis of malignancies. This paper describes the preparation, bio-distribution and absorbed dose rate of 111In, 90Y, 177Lu, and 153Sm labeled anti CD-20 antibodies (rituximab in human organs, after injection to rats. The macro cyclic bifunctional chelating agent, N-succinimidyl-1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid (DOTA-NHS for conjugation to antibody, was used to prepare DOTA-rituximab. The conjugates were purified by molecular filtration, the average number of DOTA conjugated per mAb was calculated and total concentration was determined by spectrophotometric method. Radio-labeling was performed at 40 °C for 24 hours. After the quality control studies, the final radioactive solution was injected intravenously into rats through their tail vein. The tissue uptakes of each injection were measured. Then we calculated S values for 177Lu and 153Sm by using specific absorbed fractions and data used in the manner of radio-labeled analysis and dosimetry for humans. The absorbed dose rate of each organ was calculated in the specific time by medical internal radiation dose method with linear approximation in the activity measurements.

  1. Contact planarization of ensemble nanowires

    Science.gov (United States)

    Chia, A. C. E.; LaPierre, R. R.

    2011-06-01

    The viability of four organic polymers (S1808, SC200, SU8 and Cyclotene) as filling materials to achieve planarization of ensemble nanowire arrays is reported. Analysis of the porosity, surface roughness and thermal stability of each filling material was performed. Sonication was used as an effective method to remove the tops of the nanowires (NWs) to achieve complete planarization. Ensemble nanowire devices were fully fabricated and I-V measurements confirmed that Cyclotene effectively planarizes the NWs while still serving the role as an insulating layer between the top and bottom contacts. These processes and analysis can be easily implemented into future characterization and fabrication of ensemble NWs for optoelectronic device applications.

  2. Contribution of 210Pb bremsstrahlung to the background of lead shielded gamma spectrometers

    International Nuclear Information System (INIS)

    Mrda, D.; Bikit, I.; Veskovic, M.; Forkapic, S.

    2007-01-01

    Lead, which is often used as a shielding material, contains 210 Pb (T 1/2 =22.3 y). The 46.54 keV γ-intensity of 210 Pb can be easily reduced by an inner lining, but the bremsstrahlung caused by the β-decay of its daughter, 210 Bi, with a maximal electron energy of 1.16 MeV, will contribute to the gamma detector background. The spectrum of this bremsstrahlung is calculated by numerically fitting the β-spectrum and integrating the Koch-Motz formula. The absorption of the bremsstrahlung in the lead and detection efficiencies for the HPGe detector are calculated by the effective solid angle algorithm, using corrections for the photopeak/Compton ratio of cross-sections in Ge. By comparison with the measured background spectrum, it is shown that, for the lead with 25 Bq/kg of 210 Pb up to 500 keV of gamma spectrum, the bremsstrahlung contribution to the background is about 20% for our surface-based detector system. Also, we compared our calculations with a Monte Carlo simulation of another detector system with a shield containing 1 Bq/kg of 210 Pb and found that our analytical method gives a value of roughly two times higher than the Monte Carlo one for the total bremsstrahlung contribution. The quality of the analytical semi-empirical method is proved by the reasonable agreement with the experimental results published

  3. Comparison of different Bremsstrahlung converters and collimators for Nuclear Resonance Fluorescence setup at IFUSP

    International Nuclear Information System (INIS)

    Lopez, P.N; Corrales, Y.; Manso Guevara, M.V; Martins, M.N.

    2007-01-01

    Nuclear Resonance Fluorescence (NRF) setup will install in the new electron accelerator, which is in final stage of installation at the Physics Institute of Sao Paulo University (IFUSP). The Bremsstrahlung facility and the setup for photon scattering should be designed such that the background radiation caused by scattering photons and the production of neutrons is minimized. In this order the Monte Carlo simulation studies show the best options for the different elements of the NRF setup, and how to link these elements to the particularities of the irradiation room. In the present stage the simulations has been included the studies of different Bremsstrahlung converters and collimators. Several materials (Ta, W, Au, Nb, Cu) for Bremsstrahlung converters were studied. Detailed analyses of intensity as well as the opening angles of Bremsstrahlung radiation were carried out, for different converter thickness. For the collimator two materials (Cu and Pb) were studied in the simulations. Several opening angles and thickness (40 - 100 cm) were studied. The Bremsstrahlung beam collimation for different energy bins, and the photon scattering from the collimator ,were used as quality parameters of the collimators. (Author)

  4. Beyond 18F-FDG: Characterization of PET/CT and PET/MR Scanners for a Comprehensive Set of Positron Emitters of Growing Application--18F, 11C, 89Zr, 124I, 68Ga, and 90Y.

    Science.gov (United States)

    Soderlund, A Therese; Chaal, Jasper; Tjio, Gabriel; Totman, John J; Conti, Maurizio; Townsend, David W

    2015-08-01

    This study aimed to investigate image quality for a comprehensive set of isotopes ((18)F, (11)C, (89)Zr, (124)I, (68)Ga, and (90)Y) on 2 clinical scanners: a PET/CT scanner and a PET/MR scanner. Image quality and spatial resolution were tested according to NU 2-2007 of the National Electrical Manufacturers Association. An image-quality phantom was used to measure contrast recovery, residual bias in a cold area, and background variability. Reconstruction methods available on the 2 scanners were compared, including point-spread-function correction for both scanners and time of flight for the PET/CT scanner. Spatial resolution was measured using point sources and filtered backprojection reconstruction. With the exception of (90)Y, small differences were seen in the hot-sphere contrast recovery of the different isotopes. Cold-sphere contrast recovery was similar across isotopes for all reconstructions, with an improvement seen with time of flight on the PET/CT scanner. The lower-statistic (90)Y scans yielded substantially lower contrast recovery than the other isotopes. When isotopes were compared, there was no difference in measured spatial resolution except for PET/MR axial spatial resolution, which was significantly higher for (124)I and (68)Ga. Overall, both scanners produced good images with (18)F, (11)C, (89)Zr, (124)I, (68)Ga, and (90)Y. © 2015 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

  5. Planar graphs theory and algorithms

    CERN Document Server

    Nishizeki, T

    1988-01-01

    Collected in this volume are most of the important theorems and algorithms currently known for planar graphs, together with constructive proofs for the theorems. Many of the algorithms are written in Pidgin PASCAL, and are the best-known ones; the complexities are linear or 0(nlogn). The first two chapters provide the foundations of graph theoretic notions and algorithmic techniques. The remaining chapters discuss the topics of planarity testing, embedding, drawing, vertex- or edge-coloring, maximum independence set, subgraph listing, planar separator theorem, Hamiltonian cycles, and single- or multicommodity flows. Suitable for a course on algorithms, graph theory, or planar graphs, the volume will also be useful for computer scientists and graph theorists at the research level. An extensive reference section is included.

  6. Absorbed dose profiles for 32P, 90Y, 188Re, 177Lu, 51Cr, 153Sm and 169Er: radionuclides used in radiosynoviortheses treatment

    International Nuclear Information System (INIS)

    Torres, M.; Ayra, E.; Albuerne, O.; Delgado, M.

    2008-01-01

    The remarkable advances in the design and synthesis of radiopharmaceuticals has created the opportunity of generating new agents for the treatment of radiosynoviortheses (RSV) which exhibit a minimum leakage from the synovial joint reducing, this way, the non desired absorbed doses to non target organs such as liver, spleen, kidney. Nowadays, the variety of beta emitters used in RSV ranges between 0.34 MeV - 0.33 mm penetration in tissue ( 169 Er) and 2.27 MeV - 3.6 mm penetration in tissue ( 90 Y). The half life of these isotopes goes from 2.3 hours ( 165 Dy) to 27.8 days ( 51 Cr). The selection criterion on which radionuclide should be used, in modern clinics, depends on which joints are to be treated. Thus, the smaller the joint, the lowest should be the energy of the beta emitted and the penetration in soft tissue of these particles. This leads to the use of fixed radionuclides and doses for each kind of joint. In the Isotopes Centre, we've been carrying on studies for the development of radiopharmaceuticals for the radiosynoviortheses treatment and focused our attention in the following radionuclides: 32 P, 90 Y, 188 Re, 177 Lu, 51 Cr, 153 Sm and 169 Er. The main objective of this paper was to obtain the absorbed dose profiles for radionuclides of frequent or potential use in radiosynoviortheses. These profiles reveal the absorbed dose imparted per unit activity of injected radionuclide (Gy/h*MBq) in the synovial membrane and the articular cartilage. The researched radionuclides were those previously mentioned. Also were calculated the therapeutic range of each radionuclides in synovial tissue. The therapeutic range is defined as the deepness at which the absorbed dose equals the 10 % of the maximum dose deposited in the synovial surface. This range determines the synovial thickness that can be sufficiently irradiated and thus successfully treated. The synovial membrane model consisted on a cylinder with the source uniformly distributed in its volume. This

  7. Flat panel planar optic display

    Energy Technology Data Exchange (ETDEWEB)

    Veligdan, J.T. [Brookhaven National Lab., Upton, NY (United States). Dept. of Advanced Technology

    1994-11-01

    A prototype 10 inch flat panel Planar Optic Display, (POD), screen has been constructed and tested. This display screen is comprised of hundreds of planar optic class sheets bonded together with a cladding layer between each sheet where each glass sheet represents a vertical line of resolution. The display is 9 inches wide by 5 inches high and approximately 1 inch thick. A 3 milliwatt HeNe laser is used as the illumination source and a vector scanning technique is employed.

  8. Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept

    International Nuclear Information System (INIS)

    Garin, E.; Lenoir, L.; Edeline, J.; Laffont, S.; Mesbah, H.; Poree, P.; Sulpice, L.; Boudjema, K.; Mesbah, M.; Guillygomarc'h, A.; Quehen, E.; Pracht, M.; Raoul, J.L.; Clement, B.; Rolland, Y.; Boucher, E.

    2013-01-01

    To evaluate the impact of dosimetry based on MAA SPECT/CT for the prediction of response, toxicity and survival, and for treatment planning in patients with hepatocellular carcinoma (HCC) treated with 90 Y-loaded glass microspheres (TheraSphere registered). TheraSphere registered was administered to 71 patients with inoperable HCC. MAA SPECT/CT quantitative analysis was used for the calculation of the tumour dose (TD), healthy injected liver dose (HILD), and total injected liver dose. Response was evaluated at 3 months using EASL criteria. Time to progression (TTP) and overall survival (OS) were evaluated using the Kaplan-Meier method. Factors potentially associated with liver toxicity were combined to construct a liver toxicity score (LTS). The response rate was 78.8 %. Median TD were 342 Gy for responding lesions and 191 Gy for nonresponding lesions (p 205 Gy (p = 0.0015 and not significant). Among patients with portal vein thrombosis (PVT) (n = 33), the median TTP and OS were 4.5 months (2-7 months) and 5 months (2-8 months), respectively, in patients with TD 205 Gy (p = 0.039 and 0.005). The median OS was 24.5 months (18-28.5 months) in PVT patients with TD >205 Gy and good PVT targeting on MAA SPECT/CT. The LTS was able to detect severe liver toxicity (n = 6) with a sensitivity of 83 % and overall accuracy of 97 %. Dosimetry based on MAA SPECT/CT was able to accurately predict response and survival in patients treated with glass microspheres. This method can be used to adapt the injected activity without increasing liver toxicity, thus defining a new concept of boosted selective internal radiation therapy (B-SIRT). This new concept and LTS enable fully personalized treatment planning with glass microspheres to be achieved. (orig.)

  9. SU-E-T-02: 90Y Microspheres Dosimetry Calculation with Voxel-S-Value Method: A Simple Use in the Clinic

    International Nuclear Information System (INIS)

    Maneru, F; Gracia, M; Gallardo, N; Olasolo, J; Fuentemilla, N; Bragado, L; Martin-Albina, M; Lozares, S; Pellejero, S; Miquelez, S; Rubio, A; Otal, A

    2015-01-01

    Purpose: To present a simple and feasible method of voxel-S-value (VSV) dosimetry calculation for daily clinical use in radioembolization (RE) with 90 Y microspheres. Dose distributions are obtained and visualized over CT images. Methods: Spatial dose distributions and dose in liver and tumor are calculated for RE patients treated with Sirtex Medical miscrospheres at our center. Data obtained from the previous simulation of treatment were the basis for calculations: Tc-99m maggregated albumin SPECT-CT study in a gammacamera (Infinia, General Electric Healthcare.). Attenuation correction and ordered-subsets expectation maximization (OSEM) algorithm were applied.For VSV calculations, both SPECT and CT were exported from the gammacamera workstation and registered with the radiotherapy treatment planning system (Eclipse, Varian Medical systems). Convolution of activity matrix and local dose deposition kernel (S values) was implemented with an in-house developed software based on Python code. The kernel was downloaded from www.medphys.it. Final dose distribution was evaluated with the free software Dicompyler. Results: Liver mean dose is consistent with Partition method calculations (accepted as a good standard). Tumor dose has not been evaluated due to the high dependence on its contouring. Small lesion size, hot spots in health tissue and blurred limits can affect a lot the dose distribution in tumors. Extra work includes: export and import of images and other dicom files, create and calculate a dummy plan of external radiotherapy, convolution calculation and evaluation of the dose distribution with dicompyler. Total time spent is less than 2 hours. Conclusion: VSV calculations do not require any extra appointment or any uncomfortable process for patient. The total process is short enough to carry it out the same day of simulation and to contribute to prescription decisions prior to treatment. Three-dimensional dose knowledge provides much more information than other

  10. Early post-treatment FDG PET predicts survival after {sup 90}Y microsphere radioembolization in liver-dominant metastatic colorectal cancer

    Energy Technology Data Exchange (ETDEWEB)

    Sabet, Amir; Aouf, Anas; Sabet, Amin; Ghamari, Shahab; Biersack, Hans-Juergen [University Hospital, Department of Nuclear Medicine, Bonn (Germany); Meyer, Carsten; Pieper, Claus C. [University Hospital, Department of Radiology, Bonn (Germany); Mayer, Karin [University Hospital, Department of Medicine and Oncology, Bonn (Germany); Ezziddin, Samer [University Hospital, Department of Nuclear Medicine, Bonn (Germany); Saarland University, Department of Nuclear Medicine, Homburg (Germany)

    2014-10-29

    The aim of this study was to evaluate the predictive value of early metabolic response 4 weeks post-treatment using {sup 18}F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT in patients with unresectable hepatic metastases of colorectal cancer (CRC) undergoing radioembolization (RE) with {sup 90}Y-labelled microspheres. A total of 51 consecutive patients with liver-dominant metastases of CRC were treated with RE and underwent {sup 18}F-FDG PET/CT at baseline and 4 weeks after RE. In each patient, three hepatic metastases with the highest maximum standardized uptake value (SUV{sub max}) were selected as target lesions. Metabolic response was defined as >50 % reduction of tumour to liver ratios. Survival analyses using Kaplan-Meier and multivariate analyses were performed to identify prognostic factors for overall survival (OS). Investigated baseline characteristics included age (>60 years), performance status (Eastern Cooperative Oncology Group >1), bilirubin (>1.0 mg/dl), hepatic tumour burden (>25 %) and presence of extrahepatic disease. The median OS after RE was 7 months [95 % confidence interval (CI) 5-8]; early metabolic responders (n = 33) survived longer than non-responders (p < 0.001) with a median OS of 10 months (95 % CI 3-16) versus 4 months (95 % CI 2-6). Hepatic tumour burden also had significant impact on treatment outcome (p < 0.001) with a median OS of 5 months (95 % CI, 3-7) for patients with >25 % metastatic liver replacement vs 14 months (95 % CI 6-22) for the less advanced patients. Both factors (early metabolic response and low hepatic tumour burden) remained as independent predictors of improved survival on multivariate analysis. These are the first findings to show that molecular response assessment in CRC using {sup 18}F-FDG PET/CT appears feasible as early as 4 weeks post-RE, allowing risk stratification and potentially facilitating early response-adapted treatment strategies. (orig.)

  11. SU-E-T-02: 90Y Microspheres Dosimetry Calculation with Voxel-S-Value Method: A Simple Use in the Clinic

    Energy Technology Data Exchange (ETDEWEB)

    Maneru, F; Gracia, M; Gallardo, N; Olasolo, J; Fuentemilla, N; Bragado, L; Martin-Albina, M; Lozares, S; Pellejero, S; Miquelez, S; Rubio, A [Complejo Hospitalario de Navarra, Pamplona, Navarra (Spain); Otal, A [Hospital Clinica Benidorm, Benidorm, Alicante (Spain)

    2015-06-15

    Purpose: To present a simple and feasible method of voxel-S-value (VSV) dosimetry calculation for daily clinical use in radioembolization (RE) with {sup 90}Y microspheres. Dose distributions are obtained and visualized over CT images. Methods: Spatial dose distributions and dose in liver and tumor are calculated for RE patients treated with Sirtex Medical miscrospheres at our center. Data obtained from the previous simulation of treatment were the basis for calculations: Tc-99m maggregated albumin SPECT-CT study in a gammacamera (Infinia, General Electric Healthcare.). Attenuation correction and ordered-subsets expectation maximization (OSEM) algorithm were applied.For VSV calculations, both SPECT and CT were exported from the gammacamera workstation and registered with the radiotherapy treatment planning system (Eclipse, Varian Medical systems). Convolution of activity matrix and local dose deposition kernel (S values) was implemented with an in-house developed software based on Python code. The kernel was downloaded from www.medphys.it. Final dose distribution was evaluated with the free software Dicompyler. Results: Liver mean dose is consistent with Partition method calculations (accepted as a good standard). Tumor dose has not been evaluated due to the high dependence on its contouring. Small lesion size, hot spots in health tissue and blurred limits can affect a lot the dose distribution in tumors. Extra work includes: export and import of images and other dicom files, create and calculate a dummy plan of external radiotherapy, convolution calculation and evaluation of the dose distribution with dicompyler. Total time spent is less than 2 hours. Conclusion: VSV calculations do not require any extra appointment or any uncomfortable process for patient. The total process is short enough to carry it out the same day of simulation and to contribute to prescription decisions prior to treatment. Three-dimensional dose knowledge provides much more information than

  12. Clinical impact of 99mTc-MAA SPECT/CT-based dosimetry in the radioembolization of liver malignancies with 90Y-loaded microspheres

    International Nuclear Information System (INIS)

    Garin, Etienne; Rolland, Yan; Laffont, Sophie; Edeline, Julien

    2016-01-01

    Radioembolization with 90 Y-loaded microspheres is increasingly used in the treatment of primary and secondary liver cancer. Technetium-99 m macroaggregated albumin (MAA) scintigraphy is used as a surrogate of microsphere distribution to assess lung or digestive shunting prior to therapy, based on tumoral targeting and dosimetry. To date, this has been the sole pre-therapeutic tool available for such evaluation. Several dosimetric approaches have been described using both glass and resin microspheres in hepatocellular carcinoma (HCC) and liver metastasis. Given that each product offers different specific activities and numbers of spheres injected, their radiobiological properties are believed to lightly differ. This paper summarizes and discusses the available studies focused on MAA-based dosimetry, particularly concentrating on potential confounding factors like clinical context, tumor size, cirrhosis, previous or concomitant therapy, and product used. In terms of the impact of tumoral dose in HCC, the results were concordant and a response relationship and tumoral threshold dose was clearly identified, especially in studies using glass microspheres. Tumoral dose has also been found to influence survival. The concept of treatment intensification has recently been introduced, yet despite several studies publishing interesting findings on the tumor dose-metastasis relationship, no consensus has been reached, and further clarification is thus required. Nor has the maximal tolerated dose to the liver been well documented, requiring more accurate evaluation. Lung dose was well described, despite recently identified factors influencing its evaluation, requiring further assessment. MAA SPECT/CT dosimetry is accurate in HCC and can now be used in order to achieve a fully customized approach, including treatment intensification. Yet further studies are warranted for the metastasis setting and evaluating the maximal tolerated liver dose. (orig.)

  13. Dosimetry and prescription in liver radioembolization with 90Y microspheres: 3D calculation of tumor-to-liver ratio from global 99mTc-MAA SPECT information

    Science.gov (United States)

    Mañeru, Fernando; Abós, Dolores; Bragado, Laura; Fuentemilla, Naiara; Caudepón, Fernando; Pellejero, Santiago; Miquelez, Santiago; Rubio, Anastasio; Goñi, Elena; Hernández-Vitoria, Araceli

    2017-12-01

    Dosimetry in liver radioembolization with 90Y microspheres is a fundamental tool, both for the optimization of each treatment and for improving knowledge of the treatment effects in the tissues. Different options are available for estimating the administered activity and the tumor/organ dose, among them the so-called partition method. The key factor in the partition method is the tumor/normal tissue activity uptake ratio (T/N), which is obtained by a single-photon emission computed tomography (SPECT) scan during a pre-treatment simulation. The less clear the distinction between healthy and tumor parenchyma within the liver, the more difficult it becomes to estimate the T/N ratio; therefore the use of the method is limited. This study presents a methodology to calculate the T/N ratio using global information from the SPECT. The T/N ratio is estimated by establishing uptake thresholds consistent with previously performed volumetry. This dose calculation method was validated against 3D voxel dosimetry, and was also compared with the standard partition method based on freehand regions of interest (ROI) outlining on SPECT slices. Both comparisons were done on a sample of 20 actual cases of hepatocellular carcinoma treated with resin microspheres. The proposed method and the voxel dosimetry method yield similar results, while the ROI-based method tends to over-estimate the dose to normal tissues. In addition, the variability associated with the ROI-based method is more extreme than the other methods. The proposed method is simpler than either the ROI or voxel dosimetry approaches and avoids the subjectivity associated with the manual selection of regions.

  14. Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept.

    Science.gov (United States)

    Garin, E; Lenoir, L; Edeline, J; Laffont, S; Mesbah, H; Porée, P; Sulpice, L; Boudjema, K; Mesbah, M; Guillygomarc'h, A; Quehen, E; Pracht, M; Raoul, J L; Clement, B; Rolland, Y; Boucher, E

    2013-07-01

    To evaluate the impact of dosimetry based on MAA SPECT/CT for the prediction of response, toxicity and survival, and for treatment planning in patients with hepatocellular carcinoma (HCC) treated with (90)Y-loaded glass microspheres (TheraSphere®). TheraSphere® was administered to 71 patients with inoperable HCC. MAA SPECT/CT quantitative analysis was used for the calculation of the tumour dose (TD), healthy injected liver dose (HILD), and total injected liver dose. Response was evaluated at 3 months using EASL criteria. Time to progression (TTP) and overall survival (OS) were evaluated using the Kaplan-Meier method. Factors potentially associated with liver toxicity were combined to construct a liver toxicity score (LTS). The response rate was 78.8%. Median TD were 342 Gy for responding lesions and 191 Gy for nonresponding lesions (p 205 Gy (p = 0.0015 and not significant). Among patients with portal vein thrombosis (PVT) (n = 33), the median TTP and OS were 4.5 months (2-7 months) and 5 months (2-8 months), respectively, in patients with TD 205 Gy (p = 0.039 and 0.005). The median OS was 24.5 months (18-28.5 months) in PVT patients with TD >205 Gy and good PVT targeting on MAA SPECT/CT. The LTS was able to detect severe liver toxicity (n = 6) with a sensitivity of 83% and overall accuracy of 97%. Dosimetry based on MAA SPECT/CT was able to accurately predict response and survival in patients treated with glass microspheres. This method can be used to adapt the injected activity without increasing liver toxicity, thus defining a new concept of boosted selective internal radiation therapy (B-SIRT). This new concept and LTS enable fully personalized treatment planning with glass microspheres to be achieved.

  15. Feasibility and utility of re-treatment with {sup 177}Lu-DOTATATE in GEP-NENs relapsed after treatment with {sup 90}Y-DOTATOC

    Energy Technology Data Exchange (ETDEWEB)

    Severi, Stefano; Sansovini, Maddalena; Ianniello, Annarita; Nicolini, Silvia; Caroli, Paola; Paganelli, Giovanni [Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Nuclear Medicine Unit, Meldola, FC (Italy); Bodei, Lisa [European Institute of Oncology, Division of Nuclear Medicine, Milan (Italy); Ibrahim, Toni [Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Osteoncology and Rare Tumors Center, Meldola (Italy); Di Iorio, Valentina [Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Oncology Pharmacy Laboratory, Meldola (Italy); D' Errico, Vincenzo [Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Medical Physics Unit, Meldola (Italy); Monti, Manuela [Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Unit of Biostatistics and Clinical Trials, Meldola (Italy)

    2015-12-15

    Peptide receptor radionuclide therapy (PRRT) is a valid therapy for grade 1/2 gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs). Although a median progression-free survival (PFS) of more than 20 months is frequently observed, the majority of patients relapse after 2 - 3 years. In the present study, we investigated the use of low dosage re-treatment with {sup 177}Lu-DOTATATE (Lu-PRRT) in patients with GEP-NENs who relapsed after treatment with {sup 90}Y-DOTATOC (Y-PRRT). Upon tumour progression, 26 patients with a PFS of at least 12 months after Y-PRRT were consecutively enrolled in a phase II study of re-treatment with Lu-PRRT. All patients had preserved kidney and haematological parameters and received 14.8 - 18.5 GBq of Lu-PRRT in four or five cycles. The disease control rate (DCR), toxicity, PFS and prognostic factors were evaluated. Median total activity of Lu-PRRT was 16.5 GBq in five cycles. The DCR was 84.6 %, median PFS was 22 months (95 % CI 16 months - not reached) compared to 28 months (95 % CI 20 - 36 months) after Y-PRRT. Tumour burden and number of liver metastases were important prognostic factors. Toxicity was mild after Lu-PRRT re-treatment in the majority of patients, with only two patients with grade 2 and one with grade 3 bone marrow toxicity; one patient had grade 2 and one grade 3 renal toxicity. Patients with GEP-NEN who have previously responded to Y-PRRT are suitable candidates for Lu-PRRT re-treatment on progression. Although our sample size was limited, low-dosage Lu-PRRT was safe, and led to DCR and PFS rates comparable with those observed when Y-PRRT was used as primary treatment. (orig.)

  16. Clinical impact of {sup 99m}Tc-MAA SPECT/CT-based dosimetry in the radioembolization of liver malignancies with {sup 90}Y-loaded microspheres

    Energy Technology Data Exchange (ETDEWEB)

    Garin, Etienne [Cancer Institute Eugene Marquis, Department of Nuclear Medicine, Rennes (France); University of Rennes 1, Rennes (France); INSERM, U-991, Liver Metabolisms and Cancer, Rennes (France); Rolland, Yan [Cancer Institute Eugene Marquis, Department of Medical Imaging, Rennes (France); Laffont, Sophie [University of Rennes 1, Rennes (France); Edeline, Julien [University of Rennes 1, Rennes (France); INSERM, U-991, Liver Metabolisms and Cancer, Rennes (France); Cancer Institute Eugene Marquis, Department of Medical Oncology, Rennes (France)

    2016-03-15

    Radioembolization with {sup 90}Y-loaded microspheres is increasingly used in the treatment of primary and secondary liver cancer. Technetium-99 m macroaggregated albumin (MAA) scintigraphy is used as a surrogate of microsphere distribution to assess lung or digestive shunting prior to therapy, based on tumoral targeting and dosimetry. To date, this has been the sole pre-therapeutic tool available for such evaluation. Several dosimetric approaches have been described using both glass and resin microspheres in hepatocellular carcinoma (HCC) and liver metastasis. Given that each product offers different specific activities and numbers of spheres injected, their radiobiological properties are believed to lightly differ. This paper summarizes and discusses the available studies focused on MAA-based dosimetry, particularly concentrating on potential confounding factors like clinical context, tumor size, cirrhosis, previous or concomitant therapy, and product used. In terms of the impact of tumoral dose in HCC, the results were concordant and a response relationship and tumoral threshold dose was clearly identified, especially in studies using glass microspheres. Tumoral dose has also been found to influence survival. The concept of treatment intensification has recently been introduced, yet despite several studies publishing interesting findings on the tumor dose-metastasis relationship, no consensus has been reached, and further clarification is thus required. Nor has the maximal tolerated dose to the liver been well documented, requiring more accurate evaluation. Lung dose was well described, despite recently identified factors influencing its evaluation, requiring further assessment. MAA SPECT/CT dosimetry is accurate in HCC and can now be used in order to achieve a fully customized approach, including treatment intensification. Yet further studies are warranted for the metastasis setting and evaluating the maximal tolerated liver dose. (orig.)

  17. Feasibility and utility of re-treatment with 177Lu-DOTATATE in GEP-NENs relapsed after treatment with 90Y-DOTATOC

    International Nuclear Information System (INIS)

    Severi, Stefano; Sansovini, Maddalena; Ianniello, Annarita; Nicolini, Silvia; Caroli, Paola; Paganelli, Giovanni; Bodei, Lisa; Ibrahim, Toni; Di Iorio, Valentina; D'Errico, Vincenzo; Monti, Manuela

    2015-01-01

    Peptide receptor radionuclide therapy (PRRT) is a valid therapy for grade 1/2 gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs). Although a median progression-free survival (PFS) of more than 20 months is frequently observed, the majority of patients relapse after 2 - 3 years. In the present study, we investigated the use of low dosage re-treatment with 177 Lu-DOTATATE (Lu-PRRT) in patients with GEP-NENs who relapsed after treatment with 90 Y-DOTATOC (Y-PRRT). Upon tumour progression, 26 patients with a PFS of at least 12 months after Y-PRRT were consecutively enrolled in a phase II study of re-treatment with Lu-PRRT. All patients had preserved kidney and haematological parameters and received 14.8 - 18.5 GBq of Lu-PRRT in four or five cycles. The disease control rate (DCR), toxicity, PFS and prognostic factors were evaluated. Median total activity of Lu-PRRT was 16.5 GBq in five cycles. The DCR was 84.6 %, median PFS was 22 months (95 % CI 16 months - not reached) compared to 28 months (95 % CI 20 - 36 months) after Y-PRRT. Tumour burden and number of liver metastases were important prognostic factors. Toxicity was mild after Lu-PRRT re-treatment in the majority of patients, with only two patients with grade 2 and one with grade 3 bone marrow toxicity; one patient had grade 2 and one grade 3 renal toxicity. Patients with GEP-NEN who have previously responded to Y-PRRT are suitable candidates for Lu-PRRT re-treatment on progression. Although our sample size was limited, low-dosage Lu-PRRT was safe, and led to DCR and PFS rates comparable with those observed when Y-PRRT was used as primary treatment. (orig.)

  18. Development of DOTA-Rituximab to be Labeled with 90Y for Radioimmunotherapy of B-cell Non-Hodgkin Lymphoma

    Science.gov (United States)

    Johari doha, Fariba; Rahmani, Siyavash; Rikhtechi, Pedram; Rasaneh, Samira; Sheikholislam, Zahra; Shahhosseini, Soraya

    2017-01-01

    NHL is the most common hematologic cancer in adults. Rituximab is the FDA approved treatment of relapsed or refractory low grade B-cell Non-Hodgkin Lymphoma (NHL). But patients eventually become resistant to rituximab. Since lymphocytes and lymphoma cells are highly radiosensitive, low grade NHL that has relapsed or refractory to standard therapy is treated by RIT in which a beta-emitting radionuclide coupled to anti-CD20 antibody. The association of beta emitter radionuclide to rituximab enhances its therapeutic efficacy. The cells which lack antigen or cells which cannot be reached due to poor vascularization and intratumoral pressure in a bulky tumor would be irradiated and killed by cross fire effect of beta emitter. 90Y, a pure high energy β-emitter with a half-life of 64 h, a maximum energy of 2.28 MeV, and maximum board of 11.3 mm in tissue is radionuclide of choice for radioimmunotherapy of outpatient administration. In this study, rituximab was conjugated to DOTA and radiolabeled with 90YCl3. The stability, affinity, and immunoreactivity of radiolabeled antibody was determined in vitro and the conditions were optimized. Biodistribution studies were done in normal mice. The optimum conditions of conjugation and radiolabeling was 1-2 h at 37 °C and 1 h at 45 °C, respectively. Results showed approximately 4 DOTA molecules conjugated per antibody molecule. The purified antibody was stable and intact over 6 months stored at -20 °C. The result of immunoreactivity (≈70%), affinity (≈3 nM) and biodistribution in normal mice are acceptable. PMID:28979315

  19. Evaluating the therapeutic effect of 89Sr using Bremsstrahlung imaging in patients with bone metastases

    International Nuclear Information System (INIS)

    Zhang Daping; Lou Cen; Chen Liang; Yu Linliang; Huang Huacheng

    2003-01-01

    Objective: To evaluate the therapeutic effect of 89 Sr (a pure beta emitter) using Bremsstrahlung imaging in patients with multiple bone metastases. Methods: 89 Sr Bremsstrahlung imaging was performed 1-2 weeks after injection in 14 patients with bone metastases, using GE Camstar 3200 SPECT equipped with a medium-energy collimator. To improve resolution of imaging, authors selected suitable energy level and wide window width (a 95-100% energy window around 100 KeV). Results: Abnormal uptake was seen in all and was consistent with the results of 99m Tc-MDP imaging. According to this result, authors can realize localization, retention and metabolism of 89 Sr in body. Conclusion: Bremsstrahlung imaging is useful for clinical observation and estimating the curative effect and prognosis in pure beta emitter therapy such as 89 Sr. In addition, it can be helpful in determining dose of 89 Sr if a repeated therapy is needed

  20. Bremsstrahlung emission probability in the {alpha} decay of {sup 210}Po

    Energy Technology Data Exchange (ETDEWEB)

    Boie, Hans-Hermann

    2009-06-03

    A high-statistics measurement of bremsstrahlung emitted in the {alpha} decay of {sup 210}Po has been performed. The measured differential emission probabilities, which could be followed up to {gamma}-energies of {proportional_to} 500 keV, allow for the first time for a serious test of various model calculations of the bremsstrahlung accompanied {alpha} decay. It is shown that corrections to the {alpha}-{gamma} angular correlation due to the interference between the electric dipole and quadrupole amplitudes and due to the relativistic character of the process have to be taken into account. With the experimentally derived angular correlation the measured energydifferential bremsstrahlung emission probabilities show excellent agreement with the fully quantum mechanical calculation. (orig.)

  1. Practice for dosimetry in electron and bremsstrahlung irradiation facilities for food processing. 2. ed.

    International Nuclear Information System (INIS)

    2002-01-01

    This practice describes dosimetric procedures to be followed in facility characterization, process qualification, and routine processing for electron beam and bremsstrahlung irradiation facilities for food processing to ensure that product receives an acceptable range of absorbed doses. Other procedures related to facility characterization, process qualification, and routine product processing that may influence and be used to monitor absorbed dose in the product are also discussed. Information about effective or regulatory dose limits for food products is not within the scope of this practice (see ASTM Guides F 1355 and F 1356). The electron energy range covered in this practice is from 0.3 MeV to 10 MeV. Such electrons can be generated in continuous or pulse modes. The maximum electron energy of bremsstrahlung facilities covered in this practice is 10 MeV. A photon beam can be generated by inserting a bremsstrahlung converter in the electron beam path (See ISO/ASTM Practice 51608

  2. Field-enhanced REB deposition and Bremsstrahlung production

    International Nuclear Information System (INIS)

    Halbleib, J.A. Sr.; Widner, M.M.

    1977-07-01

    Recently developed models are employed to describe the interaction of a high-current REB (relativistic electron beam) with planar gold foils in the presence of macroscopic electromagnetic fields. It is shown that, under certain conditions, azimuthal magnetic fields which either penetrate into the foil and/or exist on the transmission side of the foil can significantly enhance the specific power deposited in the foil over that which would be deposited for diode fields alone. Similar field effects suggest methods for improving the external conversion efficiencies, softening the spectra and focussing the source intensities of flash x-ray facilities. Finally, preliminary results are shown from a new trajectory-field model for self-consistent REB transport

  3. Bremsstrahlung scattering calculations for the beam stops and collimators in the APS insertion-device beamlines

    International Nuclear Information System (INIS)

    Job, P.K.; Haeffner, D.R.; Shu, D.

    1994-12-01

    Bremsstrahlung is produced in the APS storage ring by the interaction of positrons with the residual gas molecules in the vacuum chamber of the storage ring. The bremsstrahlung production causes a serious challenge in shielding the insertion-device beamlines because the entire straight section (15 meters) is in the line of sight of the beamline. The radiation emerges in a narrow cone tangential to the beam path with the characteristic emission angle 1/γ, where γ is E/mc 2 which is the ratio of the kinetic energy to the rest mass for the positrons. This high-energy gamma radiation has an approximate 1/E spectrum with the maximum energy extending up to the particle energy (7 GeV for the APS). Bremsstrahlung, being high-energy photons, produces an electromagnetic shower when it encounters the beamline elements. A beamline element not thick enough to fully contain an electromagnetic shower can cause considerable scatter of the high-energy bremsstrahlung radiation. The low-energy component of the bremsstrahlung can also be scattered and create high dose rates in the first-optical and white-beam enclosures. The fully developed electromagnetic shower will have a photon spectrum almost independent of the material. The electromagnetic showers in the high-Z materials can also produce photoneutrons. This note reports the summary of EGS4 calculations performed on bremsstrahlung scattering from different beamline components in a typical APS insertion-device beamline. The related recommendations for shielding are also given. The shielding criterion adopted is a total dose rate of 2.5μSv/h (0.25 mrem/h) at 30 cm from the shield

  4. Limits for an inverse bremsstrahlung origin of the diffuse Galactic soft gamma-ray emission

    DEFF Research Database (Denmark)

    Pohl, M.

    1998-01-01

    origin of the soft Galactic gamma-ray continuum through inverse bremsstrahlung. A flux of low-energy cosmic rays strong enough to produce the observed spectrum of gamma-rays implies substantial gamma-ray emission at a few MeV through nuclear de-excitation. It is shown that the existing limits on excess 3......-7 MeV emission from the Galactic plane, in concert with the constraints from pi(0)-decay gamma-ray emission at higher energies, are in serious conflict with an inverse bremsstrahlung origin of the Galactic soft gamma-ray emission for any physically plausible low-energy cosmic ray spectrum. While...

  5. Soft electromagnetic bremsstrahlung in inelastic hadronic collisions at high and intermediate energies

    International Nuclear Information System (INIS)

    Rueckl, R.

    1978-01-01

    Electromagnetic bremsstrahlung in hadronic collisions was studied extensively at low and intermediate energies. It was found that the infrared divergent term of the cross section describes the data well up to surprisingly large photon energies. Using essentially the same soft photon approximation, production of low mass-low energy electron pairs via internal conversion of soft virtual bremsstrahlung accompanying the production of charged hadrons in hadron-hadron collisions at very high and intermediate energies. The resulting electron yields explain, at least in part, the direct electrons with small transverse momenta seen at the ISR, and are in no contradiction to the rates observed at LAMPF

  6. Routine average effective charge calculation using visible Bremsstrahlung emission and comparison with the impurity transport code of Tore Supra

    International Nuclear Information System (INIS)

    Guirlet, R.; Mattioli, M.; DeMichelis, C.; Hess, W.; Pecquet, A.L.

    1995-01-01

    Effective charge measurements and calculations are presented for the Tore Supra, using visible Bremsstrahlung diagnostics. The measurements, are presented together with a reliability test of the results are discussed, by means of an impurity transport code simulating all available experimental data (XUV line spectroscopy, soft X-ray emission and Bremsstrahlung). (author) 5 refs.; 10 figs

  7. Complementary approaches for the evaluation of biocompatibility of 90Y-labeled superparamagnetic citric acid (Fe,Er)3O4 coated nanoparticles.

    Science.gov (United States)

    Antic, Bratislav; Boskovic, Marko; Nikodinovic-Runic, Jasmina; Ming, Yue; Zhang, Hongguo; Bozin, Emil S; Janković, Drina; Spasojevic, Vojislav; Vranjes-Djuric, Sanja

    2017-06-01

    Magnetic nanoparticles (MNPs) are of immense interest for diagnostic and therapeutic applications in medicine. Design and development of new iron oxide-based MNPs for such applications is of rather limited breadth without reliable and sensitive methods to determine their levels in body tissues. Commonly used methods, such as ICP, are quite problematic, due to the inability to decipher the origin of the detected iron, i.e. whether it originates from the MNPs or endogenous from tissues and bodily fluids. One of the approaches to overcome this problem and to increase reliability of tracing MNPs is to partially substitute iron ions in the MNPs with Er. Here, we report on the development of citric acid coated (Fe,Er) 3 O 4 nanoparticles and characterization of their physico-chemical and biological properties by utilization of various complementary approaches. The synthesized MNPs had a narrow (6-7nm) size distribution, as consistently seen in atomic pair distribution function, transmission electron microscopy, and DC magnetization measurements. The particles were found to be superparamagnetic, with a pronounced maximum in measured zero-field cooled magnetization at around 90K. Reduction in saturation magnetization due to incorporation of 1.7% Er 3+ into the Fe 3 O 4 matrix was clearly observed. From the biological standpoint, citric acid coated (Fe,Er) 3 O 4 NPs were found to induce low toxicity both in human cell fibroblasts and in zebrafish (Danio rerio) embryos. Biodistribution pattern of the MNPs after intravenous administration in healthy Wistar rats was followed by the radiotracer method, revealing that 90 Y-labeled MNPs were predominantly found in liver (75.33% ID), followed by lungs (16.70% ID) and spleen (2.83% ID). Quantitative agreement with these observations was obtained by ICP-MS elemental analysis using Er as the detected tracer. Based on the favorable physical, chemical and biological characteristics, citric acid coated (Fe,Er) 3 O 4 MNPs could be

  8. Peptide receptor radionuclide therapy with {sup 90}Y/{sup 177}Lu-labelled peptides for inoperable head and neck paragangliomas (glomus tumours)

    Energy Technology Data Exchange (ETDEWEB)

    Puranik, Ameya D.; Kulkarni, Harshad R.; Singh, Aviral; Baum, Richard P. [Zentralklinik Bad Berka, THERANOSTICS Centre for Molecular Radiotherapy and Molecular Imaging, ENETS Center of Excellence, Bad Berka (Germany)

    2015-07-15

    Head and neck paragangliomas (HNPGLs) are rare tumours arising from autonomic nervous system ganglia. Although surgery offers the best chance of complete cure, there is associated morbidity due to the crucial location of these tumours. Radiotherapy arrests tumour growth and provides symptomatic improvement, but has long-term consequences. These tumours express somatostatin receptors (SSTR) and hence peptide receptor radionuclide therapy (PRRT) is now a treatment option. We assessed the molecular, morphological and clinical responses of inoperable HNPGLs to PRRT. Nine patients with inoperable HNPGL assessed between June 2006 and June 2014 were included. Four patients had a solitary lesion, four had multifocal involvement and one had distant metastases (bone and lungs). The patients were treated with PRRT using {sup 90}Y/{sup 177}Lu-labelled peptides after positive confirmation of SSTR expression on {sup 68}Ga-DOTATOC PET/CT. All patients received two to four courses of PRRT. Subsequent serial imaging with {sup 68}Ga-DOTATOC PET/CT was carried out every 6 months to assess response to treatment. Clinical (symptomatic) response was also assessed. Based on molecular response (EORTC) criteria, four of the nine patients showed a partial molecular response to treatment seen as significant decreases in SUV{sub max}, accompanied by a reduction in tumour size. Five patients showed stable disease on both molecular and morphological criteria. Six out of nine patients were symptomatic at presentation with manifestations of cranial nerve involvement, bone destruction at the primary site and metastatic bone pain. Molecular responses were correlated with symptomatic improvement in four out of these six patients; while two patients showed small reductions in tumour size and SUV{sub max}. The three asymptomatic patients showed no new lesions or symptomatic worsening. PRRT was effective in all patients, with no disease worsening seen, either in the form of neurological symptoms or

  9. Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy

    International Nuclear Information System (INIS)

    Koukouraki, Sophia; Strauss, Ludwig G.; Dimitrakopoulou-Strauss, Antonia; Georgoulias, Vassilios; Schuhmacher, Jochen; Haberkorn, Uwe; Karkavitsas, Nikolaos

    2006-01-01

    dependent on k 1 (receptor binding) and V b (fractional blood volume). Pharmacokinetic data analysis can help to separate blood background activity (V b ) from the receptor binding (k 1 ), which may help to optimise planning of 90 Y-DOTATOC therapy. (orig.)

  10. Boosted selective internal radiation therapy with {sup 90}Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept

    Energy Technology Data Exchange (ETDEWEB)

    Garin, E.; Lenoir, L. [Comprehensive Cancer Center, Institute Eugene Marquis, Department of Nuclear Medicine, CS 44229, Rennes (France); University of Rennes 1, Rennes (France); INSERM, U-991, Liver Metabolisms and Cancer, Rennes (France); Edeline, J. [University of Rennes 1, Rennes (France); Comprehensive Cancer Center, Institute Eugene Marquis, Department of Medical Oncology, CS 44229, Rennes (France); Laffont, S. [Comprehensive Cancer Center, Institute Eugene Marquis, Department of Nuclear Medicine, CS 44229, Rennes (France); Mesbah, H.; Poree, P. [Comprehensive Cancer Center, Institute Eugene Marquis, Department of Medical Informatics, CS 44229, Rennes (France); Sulpice, L. [INSERM, U-991, Liver Metabolisms and Cancer, Rennes (France); Centre Hospitalier Universitaire Pontchaillou, Department of Digestive Surgery, Rennes (France); Boudjema, K. [University of Rennes 1, Rennes (France); INSERM, U-991, Liver Metabolisms and Cancer, Rennes (France); Centre Hospitalier Universitaire Pontchaillou, Department of Digestive Surgery, Rennes (France); Mesbah, M. [University of Pierre et Marie Curie, Paris (France); Guillygomarc' h, A. [Centre Hospitalier Universitaire Pontchaillou, Department of Hepatology, Rennes (France); Quehen, E. [Centre Hospitalier Universitaire Pontchaillou, Department of Radiology, Rennes (France); Pracht, M. [Comprehensive Cancer Center, Institute Eugene Marquis, Department of Medical Oncology, CS 44229, Rennes (France); Raoul, J.L. [Comprehensive Cancer Center, Institute Paoli Calmette, Department of Medical Oncology, Marseille (France); Clement, B. [INSERM, U-991, Liver Metabolisms and Cancer, Rennes (France); Rolland, Y. [Comprehensive Cancer Center, Institute Eugene Marquis, Department of Medical Imaging, CS 44229, Rennes (France); Boucher, E. [INSERM, U-991, Liver Metabolisms and Cancer, Rennes (France); Comprehensive Cancer Center, Institute Eugene Marquis, Department of Medical Oncology, CS 44229, Rennes (France)

    2013-07-15

    To evaluate the impact of dosimetry based on MAA SPECT/CT for the prediction of response, toxicity and survival, and for treatment planning in patients with hepatocellular carcinoma (HCC) treated with {sup 90}Y-loaded glass microspheres (TheraSphere registered). TheraSphere registered was administered to 71 patients with inoperable HCC. MAA SPECT/CT quantitative analysis was used for the calculation of the tumour dose (TD), healthy injected liver dose (HILD), and total injected liver dose. Response was evaluated at 3 months using EASL criteria. Time to progression (TTP) and overall survival (OS) were evaluated using the Kaplan-Meier method. Factors potentially associated with liver toxicity were combined to construct a liver toxicity score (LTS). The response rate was 78.8 %. Median TD were 342 Gy for responding lesions and 191 Gy for nonresponding lesions (p < 0.001). With a threshold TD of 205 Gy, MAA SPECT/CT predicted response with a sensitivity of 100 % and overall accuracy of 90 %. Based on TD and HILD, 17 patients underwent treatment intensification resulting in a good response rate (76.4 %), without increased grade III liver toxicity. The median TTP and OS were 5.5 months (2-9.5 months) and 11.5 months (2-31 months), respectively, in patients with TD <205 Gy and 13 months (10-16 months) and 23.2 months (17.5-28.5 months), respectively, in those with TD >205 Gy (p = 0.0015 and not significant). Among patients with portal vein thrombosis (PVT) (n = 33), the median TTP and OS were 4.5 months (2-7 months) and 5 months (2-8 months), respectively, in patients with TD <205 Gy and 10 months (6-15.2 months) and 21.5 months (12-28.5 months), respectively, in those with TD >205 Gy (p = 0.039 and 0.005). The median OS was 24.5 months (18-28.5 months) in PVT patients with TD >205 Gy and good PVT targeting on MAA SPECT/CT. The LTS was able to detect severe liver toxicity (n = 6) with a sensitivity of 83 % and overall accuracy of 97 %. Dosimetry based on MAA SPECT/CT was

  11. Investigation of a {sup 90}Sr/{sup 90}Y source for intra-ocular treatment of wet age-related macular degeneration

    Energy Technology Data Exchange (ETDEWEB)

    Holmes, Shannon M.; Micka, John A.; DeWerd, Larry A. [University of Wisconsin Medical Radiation Research Center, Madison, Wisconsin 53705 (United States)

    2009-10-15

    Purpose: The purpose of this study is to perform an extensive investigation of an approximately 2.5 mm long {sup 90}Sr/{sup 90}Y source designed for treating wet age-related macular degeneration. Methods: As part of this investigation, a NIST-traceable absorbed dose to water calibration technique was established, and a source deployment verification test was developed. The influence of treatment cannula construction tolerance on the measurements as well as the dose delivered to the patient was investigated using the Monte Carlo code MCNP5. Variation between production cannulae was quantified experimentally using a well-type ionization chamber, and additional measurements along with Monte Carlo calculations of the collimating insert used for source deployment verification were performed to validate the model. Results: Maximum variation in the integrated target dose was seen when the source was shifted laterally within the treatment cannula. For the well chamber measurements, the observed standard deviation in ionization current for a single source placed in different reference cannulae was {+-}0.3%, with a maximum observed range of less than {+-}0.5%. Clinical cannulae in the collimating insert showed an average of 17.8%{+-}0.4% of the reference signal when sources were fully deployed compared to 18.5% predicted by Monte Carlo calculations. This discrepancy has been attributed primarily to construction of the collimator since the collimation gap was observed to be approximately 0.025-0.075 mm smaller than specified. Construction tolerance of the well chamber insert as well as position tolerance of the cannula tip were both investigated, and their influence on the predicted signal was quantified. Additional measurements along with Monte Carlo based calculations of the collimating insert with polyethylene spacers added to the setup were performed to validate the Monte Carlo model. The shimmed Monte Carlo and measured data agree to within 1%, which is a magnitude

  12. Modeling of the electron distribution based on bremsstrahlung emission during lower hybrid current drive on PLT

    Energy Technology Data Exchange (ETDEWEB)

    Stevens, J.E.; von Goeler, S.; Bernabei, S.; Bitter, M.; Chu, T.K.; Efthimion, P.; Fisch, N.; Hooke, W.; Hosea, J.; Jobes, F.

    1985-03-01

    Lower hybrid current drive requires the generation of a high energy electron tail anisotropic in velocity. Measurements of bremsstrahlung emission produced by this tail are compared with the calculated emission from reasonable model distributions. The physical basis and the sensitivity of this modeling process are described and the plasma properties of current driven discharges which can be derived from the model are discussed.

  13. Virtual-bremsstrahlung production in proton-proton scattering and proton-deuteron capture

    NARCIS (Netherlands)

    Messchendorp, Johannes Gerhardus

    1999-01-01

    The well-known coupling of the photon with the nucleon together with the fact that photons (or any electromagnetic (e.m.) probe) interact only relatively weakly with nucleons, make bremsstrahlung production an ideal tool to study details of the nucleon-nucleon interaction. In this thesis dilepton

  14. Experimental results on 2-30 keV bremsstrahlung from thick and thin targets

    Energy Technology Data Exchange (ETDEWEB)

    Shanker, R. [Atomic Physics Laboratory, Physics Department, Banaras Hindu University, Varanasi 221005 (India)]. E-mail: rshanker@bhu.ac.in

    2006-10-15

    The recent experimental investigations on electron bremsstrahlung produced from impact of 2-30 keV electrons with thick solid and thin gaseous targets are reviewed. The theoretical models describing the energy and angular distributions of bremsstrahlung photons are discussed with their brief outlines and formulations to explain the experimental data. The results on thick target bremsstrahlung (TTB) spectra produced by keV electrons have suggested that there is a need to develop a comprehensive theory for accounting the solid state effects. It is further noted that the prediction of the modified KKD formula gives a reasonable agreement with the TTB data, whereas a semi-empirical formula gives a better fit to the data for thick targets. The available experimental data for dependence of double differential cross-sections of emitted photons on impact energy and their emission angles for gaseous atoms and molecules exhibit a good agreement with the theoretical calculations of Kissel et al., [1983. Shape functions for atomic-field bremsstrahlung from electrons of kinetic energy 1-500 keV on selected neutral atoms 1

  15. Measurement of the linear polarization of the photons in the elementary processes of bremsstrahlung production

    International Nuclear Information System (INIS)

    Bleier, W.

    1983-01-01

    The polarization of the photons in the elementary processes of the electron-nucleus and electron-electron bremsstrahlung was measured. Electrons with an energy of 300 keV were scattered by copper, gold and carbon target. The polarization in the different processes was measured by using different coincidence methods. (BEF)

  16. Lepton-pair production by bremsstrahlung in central relativistic heavy ion collisions

    International Nuclear Information System (INIS)

    Lippert, T.; Becker, U.; Gruen, N.; Scheid, W.; Soff, G.

    1988-03-01

    We study the production of lepton-pairs by classical bremsstrahlung in central relativistic heavy-ion collisions. For the stopping of the nuclei we assume a simple model of point charges and a deceleration time. Pair creation probabilities are calculated in first order perturbation theory. (orig.)

  17. Electron-positron pair production and bremsstrahlung at intermediate energies in the field of heavy atoms

    International Nuclear Information System (INIS)

    Lee, R.N.; Milstein, A.I.; Strakhovenko, V.M.; Schwartz, O.Ya.

    2006-01-01

    The Coulomb corrections (CC) to the processes of bremsstrahlung and pair production are investigated. The next-to-leading term in the high-energy asymptotics is found. This term becomes very essential in the region of intermediate energies. The influence of screening for CC is small for differential cross section, spectrum, and the total cross section of pair production. The same is true for the spectrum of bremsstrahlung, but not for the differential cross section, where the influence of screening can be very large. The corresponding screening corrections as well as the modification of the differential cross section of bremsstrahlung are found. A comparison of our results for the total cross section of pair production with the experimental data available is performed. This comparison has justified our analytical results and allowed to elaborate a simple ansatz for the next-to-leading correction. The influence of the electron beam shape on CC for bremsstrahlung is investigated. It turns out that the differential cross section is very sensitive to this shape

  18. Bremsstrahlung from relativistic bare heavy ions: Nuclear and electronic contributions in amorphous and crystalline materials

    DEFF Research Database (Denmark)

    Jensen, Tue Vissing; Sørensen, Allan Hvidkjær

    2013-01-01

    A charged particle emits bremsstrahlung while traversing matter. We calculate the radiation cross section for bare heavy ions penetrating amorphous materials and single crystals at highly relativistic energies. The main component originates in scattering of the virtual photons of screened target...... in a pronounced directional dependence of the energy loss of bare heavy ions at extreme relativistic energies....

  19. ''Atomic'' Bremsstrahlung or polarizational radiation in collision of many-electron ions

    International Nuclear Information System (INIS)

    Amusia, M.Ya.; Solov'yov, A.V.

    1991-01-01

    In this work the so-called ''Atomic'' bremsstrahlung (AB) or polarizational radiation, created in collisions of atoms or ions, is discussed. This kind of radiation arises due to the polarization of the electron shell of colliding particles. It is created by the structured projectiles and targets if the constituents are electrically charged. 6 refs, 2 figs

  20. Pauli principle in the soft-photon approach to proton-proton bremsstrahlung

    NARCIS (Netherlands)

    Liou, MK; Timmermans, R; Gibson, BF

    1996-01-01

    A relativistic and manifestly gauge-invariant soft-photon amplitude, which is consistent with the soft-photon theorem and satisfies the Pauli principle, is derived for the proton-proton bremsstrahlung process. This soft-photon amplitude is the first two-u-two-t special amplitude to satisfy all

  1. Modeling of the electron distribution based on bremsstrahlung emission during lower hybrid current drive on PLT

    International Nuclear Information System (INIS)

    Stevens, J.E.; von Goeler, S.; Bernabei, S.

    1985-03-01

    Lower hybrid current drive requires the generation of a high energy electron tail anisotropic in velocity. Measurements of bremsstrahlung emission produced by this tail are compared with the calculated emission from reasonable model distributions. The physical basis and the sensitivity of this modeling process are described and the plasma properties of current driven discharges which can be derived from the model are discussed

  2. Neutron-proton bremsstrahlung studies using the white neutron source at the LAMPF/WNR

    International Nuclear Information System (INIS)

    Wender, S.A.; Nelson, R.O.; Schillaci, M.E.; Blann, M.

    1990-01-01

    Nucleon-nucleon bremsstrahlung is a few-body radiative process that provides insight into several areas of nuclear physics. It is one of the simplest systems for studying the off-shell behavior of the nucleon-nucleon potential. The physics involved in neutron-proton bremsstrahlung (NPB) is significantly different from that of proton-proton bremsstrahlung (PPB). In particular, NPB cross sections are much larger than PPB cross sections because NPB allows E1 radiation, and the contribution to the cross section from the meson exchange currents has been calculated to be as large as the contributions from external radiation. To date there have been essentially four NPB experiments. These measurements have covered only a small part of the available phase space. A major experimental problem in performing these measurements has been the lack of a suitable intense, high-energy neutron beam. We are planning a measurement of the NPB cross section using the white neutron source at the WNR target area at the LAMPF accelerator. We plant to implement the experiment in three phases. In this first state, we shall measure inclusive hard-photon production using a multi-element gamma-ray telescope that is insensitive to neutrons. In the second phase, we shall measure the bremsstrahlung gamma-rays in coincidence with recoil protons. In the last phase, we shall detect the scattered neutrons in coincidence with the recoil protons and gamma rays. 8 refs., 6 figs

  3. Multi-Regge amplitudes for bremsstrahlung in e+e- backward scattering

    International Nuclear Information System (INIS)

    Ermolaev, B.I.; Lipatov, L.N.

    1988-01-01

    Using the method of factorization, equations are obtained for the inelastic on-shell amplitudes describing the asymptotic behavior of e + e - backward scattering with emission of bremsstrahlung photons in the doubly logarithmic approximation. Explicit expressions are found for these amplitudes in the case in which the photons are emitted with multi-Regge kinematics

  4. Study on the source of optical activity: Pt. 6. ESR spectroscopy on the asymmetrical radical yields in 90Sr-90Y β irradiated D-and L-alanine

    International Nuclear Information System (INIS)

    Wang Wenqing; Zhao Jian; Ding Xiang

    1993-01-01

    Free radical formation in 90 Sr- 90 Y β irradiated D- and L-alanine is studied by ESR spectroscopy. To calibrate the probable differences in the size of ESR tubes, the different densities of alanine and the incidental different impurities, samples are firstly irradiated with 60 Co γ rays. Then the D- and L- alanine samples are irradiated with 90 Sr- 90 Y source at 77 K. Soon after irradiation, ESR measurement is performed on each sample. The average ratio H β+γ /H γ of D- alanine is 0.147 higher than that of L- alanine, indicating that more free radicals are induced in D- alanine by β irradiation. Irradiation at 77 K is capable of diminishing the effect of thermal movement on the polarization of β electrons and freezing the free radical formation. The experiments show the stereoselective interaction of β electrons with D- and L- amino acids, and so supports the Vester-ulbricht hypothesis

  5. Country report: Serbia. Development, Preparing and Quality Assurance of Radiopharmaceuticals Based on 188Re and 90Y for Radionuclide Therapy: The Possibilities for their Production in Laboratory for Radioisotopes, Ins «Vinča»

    International Nuclear Information System (INIS)

    Djokić, Divna

    2010-01-01

    The main object of the research planed for this project was to optimize the procedures for the 90 Y and 188 Re labelling of different compounds as well as their in vitro and in vivo evaluation. The work has been involved setting up the facilities, standardization of preparing protocols, and improving existing quality assurance/quality control (QA/QC) procedures in order to supply reliable products to the national nuclear medicine community

  6. Country report: Serbia. Development, Preparing and Quality Assurance of Radiopharmaceuticals Based on {sup 188}Re and {sup 90}Y for Radionuclide Therapy: The Possibilities for their Production in Laboratory for Radioisotopes, Ins «Vinča»

    Energy Technology Data Exchange (ETDEWEB)

    Djokić, Divna [Vinča Institute of Nuclear Sciences, Laboratory for Radioisotopes, Belgrade (Serbia)

    2010-07-01

    The main object of the research planed for this project was to optimize the procedures for the {sup 90}Y and {sup 188}Re labelling of different compounds as well as their in vitro and in vivo evaluation. The work has been involved setting up the facilities, standardization of preparing protocols, and improving existing quality assurance/quality control (QA/QC) procedures in order to supply reliable products to the national nuclear medicine community.

  7. High-power, photofission-inducing bremsstrahlung source for intense pulsed active detection of fissile material

    Directory of Open Access Journals (Sweden)

    J. C. Zier

    2014-06-01

    Full Text Available Intense pulsed active detection (IPAD is a promising technique for detecting fissile material to prevent the proliferation of special nuclear materials. With IPAD, fissions are induced in a brief, intense radiation burst and the resulting gamma ray or neutron signals are acquired during a short period of elevated signal-to-noise ratio. The 8 MV, 200 kA Mercury pulsed-power generator at the Naval Research Laboratory coupled to a high-power vacuum diode produces an intense 30 ns bremsstrahlung beam to study this approach. The work presented here reports on Mercury experiments designed to maximize the photofission yield in a depleted-uranium (DU object in the bremsstrahlung far field by varying the anode-cathode (AK diode gap spacing and by adding an inner-diameter-reducing insert in the outer conductor wall. An extensive suite of diagnostics was fielded to measure the bremsstrahlung beam and DU fission yield as functions of diode geometry. Delayed fission neutrons from the DU proved to be a valuable diagnostic for measuring bremsstrahlung photons above 5 MeV. The measurements are in broad agreement with particle-in-cell and Monte Carlo simulations of electron dynamics and radiation transport. These show that with increasing AK gap, electron losses to the insert and outer conductor wall increase and that the electron angles impacting the bremsstrahlung converter approach normal incidence. The diode conditions for maximum fission yield occur when the gap is large enough to produce electron angles close to normal, yet small enough to limit electron losses.

  8. Using bremsstrahlung for electron density estimation and correction in EAST tokamak

    Energy Technology Data Exchange (ETDEWEB)

    Chen, Yingjie, E-mail: bestfaye@gmail.com; Wu, Zhenwei; Gao, Wei; Jie, Yinxian; Zhang, Jizong; Huang, Juan; Zhang, Ling; Zhao, Junyu

    2013-11-15

    Highlights: • The visible bremsstrahlung diagnostic provides a simple and effective tool for electron density estimation in steady state discharges. • This method can make up some disadvantages of present FIR and TS diagnostics in EAST tokamak. • Line averaged electron density has been deduced from central VB signal. The results can also be used for FIR n{sub e} correction. • Typical n{sub e} profiles have been obtained with T{sub e} and reconstructed bremsstrahlung profiles. -- Abstract: In EAST electron density (n{sub e}) is measured by the multi-channel far-infrared (FIR) hydrogen cyanide (HCN) interferometer and Thomson scattering (TS) diagnostics. However, it is difficult to obtain accurate n{sub e} profile for that there are many problems existing in current electron density diagnostics. Since the visible bremsstrahlung (VB) emission coefficient has a strong dependence on electron density, the visible bremsstrahlung measurement system developed to determine the ion effective charge (Z{sub eff}) may also be used for n{sub e} estimation via inverse operations. With assumption that Z{sub eff} has a flat profile and does not change significantly in steady state discharges, line averaged electron density (n{sup ¯}{sub e}) has been deduced from VB signals in L-mode and H-mode discharges in EAST. The results are in good coincidence with n{sup ¯}{sub e} from FIR, which proves that VB measurement is an effective tool for n{sub e} estimation. VB diagnostic is also applied to n{sup ¯}{sub e} correction when FIR n{sup ¯}{sub e} is wrong for the laser phase shift reversal together with noise causes errors when electron density changed rapidly in the H-mode discharges. Typical n{sub e} profiles in L-mode and H-mode phase are also deduced with reconstructed bremsstrahlung profiles.

  9. High-power, photofission-inducing bremsstrahlung source for intense pulsed active detection of fissile material

    Science.gov (United States)

    Zier, J. C.; Mosher, D.; Allen, R. J.; Commisso, R. J.; Cooperstein, G.; Hinshelwood, D. D.; Jackson, S. L.; Murphy, D. P.; Ottinger, P. F.; Richardson, A. S.; Schumer, J. W.; Swanekamp, S. B.; Weber, B. V.

    2014-06-01

    Intense pulsed active detection (IPAD) is a promising technique for detecting fissile material to prevent the proliferation of special nuclear materials. With IPAD, fissions are induced in a brief, intense radiation burst and the resulting gamma ray or neutron signals are acquired during a short period of elevated signal-to-noise ratio. The 8 MV, 200 kA Mercury pulsed-power generator at the Naval Research Laboratory coupled to a high-power vacuum diode produces an intense 30 ns bremsstrahlung beam to study this approach. The work presented here reports on Mercury experiments designed to maximize the photofission yield in a depleted-uranium (DU) object in the bremsstrahlung far field by varying the anode-cathode (AK) diode gap spacing and by adding an inner-diameter-reducing insert in the outer conductor wall. An extensive suite of diagnostics was fielded to measure the bremsstrahlung beam and DU fission yield as functions of diode geometry. Delayed fission neutrons from the DU proved to be a valuable diagnostic for measuring bremsstrahlung photons above 5 MeV. The measurements are in broad agreement with particle-in-cell and Monte Carlo simulations of electron dynamics and radiation transport. These show that with increasing AK gap, electron losses to the insert and outer conductor wall increase and that the electron angles impacting the bremsstrahlung converter approach normal incidence. The diode conditions for maximum fission yield occur when the gap is large enough to produce electron angles close to normal, yet small enough to limit electron losses.

  10. {sup 177}Lu- labeled MOv18 as compared to {sup 131}I- or {sup 90}Y-labeled MOv18 has the better therapeutic effect in eradication of alpha folate receptor-expressing tumor xenografts

    Energy Technology Data Exchange (ETDEWEB)

    Zacchetti, Alberto [Unit of Molecular Therapies, Department of Experimental Oncology and Laboratories, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan 20133 (Italy); Coliva, Angela [Department of Imaging and Nuclear Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan 20133 (Italy); Luison, Elena [Unit of Molecular Therapies, Department of Experimental Oncology and Laboratories, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan 20133 (Italy); Seregni, Ettore; Bombardieri, Emilio [Department of Imaging and Nuclear Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan 20133 (Italy); Giussani, Augusto [Helmholtz Zentrum Muenchen, German Research Center for Environmental Health, Neuherberg (Germany); Figini, Mariangela [Unit of Molecular Therapies, Department of Experimental Oncology and Laboratories, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan 20133 (Italy); Canevari, Silvana [Unit of Molecular Therapies, Department of Experimental Oncology and Laboratories, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan 20133 (Italy)], E-mail: silvana.canevari@istitutotumori.mi.it

    2009-10-15

    Introduction: The mouse monoclonal antibody MOv18, directed against the {alpha}-isoform of folate receptor (FR), was investigated to identify the optimal radioconjugate for radioimmunotherapy of minimal residual disease in ovarian cancer. Methods: Pharmacokinetics, biodistribution, long-term therapeutic efficacy and toxicity of MOv18, labeled with the beta-emitters {sup 131}I, {sup 90}Y and {sup 177}Lu, were compared in a xenografted mouse model, composed by two cell lines, A431FR and A431MK, differing only for FR expression. Results: A shorter blood clearance and a higher tumor uptake were observed for {sup 90}Y- and {sup 177}Lu- compared to {sup 131}I-MOv18, and a shorter blood pharmacokinetics was recorded in A431FR-bearing animals. At equitoxic maximum tolerable doses, the general irradiation by {sup 131}I- and {sup 90}Y-MOv18 gives rise to strong targeted effects on A431FR and nontargeted effects on A431MK tumors, while {sup 177}Lu-MOv18 was able to eradicate small size tumor masses expressing the antigen of interest exerting only mild non-targeted effects. Conclusion: {sup 177}Lu-MOv18 at the maximal tolerated dose is the immunoradioconjugate with the best therapeutic window in experimental conditions of small tumor volume.

  11. An apparatus to study the energy and angular distributions of electron-bremsstrahlung photons from gaseous targets

    International Nuclear Information System (INIS)

    Yadav, Namita; Bhatt, Pragya; Singh, Raj; Singh, B.K.; Quarles, C.A.; Shanker, R.

    2014-01-01

    An apparatus is developed to measure the energy- and angular distributions of bremsstrahlung generated from collisions of energetic electrons with isolated atoms and molecules. A considerable reduction of thick target bremsstrahlung (TTB) background produced by scattered electrons from the chamber wall is achieved. Details of the experimental setup with regard to design of its components, experimental technique, data acquisition and analysis etc. are given and discussed. The reliability and performance of the setup are demonstrated by obtaining some test results on angular- and energy distributions of bremsstrahlung produced in collisions of 4.0 keV electrons with free argon atoms. These results are compared with the theoretical predictions of the ordinary- and the polarization bremsstrahlung emissions. In this comparison, the experimental data for energy distributions of BS photons are found to be in reasonable agreement while they are found to have noticeable differences in shape of angular distributions. - Highlights: • Experimental setup is developed to study DDCS of electron-bremsstrahlung from gaseous targets. • TTB from scattering chamber's wall is reduced appreciably by using a teflon cylinder. • Shape of DDCS of bremsstrahlung compared with the theories shows a satisfactory match. • Angular distributions of bremsstrahlung show anisotropy but still affected by TTB background photons

  12. Radiation from planar channeled 5-55 GeV/c positrons and electrons

    International Nuclear Information System (INIS)

    Atkinson, M.; Sharp, P.H.; Giddings, D.; Bussey, P.J.

    1982-01-01

    The emission of radiation from 5 to 55 GeV/c planar channeled positrons and electrons passing through a 135 μ thick silicon-crystal has been investigated. The intensity of the channeling-radiation is found to be 10 to 30 times the intensity of normal bremsstrahlung. For channeled electrons no structure is found in the spectrum, whereas strong and sharp peaks are found for positrons. This peak structure is extremely sharp at 5 GeV/c and for momenta above 20 GeV/c the structure disappears. For a classical description of channeling, but using an anharmonic potential, certain energies are found for which the maximum energy of the channeling radiation is practically independent of transverse energy. The possibility of making a monoenergetic γ-source in the range of 10-100 MeV is mentioned. (orig.)

  13. Procedure to carry out leakage test in beta radiation sealed sources emitters of {sup 90}Sr/{sup 90}Y; Procedimiento para realizar prueba de fuga en fuentes selladas de radiacion beta emisoras de {sup 90}Sr/{sup 90}Y

    Energy Technology Data Exchange (ETDEWEB)

    Alvarez R, J. T., E-mail: trinidad.alvarez@inin.gob.m [ININ, Departamento de Metrologia de Radiaciones Ionizantes, Laboratorio Secundario de Calibracion Dosimetrica, Carretera Mexico-Toluca s/n, 52750 Ocoyoacac, Estado de Mexico (Mexico)

    2010-09-15

    In the alpha-beta room of the Secondary Laboratory of Dosimetric Calibration of the Metrology Department of Ionizing Radiations ophthalmic applicators are calibrated in absorbed dose terms in water D{sub w}; these applicators, basically are emitter sealed sources of pure beta radiation of {sup 90}Sr / {sup 90}Y. Concretely, the laboratory quality system indicates to use the established procedure for the calibration of these sources, which establishes the requirement of to carry out a leakage test, before to calibrate the source. However, in the Laboratory leakage test certificates sent by specialized companies in radiological protection services have been received, in which are used gamma spectrometry equipment s for beta radiation leakage tests, since it is not reliable to detect pure beta radiation with a scintillating detector with NaI crystal, (because it could detect the braking radiation produced in the detector). Therefore the Laboratory has had to verify the results of the tests with a correct technique, with the purpose of determining the presence of sources with their altered integrity and radioactive material leakage. The objective of this work is to describe a technique for beta activity measurement - of the standard ISO 7503, part 1 (1988) - and its application with a detector Gm plane (type pankage) in the realization of leakage tests in emitter sources of pure beta radiation, inside the mark of quality assurance indicated by the report ICRU 76. (Author)

  14. The planar cubic Cayley graphs

    CERN Document Server

    Georgakopoulos, Agelos

    2018-01-01

    The author obtains a complete description of the planar cubic Cayley graphs, providing an explicit presentation and embedding for each of them. This turns out to be a rich class, comprising several infinite families. He obtains counterexamples to conjectures of Mohar, Bonnington and Watkins. The author's analysis makes the involved graphs accessible to computation, corroborating a conjecture of Droms.

  15. Development of a Planar Undulator

    International Nuclear Information System (INIS)

    Deyhim, Alex; Johnson, Eric; Kulesza, Joe; Lyndaker, Aaron; Waterman, Dave; Eisert, Dave; Green, Michael A.; Rogers, Greg; Blomqvist, K. Ingvar

    2007-01-01

    The design of a planar pure permanent magnet undulator is presented. The design requirements and mechanical difficulties for holding, positioning, and driving the magnetic arrays are explored. The structural, thermal, and electrical considerations that influenced the design are then analyzed. And finally detailed magnetic measurements are presented

  16. Casimir stress inside planar materials

    Science.gov (United States)

    Griniasty, Itay; Leonhardt, Ulf

    2017-09-01

    The Casimir force between macroscopic bodies is well understood, but not the Casimir force inside bodies. Guided by a physically intuitive picture, we develop the macroscopic theory of the renormalized Casimir stress inside planar materials (where the electromagnetic properties vary in one direction). Our theory may be applied in predicting how inhomogeneous fluids respond to Casimir forces.

  17. Approximation by planar elastic curves

    DEFF Research Database (Denmark)

    Brander, David; Gravesen, Jens; Nørbjerg, Toke Bjerge

    2016-01-01

    We give an algorithm for approximating a given plane curve segment by a planar elastic curve. The method depends on an analytic representation of the space of elastic curve segments, together with a geometric method for obtaining a good initial guess for the approximating curve. A gradient......-driven optimization is then used to find the approximating elastic curve....